<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="a">
		<monograph id="1" status="active" ha="yes">
			<mono_name>abacavir (Rx)</mono_name>
			<info>
				<pronunciation>(ah-bak′ah-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x230">Ziagen</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nucleoside reverse transcriptase inhibitor (NRTI)</class>
			</info>
			<section type="confusion" id="sidelem4x33">
				<para>
					<confusion>
						<tradename id="tnidelem4x330">abacavir</tradename>
						<drug type="generic" refid="idelem4x330">amprenavir</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x37">
				<sec_title>Action:</sec_title>
				<para>Inhibitory action against HIV-1; inhibits replication of the virus by incorporating into cellular DNA by viral reverse transcriptase, thereby terminating the cellular DNA chain</para>
			</section>
			<section type="uses" id="sidelem4x42">
				<sec_title>Uses:</sec_title>
				<para>In combination with other antiretroviral agents for HIV-1 infection</para>
				<section type="none" id="sidelem4x47">
					<section type="none" id="sidelem4x48">
						<sec_title>Unlabeled uses:</sec_title>
						<para> HIV prophylaxis following occupational exposure</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x53">
				<sec_title>Contraindications</sec_title>
				<para>
					<bbw>Hypersensitivity, moderate/severe hepatic disease, lactic acidosis</bbw>
				</para>
				<section type="none" id="sidelem4x66">
					<section type="none" id="sidelem4x67">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;3 mo, granulocyte count &lt;1000/mm<emphasis style="sup">3</emphasis> or Hgb &lt;9.5 g/dl, severe renal disease, impaired hepatic function, HLA B5701+ (black, Caucasian, Asian patients), abrupt discontinuation; Guillain-Barré syndrome, immune reconstitution syndrome, MI, obesity, polymyositis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x75">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x83">
					<label>•</label>
					<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x83">
							<item>
								<label>•</label>
								<para> 300 mg bid or 600 mg/day with other antiretrovirals</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x90">
					<label>•</label>
					<sec_title>Adolescent &lt;16 yr and child ≥3 mo<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x90">
							<item>
								<label>•</label>
								<para> 8 mg/kg bid or 16 mg/kg daily, max 300 mg bid with other antiretrovirals</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x94">
					<section type="none" id="sidelem4x95">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x103">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh 5-6) (oral sol) 200 mg bid; moderate to severe hepatic disease, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x106">
						<sec_title>HIV prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x114">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x114">
									<item>
										<label>•</label>
										<para> 600 mg daily as an alternative</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x118">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 300 mg; oral sol 20 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x123">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x131">
							<label>•</label>
							<sec_title>
								<route>do not use triple therapy as a beginning treatment, resistance may occur</route>
							</sec_title>
							<para>
								<list id="lidelem4x131">
									<item>
										<label>•</label>
										<para>Give in combination with other antiretrovirals; </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x135">
								<item>
									<label>•</label>
									<para>May give without regard to food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x140">
								<item>
									<label>•</label>
									<para>Reduce dose in hepatic disease, use oral sol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x145">
								<item>
									<label>•</label>
									<para>Storage in cool environment; protect from light; oral sol stored at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x150">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x153">
					<section type="none" id="sidelem4x154">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever, headache, malaise, insomnia,</emphasis> paresthesia</para>
					</section>
					<section type="none" id="sidelem4x162">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, anorexia,</emphasis> cramps, abdominal pain, increased AST, ALT, <emphasis style="bold">hepatotoxicity, hepatomegaly with steatosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x172">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Granulocytopenia, anemia, lymphopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x179">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, hypersensitivity reactions</para>
					</section>
					<section type="none" id="sidelem4x187">
						<sec_title>META:</sec_title>
						<para> <emphasis style="bold">Lactic acidosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x194">
						<sec_title>OTHER:</sec_title>
						<para> <emphasis style="bold">Fatal hypersensitivity reactions, MI, fat redistribution, immune reconstitution, decreased bone density</emphasis></para>
					</section>
					<section type="none" id="sidelem4x201">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x206">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapid/extensive absorption, distributed to extravascular space, then erythrocytes; 50% protein binding; extensively metabolized to inactive metabolites; half-life 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; excreted in urine, feces (unchanged); onset, peak, duration unknown</para>
			</section>
			<section type="interactions" id="sidelem4x217">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x225">
					<label>•</label>
					<sec_title>
						<route>Do not coadminister with abacavir-containing products, ribavirin, interferon</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x229">
						<item>
							<para>
								<emphasis alert="nurse">Increase: possible lactic acidosis—ribavirin</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> abacavir levels—alcohol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> abacavir levels—tipranavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of—methadone</para>
				<section type="none" id="sidelem4x247">
					<section type="none" id="sidelem4x248">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose, triglycerides, LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x255">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x258">
					<section type="none" id="sidelem4x259">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x264">
								<item>
									<label>•</label>
									<para>Symptoms of HIV and possible infections; increased temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x270"/>
						<para>
							<list id="lidelem4x296">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias (anemia, granulocytopenia): bruising, fatigue, bleeding, poor healing</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x301">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, CCr before, during therapy; these may be elevated
<bbw>Hepatic studies before and monthly during therapy: bilirubin, AST, ALT, amylase, alk phos, creatine phosphokinase, creatinine</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x318">
							<label>•</label>
							<sec_title>
								<route>Blood counts;</route>
							</sec_title>
							<para>
								<list id="lidelem4x318">
									<item>
										<label>•</label>
										<para> monitor viral load and CD4 counts during treatment; watch for decreasing granulocytes, Hgb; if low, therapy may have to be discontinued and restarted after hematologic recovery; blood transfusions may be required; perform hepatitis B virus (HBr) screening to confirm correct treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x325">
							<label>•</label>
							<sec_title>Immune reconstitution syndrome<route> may occur anytime during treatment; response to CMV, Mycobacterium avium infection</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x328">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x332">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased CD4 count, decreased viral load</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x339">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x344">
								<item>
									<label>•</label>
									<para>That product is not a cure but will control symptoms; patient is still infective, may pass AIDS virus on to others, to carry emergency ID with condition, products taken, do not take other products that contain abacavir</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x349">
								<item>
									<label>•</label>
									<para>That body fat redistribution may occur; not to share product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x355">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber of sore throat, swollen lymph nodes, malaise, fever; other infections may occur; to stop product and to notify prescriber immediately if skin rash, fever, cough, shortness of breath, GI symptoms occur; advise all health care providers that allergic reaction has occurred with abacavir</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x360">
								<item>
									<label>•</label>
									<para>That follow-up visits must be continued because serious toxicity may occur; blood counts must be done</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x368">
							<label>•</label>
							<sec_title>
								<route>To consider the use of contraception during treatment; if patient is pregnant, register with the Antiretroviral Pregnancy Registry at 1-800-258-4263</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x371">
								<item>
									<label>•</label>
									<para>Give patient Medication Guide and Warning Card, discuss points on guide</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x376">
								<item>
									<label>•</label>
									<para>That other products may be necessary to prevent other infections and that drug is taken with other antiretrovirals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x381">
								<item>
									<label>•</label>
									<para>Not to drink alcohol while taking this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x386">
								<item>
									<label>•</label>
									<para>To use exactly as prescribed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>abatacept (Rx)</mono_name>
			<info>
				<pronunciation>(ab-a-ta′sept)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x3960">Orencia</tradename>
				</tradenames>
				<class type="func"> Antirheumatic agent (disease modifying)</class>
				<class type="chem"> Immunomodulator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x406">
				<sec_title>Action:</sec_title>
				<para>A selective costimulation modulator, inhibits T-lymphocytes, inhibits production of tumor necrosis factor (TNF-α), interferon-γ, interleukin-2, which are involved in immune and inflammatory reactions</para>
			</section>
			<section type="uses" id="sidelem4x411">
				<sec_title>Uses:</sec_title>
				<para>Polyarticular juvenile rheumatoid arthritis; moderate to severe rheumatoid arthritis; acute, chronic rheumatoid arthritis that has not responded to other disease-modifying agents; may use in combination with DMARDs; do not use with TNF antagonists (adalimumab, etanercept, infliximab), anakinra</para>
			</section>
			<section type="contra" id="sidelem4x416">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x421">
					<section type="none" id="sidelem4x422">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, recurrent infections, COPD, TB, viral hepatitis, immunosuppression, neoplastic disease, respiratory infection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x427">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x430">
					<section type="none" id="sidelem4x431">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x439">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x439">
									<item>
										<label>•</label>
										<para> 125 mg within 1 day after single IV loading dose, then 125 mg weekly; weekly subcut dose may be initiated without an IV loading dose for those unable to receive an infusion</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x446">
							<label>•</label>
							<sec_title>Adult &gt;100 kg (220 lb)<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x446">
									<item>
										<label>•</label>
										<para> 1 g over 30 min, give at 2, 4 wk after first infusion, then q4wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x453">
							<label>•</label>
							<sec_title>Adult 60-100 kg (132-220 lb)<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x453">
									<item>
										<label>•</label>
										<para> 750 mg over 30 min, give at 2, 4 wk after first infusion, then q4wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x460">
							<label>•</label>
							<sec_title>Adult &lt;60 kg (132 lb)<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x460">
									<item>
										<label>•</label>
										<para> 500 mg over 30 min, give at 2, 4 wk after first infusion, then q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x464">
						<sec_title>Juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)</sec_title>
						<section type="none" id="sidelem4x472">
							<label>•</label>
							<sec_title>Adolescent and child ≥6 yr and &gt;100 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x472">
									<item>
										<label>•</label>
										<para> 1 g over 30 min q2wk × 3 doses, then 1 g over 30 min q4wk starting at wk 8</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x479">
							<label>•</label>
							<sec_title>Adolescent and child ≥6 yr and 75-100 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x479">
									<item>
										<label>•</label>
										<para> 750 mg over 30 min q2wk × 2 doses, then 750 mg over 30 min q4wk starting at wk 8</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x486">
							<label>•</label>
							<sec_title>Adolescent and child ≥6 yr and &lt;75 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x486">
									<item>
										<label>•</label>
										<para> 10 mg/kg over 30 min q2wk × 3 doses, then 10 mg/kg q4wk starting at wk 8</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x490">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder, single-use vials 250 mg; sol for subcut inj 125 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x495">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x499">
								<item>
									<label>•</label>
									<para>Storage in refrigerator; do not use expired vials, protect from light, do not freeze</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x505">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x513">
								<label>•</label>
								<sec_title>
									<route>To reconstitute,</route>
								</sec_title>
								<para>
									<list id="lidelem4x513">
										<item>
											<label>•</label>
											<para> use 10 ml sterile water for injection; insert syringe needle into vial and direct stream of sterile water for inj on the wall of vial; rotate vial until mixed; vent with needle to rid foam after reconstitution (25 mg/ml);  in 100 ml NS from a 100-ml infusion bag/bottle; withdraw the needed volume (2 vials remove 20 ml; 3 vials remove 30 ml, 4 vials remove 40 ml); slowly add the reconstituted sol from each vial into the infusion bag/bottle using the same disposable syringe supplied; mix gently; discard unused portions of vials; do not use if particulate is present or discolored;  over 30 min; use non–protein-binding filter (0.2-1.2 microns); protect from light</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x523">
									<item>
										<label>•</label>
										<para>Do not admix with other sol or medications</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x528">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x532">
									<item>
										<label>•</label>
										<para>Use prefilled syringe for subcut only (do not use for IV); allow syringe to warm to room temperature (30-60 min); do not speed up warming process; the amount of liquid should be between the 2 lines on the barrel; do not use the syringe if there is more or less liquid; inject into fronts of thighs, outer area of upper arm, or abdomen except for 2-inch area around the navel; do not inject into tender, bruised area</para>
									</item>
									<item>
										<label>•</label>
										<para>Gently pinch skin and hold firmly; insert needle at 45-degree angle; inject full amount in 125-mg syringe</para>
									</item>
									<item>
										<label>•</label>
										<para>Rotate injection sites</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x548">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x551">
					<section type="none" id="sidelem4x552">
						<sec_title>CNS:</sec_title>
						<para> Headache, asthenia, dizziness</para>
					</section>
					<section type="none" id="sidelem4x557">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypo/hypertension</emphasis></para>
					</section>
					<section type="none" id="sidelem4x564">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, dyspepsia, nausea</para>
					</section>
					<section type="none" id="sidelem4x569">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="italic">inj site reaction,</emphasis> flushing, urticaria, pruritus</para>
					</section>
					<section type="none" id="sidelem4x577">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Pharyngitis, cough, URI,</emphasis> non-URI, <emphasis style="italic">rhinitis,</emphasis> wheezing</para>
					</section>
					<section type="none" id="sidelem4x589">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, malignancies, serious infections, antibody development</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x596">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life IV 13 days, subcut 14.3 days, steady-state 60 days; clearance increases with increased body weight</para>
			</section>
			<section type="interactions" id="sidelem4x601">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x609">
					<label>•</label>
					<sec_title>
						<route>Do not give concurrently with vaccines; immunizations should be brought up to date before treatment</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x615">
					<label>•</label>
					<sec_title>Do not use with TNF antagonists<route> adalimumab, etanercept, infliximab; anakinra</route></sec_title>
				</section>
				<para>
					<list id="lidelem4x618">
						<item>
							<label>•</label>
							<para>Avoid use with corticosteroids, immunosuppressives, atropine, scopolamine, halothane, nitrous oxide</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x623">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x626">
					<section type="none" id="sidelem4x627">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x635">
							<label>•</label>
							<sec_title>RA</sec_title>
							<para>
								<list id="lidelem4x635">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">RA:</emphasis> pain, stiffness, ROM, swelling of joints during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x639">
								<item>
									<label>•</label>
									<para>For latent/active TB, viral hepatitis before beginning treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x644">
								<item>
									<label>•</label>
									<para>For inj site pain, swelling</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x649">
								<item>
									<label>•</label>
									<para>Patient’s overall health at each visit; product should not be given with active infections; parenteral product contains maltose, glucose monitoring must be done with glucose-specific testing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x655">
								<item>
									<para>
										<emphasis alert="nurse">Infection: sinusitis, urinary tract infection, influenza, bronchitis; serious infections have occurred</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x660">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x664">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation, pain in joints</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x670">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x674">
								<item>
									<label>•</label>
									<para>That product must be continued for prescribed time to be effective</para>
								</item>
								<item>
									<label>•</label>
									<para>To use caution when driving; dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to have vaccinations while taking this product or use alcohol, TNF antagonists, other immunosuppressants</para>
								</item>
								<item>
									<label>•</label>
									<para>About patient information included in packaging</para>
								</item>
								<item>
									<label>•</label>
									<para>How to inject and rotate inj sites</para>
								</item>
								<item>
									<label>•</label>
									<para>To report signs of infection</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active" ha="yes">
			<mono_name>abiraterone</mono_name>
			<info>
				<pronunciation>(a′bir-a′ter-one)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7120">Zytiga</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x722">
				<sec_title>Action:</sec_title>
				<para>Converted to abiraterone, which inhibits CYP17, the enzyme required for androgen biosynthesis; androgen-sensitive prostate cancer responds to treatment that decreases androgens</para>
			</section>
			<section type="uses" id="sidelem4x727">
				<sec_title>Uses:</sec_title>
				<para>Metastatic castration-resistant prostate cancer in combination with predniSONE</para>
			</section>
			<section type="contra" id="sidelem4x732">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), women, children</para>
				<section type="none" id="sidelem4x737">
					<section type="none" id="sidelem4x738">
						<sec_title>Precautions:</sec_title>
						<para> Adrenal insufficiency, cardiac disease, MI, heart failure, hepatic disease, hypertension, hypokalemia, infection, surgery, ventricular dysrhythmia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x743">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x751">
					<label>•</label>
					<sec_title>Adult males<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x751">
							<item>
								<label>•</label>
								<para> 1000 mg/day with predniSONE 5 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x755">
					<section type="none" id="sidelem4x756">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x764">
							<label>•</label>
							<sec_title>Adult males (Child-Pugh B, 7-9)<route> PO 250 mg/day with predniSONE, permanently discontinue if AST/ALT &gt;5 × the upper normal limit (ULN) or total bilirubin &gt;3 × (ULN) (Child-Pugh C, &gt;10) do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x767">
						<sec_title>Available forms:</sec_title>
						<para>Tabs 250 mg</para>
					</section>
					<section type="none" id="sidelem4x772">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x775">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x780">
									<item>
										<label>•</label>
										<para>Give whole, on empty stomach 2 hr before or 1 hr after meals with full glass of water</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x786">
									<item>
										<para>
											<emphasis alert="nurse">Women who are pregnant or may become pregnant should not touch tabs without gloves</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x791">
									<item>
										<label>•</label>
										<para>Store tabs at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x796">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x799">
					<section type="none" id="sidelem4x800">
						<sec_title>CV:</sec_title>
						<para> Angina, dysrhythmia exacerbation, <emphasis style="bold">atrial flutter/fibrillation/tachycardia, AV block,</emphasis> chest pain, edema, heart failure, <emphasis style="bold">MI,</emphasis> hypertension, <emphasis style="bold">QT prolongation,</emphasis> sinus tachycardia, <emphasis style="bold">supraventricular tachycardia, ventricular tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x818">
						<sec_title>ENDO:</sec_title>
						<para> Hot flashes</para>
					</section>
					<section type="none" id="sidelem4x823">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, dyspepsia, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x830">
						<sec_title>GU:</sec_title>
						<para> Increased urinary frequency, nocturia, urinary tract infection</para>
					</section>
					<section type="none" id="sidelem4x835">
						<sec_title>META:</sec_title>
						<para> Adrenocortical insufficiency, hyperbilirubinemia, hypertriglyceridemia, hypokalemia, hypophosphatemia</para>
					</section>
					<section type="none" id="sidelem4x840">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia</para>
					</section>
					<section type="none" id="sidelem4x845">
						<sec_title>RESP:</sec_title>
						<para> Cough, upper respiratory infection</para>
					</section>
					<section type="none" id="sidelem4x850">
						<sec_title>SYST:</sec_title>
						<para> Infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x855">
				<sec_title>Pharmacokinetics</sec_title>
				<para>99% protein binding, converted to abiraterone (active metabolite), mean terminal half-life 12 hr; excreted 88% (feces), 5% (urine); high-fat food increases effect, give on empty stomach; increased effect in hepatic disease</para>
			</section>
			<section type="interactions" id="sidelem4x860">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x864">
						<item>
							<label>•</label>
							<para>Decrease: abiraterone effect—CYP3A4 inhibitors (clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole, ketoconazole, itraconazole), loperamide, naprosen, pioglitazone, pitavastin, repaglinide, rosiglitazone</para>
						</item>
						<item>
							<label>•</label>
							<para>Avoid use with: CYP3A4 inducers (carBAMazepine, phenytoin, rifampin, rifabutin, rifapentine, PHENobarbital)</para>
						</item>
						<item>
							<label>•</label>
							<para>Increase: action of CYP2D6 substrates—dextromethorphan, thioridazine; dose of these products should be reduced</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x880">
					<section type="none" id="sidelem4x881">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> abiraterone action—must be taken on an empty stomach</para>
					</section>
					<section type="none" id="sidelem4x888">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, bilirubin, triglycerides, cholesterol, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, phosphate, testosterone</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x899">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x902">
					<section type="none" id="sidelem4x903">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x911">
							<label>•</label>
							<sec_title>Prostate cancer</sec_title>
							<para>
								<list id="lidelem4x911">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Prostate cancer:</emphasis> monitor prostate-specific antigen (PSA), serum potassium, serum bilirubin</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x916">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: monitor liver function tests (AST/ALT) at baseline, every 2 wk for 3 mo, monthly thereafter in patients with no known hepatic disease; interrupt treatment in patients without known hepatic disease at baseline who develop ALT/AST &gt;5 × ULN or total bilirubin &gt;3 × ULN; patients with moderate hepatic disease at baseline, measure ALT, AST, bilirubin before the start of treatment, every wk for 1 mo, every 2 wk for the following 2 mo, monthly thereafter; if elevations in ALT and/or AST &gt;5 × ULN or total bilirubin &gt;3 × ULN occur in patients with moderate hepatic impairment at baseline, discontinue and do NOT restart; measure serum total bilirubin, AST/ALT if hepatotoxicity is suspected; elevations of AST, ALT, bilirubin from baseline should prompt more frequent monitoring</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x924">
							<label>•</label>
							<sec_title>Musculoskeletal pain, joint swelling, discomfort</sec_title>
							<para>
								<list id="lidelem4x924">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Musculoskeletal pain, joint swelling, discomfort:</emphasis> arthritis, arthralgia, joint swelling, and joint stiffness, some severe; muscle discomfort that includes muscle spasms, musculoskeletal pain, myalgia, musculoskeletal discomfort, and musculoskeletal stiffness may be relieved with analgesics</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x928">
								<item>
									<label>•</label>
									<para>Signs, symptoms of adrenocorticoid insufficiency; monthly for hypertension, hypokalemia, fluid retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x934">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: Monitor ECG for QT prolongation, ejection fraction in patients with cardiac disease, small increases in the QTc interval such as &lt;10 ms have occurred; monitor for arrhythmia exacerbation such as sinus tachycardia, atrial fibrillation, supraventricular tachycardia (SVT), atrial tachycardia, ventricular tachycardia, atrial flutter, bradycardia, AV block complete, conduction disorder, bradyarrhythmia</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x939">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x945">
								<item>
									<para>
										<emphasis alert="nurse">That women must not come in contact with tabs; wear gloves if product needs to be handled, pregnancy (X)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x950">
								<item>
									<label>•</label>
									<para>To report chest pain, swelling of joints, burning/pain when urinating</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x955">
								<item>
									<label>•</label>
									<para>Not to use with other meds, herbs without prescriber approval</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>acamprosate</mono_name>
			<info>
				<pronunciation>(a-kam-pro′sate)</pronunciation>
				<class type="func"> Alcohol deterrent</class>
				<class type="chem"> Synthetic amino acid neurotransmitter analog</class>
			</info>
			<section type="actions" id="sidelem4x974">
				<sec_title>Action:</sec_title>
				<para>Not completely understood; in vitro data suggest it has affinity for type A and type B GABA receptors, lowers neuronal excitability, centrally mediated</para>
			</section>
			<section type="uses" id="sidelem4x979">
				<sec_title>Uses:</sec_title>
				<para>Alcohol abstinence management</para>
			</section>
			<section type="contra" id="sidelem4x984">
				<sec_title>Contraindications</sec_title>
				<para>Hypersensitivity to this product or sulfites, creatinine clearance ≤30 ml/min</para>
				<section type="none" id="sidelem4x989">
					<section type="none" id="sidelem4x990">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, infants, children, ethanol intoxication, renal impairment, depression, suicidal ideation, driving or operating machinery, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x995">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1003">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1003">
							<item>
								<label>•</label>
								<para> 666 mg tid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1007">
					<section type="none" id="sidelem4x1008">
						<sec_title>Renal dosage</sec_title>
						<section type="none" id="sidelem4x1016">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-50 ml/min 333 mg tid; CCr &lt;30 ml/min do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1019">
						<sec_title>Available forms:</sec_title>
						<para> Del-rel tabs 333 mg</para>
					</section>
					<section type="none" id="sidelem4x1024">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1028">
								<item>
									<label>•</label>
									<para>Without regard to food; do not crush, chew, break del-rel tab</para>
								</item>
								<item>
									<label>•</label>
									<para>Use only after alcohol is stopped</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1044">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1047">
					<section type="none" id="sidelem4x1048">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, depression, dizziness, headache, insomnia, paresthesias, <emphasis style="bold">suicidal ideation,</emphasis> tremors, abnormal thoughts, chills, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x1056">
						<sec_title>CV:</sec_title>
						<para> Palpitations, hypertension, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x1061">
						<sec_title>EENT:</sec_title>
						<para> Rhinitis, pharyngitis, abnormal vision</para>
					</section>
					<section type="none" id="sidelem4x1066">
						<sec_title>GI:</sec_title>
						<para> Anorexia, constipation, diarrhea, dry mouth, abdominal pain, flatulence, nausea, vomiting, taste change, weight gain</para>
					</section>
					<section type="none" id="sidelem4x1071">
						<sec_title>GU:</sec_title>
						<para> Impotence</para>
					</section>
					<section type="none" id="sidelem4x1076">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, increased sweating</para>
					</section>
					<section type="none" id="sidelem4x1081">
						<sec_title>MISC:</sec_title>
						<para> Infection, flulike symptoms</para>
					</section>
					<section type="none" id="sidelem4x1086">
						<sec_title>MS:</sec_title>
						<para> Back pain, myalgias, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x1091">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, bronchitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1096">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3-8 hr, half-life 20-33 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1101">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1104">
					<section type="none" id="sidelem4x1105">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, blood glucose, bilirubin, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1116">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1119">
					<section type="none" id="sidelem4x1120">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1128">
							<label>•</label>
							<sec_title>Mental status<route> depression, abnormal thinking, suicidal thoughts/behaviors, length of alcohol use, date of discontinuing alcohol use</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1131">
								<item>
									<label>•</label>
									<para>B/P baseline and periodically</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1136">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1140">
								<item>
									<label>•</label>
									<para>Therapeutic response: continued alcohol abstinence</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1146">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x1154">
							<label>•</label>
							<sec_title>
								<route>suicidal thoughts/behaviors</route>
							</sec_title>
							<para>
								<list id="lidelem4x1154">
									<item>
										<label>•</label>
										<para>To notify prescriber of depression, abnormal thoughts, </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1158">
								<item>
									<label>•</label>
									<para>To take without regard to food; not to break, crush, chew del-rel tabs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1163">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; to use effective contraception</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1168">
								<item>
									<label>•</label>
									<para>Not to engage in hazardous activities until effect is known, may impair thinking, monitor skills</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1173">
								<item>
									<label>•</label>
									<para>Not to use alcohol, continue treatment for alcohol addiction</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>acarbose (Rx)</mono_name>
			<info>
				<pronunciation>(ay-car′bose)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x11832">
						<country code="CAN">Glucobay</country>
					</tradename>
					<tradename id="tnidelem4x11831">
						<country code="CAN">Prandase</country>
					</tradename>
					<tradename id="tnidelem4x11830">Precose</tradename>
				</tradenames>
				<class type="func"> Oral antidiabetic</class>
				<class type="chem"> α-Glucosidase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1199">
				<para>
					<confusion>
						<tradename id="tnidelem4x11990">Precose</tradename>
						<drug type="generic" refid="idelem4x11990">preCare</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1203">
				<sec_title>Action:</sec_title>
				<para>Delays digestion/absorption of ingested carbohydrates by inhibiting α-glucosidase, results in smaller rise in postprandial blood glucose after meals; does not increase insulin production</para>
			</section>
			<section type="uses" id="sidelem4x1210">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus, alone or in combination with a sulfonylurea, metformin, insulin</para>
				<section type="none" id="sidelem4x1215">
					<section type="none" id="sidelem4x1216">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Adjunct in type 1 diabetes mellitus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1221">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity, diabetic ketoacidosis, cirrhosis, inflammatory bowel disease, ileus, colonic ulceration, partial intestinal obstruction, chronic intestinal disease, serum creatinine &gt;2 mg/dl, CCr &lt;25 ml/min</para>
				<section type="none" id="sidelem4x1226">
					<section type="none" id="sidelem4x1227">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), children, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1232">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1240">
					<label>•</label>
					<sec_title>Adult &gt;60 kg (&gt;132 lb)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1240">
							<item>
								<label>•</label>
								<para> 25 mg tid initially, with 1st bite of meal; maintenance dose may be increased to 50-100 mg tid; dosage adjustment at 4- to 8-wk intervals, individualized</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1247">
					<label>•</label>
					<sec_title>Adult &lt;60 kg (&lt;132 lb)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1247">
							<item>
								<label>•</label>
								<para> max 50 mg tid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1251">
					<section type="none" id="sidelem4x1252">
						<sec_title>Type 1 diabetes mellitus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1260">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1260">
									<item>
										<label>•</label>
										<para> 50 mg tid with meals × 2 wk, then 100 mg tid with meals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1264">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x1269">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1272">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1276">
									<item>
										<label>•</label>
										<para>With 1st bite of each meal 3×/day</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in a tight container, cool environment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1287">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1290">
					<section type="none" id="sidelem4x1291">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain, diarrhea, flatulence</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1298">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Poor systemic absorption, peak 1 hr, duration 2-4 hr, metabolized in GI tract, excreted as intact product in urine, half-life 2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1303">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x1307">
						<item>
							<label>•</label>
							<para>Do not use with gatifloxacin</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> acetaminophen toxicity—acetaminophen combined with alcohol</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> glycemic control—androgens, lithium, bortezomib, quinolones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—sulfonylureas, insulin, MAOIs, salicylates, fibric acid derivatives, bile acid sequestrants, ACE inhibitors, angiotensin II receptor antagonists, β-blockers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect, increase hyperglycemia—digestive enzymes, intestinal absorbents, thiazide diuretics, loop diuretics, corticosteroids, estrogen, progestins, oral contraceptives, sympathomimetics, isoniazid, phenothiazines; protease inhibitors, atypical antipsychotics, carbonic anhydrase inhibitors, cycloSPORINE, tacrolimus, baclofen</para>
				<section type="none" id="sidelem4x1333">
					<section type="none" id="sidelem4x1334">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypoglycemia—chromium, garlic, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x1341">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, vit B<emphasis style="inf">6</emphasis>, Hgb, Hct</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> urine glucose tests, 1,5-AG assay</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1359">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1362">
					<section type="none" id="sidelem4x1363">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1371">
							<label>•</label>
							<sec_title>
								<route>Hypoglycemia</route>
							</sec_title>
							<para>
								<list id="lidelem4x1371">
									<item>
										<label>•</label>
										<para> (weakness, hunger, dizziness, tremors, anxiety, tachycardia, sweating), hyperglycemia; even though product does not cause hypoglycemia, if patient is on sulfonylureas or insulin, hypoglycemia may be additive; if hypoglycemia occurs, treat with dextrose, or, if severe, with IV glucose or glucagon</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1375">
								<item>
									<label>•</label>
									<para>For stress, surgery, or other trauma that may require change in dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1380">
								<item>
									<label>•</label>
									<para>Monitor AST, ALT q3mo × 1 yr and periodically thereafter; if elevated, dose may need to be reduced or discontinued, usually increased with doses ≥300 mg/day; dose-related elevations may occur and patients are usually asymptomatic; if symptomatic, dosage reduction or withdrawal is needed; A1c q3mo, monitor serum glucose, 1 hr PP throughout treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1385">
								<item>
									<label>•</label>
									<para>GI side effects for tolerability/compliance</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1390">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1394">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved signs/symptoms of diabetes mellitus (decreased polyuria, polydipsia, polyphagia; clear sensorium, absence of dizziness, stable gait)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1402">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1406">
								<item>
									<label>•</label>
									<para>The symptoms of hypo/hyperglycemia; what to do about each</para>
								</item>
								<item>
									<label>•</label>
									<para>That medication must be taken as prescribed; that must be taken with food; explain consequences of discontinuing medication abruptly; that insulin may need to be used for stress, including trauma, surgery, fever</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid medications and herbal supplements unless approved by health care provider</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that the diet and exercise regimen must be followed; that this product is not a cure</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID and a glucose source; to avoid sugar, because sugar is blocked by acarbose</para>
								</item>
								<item>
									<label>•</label>
									<para>That blood glucose monitoring is required to assess product effect</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid breastfeeding if using acarbose with other antidiabetics</para>
								</item>
								<item>
									<label>•</label>
									<para>That GI side effects may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>acetaminophen (OTC) (Paracetamol)</mono_name>
			<info>
				<pronunciation>(a-seat-a-mee′noe-fen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x145238">
						<country code="CAN">222AF</country>
					</tradename>
					<tradename id="tnidelem4x145237">
						<country code="CAN">Abenol</country>
					</tradename>
					<tradename id="tnidelem4x145236">Acephen</tradename>
					<tradename id="tnidelem4x145235">
						<country code="CAN">ACET</country>
					</tradename>
					<tradename id="tnidelem4x145234">
						<country code="CAN">Acetab</country>
					</tradename>
					<tradename id="tnidelem4x145233">Apacet</tradename>
					<tradename id="tnidelem4x145232">APAP</tradename>
					<tradename id="tnidelem4x145231">Apra</tradename>
					<tradename id="tnidelem4x145230">
						<country code="CAN">Atasol</country>
					</tradename>
					<tradename id="tnidelem4x145229">Children’s FeverAll</tradename>
					<tradename id="tnidelem4x145228">Equaline Children’s Pain Relief</tradename>
					<tradename id="tnidelem4x145227">Equaline Infant’s Pain Relief</tradename>
					<tradename id="tnidelem4x145226">
						<country code="CAN">Fortolin</country>
					</tradename>
					<tradename id="tnidelem4x145225">Genapap</tradename>
					<tradename id="tnidelem4x145224">GoodSense Acetaminophen</tradename>
					<tradename id="tnidelem4x145223">GoodSense Children’s Pain Relief</tradename>
					<tradename id="tnidelem4x145222">Infantaire</tradename>
					<tradename id="tnidelem4x145221">Leader Children’s Pain Reliever</tradename>
					<tradename id="tnidelem4x145220">Mapap</tradename>
					<tradename id="tnidelem4x145219">NeoPAP</tradename>
					<tradename id="tnidelem4x145218">
						<country code="CAN">Novo-Gesic</country>
					</tradename>
					<tradename id="tnidelem4x145217">Ofirmev</tradename>
					<tradename id="tnidelem4x145216">
						<country code="CAN">Pediaphen</country>
					</tradename>
					<tradename id="tnidelem4x145215">
						<country code="CAN">Pediatrix</country>
					</tradename>
					<tradename id="tnidelem4x145214">Q-Pap</tradename>
					<tradename id="tnidelem4x145213">Q-Pap Children’s</tradename>
					<tradename id="tnidelem4x145212">
						<country code="CAN">Rapid Action Relief</country>
					</tradename>
					<tradename id="tnidelem4x145211">Redutemp</tradename>
					<tradename id="tnidelem4x145210">Ridenol</tradename>
					<tradename id="tnidelem4x14529">
						<country code="CAN">Robigesic</country>
					</tradename>
					<tradename id="tnidelem4x14528">
						<country code="CAN">Rounox</country>
					</tradename>
					<tradename id="tnidelem4x14527">Silapap</tradename>
					<tradename id="tnidelem4x14526">
						<country code="CAN">Taminol</country>
					</tradename>
					<tradename id="tnidelem4x14525">
						<country code="CAN">Tempra</country>
					</tradename>
					<tradename id="tnidelem4x14524">T-Painol</tradename>
					<tradename id="tnidelem4x14523">Tylenol</tradename>
					<tradename id="tnidelem4x14522">
						<country code="CAN">Vick’s Custom Care Body Aches</country>
					</tradename>
					<tradename id="tnidelem4x14521">Walgreen’s Non-Aspirin</tradename>
					<tradename id="tnidelem4x14520">XS pain reliever</tradename>
				</tradenames>
				<class type="func"> Nonopioid analgesic, antipyretic</class>
				<class type="chem"> Nonsalicylate, paraaminophenol derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x1507">
				<sec_title>Action:</sec_title>
				<para>May block pain impulses peripherally that occur in response to inhibition of prostaglandin synthesis; does not possess antiinflammatory properties; antipyretic action results from inhibition of prostaglandins in the CNS (hypothalamic heat-regulating center)</para>
			</section>
			<section type="uses" id="sidelem4x1512">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate pain or fever, arthralgia, dental pain, dysmenorrhea, headache, myalgia, osteoarthritis</para>
				<section type="none" id="sidelem4x1517">
					<section type="none" id="sidelem4x1518">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Migraine</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1523">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or phenacetin</para>
				<section type="none" id="sidelem4x1529">
					<section type="none" id="sidelem4x1530">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), (C) IV; breastfeeding, geriatric patients, anemia, renal/hepatic disease, chronic alcoholism</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1535">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1543">
					<label>•</label>
					<sec_title>Adult/child &gt;12 yr<route> PO/RECT</route></sec_title>
					<para>
						<list id="lidelem4x1543">
							<item>
								<label>•</label>
								<para> 325-650 mg q4-6hr prn, max 4 g/day; weight ≥50 kg IV 1000 mg q6hr or 650 mg q4hr prn, max single dose 1000 mg, min dosing interval 4 hr; weight &lt;50 kg IV 15 mg/kg/dose q6hr or 12.5 mg/kg/dose q4hr, max single dose 15 mg/kg, min dosing interval 4 hr, max 75 mg/kg/day from all sources, ext rel 650-1300 mg q8hr as needed, max 4 g/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1550">
					<label>•</label>
					<sec_title>Child ≥2 yr and &lt;50 kg<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x1550">
							<item>
								<label>•</label>
								<para> 15 mg/kg/dose q6hr or 12.5 mg/kg/dose q4hr, max single dose 15 mg/kg, min dosing interval 4 hr, max 75 mg/kg/day from all sources</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1554">
					<section type="none" id="sidelem4x1555">
						<sec_title>Migraine (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1563">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO/RECT</route></sec_title>
							<para>
								<list id="lidelem4x1563">
									<item>
										<label>•</label>
										<para> 500-1000 mg, max 1 g/dose or max 4 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1567">
						<sec_title>Available forms:</sec_title>
						<para> Rect supp 120, 325, 650 mg; soft chew tabs 80 mg; caps 500 mg; elix 120, 160, 325 mg/5 ml; oral disintegrating tab 80, 160 ml; oral drops 80 mg/0.8 ml, liquid 500 mg/5 ml, 160/5 ml, 1000/30 ml; ext rel 650 mg, 80 mg/ml; tabs 325, 500, 650 mg; sol for inj 1000 mg/100 ml</para>
					</section>
					<section type="none" id="sidelem4x1572">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1575">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1579">
									<item>
										<label>•</label>
										<para>Do not confuse 2 × 325 (650 mg), with 650 mg ER tab</para>
									</item>
									<item>
										<label>•</label>
										<para>Crushed or whole, do not crush EXT REL product; chewable tabs may be chewed; give with full glass of water</para>
									</item>
									<item>
										<label>•</label>
										<para>With food or milk to decrease gastric symptoms if needed</para>
									</item>
									<item>
										<label>•</label>
										<para>Susp after shaken well; check elixir, liquid, suspension concentration carefully; susp and cups are bioequivalent</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1600">
							<sec_title>Rectal route</sec_title>
							<para>
								<list id="lidelem4x1604">
									<item>
										<label>•</label>
										<para>Store suppositories &lt;80° F (27° C)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1610">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1614">
									<item>
										<label>•</label>
										<para>No further dilution needed; do not add other medications to vial or infusion device</para>
									</item>
									<item>
										<label>•</label>
										<para>For doses equal to single vial, averted IV set may be used to deliver directly from vial; for doses less than a single vial, withdraw dose and place in an empty sterile syringe, plastic IV container, or glass bottle; infuse over 15 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard unused portion; if seal is broken, vial penetrated, or drug transferred to another container, give within 6 hr
<bbw>Check IV dose carefully to prevent dosing errors</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1639">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1642">
					<section type="none" id="sidelem4x1643">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, abdominal pain; <emphasis style="bold">hepatotoxicity, hepatic seizure (overdose), GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1650">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure (high, prolonged doses)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1657">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, neutropenia, hemolytic anemia (long-term use), thrombocytopenia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1664">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, inj site pain</para>
					</section>
					<section type="none" id="sidelem4x1669">
						<sec_title>SYST:</sec_title>
						<para>
							<emphasis alert="lifethreat"> Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x1675">
						<sec_title>TOXICITY:</sec_title>
						<para> <emphasis style="bold">Cyanosis, anemia, neutropenia, jaundice, pancytopenia, CNS stimulation, delirium followed by vascular collapse, seizures, coma, death</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1682">
				<sec_title>Pharmacokinetics</sec_title>
				<para>85%-90% metabolized by liver, excreted by kidneys; metabolites may be toxic if overdose occurs; widely distributed; crosses placenta in low concentrations; excreted in breast milk; half-life 1-4 hr</para>
				<section type="none" id="sidelem4x1687">
					<section type="none" id="sidelem4x1688">
						<sec_title>PO:</sec_title>
						<para> Onset 10-30 min, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr, duration 4-6 hr, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x1699">
						<sec_title>IV:</sec_title>
						<para> Peak 30-120 min</para>
					</section>
					<section type="none" id="sidelem4x1704">
						<sec_title>RECT:</sec_title>
						<para> Onset slow, peak 1-2 hr, duration 4-6 hr, absorption varies</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1709">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x1713">
						<item>
							<label>•</label>
							<para>Avoid use with salicylates</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> renal adverse reactions—NSAIDs, salicylates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoprothrombinemia—warfarin, long-term use, high doses of acetaminophen</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hepatotoxicity—barbiturates, alcohol, carBAMazepine, hydantoins, rifampin, rifabutin, isoniazid, diflunisal, zidovudine, lamoTRIgine, imatinib, dasatinib, mipomersen</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—colestipol, cholestyramine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> zidovudine effect</para>
				<section type="none" id="sidelem4x1740">
					<section type="none" id="sidelem4x1741">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> heptatotoxicity—St. John’s wort, due to acetaminophen metabolism</para>
					</section>
					<section type="none" id="sidelem4x1748">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> urinary 5-HIAA</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, potassium, bilirubin, LDH, pro-time</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct, WBC, RBC, platelets; albumin, magnesium, phosphate (pediatrics)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1763">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1766">
					<section type="none" id="sidelem4x1767">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1775">
							<label>•</label>
							<sec_title>Hepatic studies</sec_title>
							<para>
								<list id="lidelem4x1775">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic studies:</emphasis> AST, ALT, bilirubin, creatinine before therapy if long-term therapy is anticipated; may cause hepatic toxicity at doses &gt;4 g/day with chronic use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1782">
							<label>•</label>
							<sec_title>Renal studies</sec_title>
							<para>
								<list id="lidelem4x1782">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Renal studies:</emphasis> BUN, urine creatinine, occult blood, albumin, if patient is on long-term therapy; presence of blood or albumin indicates nephritis</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1789">
							<label>•</label>
							<sec_title>Blood studies</sec_title>
							<para>
								<list id="lidelem4x1789">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blood studies:</emphasis> CBC, PT if patient is on long-term therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1793">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; decreasing output may indicate renal failure (long-term therapy)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1801">
							<label>•</label>
							<sec_title>For fever and pain</sec_title>
							<para>
								<list id="lidelem4x1801">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For fever and pain:</emphasis> type of pain, location, intensity, duration</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1808">
							<label>•</label>
							<sec_title>Chronic poisoning<route> rapid, weak pulse; dyspnea; cold, clammy extremities; report immediately to prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1823">
							<label>•</label>
							<sec_title>Potentially fatal hypersensitivity<route> Allergic reactions</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1829">
							<label>•</label>
							<sec_title>
								<route>Stevens-Johnson syndrome, toxic epidermal necrolysis may occur during beginning treatment or any other dose</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1832">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1836">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain using pain scoring; fever</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1842">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Not to exceed recommended dosage; the elixir, liquid, suspension come in several concentrations, read label carefully; acute poisoning with liver damage may result; tell parents of children to check products carefully; that acute toxicity includes symptoms of nausea, vomiting, abdominal pain and that prescriber should be notified immediately; that toxicity may occur when used with other combination products</bbw>
						</para>
						<para>
							<list id="lidelem4x1858">
								<item>
									<label>•</label>
									<para>Not to use with alcohol, herbals, OTC products without approval of prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1863">
								<item>
									<label>•</label>
									<para>May be used when breastfeeding, short-term</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1871">
							<label>•</label>
							<sec_title>To recognize signs of chronic overdose<route> bleeding, bruising, malaise, fever, sore throat</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1874">
								<item>
									<label>•</label>
									<para>That those with diabetes may notice blood glucose monitoring changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1879">
								<item>
									<label>•</label>
									<para>To notify prescriber of pain or fever lasting more than 3 days, not to be used in patients &lt;2 yr unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x1884">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Product level, gastric lavage, activated charcoal; administer oral acetylcysteine to prevent hepatic damage <emphasis style="italic">(see acetylcysteine monograph)</emphasis>; monitor for bleeding</para>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>acetaZOLAMIDE (Rx)</mono_name>
			<info>
				<pronunciation>(a-set-a-zole′a-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x18971">
						<country code="CAN">Diamox</country>
					</tradename>
					<tradename id="tnidelem4x18970">
						<country code="CAN">Novo-Zolamide</country>
					</tradename>
				</tradenames>
				<class type="func"> Diuretic, carbonic anhydrase inhibitor, antiglaucoma agent, antiepileptic</class>
				<class type="chem"> Sulfonamide derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1912">
				<para>
					<confusion>
						<tradename id="tnidelem4x19120">acetaZOLAMIDE</tradename>
						<drug type="generic" refid="idelem4x19120">acetoHEXAMIDE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1919">
				<sec_title>Action:</sec_title>
				<para>Inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate resulting in increased urine volume and alkalinization of urine; decreases carbonic anhydrase in CNS, increasing seizure threshold; able to decrease secretion of aqueous humor in eye, which lowers intraocular pressure</para>
			</section>
			<section type="uses" id="sidelem4x1926">
				<sec_title>Uses:</sec_title>
				<para>Open-angle glaucoma, angle-closure glaucoma (preoperatively, if surgery delayed), mixed, tonic-clonic, myoclonic, refractory, epilepsy (petit mal, grand mal, absence), edema in CHF, product-induced edema, acute altitude sickness</para>
				<section type="none" id="sidelem4x1931">
					<section type="none" id="sidelem4x1932">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Urine alkalinization, metabolic alkalosis in mechanical ventilation, decrease CSF production in infants with hydrocephalus, familial periodic paralysis, nystagmus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1937">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sulfonamides, severe renal/hepatic disease, electrolyte imbalances (hyponatremia, hypokalemia), hyperchloremic acidosis, Addison’s disease, long-term use for closed-angle glaucoma, adrenocortical insufficiency, metabolic acidosis, acidemia, anuria</para>
				<section type="none" id="sidelem4x1942">
					<section type="none" id="sidelem4x1943">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, hypercalciuria, respiratory acidosis, pulmonary obstruction/emphysema, COPD</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1948">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1951">
					<section type="none" id="sidelem4x1952">
						<sec_title>Angle-closure glaucoma</sec_title>
						<section type="none" id="sidelem4x1960">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x1960">
									<item>
										<label>•</label>
										<para> 250 mg q4hr or 250 mg bid for short-term therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1964">
						<sec_title>Chronic open-angle glaucoma</sec_title>
						<section type="none" id="sidelem4x1972">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x1972">
									<item>
										<label>•</label>
										<para> 250 mg 1-4 times per day or 500 mg  bid, max 1 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1982">
							<label>•</label>
							<sec_title>Child (Unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1982">
									<item>
										<label>•</label>
										<para> 8-30 mg/kg/day in divided doses tid or qid, or 300-900 mg/m<emphasis style="sup">2</emphasis>/day, max 1 g/day;  5-10 mg q6hr, max 1 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1992">
						<sec_title>Edema in CHF</sec_title>
						<section type="none" id="sidelem4x2000">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x2000">
									<item>
										<label>•</label>
										<para> 250-375 mg/day or 5 mg/kg in <emphasis style="smallcaps">am</emphasis>, give for 2 days, then 1-2 days drug free</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2010">
							<label>•</label>
							<sec_title>Child (Unlabeled)<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x2010">
									<item>
										<label>•</label>
										<para> 5 mg/kg/day or 150 mg/m<emphasis style="sup">2</emphasis> in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2019">
						<sec_title>Seizures</sec_title>
						<section type="none" id="sidelem4x2027">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x2027">
									<item>
										<label>•</label>
										<para> 8-30 mg/kg/day, in 1-4 divided doses, usual range 375-1000 mg/day;  not recommended with seizures</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2034">
						<sec_title>Altitude sickness</sec_title>
						<section type="none" id="sidelem4x2042">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2042">
									<item>
										<label>•</label>
										<para> 125 mg bid, start therapy 24-48 hr before ascent and give for ≥48 hr after arrival at high altitude</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2049">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2049">
									<item>
										<label>•</label>
										<para> 250 mg bid, use lowest effective dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2053">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2061">
							<label>•</label>
							<sec_title>Adult<route> PO/IV CCr 50-80 ml/min give dose ≥q6hr regular release or IV; CCr 10-50 ml/min give dose q12hr; CCr &lt;10 ml/min, avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2064">
						<sec_title>Urine alkalinization (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2072">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x2072">
									<item>
										<label>•</label>
										<para> 5 mg/kg/dose, repeat 2-3× over 24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2076">
						<sec_title>Familial periodic paralysis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2084">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2084">
									<item>
										<label>•</label>
										<para> 250-375 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2088">
						<sec_title>Metabolic alkalosis in mechanical ventilation (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2096">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x2096">
									<item>
										<label>•</label>
										<para> 500 mg as a single dose or 250 mg q6hr × 4 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2100">
						<sec_title>Vestibular nystagmus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2108">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2108">
									<item>
										<label>•</label>
										<para> 250 mg, increase by 250 mg q3days; max 3 g/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2112">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 125, 250 mg; ext rel caps 500 mg; inj 500 mg</para>
					</section>
					<section type="none" id="sidelem4x2117">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2121">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> to avoid interference with sleep if using product as diuretic</para>
								</item>
								<item>
									<label>•</label>
									<para>Potassium replacement if potassium level is &lt;3 mg/dl</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2135">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x2139">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew ext rel caps; this product should be used for altitude sickness, glaucoma; store at room temperature</para>
									</item>
									<item>
										<label>•</label>
										<para>With food if nausea occurs; absorption may be decreased slightly</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2150">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x2158">
								<label>•</label>
								<sec_title>direct IV</sec_title>
								<para>
									<list id="lidelem4x2158">
										<item>
											<label>•</label>
											<para>Reconstitute with 500 mg in ≥5 ml sterile water for inj; <emphasis style="bold">direct IV:</emphasis> give at 100-500 mg/min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x2163">
									<item>
										<label>•</label>
										<para>Store in cool, dark area; use reconstituted solution within 24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2168">
						<sec_title>Additive compatibilities:</sec_title>
						<para>cimetidine, ranitidine</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2174">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2177">
					<section type="none" id="sidelem4x2178">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, <emphasis style="italic">confusion,</emphasis><emphasis style="bold">seizures,</emphasis><emphasis style="italic">depression,</emphasis> dizziness, <emphasis style="italic">drowsiness, fatigue,</emphasis> headache, <emphasis style="italic">paresthesia,</emphasis> stimulation</para>
					</section>
					<section type="none" id="sidelem4x2196">
						<sec_title>EENT:</sec_title>
						<para> Myopia, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x2201">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="italic">Hyper/hypoglycemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2208">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea,</emphasis> melena, <emphasis style="italic">weight loss,</emphasis><emphasis style="bold">hepatic insufficiency, cholestatic jaundice, fulminant hepatic necrosis,</emphasis><emphasis style="italic">taste alterations,</emphasis><emphasis style="bold">bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2224">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Frequency, polyuria,</emphasis><emphasis style="bold">uremia,</emphasis> glucosuria, hematuria, dysuria, crystalluria, renal calculi</para>
					</section>
					<section type="none" id="sidelem4x2234">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Aplastic anemia, hemolytic anemia, leukopenia, thrombocytopenia, purpura, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2241">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus, urticaria, fever, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> photosensitivity, flushing, <emphasis style="bold">toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2254">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hypokalemia, hyperchloremic acidosis,</emphasis> hyponatremia, sulfonamide-like reactions, metabolic acidosis, growth inhibition in children, hyperuricemia, hypercalcemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2262">
				<sec_title>Pharmacokinetics</sec_title>
				<para>65% absorbed if fasting (oral), 75% absorbed if given with food; half-life 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-5<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; excreted unchanged by kidneys (80% within 24 hr), crosses placenta</para>
				<section type="none" id="sidelem4x2279">
					<section type="none" id="sidelem4x2280">
						<sec_title>PO:</sec_title>
						<para> Onset 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, peak 1-4 hr, duration 8-12 hr</para>
					</section>
					<section type="none" id="sidelem4x2291">
						<sec_title>PO-EXT REL:</sec_title>
						<para> Onset 2 hr, peak 3-6 hr, duration 18-24 hr</para>
					</section>
					<section type="none" id="sidelem4x2296">
						<sec_title>IV:</sec_title>
						<para> Onset 2 min, peak 15 min, duration 4-5 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2301">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of—amphetamines, flecainide, memantine, phenytoin, procainamide, quiNIDine, anticholinergics, methenamine, mecamylamine, ePHEDrine, memantine, mexiletine, folic acid antagonists</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> excretion of lithium, primidone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> acidosis (respiratory disorders)—β-blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> osteomalacia—carBAMazepine, ethotoin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—salicylates, cycloSPORINE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—corticosteroids, amphotericin B, corticotropin, ACTH</para>
				<para>
					<emphasis alert="lifethreat">Increase: cardiac toxicity if hypokalemia develops—arsenic trioxide, cardiac glycosides, levomethadyl</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> renal stone formation, heat stroke—topiramate (avoid concurrent use)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> primidone levels</para>
				<section type="none" id="sidelem4x2339">
					<section type="none" id="sidelem4x2340">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> thyroid iodine uptake, sodium, Hct/Hgb, WBC, platelets</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urinary protein, 17 hydroxysteroid</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2355">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2358">
					<section type="none" id="sidelem4x2359">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Severe reactions:</emphasis> Stevens-Johnson syndrome, toxic epidermal necrolysis, blood dyscrasias, discontinue if these occur</bbw>
						</para>
						<para>
							<list id="lidelem4x2376">
								<item>
									<label>•</label>
									<para>Edema: weight daily, I&amp;O daily to determine fluid loss; effect of product may be decreased if used daily; monitor geriatric patients for dehydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2381">
								<item>
									<label>•</label>
									<para>Ocular status: intraocular pressure, ophthalmologic examination</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2386">
								<item>
									<label>•</label>
									<para>B/P lying, standing; postural hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2391">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chloride; also BUN, blood glucose, CBC, serum creatinine, blood pH, ABGs, LFTs; I&amp;O, platelet count, patient may need to be on a high-potassium diet; identify signs of hypokalemia (vomiting, fatigue, weakness)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2399">
							<label>•</label>
							<sec_title>Seizures<route> neurologic status, provide seizure precaution</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2402">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2406">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in edema of feet, legs, sacral area daily if medication is being used for CHF; decrease in aqueous humor if medication is being used for glaucoma; decreased frequency of seizures, prevention of altitude sickness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2412">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2417">
								<item>
									<label>•</label>
									<para>To take exactly as prescribed; if dose is missed, take as soon as remembered; do not double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2423">
								<item>
									<label>•</label>
									<para>Altitude sickness: to avoid rapid ascent</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2428">
								<item>
									<label>•</label>
									<para>Diabetic: that drug may alter blood glucose and to monitor blood glucose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2433">
								<item>
									<label>•</label>
									<para>To use sunscreen to prevent photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2438">
								<item>
									<label>•</label>
									<para>To avoid prolonged sun exposure</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2443">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsiness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2448">
								<item>
									<label>•</label>
									<para>To increase fluids to 2-3 L/day if not contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2454">
								<item>
									<para>
										<emphasis alert="nurse">To report nausea, vertigo, rapid weight gain, change in stools, weakness, numbness, rash, sore throat, bleeding/bruising; Stevens-Johnson syndrome, toxic epidermal necrolysis (blistering, red rash that spreads)</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x2459">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if taken orally; monitor electrolytes; administer dextrose in saline; monitor hydration, CV, renal status</para>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>acetylcholine ophthalmic</mono_name>
			<section type="none" id="sidelem4x2467">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>acetylcysteine (Rx)</mono_name>
			<info>
				<pronunciation>(a-se-teel-sis′tay-een)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24763">Acetadote</tradename>
					<tradename id="tnidelem4x24762">
						<country code="CAN">Airbron</country>
					</tradename>
					<tradename id="tnidelem4x24761">
						<country code="CAN">Mucomyst </country>
					</tradename>
					<tradename id="tnidelem4x24760">
						<country code="CAN">Parvolex</country>
					</tradename>
				</tradenames>
				<class type="func"> Mucolytic; antidote—acetaminophen</class>
				<class type="chem"> Amino acid -cysteine</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2497">
				<para>
					<confusion>
						<tradename id="tnidelem4x24970">acetylcysteine</tradename>
						<drug type="generic" refid="idelem4x24970">acetylcholine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2504">
				<sec_title>Action:</sec_title>
				<para>Decreases viscosity of secretions by breaking disulfide links of mucoproteins; serves as a substrate in place of glutathione, which is necessary to inactivate toxic metabolites with acetaminophen overdose</para>
			</section>
			<section type="uses" id="sidelem4x2509">
				<sec_title>Uses:</sec_title>
				<para>Acetaminophen toxicity; bronchitis; cystic fibrosis; COPD; atelectasis</para>
				<section type="none" id="sidelem4x2514">
					<section type="none" id="sidelem4x2515">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Prevention of contrast medium nephrotoxicity, meconium ileus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2520">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x2525">
					<section type="none" id="sidelem4x2526">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, hypothyroidism, Addison’s disease, CNS depression, brain tumor, asthma, renal/hepatic disease, COPD, psychosis, alcoholism, seizure disorders, bronchospasms, anaphylactoid reactions, fluid restriction, weight &lt;40 kg, increased intracranial pressure, status asthmaticus</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2531">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2534">
					<section type="none" id="sidelem4x2535">
						<sec_title>Acetaminophen toxicity</sec_title>
						<section type="none" id="sidelem4x2543">
							<label>•</label>
							<sec_title>Adult and child &gt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2543">
									<item>
										<label>•</label>
										<para> 140 mg/kg, then 70 mg/kg q4hr × 17 doses to total of 1330 mg/kg;  loading dose 150 mg/kg over 60 min (dilution 150 mg/kg in 200 ml of D<emphasis style="inf">5</emphasis>W); then 50 mg/kg over 4 hr (dilution 50 mg/kg in 500 ml D<emphasis style="inf">5</emphasis>W); then 100 mg/kg over 16 hr (dilution 100 mg/kg in 1000 D<emphasis style="inf">5</emphasis>W)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2562">
							<label>•</label>
							<sec_title>Child/Adolescent 21-40 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x2562">
									<item>
										<label>•</label>
										<para> 150 mg/kg in 100 ml diluent over 1 hr, then 50 mg/kg in 250 ml over 4 hr, then 100 mg/kg in 500 mg over 16 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2569">
							<label>•</label>
							<sec_title>Infant/Child 5-20 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x2569">
									<item>
										<label>•</label>
										<para> 150 mg/kg in 3 ml/kg diluent over 1 hr, then 50 mg/kg in 7 ml/kg diluent over 4 hr, then 100 mg/kg in 14 ml/kg diluent over 16 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2573">
						<sec_title>Mucolytic</sec_title>
						<section type="none" id="sidelem4x2581">
							<label>•</label>
							<sec_title>Adult and child<route> INSTILL</route></sec_title>
							<para>
								<list id="lidelem4x2581">
									<item>
										<label>•</label>
										<para> 1-2 ml (10%-20% sol) q6-8hr prn or 3-5 ml (20% sol) or 6-10 ml (10% sol) tid or qid; nebulization (face mask, mouthpiece, tracheostomy) 1-10 ml of a 20% sol, or 2-20 ml of a 10% sol, q2-8hr; nebulization (tent, croupette) may require large dose, up to 300 ml/treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2585">
						<sec_title>Contrast-induced nephrotoxicity (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2593">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2593">
									<item>
										<label>•</label>
										<para> 600-1200 mg bid × 2 days (beginning the day before the procedure)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2597">
						<sec_title>Available forms:</sec_title>
						<para> Oral sol 10%, 20%; inj 20% (200 mg/ml)</para>
					</section>
					<section type="none" id="sidelem4x2602">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2605">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x2613">
								<label>•</label>
								<sec_title>Antidotal use</sec_title>
								<para>
									<list id="lidelem4x2613">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Antidotal use:</emphasis> give within 24 hr; dilute 10% or 20% sol to a 5% sol with diet soda, may use water if giving via gastric tube; dilution of 10% sol 1:1, 20% sol 1:3, store open undiluted solution refrigerated ≤96 hr</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x2619">
							<sec_title>Direct intratracheal instill route</sec_title>
							<para>
								<list id="lidelem4x2623">
									<item>
										<label>•</label>
										<para>By syringe: 1-2 ml of 10%-20% sol up to q1hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Decreased dose to geriatric patients; metabolism may be slowed ​</para>
									</item>
									<item>
										<label>•</label>
										<para>Only if suction machine is available</para>
									</item>
									<item>
										<label>•</label>
										<para>Only after patient clears airway by deep breathing, coughing</para>
									</item>
									<item>
										<label>•</label>
										<para>Assistance with inhaled dose: bronchodilator if bronchospasm occurs; mechanical suction if cough insufficient to remove excess bronchial secretions</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2649">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x2657">
								<label>•</label>
								<sec_title>21-hr regimen</sec_title>
								<para>
									<list id="lidelem4x2657">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">21-hr regimen:</emphasis> loading dose: dilute 150 mg/kg in 200 ml D<emphasis style="inf">5</emphasis>W; maintenance dose 1: dilute 50 mg/kg in 500 ml D<emphasis style="inf">5</emphasis>W; maintenance dose 2: dilute 100 mg/kg in 1000 ml D<emphasis style="inf">5</emphasis>W; give loading dose over 15 min; give maintenance dose 1 over 4 hr; give maintenance dose 2 over 16 hr, administer sequentially without time between doses</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x2670">
									<item>
										<label>•</label>
										<para>Store in refrigerator; use within 96 hr of opening</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2675">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2678">
					<section type="none" id="sidelem4x2679">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> headache, fever, chills</para>
					</section>
					<section type="none" id="sidelem4x2687">
						<sec_title>CV:</sec_title>
						<para> Hypotension, flushing tachycardia</para>
					</section>
					<section type="none" id="sidelem4x2692">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Rhinorrhea,</emphasis> tooth damage</para>
					</section>
					<section type="none" id="sidelem4x2700">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> stomatitis, constipation, vomiting, anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x2708">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria, rash, fever, clamminess, pruritus</para>
					</section>
					<section type="none" id="sidelem4x2713">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> burning, <emphasis style="bold">hemoptysis,</emphasis> chest tightness, cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x2724">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema,</emphasis> unpleasant odor</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2732">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2735">
					<section type="none" id="sidelem4x2736">
						<sec_title>IV:</sec_title>
						<para> Excreted in urine, half-life 5.6 hr (adult), 11 hr (newborn), protein binding 83%, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2747">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x2751">
						<item>
							<label>•</label>
							<para>Do not use with activated charcoal</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x2757">
				<sec_title>Nursing considerations</sec_title>
				<para/>
				<section type="none" id="sidelem4x2761">
					<section type="none" id="sidelem4x2762">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2770">
							<label>•</label>
							<sec_title>Mucolytic use</sec_title>
							<para>
								<list id="lidelem4x2770">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Mucolytic use:</emphasis> cough—type, frequency, character, including sputum; bronchospasm</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2774">
								<item>
									<label>•</label>
									<para>Rate, rhythm of respirations, increased dyspnea; sputum; discontinue if bronchospasm occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2779">
								<item>
									<label>•</label>
									<para>VS, cardiac status including checking for dysrhythmias, increased rate, palpitations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2784">
								<item>
									<label>•</label>
									<para>ABGs for increased CO<emphasis style="inf">2</emphasis> retention in asthma patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2795">
							<label>•</label>
							<sec_title>Antidotal use</sec_title>
							<para>
								<list id="lidelem4x2795">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Antidotal use:</emphasis> LFTs, PT, BUN, creatinine, glucose, electrolytes, acetaminophen levels; inform prescriber if dose is vomited or vomiting is persistent; 150 mg/kg may be toxic, check acetaminophen level q4hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2802">
							<label>•</label>
							<sec_title>Hypersensitivity<route> Anaphylaxis may occur with IV dose; if present, stop infusion, treat, restart</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2808">
							<label>•</label>
							<sec_title>
								<route>Nausea, vomiting, rash; notify prescriber if these occur</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2811">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2815">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of purulent secretions when coughing, clear lung sounds (mucolytic use); absence of hepatic damage with acetaminophen toxicity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2821">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2825">
								<item>
									<label>•</label>
									<para>That foul odor and smell may be unpleasant</para>
								</item>
								<item>
									<label>•</label>
									<para>To clear airway for inhalation</para>
								</item>
								<item>
									<label>•</label>
									<para>To report vomiting because dose may need to be repeated</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>aclidinium</mono_name>
			<info>
				<pronunciation>(a′kli-din′ee-um)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x28460">Tudorza Pressair</tradename>
				</tradenames>
				<class type="func"> Anticholinergic, bronchodilator</class>
				<class type="chem"> Synthetic quaternary ammonium compound</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2856">
				<sec_title>Action:</sec_title>
				<para>Inhibits interaction of acetylcholine at receptor sites on the bronchial smooth muscle, thereby resulting in decreased cGMP and bronchodilation</para>
			</section>
			<section type="uses" id="sidelem4x2862">
				<sec_title>Uses:</sec_title>
				<para>Long-term maintenance treatment of bronchospasm in COPD, emphysema, chronic bronchitis, not indicated for initial treatment of acute episodes</para>
			</section>
			<section type="contra" id="sidelem4x2867">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x2872">
					<section type="none" id="sidelem4x2873">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, milk sensitivity, contact lenses, narrow-angle glaucoma, neonates, ocular exposure, prostatic hypertrophy, bladder obstruction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2878">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2886">
					<label>•</label>
					<sec_title>Adults, including geriatric patients</sec_title>
					<para>
						<list id="lidelem4x2886">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adults, including geriatric patients:</emphasis> Oral inhalation 400 mcg (1 actuation) bid; doses should be 12 hours apart</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2890">
					<section type="none" id="sidelem4x2891">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inhalation 400 mcg/actuation</para>
					</section>
					<section type="none" id="sidelem4x2896">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2899">
							<sec_title>Oral inhalation route</sec_title>
							<para>
								<list id="lidelem4x2903">
									<item>
										<label>•</label>
										<para>Before initial use, remove inhaler from pouch; remove the cap by squeezing the arrows marked on each side and pulling outward; instruct the patient to hold the inhaler with the mouthpiece facing patient but not inside the mouth; the green button should be facing straight up</para>
									</item>
									<item>
										<label>•</label>
										<para>Before placing the inhaler into the mouth, the green button should be pushed all the way down and then released; patient should not continue to hold it down; once the green button is pressed, the control window changes from red to green, indicating that the medication is ready for inhalation; if the control window remains red, repeat the press-and-release actions until the control window is green</para>
									</item>
									<item>
										<label>•</label>
										<para>Before inhaling the dose, have patient breathe out completely away from the inhaler; patient should never breathe out into the inhaler</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient to put his/her lips tightly around the mouthpiece and to breathe in quickly and deeply through the mouth until a clicking sound is heard</para>
									</item>
									<item>
										<label>•</label>
										<para>The patient should remove the inhaler from the mouth and hold breath for as long as is comfortable, then breathe out slowly through the nose</para>
									</item>
									<item>
										<label>•</label>
										<para>The control window should turn red after the full dose has been inhaled. If it remains green after the dose is inhaled, the inhalation process should be repeated. If correct inhalation has not been achieved after several attempts, the doctor or health care professional should be contacted</para>
									</item>
									<item>
										<label>•</label>
										<para>Once the window has turned red, the protective cap should be placed back onto the inhaler by pressing it back onto the mouthpiece</para>
									</item>
									<item>
										<label>•</label>
										<para>The dose indicator displays how many doses are left. The first time the inhaler is used, the indicator displays the number 60. The indicator number counts down as the patient uses the inhaler</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard inhaler when the marking “0” with red background shows in the middle of the dose indicator, the device locks out after 45 days (whichever comes first); the inhaler does not need to be cleaned</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2949">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2952">
					<section type="none" id="sidelem4x2953">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Anxiety, dizziness, headache,</emphasis> nervousness</para>
					</section>
					<section type="none" id="sidelem4x2961">
						<sec_title>CV:</sec_title>
						<para> Palpitation</para>
					</section>
					<section type="none" id="sidelem4x2966">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth, blurred vision, nasopharyngitis congestion</para>
					</section>
					<section type="none" id="sidelem4x2971">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2978">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x2983">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, worsening of symptoms,</emphasis><emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2992">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 5-8 hr</para>
			</section>
			<section type="interactions" id="sidelem4x2997">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—other bronchodilators</para>
			</section>
			<section type="considerations" id="sidelem4x3004">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3007">
					<section type="none" id="sidelem4x3008">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3012">
								<item>
									<label>•</label>
									<para>Tolerance over long-term therapy; dose might have to be increased or changed</para>
								</item>
								<item>
									<label>•</label>
									<para>Respiratory status: rate, rhythm, auscultate breath sounds before and after administration; pulmonary function tests at baseline and periodically</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3023">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3027">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to breathe adequately</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3034">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3038">
								<item>
									<label>•</label>
									<para>That compliance is necessary with number of inhalations/24 hr or overdose can occur; that max therapeutic effects can take 2-3 mo</para>
								</item>
								<item>
									<label>•</label>
									<para>About the correct method of inhalation</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any visual effects or urinary retention</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>acyclovir (Rx)</mono_name>
			<info>
				<pronunciation>(ay-sye′kloe-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x30591">Sitavig</tradename>
					<tradename id="tnidelem4x30590">Zovirax</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Purine nucleoside analog</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3069">
				<para>
					<confusion>
						<tradename id="tnidelem4x30690">Zovirax</tradename>
						<drug type="generic" refid="idelem4x30690">Zyvox/Valtrex/Zostrix</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3073">
				<sec_title>Action:</sec_title>
				<para>Interferes with DNA synthesis by conversion to acyclovir triphosphate, thereby causing decreased viral replication</para>
			</section>
			<section type="uses" id="sidelem4x3078">
				<sec_title>Uses:</sec_title>
				<para>Mucocutaneous herpes simplex virus, herpes genitalis (HSV-1, HSV-2), varicella infections, herpes zoster, herpes simplex encephalitis</para>
				<section type="none" id="sidelem4x3083">
					<section type="none" id="sidelem4x3084">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bell’s palsy, prevention of CMV, Epstein-Barr virus, esophagitis, hairy leukoplakia, prevention of herpes labialis, herpes simplex, herpes simplex ocular prophylaxis, keratoconjunctivitis, pharyngitis, pneumonitis, prevention of postherpetic neuralgia, proctitis, stomatitis, tracheobronchitis, varicella prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3089">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, valacyclovir</para>
				<section type="none" id="sidelem4x3094">
					<section type="none" id="sidelem4x3095">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, renal/hepatic/neurologic disease, electrolyte imbalance, dehydration, hypersensitivity to famciclovir, ganciclovir, penciclovir, valganciclovir, obesity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3100">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<emphasis alert="lifethreat">Base dose in obese patients on ideal body weight, not actual body weight</emphasis>
				</para>
				<section type="none" id="sidelem4x3106">
					<section type="none" id="sidelem4x3107">
						<sec_title>Herpes simplex (recurrent)</sec_title>
						<section type="none" id="sidelem4x3115">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3115">
									<item>
										<label>•</label>
										<para> 400 mg 3×/day for 5 days or 200 mg 5×/day × 5 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3122">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x3122">
									<item>
										<label>•</label>
										<para> 5 mg/kg over 1 hr q8hr × 7 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3129">
							<label>•</label>
							<sec_title>Infant &gt;3 mo/child &lt;12 yr<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x3129">
									<item>
										<label>•</label>
										<para> 10 mg/kg q8hr × 7 day; if HIV infected 5-10 mg/kg q8hr (moderate to severe)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3136">
							<label>•</label>
							<sec_title>Neonate<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x3136">
									<item>
										<label>•</label>
										<para> 10 mg/kg q8hr × 10 days, may use higher dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3140">
						<sec_title>Genital herpes</sec_title>
						<section type="none" id="sidelem4x3148">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3148">
									<item>
										<label>•</label>
										<para> 200 mg q4hr (5×/day while awake) for 5 days to 12 mo depending on whether initial, recurrent, or chronic;  5 mg/kg q8hr × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3155">
						<sec_title>Genital herpes, initial limited, mucocutaneous HSV in immunocompromised patients, non–life-threatening</sec_title>
						<section type="none" id="sidelem4x3163">
							<label>•</label>
							<sec_title>Adult/child ≥12 yr<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x3163">
									<item>
										<label>•</label>
										<para> cover lesions q3hr 6 times/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3167">
						<sec_title>Herpes simplex encephalitis</sec_title>
						<section type="none" id="sidelem4x3175">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3175">
									<item>
										<label>•</label>
										<para> 10 mg/kg over 1 hr q8hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3182">
							<label>•</label>
							<sec_title>Child 3 mo-12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3182">
									<item>
										<label>•</label>
										<para> 20 mg/kg q8hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3189">
							<label>•</label>
							<sec_title>Child birth-3 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3189">
									<item>
										<label>•</label>
										<para> 20 mg/kg q8hr × 21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3193">
						<sec_title>Herpes labialis, recurrent</sec_title>
						<section type="none" id="sidelem4x3201">
							<label>•</label>
							<sec_title>Adult/child ≥12 yr</sec_title>
							<para>
								<list id="lidelem4x3201">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/child ≥12 yr:</emphasis> top apply cream 5×/day for 4 days, start as soon as symptoms appear</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3205">
						<sec_title>Herpes, labialis, recurrent in immunocompetent patients</sec_title>
						<section type="none" id="sidelem4x3213">
							<label>•</label>
							<sec_title>Adult<route> Buccal</route></sec_title>
							<para>
								<list id="lidelem4x3213">
									<item>
										<label>•</label>
										<para> 50 mg as a single dose in upper gum region within 1 hr after prodromal symptoms and before cold sore formation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3217">
						<sec_title>Herpes zoster</sec_title>
						<section type="none" id="sidelem4x3225">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3225">
									<item>
										<label>•</label>
										<para> 800 mg q4hr 5×/day while awake × 7-10 days;  10 mg/kg q8hr × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3232">
						<sec_title>Herpes zoster (shingles) immunocompromised patients</sec_title>
						<section type="none" id="sidelem4x3240">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3240">
									<item>
										<label>•</label>
										<para> 800 mg q4hr 5×/day for 7-10 days;  10 mg/kg q8hr × 7 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3250">
							<label>•</label>
							<sec_title>Child ≥12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3250">
									<item>
										<label>•</label>
										<para> 10 mg/kg/dose q8hr × 7 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3257">
							<label>•</label>
							<sec_title>Infant/child &lt;12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3257">
									<item>
										<label>•</label>
										<para> 20 mg/kg/dose q8hr × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3262">
						<sec_title>Herpes zoster (shingles) immunocompetent</sec_title>
						<section type="none" id="sidelem4x3270">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3270">
									<item>
										<label>•</label>
										<para> 800 mg q4hr 5×/day × 7-10 days; start within 48-72 hr of rash onset</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3274">
						<sec_title>Varicella (chickenpox) immunocompetent</sec_title>
						<section type="none" id="sidelem4x3282">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3282">
									<item>
										<label>•</label>
										<para> 800 mg 4×/day × 5 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3289">
							<label>•</label>
							<sec_title>Child ≥2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3289">
									<item>
										<label>•</label>
										<para> 20 mg/kg/dose (max 800 mg) 4×/day × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3293">
						<sec_title>Mucosal/cutaneous herpes simplex infections in immunosuppressed patients</sec_title>
						<section type="none" id="sidelem4x3301">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3301">
									<item>
										<label>•</label>
										<para> 5 mg/kg q8hr × 7 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3308">
							<label>•</label>
							<sec_title>Infant &gt;3 mo/child &lt;12<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3308">
									<item>
										<label>•</label>
										<para> 10 mg/kg q8hr × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3312">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3320">
							<label>•</label>
							<sec_title>Adult and child<route> PO/IV CCr &gt;50 ml/min 100% dose q8hr, CCr 25-50 ml/min 100% dose q12hr, CCr 10-25 ml/min 100% dose q24hr, CCr 0-10 ml/min 50% dose q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3323">
						<sec_title>Recurrent ocular herpes, prevention (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3331">
							<label>•</label>
							<sec_title>Adult/child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3331">
									<item>
										<label>•</label>
										<para> 600-800 mg every day × 8-12 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3335">
						<sec_title>CMV prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3343">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3343">
									<item>
										<label>•</label>
										<para> 500 mg/m<emphasis style="sup">2</emphasis> q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3350">
						<sec_title>Herpes simplex in pneumonitis/esophagitis/tracheobronchitis/proctitis/stomatitis/pharyngitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3358">
							<label>•</label>
							<sec_title>Adult and adolescent<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3358">
									<item>
										<label>•</label>
										<para> 5-10 mg/kg q8hr × 2-7 days or  200 mg q4hr 5×/day × 7-10 days or 400 mg 3-5×/day × ≥10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3368">
							<label>•</label>
							<sec_title>Child 6 mo-12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3368">
									<item>
										<label>•</label>
										<para> 1000 mg/day in 3-5 divided doses × 7-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3372">
						<sec_title>Herpes simplex prophylaxis for chronic suppression therapy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3380">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3380">
									<item>
										<label>•</label>
										<para> 400 mg bid up to 12 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3384">
						<sec_title>Available forms:</sec_title>
						<para> Caps 200 mg; tabs 400, 800 mg; powder for inj 500, 1000 mg; sol for inj 50 mg/ml; oral susp 200 mg/5 ml; ointment/cream 5%; buccal tab 50 mg</para>
					</section>
					<section type="none" id="sidelem4x3389">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3392">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3396">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew caps</para>
									</item>
									<item>
										<label>•</label>
										<para>May give without regard to meals, with 8 oz of water</para>
									</item>
									<item>
										<label>•</label>
										<para>Shake susp before use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3412">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x3416">
									<item>
										<label>•</label>
										<para>Use finger cot or glove to cover all lesions completely; do not get in eye; wash hands after use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3422">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3426">
									<item>
										<label>•</label>
										<para>Increase fluids to 3 L/day to decrease crystalluria; most critical during first 2 hr after IV</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitute with 10 ml compatible sol/500 mg or 20 ml/1 g of product, concentrations of 50 mg/ml, shake, further dilute in 50-125 ml compatible sol; use within 12 hr; give over at least 1 hr (constant rate) by infusion pump to prevent nephrotoxicity; do not reconstitute with sol containing benzyl alcohol in neonates</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature for up to 12 hr after reconstitution; if refrigerated, sol may show a precipitate that clears at room temperature; yellow discoloration does not affect potency</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>W, LR, or NaCl (D<emphasis style="inf">5</emphasis> 0.9% NaCl, 0.9% NaCl) sol</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, allopurinol, amikacin, aminophylline, amphotericin B cholesteryl, amphotericin B liposome, ampicillin, anidulafungin, argatroban, atracurium, bivalirudin, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, cefazolin, cefonicid, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cholesteryl sulfate complex, cimetidine, clindamycin, dexamethasone sodium phosphate, dimenhyDRINATE, DOXOrubicin, doxycycline, erythromycin, famotidine, filgrastim, fluconazole, gallium, gentamicin, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, LORazepam, magnesium sulfate, melphalan, methylPREDNISolone sodium succinate, metoclopramide, metroNIDAZOLE, multivitamin, nafcillin, oxacillin, paclitaxel, penicillin G potassium, PENTobarbital, perphenazine, piperacillin, potassium chloride, propofol, ranitidine, remifentanil, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, tobramycin, trimethoprim-sulfamethoxazole, vancomycin, vasopressin, voriconazole, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3458">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3461">
					<section type="none" id="sidelem4x3462">
						<sec_title>CNS:</sec_title>
						<para> Tremors, confusion, lethargy, hallucinations, <emphasis style="bold">seizures,</emphasis> dizziness, headache, encephalopathic changes</para>
					</section>
					<section type="none" id="sidelem4x3470">
						<sec_title>EENT:</sec_title>
						<para> Gingival hyperplasia</para>
					</section>
					<section type="none" id="sidelem4x3475">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, increased ALT/AST, abdominal pain, glossitis, colitis</para>
					</section>
					<section type="none" id="sidelem4x3480">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Oliguria, proteinuria, hematuria,</emphasis> vaginitis, moniliasis, <emphasis style="bold">glomerulonephritis, acute renal failure,</emphasis> changes in menses, polydipsia</para>
					</section>
					<section type="none" id="sidelem4x3491">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombotic thrombocytopenia purpura, hemolytic uremic syndrome</emphasis> (immunocompromised patients)</para>
					</section>
					<section type="none" id="sidelem4x3499">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus, pain or phlebitis at IV site, unusual sweating, alopecia, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3506">
						<sec_title>MS:</sec_title>
						<para> Joint pain, leg pain, muscle cramps</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3511">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Distributed widely; crosses placenta; CSF concentrations are 50% plasma; protein binding 9%-33%</para>
				<section type="none" id="sidelem4x3516">
					<section type="none" id="sidelem4x3517">
						<sec_title>PO:</sec_title>
						<para> Absorbed minimally, onset unknown, peak 1.5-2 hr, terminal half-life 2.5-3.3 hr</para>
					</section>
					<section type="none" id="sidelem4x3522">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, peak immediate, duration unknown, half-life 20 min-3 hr (terminal); metabolized by liver, excreted by kidneys as unchanged product (95%)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3527">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS side effects—zidovudine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels, toxicity—probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nephrotoxicity—aminoglycosides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> concentrations of—entecavir, pemetrexed, tenofovir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of—hydantoins, valproic acid</para>
				<section type="none" id="sidelem4x3550">
					<section type="none" id="sidelem4x3551">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, creatinine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3558">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3561">
					<section type="none" id="sidelem4x3562">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3567">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3575">
							<label>•</label>
							<sec_title>Toxicity<route> any patient with compromised renal system because product is excreted slowly with poor renal system function; toxicity may occur rapidly</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3581">
							<label>•</label>
							<sec_title>Hepatic, renal studies<route> AST, ALT; urinalysis, protein, BUN, creatinine, CCr, watch for increasing BUN and serum creatinine or decreased CCr; I&amp;O ratio; report hematuria, oliguria, fatigue, weakness; may indicate nephrotoxicity; check for protein in urine during treatment</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x3584">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3589">
								<item>
									<label>•</label>
									<para>Skin eruptions: rash, urticaria, itching</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3594">
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction of each medication; place allergies on chart in bright red letters</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3599">
								<item>
									<label>•</label>
									<para>Neurologic status with herpes encephalitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3604">
								<item>
									<label>•</label>
									<para>Provide adequate intake of fluids (2 L) to prevent deposits in kidneys, more likely to occur with rapid administration or in dehydration</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3609">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3613">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of itching, painful lesions; crusting and healed lesions; decreased symptoms of chickenpox; healing, decreased pain with herpes zoster</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3619">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3623">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, take as soon as remembered up to 1 hr before next dose; do not double dose</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may be taken orally before infection occurs; product should be taken when itching or pain occurs, usually before eruptions</para>
								</item>
								<item>
									<label>•</label>
									<para>That sexual partners need to be told that patient has herpes because they can become infected; condoms must be worn to prevent reinfections</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to touch lesions to avoid spreading infection to new sites</para>
								</item>
								<item>
									<label>•</label>
									<para>That product does not cure infection, just controls symptoms and does not prevent infecting others</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals around the clock to maintain blood levels for duration of therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>To seek dental care during treatment to prevent gingival hyperplasia</para>
								</item>
								<item>
									<label>•</label>
									<para>That women with genital herpes are more likely to develop cervical cancer; to keep all gynecologic appointments</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x3665">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Discontinue product, hemodialysis, resuscitate if needed</para>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>adalimumab (Rx)</mono_name>
			<info>
				<pronunciation>(add-a-lim′yu-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x36750">Humira</tradename>
				</tradenames>
				<class type="func"> Antirheumatic agent (disease modifying), immunomodulator, anti-TNF</class>
				<class type="chem"> Recombinant human IgG1 monoclonal antibody, DMARD</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3685">
				<para>
					<confusion>
						<tradename id="tnidelem4x36850">Humira</tradename>
						<drug type="generic" refid="idelem4x36850">Humulin/Humalog</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3689">
				<sec_title>Action:</sec_title>
				<para>A form of human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF-α); elevated levels of TNF-α are found in patients with rheumatoid arthritis</para>
			</section>
			<section type="uses" id="sidelem4x3694">
				<sec_title>Uses:</sec_title>
				<para>Reduction of signs and symptoms and inhibition of progression of structural damage in patients with moderate to severe active rheumatoid arthritis who are ≥18 years of age and who have not responded to other disease-modifying agents, juvenile rheumatoid arthritis (JRA), psoriatic arthritis, Crohn’s disease, moderate to severe plaque psoriasis, ankylosing spondylitis, ulcerative colitis</para>
			</section>
			<section type="contra" id="sidelem4x3699">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x3704">
					<section type="none" id="sidelem4x3705">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, CNS demyelinating disease, lymphoma, CHF, hepatitis B carriers, manitol hypersensitivity, latex allergy, neoplastic disease</para>
						<para>
							<bbw>Active infections, risk of lymphomas/leukemias, TB</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3720">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3723">
					<section type="none" id="sidelem4x3724">
						<sec_title>Rheumatoid arthritis/ankylosing spondylitis/psoriatic arthritis</sec_title>
						<section type="none" id="sidelem4x3732">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3732">
									<item>
										<label>•</label>
										<para> 40 mg every other wk or every wk if not combined with methotrexate</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3736">
						<sec_title>Juvenile rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x3744">
							<label>•</label>
							<sec_title>Child ≥2 yr/adolescent ≥30 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3744">
									<item>
										<label>•</label>
										<para> 40 mg every other wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3751">
							<label>•</label>
							<sec_title>Child ≥2 yr/adolescent ≥15 kg to &lt;30 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3751">
									<item>
										<label>•</label>
										<para> 20 mg every other wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3758">
							<label>•</label>
							<sec_title>Child ≥2 yr/adolescent 10-&lt;15 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3758">
									<item>
										<label>•</label>
										<para> 10 mg every other wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3762">
						<sec_title>Crohn’s disease/ulcerative colitis</sec_title>
						<section type="none" id="sidelem4x3770">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3770">
									<item>
										<label>•</label>
										<para> 160 mg given as 4 inj, on day 1 or 2 inj each on days 1 and 2, then 80 mg at wk 2 and 40 mg every other wk starting at wk 4</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3774">
						<sec_title>Plaque psoriasis</sec_title>
						<section type="none" id="sidelem4x3782">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3782">
									<item>
										<label>•</label>
										<para> 80 mg baseline as 2 inj, then 40 mg every other wk starting 1 wk after initial dose × 16 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3786">
						<sec_title>Available form:</sec_title>
						<para> Inj 40 mg/0.8 ml; 20 mg/0.4 ml (pediatric)</para>
					</section>
					<section type="none" id="sidelem4x3791">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3794">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x3798">
									<item>
										<label>•</label>
										<para>Do not admix with other sol or medications; do not use filter; protect from light; give at 45-degree angle using abdomen, thighs; rotate inj sites; discard unused portions</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3804">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3807">
					<section type="none" id="sidelem4x3808">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis><emphasis style="bold">Guillain-Barré syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3817">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypertension,</emphasis> CHF</para>
					</section>
					<section type="none" id="sidelem4x3825">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Sinusitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3832">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, nausea, hepatic damage, <emphasis style="bold">GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3839">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia pancytopenia, aplastic anemia, agranulocytopenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3846">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, inj site reaction</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3853">
						<sec_title>MISC:</sec_title>
						<para> Flulike symptoms, UTI, back pain, lupus-like syndrome, <emphasis style="bold">increased cancer risk,</emphasis><emphasis style="italic">antibody development to this drug;</emphasis><emphasis style="bold">risk of infection (TB, invasive fungal infections, other opportunistic infections), may be fatal, Stevens-Johnson syndrome, anaphylaxis, hypercholesterolemia, hyperlipidemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3865">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">URI,</emphasis><emphasis style="bold">pulmonary fibrosis, bronchitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3874">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption 65%, terminal half-life 2 wk, lower clearance with advancing age (40-75 yr)</para>
			</section>
			<section type="interactions" id="sidelem4x3879">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> serious infections—other TNF blockers, rilonacept</bbw>
				</para>
				<section type="none" id="sidelem4x3898">
					<label>•</label>
					<sec_title>
						<route>Do not use with anakinra; serious infections may occur</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x3901">
						<item>
							<label>•</label>
							<para>Do not give concurrently with live virus vaccines; immunizations should be brought up to date before treatment</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x3906">
					<section type="none" id="sidelem4x3907">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, cholesterol, lipids</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3914">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3917">
					<section type="none" id="sidelem4x3918">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3926">
							<label>•</label>
							<sec_title>RA</sec_title>
							<para>
								<list id="lidelem4x3926">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">RA:</emphasis> pain, stiffness, ROM, swelling of joints before, during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3930">
								<item>
									<label>•</label>
									<para>For inj site pain, swelling, redness—usually occur after 2 inj (4-5 days)—use cold compress to relieve pain/swelling
<bbw>For infections (fever, flulike symptoms, dyspnea, change in urination, redness/swelling around any wounds), stop treatment if present; some serious infections including sepsis may occur, may be fatal; patients with active infections should not be started on this product</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3947">
							<label>•</label>
							<sec_title>
								<route>May reactivate hepatitis B in chronic carriers, may be fatal</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x3962">
							<label>•</label>
							<sec_title>Anaphylaxis, latex allergy<route> stop therapy if lupus-like syndrome develops</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3968">
							<label>•</label>
							<sec_title>Blood dyscrasias<route> CBC, differential periodically</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3980">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3984">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation, pain in joints, decreased joint destruction</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3990">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3995">
								<item>
									<label>•</label>
									<para>About self-administration if appropriate: inj should be made in thigh, abdomen, upper arm; rotate sites at least 1 inch from old site; do not inject in areas that are bruised, red, hard</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4000">
								<item>
									<label>•</label>
									<para>That if medication is not taken when due, inject next dose as soon as remembered and inject next dose as scheduled</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4005">
								<item>
									<label>•</label>
									<para>Not to take any live virus vaccines during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4013">
							<label>•</label>
							<sec_title>
								<route>To report signs of infection, allergic reaction, or lupus-like syndrome, immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>adefovir (Rx)</mono_name>
			<info>
				<pronunciation>(add-ee-foh′veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x40210">Hepsera</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Nucleoside</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4031">
				<sec_title>Action:</sec_title>
				<para>Inhibits hepatitis B virus DNA polymerase by competing with natural substrates and by causing DNA termination after its incorporation into viral DNA; causes viral DNA death</para>
			</section>
			<section type="uses" id="sidelem4x4036">
				<sec_title>Uses:</sec_title>
				<para>Chronic hepatitis B</para>
			</section>
			<section type="contra" id="sidelem4x4041">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x4046">
					<section type="none" id="sidelem4x4047">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), labor, breastfeeding, children, geriatric patients, dialysis, females, obesity, organ transplant</para>
						<para>
							<bbw>Severe renal disease, impaired hepatic function, lactic acidosis, HIV</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4063">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4071">
					<label>•</label>
					<sec_title>Adult/adolescent<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4071">
							<item>
								<label>•</label>
								<para> 10 mg/day, optimal duration unknown</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4075">
					<section type="none" id="sidelem4x4076">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4084">
							<label>•</label>
							<sec_title>Adult<route> PO CCr ≥50 ml/min 10 mg q24hr; CCr 30-49 ml/min 10 mg q48hr; CCr 10-29 ml/min 10 mg q72hr; hemodialysis 10 mg q7days after dialysis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4087">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10 mg</para>
					</section>
					<section type="none" id="sidelem4x4092">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4096">
								<item>
									<label>•</label>
									<para>By mouth without regard for food</para>
								</item>
								<item>
									<label>•</label>
									<para>Take with full glass of water</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment; protect from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4112">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4115">
					<section type="none" id="sidelem4x4116">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4123">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dyspepsia,</emphasis> abdominal pain, nausea, vomiting, diarrhea, hepatomegaly, flatulence, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4133">
						<sec_title>GU:</sec_title>
						<para> Hematuria, glycosuria, <emphasis style="bold">nephrotoxicity, Fanconi syndrome, renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4140">
						<sec_title>MISC:</sec_title>
						<para> Fever, rash, weight loss, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4145">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x4148">
					<section type="none" id="sidelem4x4149">
						<sec_title>PO:</sec_title>
						<para> Rapidly absorbed from GI tract, peak 1<emphasis style="sup">3</emphasis>/<emphasis style="inf">4</emphasis> hr, excreted by kidneys 45%, terminal half-life 7.48 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4160">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x4168">
					<label>•</label>
					<sec_title>
						<route>Do not use in combination with emtricitabine/tenofovir, emtricitabine/rilpivirine, emtricitabine/efavirenz/tenofovir</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum concentrations and possible nephrotoxicity—aminoglycosides, memantine, emtricitabine, efavirenz, dofetilide, digoxin, cycloSPORINE, aMILoride, quiNINE, quiNIDine, procainamide, PEMEtrexed, midodrine, metFORMIN, NSAIDs, vancomycin, trospium, triamterene, tenofovir, tacrolimus, ranitidine, cimetidine, morphine</para>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> lactic acidosis, severe hepatomegaly, NNRTIs, NRTIs, antiretroviral protease inhibitors</bbw>
				</para>
				<section type="none" id="sidelem4x4187">
					<section type="none" id="sidelem4x4188">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, amylase, creatine kinase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4195">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4198">
					<section type="none" id="sidelem4x4199">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Nephrotoxicity: increasing CCr, BUN</bbw>
						</para>
						<para>
							<bbw>HIV antibody testing before beginning treatment, HIV resistance may occur in chronic hepatitis B patients</bbw>
						</para>
						<para>
							<bbw>For lactic acidosis, severe hepatomegaly with stenosis; for use of NNRTIs, NRTIs, antiretroviral protease inhibitors (PIs), lactic acidosis with severe hepatomegaly is more common in females, obese patients, and with prolonged nucleoside use</bbw>
						</para>
						<para>
							<list id="lidelem4x4230">
								<item>
									<label>•</label>
									<para>Geriatric patients more carefully; may develop renal, cardiac symptoms more rapidly
<bbw>For exacerbations of hepatitis after discontinuing treatment, monitor LFTs, hepatitis B serology</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Pregnancy: If planned or suspected; if pregnant call the Pregnancy Registry: 800-258-4263</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4250">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4254">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of chronic hepatitis B, improving LFTs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4260">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4265">
								<item>
									<label>•</label>
									<para>That optimal duration of treatment is unknown; that product is not a cure; that transmission may still occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4270">
								<item>
									<label>•</label>
									<para>To avoid use with other medications unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4275">
								<item>
									<label>•</label>
									<para>To notify prescriber of decreased urinary output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4280">
								<item>
									<label>•</label>
									<para>Not to stop abruptly unless directed; worsening of hepatitis may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4289">
							<label>•</label>
							<sec_title>
								<route>To report immediately dyspnea, nausea, vomiting, abdominal pain, weakness, dizziness, cold extremities</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4292">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; avoid breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active" ha="yes">
			<mono_name>adenosine (Rx)</mono_name>
			<info>
				<pronunciation>(a-den′oh-seen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x43040">Adenocard</tradename>
				</tradenames>
				<class type="func"> Antidysrhythmic</class>
				<class type="chem"> Endogenous nucleoside</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4314">
				<para>
					<confusion>
						<tradename id="tnidelem4x43140">adenosine</tradename>
						<drug type="generic" refid="idelem4x43140">adeosine phosphate</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4318">
				<sec_title>Action:</sec_title>
				<para>Slows conduction through AV node, can interrupt reentry pathways through AV node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia; decreases cardiac oxygen demand, decreasing hypoxia</para>
			</section>
			<section type="uses" id="sidelem4x4323">
				<sec_title>Uses:</sec_title>
				<para>PSVT, as a diagnostic aid to assess myocardial perfusion defects in CAD, Wolff-Parkinson-White syndrome</para>
				<section type="none" id="sidelem4x4328">
					<section type="none" id="sidelem4x4329">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Wide-complex tachycardia diagnosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4334">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, 2nd- or 3rd-degree AV block, sick sinus syndrome, bradycardia</para>
				<section type="none" id="sidelem4x4339">
					<section type="none" id="sidelem4x4340">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, asthma, atrial flutter, atrial fibrillation, ventricular tachycardia, bronchospastic lung disease, symptomatic bradycardia, bundle branch block, heart transplant, unstable angina, COPD, hypotension, hypovolemia, vascular heart disease, CV disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4345">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4348">
					<section type="none" id="sidelem4x4349">
						<sec_title>Antidysrhythmic</sec_title>
						<section type="none" id="sidelem4x4357">
							<label>•</label>
							<sec_title>Adult and child &gt;50 kg<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x4357">
									<item>
										<label>•</label>
										<para> 6 mg; if conversion to normal sinus rhythm does not occur within 1-2 min, give 12 mg by rapid  may repeat 12-mg dose again in 1-2 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4367">
							<label>•</label>
							<sec_title>Infant and child &lt;50 kg<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x4367">
									<item>
										<label>•</label>
										<para> 0.1 mg/kg; if not effective, increase dose by 0.05-0.1 mg/kg q2min to a max of 0.3 mg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4374">
							<label>•</label>
							<sec_title>Neonate<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x4374">
									<item>
										<label>•</label>
										<para> 0.05 mg/kg by rapid IV BOL, may increase by 0.05 mg/kg q2min, max 0.3 mg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4378">
						<sec_title>Available forms:</sec_title>
						<para> 3 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x4383">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4386">
							<sec_title>IV, direct route</sec_title>
							<para>
								<list id="lidelem4x4390">
									<item>
										<label>•</label>
										<para>Warm to room temperature; crystals will dissolve</para>
									</item>
									<item>
										<label>•</label>
										<para>Undiluted; give 6 mg or less by rapid inj over 1-2 sec; if using an IV line, use port near insertion site, flush with NS (20 ml), then elevate arm</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature; sol should be clear; discard unused product</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> abciximab</para>
							<para>
								<emphasis style="bold">
									<emphasis style="bold">Solution compatibilities:</emphasis>
								</emphasis> D<emphasis style="inf">5</emphasis>LR, D<emphasis style="inf">5</emphasis>W, LR, 0.9% NaCl</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4421">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4424">
					<section type="none" id="sidelem4x4425">
						<sec_title>CNS:</sec_title>
						<para> Lightheadedness, dizziness, arm tingling, numbness, headache</para>
					</section>
					<section type="none" id="sidelem4x4430">
						<sec_title>CV:</sec_title>
						<para> Chest pain, pressure, <emphasis style="bold">atrial tachydysrhythmias,</emphasis> sweating, palpitations, hypotension, <emphasis style="italic">facial flushing,</emphasis><emphasis style="bold">AV block, cardiac arrest, ventricular dysrhythmias, atrial fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4442">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> metallic taste</para>
					</section>
					<section type="none" id="sidelem4x4450">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Dyspnea, chest pressure,</emphasis> hyperventilation, <emphasis style="bold">bronchospasm (asthmatics)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4460">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Cleared from plasma in &lt;30 sec, half-life 10 sec, converted to inosine/adenosine monophosphate</para>
			</section>
			<section type="interactions" id="sidelem4x4465">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk for higher degree of heart block—carBAMazepine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk for ventricular fibrillation—digoxin, verapamil<list id="lidelem4x4476">
						<item>
							<label>•</label>
							<para>Smoking: increase tachycardia</para>
						</item>
					</list></para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of adenosine—dipyridamole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> activity of adenosine—theophylline or other methylxanthines (caffeine)</para>
				<section type="none" id="sidelem4x4491">
					<section type="none" id="sidelem4x4492">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> adenosine effect—ginger</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> adenosine effect—guarana, green tea</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4503">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4506">
					<section type="none" id="sidelem4x4507">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4515">
							<label>•</label>
							<sec_title>Cardiopulmonary status<route> B/P, pulse, respiration, rhythm, ECG intervals (PR, QRS, QT); check for transient dysrhythmias (PVCs, PACs, sinus tachycardia, AV block)</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4521">
							<label>•</label>
							<sec_title>Respiratory status<route> rate, rhythm, lung fields for crackles; watch for respiratory depression; bilateral crackles may occur in CHF patient; increased respiration, increased pulse, product should be discontinued</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4524">
								<item>
									<label>•</label>
									<para>CNS effects: dizziness, confusion, psychosis, paresthesias, seizures; product should be discontinued</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4529">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4533">
								<item>
									<label>•</label>
									<para>Therapeutic response: normal sinus rhythm or diagnosis of perfusion defect</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4539">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4543">
								<item>
									<label>•</label>
									<para>To report facial flushing, dizziness, sweating, palpitations, chest pain; usually transient</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x4549">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Defibrillation, vasopressor for hypotension, theophylline</para>
			</section>
		</monograph>
<monograph id="15" status="active" ha="yes">
			<mono_name>ado-trastuzumab</mono_name>
			<info>
				<pronunciation>(a′doe-tras-tooz′ue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x45610">Kadcyla</tradename>
				</tradenames>
			</info>
			<section type="confusion" id="sidelem4x4571">
				<para>
					<confusion>
						<tradename id="tnidelem4x45710">ado-trastuzumab</tradename>
						<drug type="generic" refid="idelem4x45710">trastuzumab</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4575">
				<sec_title>Action:</sec_title>
				<para>Humanized anti-HER2 monoclonal antibody that is linked to DM1, a small molecule microtubular inhibitor; once the antibody is bound to the HER2 receptor, the complex is internalized and the DM1 is released to bind with tubulin to lead to apoptosis</para>
			</section>
			<section type="uses" id="sidelem4x4580">
				<sec_title>Uses:</sec_title>
				<para>Breast cancer; metastatic with overexpression of HER2, who previously received trastuzumab and a taxane, separately or in combination</para>
			</section>
			<section type="contra" id="sidelem4x4585">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, Chinese hamster ovary cell protein, pregnancy (D)</para>
				<section type="none" id="sidelem4x4590">
					<section type="none" id="sidelem4x4591">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, pulmonary disease, acute bronchospasm, anticoagulant, Asian patients, asthma, COPD, extravasation, fever, hepatitis, human anti-human antibody, hypotension, neuropathy, hepatotoxicity; cardiomyopathy/CHF; interstitial lung disease/pneumonitis; extravasation; thrombocytopenia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4596">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4604">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x4604">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis> IV 3.6 mg/kg over 30-90 min q3wk; give first infusion over 90 min; if tolerated, give over 30 min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4609">
					<section type="none" id="sidelem4x4610">
						<sec_title>Dosage adjustments for toxicities:</sec_title>
						<section type="none" id="sidelem4x4613">
							<sec_title>Hepatotoxicity:</sec_title>
							<section type="none" id="sidelem4x4621">
								<label>•</label>
								<sec_title>AST/ALT &gt;5 to ≤20 × ULN<route> withhold, resume at a reduced dose when AST/ALT is ≤5 × ULN; first dose reduction</route></sec_title>
							</section>
							<section type="none" id="sidelem4x4627">
								<label>•</label>
								<sec_title>AST/ ALT &gt;20× ULN<route> discontinue</route></sec_title>
							</section>
							<section type="none" id="sidelem4x4633">
								<label>•</label>
								<sec_title>Total bilirubin &gt;3 to ≤10× ULN<route> withhold, resume treatment at a reduced dose when total bilirubin recovers to ≤1.5; first dose reduction</route></sec_title>
							</section>
							<section type="none" id="sidelem4x4639">
								<label>•</label>
								<sec_title>Total bilirubin &gt;10× ULN<route> permanently discontinue; permanently discontinue treatment in patients with AST/ALT &gt;3× ULN and total bilirubin &gt;2× ULN; permanently discontinue treatment in patients diagnosed with nodular regenerative hyperplasia (NRH)</route></sec_title>
							</section>
							<section type="none" id="sidelem4x4645">
								<label>•</label>
								<sec_title>Left ventricular ejection fraction (LVEF); LVEF 40%-45% and decrease is &lt;10% points from baseline<route> continue treatment; repeat LVEF assessment within 3 wk; LVEF 40%-45% and decrease is ≥10% points from baseline</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x4661">
							<sec_title>Thrombocytopenia:</sec_title>
							<section type="none" id="sidelem4x4669">
								<label>•</label>
								<sec_title>Platelet count 25,000/mm3 to &lt;50,000/mm3<route> withhold; resume treatment at same dose when platelet count recovers to ≥75,000/mm3</route></sec_title>
							</section>
							<section type="none" id="sidelem4x4683">
								<label>•</label>
								<sec_title>Platelet count &lt;25,000/mm3<route> withhold; resume treatment at a reduced dose when platelet count recovers to ≥75,000/mm3</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x4692">
							<sec_title>Pulmonary toxicity:</sec_title>
							<section type="none" id="sidelem4x4700">
								<label>•</label>
								<sec_title>
									<route>Permanently discontinue in patients diagnosed with interstitial lung disease or pneumonitis</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x4703">
							<sec_title>Peripheral neuropathy:</sec_title>
							<section type="none" id="sidelem4x4711">
								<label>•</label>
								<sec_title>
									<route>Withhold in patients experiencing grade 3 or 4 peripheral neuropathy; resume treatment upon resolution to ≤grade 2</route>
								</sec_title>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x4714">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder 100, 160 mg</para>
					</section>
					<section type="none" id="sidelem4x4719">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4722">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x4726">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Give as (IV) infusion with a 0.2 or 0.22 micron in-line filter; do not administer as an IV push or bolus</para>
									</item>
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures; do not mix with, or administer as an infusion with, other IV products</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4742">
							<sec_title>Reconstitution:</sec_title>
							<para>
								<list id="lidelem4x4746">
									<item>
										<label>•</label>
										<para>Slowly inject 5 ml of sterile water for injection into each 100-mg vial, or 8 ml of sterile water for injection into each 160-mg vial to yield a single-use solution of 20 mg/ml</para>
									</item>
									<item>
										<label>•</label>
										<para>Direct the stream of sterile water toward the wall of the vial and not directly at the cake or powder</para>
									</item>
									<item>
										<label>•</label>
										<para>Gently swirl the vial to aid in dissolution; do not shake</para>
									</item>
									<item>
										<label>•</label>
										<para>After reconstitution, withdraw desired amount from the vial and dilute immediately in 250 ml of 0.9% sodium chloride; do not use dextrose 5% solution; gently invert the bag to mix the solution in order to avoid foaming</para>
									</item>
									<item>
										<label>•</label>
										<para>The reconstituted single-use product does not contain a preservative; use the diluted solution immediately or store at 2-8° C (36-46° F) for up to 24 hr after reconstitution; discard any unused drug after 24 hr; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4772">
							<sec_title>IV infusion</sec_title>
							<para>
								<list id="lidelem4x4777">
									<item>
										<label>•</label>
										<para>Closely monitor for possible subcutaneous infiltration during drug administration</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4785">
								<label>•</label>
								<sec_title>
									<route>First infusion</route>
								</sec_title>
								<para>
									<list id="lidelem4x4785">
										<item>
											<label>•</label>
											<para>: give over 90 min; the infusion rate should be slowed or interrupted if the patient develops an infusion-related reaction; patients should be observed for at least 90 min following the initial dose for fever, chills, or other infusion-related reactions; permanently discontinue for life-threatening infusion-related reactions</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4792">
								<label>•</label>
								<sec_title>
									<route>Subsequent infusions</route>
								</sec_title>
								<para>
									<list id="lidelem4x4792">
										<item>
											<label>•</label>
											<para>: administer over 30 min if prior infusions were well tolerated; the infusion rate should be slowed or interrupted if the patient develops an infusion-related reaction; patients should be observed for at least 30 min after the infusion; permanently discontinue for life-threatening infusion-related reactions</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4796">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4799">
					<section type="none" id="sidelem4x4800">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, insomnia, neuropathy, chills, fatigue, fever, flushing, headache, neuropathy</para>
					</section>
					<section type="none" id="sidelem4x4805">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure,</emphasis> tachycardia</para>
					</section>
					<section type="none" id="sidelem4x4813">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, conjunctivitis, stomatitis</para>
					</section>
					<section type="none" id="sidelem4x4818">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, vomiting, abdominal pain, constipation, dyspepsia, hepatotoxicity</para>
					</section>
					<section type="none" id="sidelem4x4824">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, bleeding, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4831">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x4836">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
					<section type="none" id="sidelem4x4841">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, <emphasis style="bold">bronchospasm, pneumonitis, interstitial lung disease</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4848">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4855">
						<sec_title>Other:</sec_title>
						<para> Elevated LFTs, <emphasis style="bold">hand-foot syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4862">
				<sec_title>Pharmacokinetics</sec_title>
				<para>93% protein binding, metabolized in the liver</para>
			</section>
			<section type="interactions" id="sidelem4x4867">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x4870">
					<section type="none" id="sidelem4x4871">
						<sec_title>Increase:</sec_title>
						<para> bleeding risk—warfarin; avoid use with CYP3A4 inhibitors with strong CYP3A4 inhibitors; platelet inhibitors; anticoagulants<list id="lidelem4x4876">
								<item>
									<label>•</label>
									<para>Do not give with other IV products; do not give with 5% dextrose</para>
								</item>
							</list></para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4882">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4885">
					<section type="none" id="sidelem4x4886">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4891">
								<item>
									<label>•</label>
									<para>Pregnancy test CBC, HER2 overexpression, differential
<bbw>CHF, other cardiac symptoms: dyspnea, coughing; gallop; obtain full cardiac workup including ECG, echo, MUGA, ejection fraction</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4905">
								<item>
									<label>•</label>
									<para>Symptoms of infection; may be masked by product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4910">
								<item>
									<label>•</label>
									<para>CNS reaction: LOC, mental status, dizziness, confusion
<bbw>Hypersensitive reactions, anaphylaxis</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4927">
							<label>•</label>
							<sec_title>Infusion reactions that may be fatal<route> fever, chills, nausea, vomiting, pain, headache, dizziness, hypotension; discontinue product</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4933">
							<label>•</label>
							<sec_title>Pulmonary toxicity<route> dyspnea, interstitial pneumonitis, pulmonary hypertension, ARDs; can occur after infusion reaction; those with lung disease may have more severe toxicity, discontinue</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4939">
							<label>•</label>
							<sec_title>Bleeding<route> Monitor for bleeding, grade 3 or 4 bleeding with fatalities have occurred, check platelets baseline and before each dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4942">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4946">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size of tumors
<bbw>Hepatic disease: may be fatal, monitor LFTs, bilirubin baseline and before each dose</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4961">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4965">
								<item>
									<label>•</label>
									<para>To take acetaminophen for fever</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous tasks because confusion, dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To report signs of infection: sore throat, fever, diarrhea, vomiting; bleeding; decreased heart function/SOB with exertion</para>
								</item>
								<item>
									<label>•</label>
									<para>That emotional lability is common; to notify prescriber if severe or incapacitating
<bbw>To use contraception while taking this product and for additional 7 mo after discontinuing this drug; pregnancy (D); not to breastfeed</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To report pain at infusion site</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active" ha="yes">
			<mono_name>afatinib</mono_name>
			<info>
				<pronunciation>(a-fat′i-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x50080">Gilotrif</tradename>
				</tradenames>
				<class type="func"> Antineoplastic biologic response modifiers</class>
				<class type="chem"> Signal transduction inhibitors (STIs), epidermal growth factor receptor, tyrosine kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5018">
				<para>
					<confusion>
						<tradename id="tnidelem4x50180">Afatinib</tradename>
						<drug type="generic" refid="idelem4x50180">afinitor/axitinib</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5022">
				<sec_title>Action:</sec_title>
				<para>Selective inhibitor of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4); irreversible, covalent binding of intracellular tyrosine kinase inhibiting (and causing regression) tumor growth by decreasing EGFR signal transduction, cell cycle arrest, and inhibition of angiogenesis</para>
			</section>
			<section type="uses" id="sidelem4x5028">
				<sec_title>Uses:</sec_title>
				<para>Treatment of non-small cell lung cancer whose tumors have epidermal growth factor receptor Exon 19 deletions or 21 substitution mutations</para>
			</section>
			<section type="contra" id="sidelem4x5033">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x5038">
					<section type="none" id="sidelem4x5039">
						<sec_title>Precautions:</sec_title>
						<para> Contact lens, dehydration, inflammation, keratitis, ocular disease, pneumonitis, pulmonary disease, renal disease, respiratory distress syndrome, serious rash, skin disease, diarrhea, hepatic disease, ocular disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5044">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5052">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5052">
							<item>
								<label>•</label>
								<para> 40 mg daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5056">
					<section type="none" id="sidelem4x5057">
						<sec_title>Dose adjustments for toxicities:</sec_title>
						<section type="none" id="sidelem4x5065">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> Hold therapy in patients who develop worsening liver function; when toxicity resolves to grade 1 or less, resume therapy at a reduced dose (10 mg/day less than the dose causing hepatotoxicity); permanently discontinue for severe drug-induced hepatic impairment or if hepatotoxicity persists at a dose of 20 mg/day</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5071">
							<label>•</label>
							<sec_title>Grade 2 or higher renal toxicity (CCr &gt;1.5 × ULN)<route> Hold until the toxicity resolves to grade 1 or less (CCr &lt;1.5 × ULN), then resume at a reduced dose (10 mg/day less than the dose causing nephrotoxicity); permanently discontinue if nephrotoxicity persists at a dose of 20 mg/day</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5077">
							<label>•</label>
							<sec_title>Grade 2 diarrhea, lasting 2 or more consecutive days while taking anti-diarrheal medication, or any grade 3 diarrhea<route> Hold until the toxicity resolves to grade 1 or less, then resume therapy at a reduced dose (10 mg/day less than the dose causing toxicity); antidiarrheal therapy should continue until no loose bowel movement for 12 hr; permanently discontinue if toxicity persists at a dose of 20 mg/day</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5083">
							<label>•</label>
							<sec_title>Grade 2 cutaneous reactions that last more than 7 days or are intolerable<route> Hold until the toxicity resolves to grade 1 or less, then resume at a reduced dose (10 mg/day less than the dose causing toxicity); permanently discontinue for life-threatening bullous, blistering, or exfoliative skin lesions, or if toxicity persists at a dose of 20 mg/day</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5089">
							<label>•</label>
							<sec_title>Confirmed interstitial lung disease, persistent ulcerative keratitis, symptomatic left ventricular dysfunction, or any severe/intolerable adverse reaction occurring at a dose of 20 mg/day<route> Permanently discontinue</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5095">
							<label>•</label>
							<sec_title>Any grade 3 or higher adverse event<route> Hold until the toxicity resolves to grade 1 or less, then resume therapy at a reduced dose (10 mg/day less than the dose causing toxicity); permanently discontinue if toxicity persists at a dose of 20 mg/day</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5101">
							<label>•</label>
							<sec_title>
								<route>Permanently discontinue for any severe or intolerable adverse event that occurs at a dose of 20 mg/day.</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5104">
						<sec_title>Dosage Guidance in Patients on P-glycoprotein (P-gp) inhibitors/inducers:</sec_title>
						<section type="none" id="sidelem4x5112">
							<label>•</label>
							<sec_title>P-gp inhibitors<route> If use of a P-gp inhibitor is required, reduce the initial daily afatinib dosage to 30 mg/day if not tolerated; resume original dose after discontinuation of the P-gp inhibitor as tolerated</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5118">
							<label>•</label>
							<sec_title>P-gp inducers<route> If use of a P-gp inducer is required, increase the initial daily afatinib dosage to 50 mg/day as tolerated; resume original dose 2-3 days after discontinuation of the P-gp inducer</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5121">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 20, 30, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x5126">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5129">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5133">
									<item>
										<label>•</label>
										<para>Give on empty stomach 1 hr before, 2 hr after food; give at same time of day</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not take a missed dose if within 12 hr of the next dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5144">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5147">
					<section type="none" id="sidelem4x5148">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, fever</para>
					</section>
					<section type="none" id="sidelem4x5153">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5160">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x5165">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, vomiting, stomatitis, decreased appetite</para>
					</section>
					<section type="none" id="sidelem4x5170">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">neutropenia,</emphasis> leukopenia, epistaxis</para>
					</section>
					<section type="none" id="sidelem4x5178">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, acne vulgaris, photosensitivity, nail bed infections</para>
					</section>
					<section type="none" id="sidelem4x5183">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
					<section type="none" id="sidelem4x5189">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, acute respiratory distress syndrome, interstitial lung disease, pneumonitis</para>
					</section>
					<section type="none" id="sidelem4x5194">
						<sec_title>Other:</sec_title>
						<para> Elevated LFTs, infection, hand and foot syndrome, dehydration, renal failure, cystitis, hypokalemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5199">
				<sec_title>Pharmacokinetics</sec_title>
				<para>95% protein binding, half-life 37 hr, primarily excreted as unchanged drug in feces; peak 2-5 hr after dose; time to steady-state is approximately 8 days</para>
			</section>
			<section type="interactions" id="sidelem4x5204">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> afatinib—P-gp inhibitors effect</para>
				<section type="none" id="sidelem4x5211">
					<section type="none" id="sidelem4x5212">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> afatinib concentration—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x5219">
						<sec_title>Drug/Food Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> afatinib effect—grapefruit juice; avoid use while taking product</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5226">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5229">
					<section type="none" id="sidelem4x5230">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Myelosuppression: anemia, neutropenia; obtain weekly × 1 mo, then monthly as needed; LFTs every mo × 3 mo, then as clinically indicated; hepatic failure may occur</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x5243">
						<sec_title>Evaluate:</sec_title>
						<para> Therapeutic response: decrease in progression of disease</para>
					</section>
					<section type="none" id="sidelem4x5248">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5252">
								<item>
									<label>•</label>
									<para>To report adverse reactions immediately; bleeding</para>
								</item>
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>To use effective contraception during treatment and up to 30 days after discontinuing treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To treat skin rash with topicals and oral antibiotics; use loperamide for diarrhea; if any side effect is severe or persistent, contact prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That complicated dosing changes may occur based on toxicity or drug-drug interaction</para>
								</item>
								<item>
									<label>•</label>
									<para>To take on empty stomach 1 hr before or 2 hr after meal; not to take missed dose within 12 hr of next scheduled dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>aflibercept</mono_name>
			<info>
				<pronunciation>(a-fli-ber′sept)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x52880">EYLEA</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier; signal transduction inhibitor (STIs) (Ophthalmic)</class>
			</info>
			<section type="actions" id="sidelem4x5294">
				<sec_title>Action:</sec_title>
				<para>A recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to human IgG1; acts as a soluble decoy receptor that binds vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF); can act as mitogenic, chemotactic, vascular permeability factors for endothelial cells; VEGF-A interacts with VEGFR-1 and VEGFR-2 on the surface of endothelial cells; results in neovascularization and vascular permeability; binding of aflibercept to VEGF-A and PIGF prevents activation of these receptors</para>
			</section>
			<section type="uses" id="sidelem4x5299">
				<sec_title>Uses:</sec_title>
				<para>For treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema after central retinal vein, diabetic retinopathy with diabetic macular edema</para>
			</section>
			<section type="contra" id="sidelem4x5304">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, ocular/periocular infection, active intraocular inflammation</para>
				<section type="none" id="sidelem4x5309">
					<section type="none" id="sidelem4x5310">
						<sec_title>Precautions:</sec_title>
						<para> Neonates, infants, children, adolescents, pregnancy (C), breastfeeding; history of glaucoma, ocular surgery; driving or operating machinery, increased intraocular pressure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5315">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5323">
					<label>•</label>
					<sec_title>Adult<route> Intravitreal INJ</route></sec_title>
					<para>
						<list id="lidelem4x5323">
							<item>
								<label>•</label>
								<para> 2 mg (0.05 ml) into affected eye(s) q4wk × 12 wk, then 2 mg (0.05 ml) q8wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5327">
					<section type="none" id="sidelem4x5328">
						<sec_title>Available forms:</sec_title>
						<para> Solution for injection 2 mg/0.05 ml</para>
					</section>
					<section type="none" id="sidelem4x5333">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5336">
							<sec_title>Intravitreal route</sec_title>
							<para>
								<list id="lidelem4x5340">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter, discoloration before use; do not use if particulates, cloudiness, discoloration are visible; only for use by physicians trained in administration</para>
									</item>
									<item>
										<label>•</label>
										<para>Use controlled aseptic conditions (sterile gloves, sterile drape, sterile eyelid speculum); adequate anesthesia, topical broad-spectrum antiinfective should be given before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Use each vial for treatment of single eye only; if other eye is being treated, use new vial and change the sterile field, syringe, gloves, drapes, eyelid speculum, filter, injection needles before administering to the other eye</para>
									</item>
									<item>
										<label>•</label>
										<para>Use aseptic technique: withdraw all of vial contents through a 5-micron 19-G filter needle attached to 1-ml syringe supplied by manufacturer; after vial contents are withdrawn, discard filter needle and replace with sterile 30-G × ½ inch needle for intravitreal injection; expel any air bubbles and contents of syringe until plunger tip is aligned with line that marks 0.05 ml</para>
									</item>
									<item>
										<label>•</label>
										<para>Immediately after the intravitreal injection, monitor patient for elevation in intraocular pressure (IOP); appropriate monitoring may consist of a check for perfusion of optic nerve head or tonometry; sterile paracentesis needle should be available if required</para>
									</item>
									<item>
										<label>•</label>
										<para>Storage: do not freeze, protect from light, refrigerate, store in original package until time of use</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5373">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5376">
					<section type="none" id="sidelem4x5377">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Arterial thromboembolism, nonfatal stroke, nonfatal myocardial infarction, vascular death</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5384">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Ocular hemorrhage, ocular pain, cataracts, vitreous detachment, vitreous floaters,</emphasis> conjunctival hyperemia, corneal erosion, detachment of retinal pigment epithelium, injection site pain, foreign body sensation, increased lacrimation, blurred vision, retinal pigment epithelium tear, injection site hemorrhage, blepharedema, corneal edema, increased intraocular pressure/ocular hypertension</para>
					</section>
					<section type="none" id="sidelem4x5392">
						<sec_title>SYST:</sec_title>
						<para> Hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5397">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorbed into systemic circulation; present in its unbound form and stable inactive form bound with endogenous VEGF; elimination by binding to free endogenous VEGF; metabolism by proteolysis; terminal half-life in plasma 5-6 days</para>
			</section>
			<section type="considerations" id="sidelem4x5402">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5405">
					<section type="none" id="sidelem4x5406">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5414">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x5414">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> monitor for infection during week after injection to permit early treatment of any ocular infection that may develop; proper aseptic injection technique should be used to minimize infection</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5421">
							<label>•</label>
							<sec_title>Increased intraocular pressure</sec_title>
							<para>
								<list id="lidelem4x5421">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Increased intraocular pressure:</emphasis> monitor for acute increases in intraocular pressure within 60 min of injection; sustained increases in intraocular pressure have been reported after repeated intravitreal dosing; monitor intraocular pressure and optic nerve head perfusion, a sterile paracentesis needle should be available</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5425">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5429">
								<item>
									<label>•</label>
									<para>Prevention of further vision loss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5435">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<emphasis alert="nurse">To seek immediate care if symptoms of endophthalmitis or retinal detachment develop (ocular pain, hyperemia of the conjunctiva, photophobia, blurry vision)</emphasis>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active">
			<mono_name>albumin, human 5% (Rx)</mono_name>
			<info>
				<pronunciation>(al-byoo′min)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x54484">Albumarc</tradename>
					<tradename id="tnidelem4x54483">Albuminar-5</tradename>
					<tradename id="tnidelem4x54482">Albutein 5%</tradename>
					<tradename id="tnidelem4x54481">Buminate 5%</tradename>
					<tradename id="tnidelem4x54480">Plasbumin-5</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="19" status="active">
			<mono_name>albumin, human 25%</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x54533">Albuminar-25</tradename>
					<tradename id="tnidelem4x54532">Albutein 25%</tradename>
					<tradename id="tnidelem4x54531">Buminate 25%</tradename>
					<tradename id="tnidelem4x54530">Plasbumin-25</tradename>
				</tradenames>
				<class type="func"> Plasma volume expander</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5459">
				<sec_title>Action:</sec_title>
				<para>Exerts oncotic pressure, which expands volume of circulating blood and maintains cardiac output</para>
			</section>
			<section type="uses" id="sidelem4x5464">
				<sec_title>Uses:</sec_title>
				<para>Restores plasma volume after burns, hyperbilirubinemia, shock, hypoproteinemia, prevention of cerebral edema, cardiopulmonary bypass procedures, ARDS, nephrotic syndrome</para>
			</section>
			<section type="contra" id="sidelem4x5471">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, CHF, severe anemia, renal insufficiency, pulmonary edema</para>
				<section type="none" id="sidelem4x5476">
					<section type="none" id="sidelem4x5477">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), decreased salt intake, decreased cardiac reserve, lack of albumin deficiency, renal/hepatic disease, chronic anemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5482">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5485">
					<section type="none" id="sidelem4x5486">
						<sec_title>Burns</sec_title>
						<section type="none" id="sidelem4x5494">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5494">
									<item>
										<label>•</label>
										<para> dose to maintain plasma albumin at 3-4 mg/dl</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5498">
						<sec_title>Hypovolemic Shock</sec_title>
						<section type="none" id="sidelem4x5506">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5506">
									<item>
										<label>•</label>
										<para> rapidly give 5% sol, when close to normal infusion at ≤2-4 ml/min (25% sol ≤1 ml/min)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5513">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5513">
									<item>
										<label>•</label>
										<para> 0.5-1 g/kg/dose 5% sol, may repeat as needed, max 6 g/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5517">
						<sec_title>Nephrotic Syndrome</sec_title>
						<section type="none" id="sidelem4x5525">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5525">
									<item>
										<label>•</label>
										<para> 100-200 ml of 25% and loop diuretic × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5529">
						<sec_title>Hypoproteinemia</sec_title>
						<section type="none" id="sidelem4x5537">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5537">
									<item>
										<label>•</label>
										<para> 25 g, may repeat in 15-30 min, or 50-75 g of 25% albumin infused at ≤2 ml/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5544">
							<label>•</label>
							<sec_title>Child and infant<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5544">
									<item>
										<label>•</label>
										<para> 0.5-1 g/kg/dose over 2-4 hr, may repeat q1-2days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5548">
						<sec_title>Hyperbilirubinemia/erythroblastosis fetalis</sec_title>
						<section type="none" id="sidelem4x5556">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5556">
									<item>
										<label>•</label>
										<para> 1 g/kg 1-2 hr before transfusion</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5560">
						<sec_title>Available forms:</sec_title>
						<para> Inj (5%) 50 mg/ml, (25%) 250 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x5565">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5568">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x5572">
									<item>
										<label>•</label>
										<para>Slowly, to prevent fluid overload; dilute with NS for injection or D<emphasis style="inf">5</emphasis>W; 5% is given undiluted; 25% may be given diluted or undiluted; give over 30-60 min, use infusion pump, use large-gauge needle; infusion must be completed within 4 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>5% solution may be used with hypovolemic/intravascular depletion</para>
									</item>
									<item>
										<label>•</label>
										<para>25% solution may be used with sodium/fluid restrictions</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> LR, NaCl, Ringer’s, D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">10</emphasis>W, D<emphasis style="inf">21/2</emphasis>W, NaCl 0.9%, dextrose/Ringer’s, dextrose/LR</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Diltiazem, LORazepam</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5608">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5611">
					<section type="none" id="sidelem4x5612">
						<sec_title>CNS:</sec_title>
						<para> Fever, chills, flushing, headache</para>
					</section>
					<section type="none" id="sidelem4x5617">
						<sec_title>CV:</sec_title>
						<para> Fluid overload, hypotension, erratic pulse, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x5622">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, increased salivation</para>
					</section>
					<section type="none" id="sidelem4x5627">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria</para>
					</section>
					<section type="none" id="sidelem4x5632">
						<sec_title>RESP:</sec_title>
						<para> Altered respirations, <emphasis style="bold">pulmonary edema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5639">
				<sec_title>Pharmacokinetics</sec_title>
				<para>In hyponutrition states, metabolized as protein/energy source; terminal half-life 16-24 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5644">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5647">
					<section type="none" id="sidelem4x5648">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum albumin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5655">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5658">
					<section type="none" id="sidelem4x5659">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5664">
								<item>
									<label>•</label>
									<para>Blood studies Hct, Hgb; if serum protein declines, dyspnea, hypoxemia can result</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5669">
								<item>
									<label>•</label>
									<para>Decreased B/P, erratic pulse, respiration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5674">
								<item>
									<label>•</label>
									<para>I&amp;O ratio: urinary output may decrease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5679">
								<item>
									<label>•</label>
									<para>Adequate hydration before, during administration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5684">
								<item>
									<label>•</label>
									<para>Check type of albumin; some stored at room temperature; some need to be refrigerated; use within 4 hr of opening</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5690">
								<item>
									<para>
										<emphasis alert="nurse">Circulatory/pulmonary overload: CVP, pulmonary wedge pressure distended neck veins indicate circulatory overload; shortness of breath, anxiety, insomnia, expiratory crackles, frothy blood-tinged cough, cyanosis indicate pulmonary overload</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5698">
							<label>•</label>
							<sec_title>Allergy<route> fever, rash, itching, chills, flushing, urticaria, nausea, vomiting, hypotension, requires discontinuation of infusion, use of new lot if therapy reinstituted; premedicate with diphenhydrAMINE</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5701">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5705">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased B/P, decreased edema, increased serum albumin levels, increased plasma protein</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5711">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5715">
								<item>
									<label>•</label>
									<para>Reason for product; to report hypersensitivity</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>albuterol (Rx)</mono_name>
			<info>
				<pronunciation>(al-byoo′ter-ole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x57279">Accuneb</tradename>
					<tradename id="tnidelem4x57278">
						<country code="CAN">Airomir </country>
					</tradename>
					<tradename id="tnidelem4x57277">ProAir HFA</tradename>
					<tradename id="tnidelem4x57276">ProAir RespiClick</tradename>
					<tradename id="tnidelem4x57275">Proventil</tradename>
					<tradename id="tnidelem4x57274">Proventil HFA</tradename>
					<tradename id="tnidelem4x57273">ReliOn</tradename>
					<tradename id="tnidelem4x57272">
						<country code="CAN">Salbutamol </country>
					</tradename>
					<tradename id="tnidelem4x57271">Ventolin HFA</tradename>
					<tradename id="tnidelem4x57270">VoSpire ER</tradename>
				</tradenames>
				<class type="func"> Adrenergic β-agonist, sympathomimetic, bronchodilator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5742">
				<para>
					<confusion>
						<tradename id="tnidelem4x57420">albuterol</tradename>
						<drug type="generic" refid="idelem4x57420">atenolol/Albutein</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5752">
				<sec_title>Action:</sec_title>
				<para>Causes bronchodilation by action on β<emphasis style="inf">2</emphasis> (pulmonary) receptors by increasing levels of cAMP, which relaxes smooth muscle; produces bronchodilation, CNS, cardiac stimulation as well as increased diuresis and gastric acid secretion; longer acting than isoproterenol</para>
			</section>
			<section type="uses" id="sidelem4x5760">
				<sec_title>Uses:</sec_title>
				<para>Prevention of exercise-induced asthma, acute bronchospasm, bronchitis, emphysema, bronchiectasis, or other reversible airway obstruction</para>
				<section type="none" id="sidelem4x5765">
					<section type="none" id="sidelem4x5766">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hyperkalemia in dialysis patients, COPD, emphysema</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5771">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics</para>
				<section type="none" id="sidelem4x5776">
					<section type="none" id="sidelem4x5777">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, cardiac/renal disease, hyperthyroidism, diabetes mellitus, hypertension, prostatic hypertrophy, angle-closure glaucoma, seizures, exercise-induced bronchospasm (aerosol) in children &lt;12 yr, hypoglycemia, tachydysrhythmias, severe cardiac disease, heart block</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5782">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5785">
					<section type="none" id="sidelem4x5786">
						<sec_title>Bronchospasm prophylaxis/treatment</sec_title>
						<section type="none" id="sidelem4x5794">
							<label>•</label>
							<sec_title>Adult and child ≥4 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x5794">
									<item>
										<label>•</label>
										<para> (metered-dose inhaler) 2 puffs (180 mcg) q4-6hr as needed;  (powdered inhaler) (ProAir RespiClick) <emphasis style="bold">&gt;12 yr:</emphasis> 180 mcg (2 INH) q4-6hr as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5804">
						<sec_title>Other respiratory conditions</sec_title>
						<section type="none" id="sidelem4x5812">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x5812">
									<item>
										<label>•</label>
										<para> (metered-dose inhaler) 1 puff q4-6hr;  2-4 mg tid-qid, max 32 mg;  2.5 mg tid-qid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5825">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5825">
									<item>
										<label>•</label>
										<para> 2 mg tid-qid, may increase gradually to 8 mg tid-qid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5832">
							<label>•</label>
							<sec_title>Child 2-12 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x5832">
									<item>
										<label>•</label>
										<para> (metered-dose inhaler) 0.1 mg/kg tid (max 2.5 mg tid-qid);  0.1-0.15 mg/kg/dose tid-qid or 1.25 mg tid-qid for child 10-15 kg or 2.5 mg tid-qid for child &gt;15 kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5839">
						<sec_title>Hyperkalemia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5847">
							<label>•</label>
							<sec_title>Adult<route> ORAL INH</route></sec_title>
							<para>
								<list id="lidelem4x5847">
									<item>
										<label>•</label>
										<para> (albuterol nebulizer sol) 10-20 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5851">
						<sec_title>Available forms:</sec_title>
						<para> INH aerosol 108 mcg/actuation; oral syr 2 mg/5 ml; tabs 2, 4 mg; ext rel 4, 8 mg; INH sol 0.63 mg/3 ml, 1.25 mg/3 ml; 0.083%, 0.5%, 0.042%, 0.021%; powder inhaler 90 mcg/actuation</para>
					</section>
					<section type="none" id="sidelem4x5856">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5860">
								<item>
									<label>•</label>
									<para>Store in light-resistant container; do not expose to temperatures of more than 86° F (30° C)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5866">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5871">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew ext rel tabs; give with meals to decrease gastric irritation</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5879">
								<label>•</label>
								<sec_title>
									<route>Oral sol</route>
								</sec_title>
								<para>
									<list id="lidelem4x5879">
										<item>
											<label>•</label>
											<para> to children (no alcohol, sugar)</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x5883">
							<sec_title>Inhalation route</sec_title>
							<para>
								<list id="lidelem4x5887">
									<item>
										<label>•</label>
										<para>For geriatric patients and children, a spacing device is advised</para>
									</item>
									<item>
										<label>•</label>
										<para>After shaking metered-dose inhaler, exhale, place mouthpiece in mouth, inhale slowly while depressing inhaler, hold breath, remove, exhale slowly; give INH at least 1 min apart</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5898">
						<sec_title>ProAir Respistick: </sec_title>
						<section type="none" id="sidelem4x5909">
							<label>•</label>
							<sec_title>
								<route>NEB/IPPB</route>
							</sec_title>
							<para>
								<list id="lidelem4x5909">
									<item>
										<label>•</label>
										<para> diluting 5 mg/ml sol/2.5 ml 0.9% NaCl for INH; other sol do not require dilution; for neb O<emphasis style="inf">2</emphasis> flow or compressed air 6-10 L/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5916">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5919">
					<section type="none" id="sidelem4x5920">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, anxiety,</emphasis> insomnia, headache, dizziness, stimulation, <emphasis style="italic">restlessness,</emphasis> hallucinations, flushing, irritability</para>
					</section>
					<section type="none" id="sidelem4x5931">
						<sec_title>CV:</sec_title>
						<para> Palpitations, tachycardia, angina, hypo/hypertension, dysrhythmias</para>
					</section>
					<section type="none" id="sidelem4x5936">
						<sec_title>EENT:</sec_title>
						<para> Dry nose, irritation of nose and throat</para>
					</section>
					<section type="none" id="sidelem4x5941">
						<sec_title>GI:</sec_title>
						<para> Heartburn, nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x5946">
						<sec_title>MISC:</sec_title>
						<para> Flushing, sweating, anorexia, bad taste/smell changes, hypokalemia, metabolic acidosis</para>
					</section>
					<section type="none" id="sidelem4x5951">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x5956">
						<sec_title>RESP:</sec_title>
						<para> Cough, wheezing, dyspnea, <emphasis style="bold">paradoxical bronchospasm,</emphasis> dry throat</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5964">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Extensively metabolized in the liver and tissues, crosses placenta, breast milk, blood-brain barrier</para>
				<section type="none" id="sidelem4x5969">
					<section type="none" id="sidelem4x5970">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, peak 2-3 hr, duration 4-6 hr, half-life 2.7-6 hr, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x5981">
						<sec_title>PO-ER:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; peak 2-3 hr; duration 8-12 hr</para>
					</section>
					<section type="none" id="sidelem4x5992">
						<sec_title>INH:</sec_title>
						<para> Onset 5-15 min, peak 11⁄2-2 hr, duration 2-6 hr, half-life 4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5997">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QTc prolongation—other drugs that increase QT prolongation</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin level—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS stimulation—CNS stimulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ECG changes/hypokalemia—potassium-losing diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe hypotension—oxytocics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of aerosol bronchodilators</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of albuterol—tricyclics, MAOIs, other adrenergics; do not use together</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CV effects—atomoxetine, selegiline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> albuterol—other β-blockers</para>
				<section type="none" id="sidelem4x6039">
					<section type="none" id="sidelem4x6040">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> stimulation—caffeine (cola nut, green/black tea, guarana, yerba maté, coffee, chocolate)</para>
					</section>
					<section type="none" id="sidelem4x6047">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6054">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6057">
					<section type="none" id="sidelem4x6058">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6066">
							<label>•</label>
							<sec_title>Respiratory function</sec_title>
							<para>
								<list id="lidelem4x6066">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory function:</emphasis> vital capacity, forced expiratory volume, ABGs; lung sounds, heart rate and rhythm, B/P, sputum (baseline and peak); whether patient has not received theophylline therapy before giving dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6070">
								<item>
									<label>•</label>
									<para>Patient’s ability to self-medicate</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6075">
								<item>
									<label>•</label>
									<para>For evidence of allergic reactions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6083">
							<label>•</label>
							<sec_title>
								<route>For paradoxical bronchospasm; hold medication, notify prescriber if bronchospasm occurs</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6086">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6090">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of dyspnea, wheezing after 1 hr, improved airway exchange, improved ABGs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6096">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6101">
								<item>
									<label>•</label>
									<para>To use exactly as prescribed; to take missed dose when remembered, alter dosing schedule; not to use OTC medications; that excess stimulation may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6108">
								<item>
									<label>•</label>
									<para>About use of inhaler: review package insert with patient; use demonstration; return demonstration; shake, prime before 1st use and when not used for &gt;2 wk; release 4 test sprays into air, away from the face; about when empty and when to renew</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6113">
								<item>
									<label>•</label>
									<para>To avoid getting aerosol in eyes (blurring of vision may result) or using near flames or sources of heat</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6118">
								<item>
									<label>•</label>
									<para>To wash inhaler in warm water daily and dry; to track number of inhalations used and to discard product when labeled inhalations have been used</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6123">
								<item>
									<label>•</label>
									<para>To avoid smoking, smoke-filled rooms, persons with respiratory infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6129">
								<item>
									<para>
										<emphasis alert="nurse">That paradoxical bronchospasm may occur; to stop product immediately, call prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6134">
								<item>
									<label>•</label>
									<para>To limit caffeine products such as chocolate, coffee, tea, colas</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x6139">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Administer β<emphasis style="inf">1</emphasis>-adrenergic blocker, IV fluids</para>
			</section>
		</monograph>
<monograph id="21" status="active" ru="yes">
			<mono_name>alemtuzumab</mono_name>
			<info>
				<pronunciation>(al′em-tooz′ue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x61540">Lemtrada</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier</class>
			</info>
			<section type="uses" id="sidelem4x6160">
				<sec_title>Uses:</sec_title>
				<para>Reserved for those with multiple sclerosis with inadequate response to ≥2 drugs because of severe adverse reactions</para>
			</section>
			<section type="contra" id="sidelem4x6165">
				<sec_title>Contraindications:</sec_title>
				<para>HIV</para>
			</section>
			<section type="doses" id="sidelem4x6170">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6178">
					<label>•</label>
					<sec_title>Adults<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x6178">
							<item>
								<label>•</label>
								<para> 12 mg daily 5 consecutive days (total 60 mg) for a first treatment course; follow 12 months later with 12 mg daily for 3 consecutive days (total 36 mg) for a second treatment course</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>alendronate (Rx)</mono_name>
			<info>
				<pronunciation>(al-en-drone′ate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x61872">Binosto</tradename>
					<tradename id="tnidelem4x61871">Fosamax</tradename>
					<tradename id="tnidelem4x61870">Fosamax plus D</tradename>
				</tradenames>
				<class type="func"> Bone-resorption inhibitor</class>
				<class type="chem"> Bisphosphonate</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6197">
				<para>
					<confusion>
						<tradename id="tnidelem4x61970">Fosamax</tradename>
						<drug type="generic" refid="idelem4x61970">Flomax</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6201">
				<sec_title>Action:</sec_title>
				<para>Decreases rate of bone resorption and may directly block dissolution of hydroxyapatite crystals of bone; inhibits osteoclast activity</para>
			</section>
			<section type="uses" id="sidelem4x6206">
				<sec_title>Uses:</sec_title>
				<para>Treatment and prevention of osteoporosis in postmenopausal women, treatment of osteoporosis in men, Paget’s disease, treatment of corticosteroid-induced osteoporosis in postmenopausal women not receiving estrogen and in men who are on continuing corticosteroid treatment with low bone mass</para>
			</section>
			<section type="contra" id="sidelem4x6211">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to bisphosphonates, delayed esophageal emptying, inability to sit or stand for 30 min, hypocalcemia</para>
				<section type="none" id="sidelem4x6216">
					<section type="none" id="sidelem4x6217">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, CCr &lt;35 ml/min, esophageal disease, ulcers, gastritis, poor dental health, increased esophageal cancer risk</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6222">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6225">
					<section type="none" id="sidelem4x6226">
						<sec_title>Osteoporosis in postmenopausal women</sec_title>
						<section type="none" id="sidelem4x6234">
							<label>•</label>
							<sec_title>Adult and geriatic<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6234">
									<item>
										<label>•</label>
										<para> 10 mg/day or 70 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6238">
						<sec_title>Paget’s disease</sec_title>
						<section type="none" id="sidelem4x6246">
							<label>•</label>
							<sec_title>Adult and geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6246">
									<item>
										<label>•</label>
										<para> 40 mg/day × 6 mo, consider retreatment for relapse</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6250">
						<sec_title>Prevention of osteoporosis</sec_title>
						<section type="none" id="sidelem4x6258">
							<label>•</label>
							<sec_title>Adult/postmenopausal female<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6258">
									<item>
										<label>•</label>
										<para> 5 mg/day or 35 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6262">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6270">
							<label>•</label>
							<sec_title>Adult<route> PO CCr ≤35 ml/min, not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6273">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 35, 40, 70 mg; tabs 70 mg with 2800 IU vit D<emphasis style="inf">3</emphasis>, 70 mg with 5600 IU vit D<emphasis style="inf">3</emphasis>; oral sol 70 mg/75 ml, effervescent tab 70 mg</para>
					</section>
					<section type="none" id="sidelem4x6286">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6291">
								<item>
									<label>•</label>
									<para>For 6 mo to be effective for Paget’s disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6296">
								<item>
									<label>•</label>
									<para>Store in cool environment, out of direct sunlight</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6304">
							<label>•</label>
							<sec_title>Tablet</sec_title>
							<para>
								<list id="lidelem4x6304">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Tablet:</emphasis> take with 8 oz of water 30 min before 1st food, beverage, or medication of the day</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6308">
								<item>
									<label>•</label>
									<para>Do not lie down for ≥30 min after dose; do not take at bedtime or before rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6316">
							<label>•</label>
							<sec_title>Liquid</sec_title>
							<para>
								<list id="lidelem4x6316">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Liquid:</emphasis> use oral syringe or calibrated device; give in <emphasis style="smallcaps">am</emphasis> with ≥2 oz of water ≥30 min before food, beverage, or medication</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6323">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6326">
					<section type="none" id="sidelem4x6327">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x6332">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, constipation, nausea, vomiting, esophageal ulceration, acid reflux, dyspepsia, <emphasis style="bold">esophageal perforation</emphasis>, diarrhea, <emphasis style="bold">esophageal cancer</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6342">
						<sec_title>META:</sec_title>
						<para> Hypophosphatemia, hypocalcemia</para>
					</section>
					<section type="none" id="sidelem4x6347">
						<sec_title>MS:</sec_title>
						<para> Bone pain, osteonecrosis of the jaw, bone fractures</para>
					</section>
					<section type="none" id="sidelem4x6352">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6359">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 78%, rapidly cleared from circulation, taken up mainly by bones, eliminated primarily through kidneys, bound to bone, half-life &gt;10 yr</para>
			</section>
			<section type="interactions" id="sidelem4x6364">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI adverse reactions—NSAIDs, salicylates, H<emphasis style="inf">2</emphasis> blockers, proton pump inhibitors, gastric mucosal agents</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—antacids, calcium supplements</para>
				<section type="none" id="sidelem4x6378">
					<section type="none" id="sidelem4x6379">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption when used with caffeine, orange juice, food</para>
					</section>
					<section type="none" id="sidelem4x6386">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, phosphate</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6393">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6396">
					<section type="none" id="sidelem4x6397">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6403">
								<item>
									<para>
										<emphasis alert="nurse">Serious reactions: angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, atrial fibrillation</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6408">
								<item>
									<label>•</label>
									<para>Hormonal status in women, before treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6416">
							<label>•</label>
							<sec_title>For osteoporosis</sec_title>
							<para>
								<list id="lidelem4x6416">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For osteoporosis:</emphasis> bone density test before and during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6423">
							<label>•</label>
							<sec_title>For Paget’s disease</sec_title>
							<para>
								<list id="lidelem4x6423">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For Paget’s disease:</emphasis> increased skull size, bone pain, headache; decreased vision, hearing</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6427">
								<item>
									<label>•</label>
									<para>Electrolytes; BUN/creatinine; calcium, phosphorous, magnesium, potassium</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6435">
							<label>•</label>
							<sec_title>For hypercalcemia</sec_title>
							<para>
								<list id="lidelem4x6435">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For hypercalcemia:</emphasis> paresthesia, twitching, laryngospasm; Chvostek’s, Trousseau’s signs</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6439">
								<item>
									<label>•</label>
									<para>Alk phos levels, baseline and periodically, 2× upper limit of normal is indicative of Paget’s disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6444">
								<item>
									<label>•</label>
									<para>Dental status: regular dental exams should be performed; dental extractions (cover with antiinfectives before procedure)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6449">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6453">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased bone mass, absence of fractures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6459">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6463">
								<item>
									<label>•</label>
									<para>To remain upright for 30 min after dose to prevent esophageal irritation; if dose is missed, skip dose, do not double doses or take later in day; to take in <emphasis style="smallcaps">am</emphasis> before food, other meds; to take with 6-8 oz of water only (no mineral water)</para>
								</item>
								<item>
									<label>•</label>
									<para>To take calcium, vit D if instructed by health care provider</para>
								</item>
								<item>
									<label>•</label>
									<para>To perform weight-bearing exercise to increase bone density</para>
								</item>
								<item>
									<label>•</label>
									<para>To let health care provider know if pregnant or if pregnancy is planned or if breastfeeding; to inform dentist of the use of this product</para>
								</item>
								<item>
									<label>•</label>
									<para>To maintain good oral hygiene</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>alfuzosin (Rx)</mono_name>
			<info>
				<pronunciation>(al-fyoo′zoe-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x64981">Uroxatral</tradename>
					<tradename id="tnidelem4x64980">
						<country code="CAN">Xatral </country>
					</tradename>
				</tradenames>
				<class type="func"> Urinary tract, antispasmodic, α-agonist</class>
				<class type="chem"> Quinazolone</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x6513">
				<sec_title>Action:</sec_title>
				<para>Binds to α<emphasis style="inf">1A</emphasis>-adrenoceptor subtype located mainly in the prostate, relaxing smooth muscles</para>
			</section>
			<section type="uses" id="sidelem4x6521">
				<sec_title>Uses:</sec_title>
				<para>Symptoms of benign prostatic hyperplasia</para>
				<section type="none" id="sidelem4x6526">
					<section type="none" id="sidelem4x6527">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Erectile dysfunction with sildenafil</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6532">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, moderate to severe hepatic impairment; not indicated for use in women or children, breastfeeding</para>
				<section type="none" id="sidelem4x6537">
					<section type="none" id="sidelem4x6538">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) but not used in females, geriatric patients; CAD, coronary insufficiency, mild hepatic disease, mild/moderate/severe renal disease, history of QT prolongation or coadministration with meds known to prolong QT interval, torsades de pointes, syncope, surgery, prostate cancer, orthostatic hypotension, ocular surgery, dysrhythmias, angina</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6543">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6551">
					<label>•</label>
					<sec_title>Adult<route> PO EXT REL</route></sec_title>
					<para>
						<list id="lidelem4x6551">
							<item>
								<label>•</label>
								<para> 10 mg/day, taken after same meal each day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6555">
					<section type="none" id="sidelem4x6556">
						<sec_title>Available forms:</sec_title>
						<para> Ext rel tabs 10 mg</para>
					</section>
					<section type="none" id="sidelem4x6561">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6564">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6568">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew tabs; give with food; take at same time each day</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight container in cool environment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6579">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6582">
					<section type="none" id="sidelem4x6583">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> fatigue, flushing</para>
					</section>
					<section type="none" id="sidelem4x6591">
						<sec_title>CV:</sec_title>
						<para> Postural hypotension (dizziness, lightheadedness, fainting) within a few hours of administration, chest pain, tachycardia, angina</para>
					</section>
					<section type="none" id="sidelem4x6596">
						<sec_title>GI:</sec_title>
						<para> Nausea, abdominal pain, dyspepsia, constipation, diarrhea, liver injury, jaundice</para>
					</section>
					<section type="none" id="sidelem4x6601">
						<sec_title>GU:</sec_title>
						<para> Impotence, priapism</para>
					</section>
					<section type="none" id="sidelem4x6606">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6613">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, <emphasis style="bold">angioedema,</emphasis> pruritus, <emphasis style="bold">toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6623">
						<sec_title>MISC:</sec_title>
						<para> Body pain in general, xerostomia, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x6628">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory infection, pharyngitis, bronchitis, sinusitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6633">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 8 hr, elimination half-life 10 hr, extensively metabolized in liver by CYP3A4 enzyme, excreted via urine (11% unchanged), moderately protein binding (82%-90%)</para>
			</section>
			<section type="interactions" id="sidelem4x6638">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x6646">
					<label>•</label>
					<sec_title>
						<route>Not to be taken with prazosin, terazosin, doxazosin</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation (slight)—class IA/III antidysrhythmics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of alfuzosin—alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—CYP3A4 inhibitors (ketoconazole, itraconazole, cimetidine and ritonavir); do not use together</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—β-blockers, phosphodiesterase type 5 inhibitors, nitrates, antihypertensives</para>
			</section>
			<section type="considerations" id="sidelem4x6664">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6667">
					<section type="none" id="sidelem4x6668">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6676">
							<label>•</label>
							<sec_title>Prostatic hyperplasia</sec_title>
							<para>
								<list id="lidelem4x6676">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Prostatic hyperplasia:</emphasis> change in urinary patterns (hesitancy, dribbling, dysuria, urgency), baseline and throughout treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6683">
							<label>•</label>
							<sec_title>Serious skin reactions<route> angioedema, toxic epidermal necrolysis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6686">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6690">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of benign prostatic hyperplasia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6696">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6700">
								<item>
									<label>•</label>
									<para>To take at same time each day with food; to not double doses</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to drive or operate machinery for 4 hr after 1st dose or after dosage increase, dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>About orthostatic hypotension; to rise slowly from sitting or lying</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid all OTC products, meds, herbs unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of fainting, dizziness</para>
								</item>
								<item>
									<label>•</label>
									<para>That erectile dysfunction is a side effect and is temporary</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>aliskiren (Rx)</mono_name>
			<info>
				<pronunciation>(a-lis′kir-en)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x67381">
						<country code="CAN">Rasilez </country>
					</tradename>
					<tradename id="tnidelem4x67380">Tekturna</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Direct renin inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x6751">
				<sec_title>Action:</sec_title>
				<para>Renin inhibitor that acts on the renin-angiotensin system (RAS)</para>
			</section>
			<section type="uses" id="sidelem4x6756">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with other antihypertensives</para>
			</section>
			<section type="contra" id="sidelem4x6761">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x6776">
					<section type="none" id="sidelem4x6777">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, angioedema, aortic/renal artery stenosis, cirrhosis, CAD, dialysis, hyper/hypokalemia, hyponatremia, hypotension, hypovolemia, renal/hepatic disease, surgery, diabetes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6782">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6790">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6790">
							<item>
								<label>•</label>
								<para> 150 mg/day, may increase to 300 mg/day if needed, max 300 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6794">
					<section type="none" id="sidelem4x6795">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 150, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x6800">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6804">
								<item>
									<label>•</label>
									<para>May use with other antihypertensives</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use with a high-fat meal</para>
								</item>
								<item>
									<label>•</label>
									<para>Daily with a full glass of water, titrate up to achieve correct dose</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not discontinue abruptly, correct electrolyte/volume depletion before treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6830">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6833">
					<section type="none" id="sidelem4x6834">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, hypotension</para>
					</section>
					<section type="none" id="sidelem4x6839">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6846">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6853">
						<sec_title>GU:</sec_title>
						<para> Renal stones, increased uric acid</para>
					</section>
					<section type="none" id="sidelem4x6858">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x6863">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x6868">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Angioedema,</emphasis> cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6876">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Poorly absorbed, bioavailability 2.5%, peak 1-3 hr, steady state 7-8 days, 91% excreted unchanged in the feces, half-life 24 hr</para>
			</section>
			<section type="interactions" id="sidelem4x6881">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x6889">
					<label>•</label>
					<sec_title>
						<route>Do not use with ACE inhibitors, angiotensin II receptor antagonists in diabetes mellitus</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> potassium levels—ACE inhibitors, angiotensin II receptor antagonists, potassium supplements, potassium-sparing diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—other antihypertensives, diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> aliskiren levels—atorvastatin, itraconazole, ketoconazole, cycloSPORINE; concurrent use is not recommended</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of warfarin</para>
				<section type="none" id="sidelem4x6908">
					<section type="none" id="sidelem4x6909">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> aliskiren effect—high-fat meal, grapefruit</para>
					</section>
					<section type="none" id="sidelem4x6916">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid, BUN, serum creatinine, potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6923">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6926">
					<section type="none" id="sidelem4x6927">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6932">
								<item>
									<label>•</label>
									<para>Renal studies: uric acid, serum creatinine, BUN may be increased; potassium, hyperkalemia may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6938">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions: angioedema may occur (swelling of face; trouble breathing, swallowing)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6943">
								<item>
									<label>•</label>
									<para>Daily dependent edema in feet, legs; weight, B/P, orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6951">
							<label>•</label>
							<sec_title>Diabetes<route> identify the use of ACE inhibitors, angiotensin II receptor antagonists if in use, do not use aliskiren</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6954">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6958">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6964">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6969">
								<item>
									<label>•</label>
									<para>About the importance of complying with dosage schedule even if feeling better; that if dose is missed, take as soon as possible; that if it is almost time for the next dose, take only that dose; do not double dose
<bbw>To notify if pregnancy is planned or suspected; if pregnant, product will need to be discontinued, pregnancy (D)</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6985">
								<item>
									<label>•</label>
									<para>How to take B/P and normal reading for age group</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6990">
								<item>
									<label>•</label>
									<para>Not to use OTC products including herbs, supplements unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6998">
							<label>•</label>
							<sec_title>To report to prescriber immediately<route> dizziness, faintness, chest pain, palpitations, uneven or rapid heart beat, headache, severe diarrhea, swelling of tongue or lips, trouble breathing, difficulty swallowing, tightening of the throat</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7001">
								<item>
									<label>•</label>
									<para>Not to operate machinery or perform hazardous tasks if dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7006">
								<item>
									<label>•</label>
									<para>To rise slowly; to avoid faintness</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>allopurinol (Rx)</mono_name>
			<info>
				<pronunciation>(al-oh-pure′i-nole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x70163">
						<country code="CAN">Alloprin </country>
					</tradename>
					<tradename id="tnidelem4x70162">Aloprim</tradename>
					<tradename id="tnidelem4x70161">Purinol 1</tradename>
					<tradename id="tnidelem4x70160">Zyloprim</tradename>
				</tradenames>
				<class type="func"> Antigout drug, antihyperuricemic</class>
				<class type="chem"> Xanthine oxidase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7029">
				<para>
					<confusion>
						<tradename id="tnidelem4x70290">Zyloprim</tradename>
						<drug type="generic" refid="idelem4x70290">Zovirax/Zorprin/zolpidem</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7033">
				<sec_title>Action:</sec_title>
				<para>Inhibits the enzyme xanthine oxidase, reducing uric acid synthesis</para>
			</section>
			<section type="uses" id="sidelem4x7038">
				<sec_title>Uses:</sec_title>
				<para>Chronic gout, hyperuricemia associated with malignancies, recurrent calcium oxalate calculi, uric acid calculi</para>
			</section>
			<section type="contra" id="sidelem4x7043">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x7048">
					<section type="none" id="sidelem4x7049">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7054">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7057">
					<section type="none" id="sidelem4x7058">
						<sec_title>Increased uric acid levels in malignancies</sec_title>
						<section type="none" id="sidelem4x7066">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7066">
									<item>
										<label>•</label>
										<para> 600-800 mg/day in divided doses for 2-3 days; start up to 1-2 days before chemotherapy;  200-400 mg/m<emphasis style="sup">2</emphasis>/day, max 600 mg/day 24-48 hr before chemotherapy, may be divided at 6-, 8-, 12-hr intervals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7079">
							<label>•</label>
							<sec_title>Child 6-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7079">
									<item>
										<label>•</label>
										<para> 300 mg/day, adjust dose after 48 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7086">
							<label>•</label>
							<sec_title>Child &lt;6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7086">
									<item>
										<label>•</label>
										<para> 150 mg/day, adjust dose after 48 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7093">
							<label>•</label>
							<sec_title>Child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7093">
									<item>
										<label>•</label>
										<para> 200 mg/m<emphasis style="sup">2</emphasis>/day, initially as a single dose or divided q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7100">
						<sec_title>Recurrent calculi</sec_title>
						<section type="none" id="sidelem4x7108">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7108">
									<item>
										<label>•</label>
										<para> 200-300 mg/day in a single dose or divided bid-tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7112">
						<sec_title>Uric acid nephropathy prevention</sec_title>
						<section type="none" id="sidelem4x7120">
							<label>•</label>
							<sec_title>Adult and child &gt;10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7120">
									<item>
										<label>•</label>
										<para> 600-800 mg/day × 2-3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7124">
						<sec_title>Gout (mild)</sec_title>
						<section type="none" id="sidelem4x7132">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7132">
									<item>
										<label>•</label>
										<para> 200-300 mg/day, increase weekly based on uric acid levels, max 800 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7136">
						<sec_title>Gout (moderate-severe)</sec_title>
						<section type="none" id="sidelem4x7144">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7144">
									<item>
										<label>•</label>
										<para> 400-600 mg/day in a single dose or divided bid-tid, max 800 mg/day, doses &gt;300 mg should be given in divided doses, may start during an acute attack as long as antiinflammatory drugs are being used</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7148">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7156">
							<label>•</label>
							<sec_title>Adult<route> PO/IV CCr 81-100 ml/min 300 mg/day; CCr 61-80 ml/min 250 mg/day; CCr 41-60 ml/min 200 mg/day; 21-40 ml/min 150 mg/day; CCr 10-20 ml/min 100-200 mg/day; CCr 3-9 ml/min 100 mg/day or 100 mg every other day; CCr &lt;3 ml/min 100 mg q24hr or longer or 100 mg every 3rd day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7159">
						<sec_title>Available forms:</sec_title>
						<para> Tabs, scored 100, 300 mg; powder for inj 500 mg/vial</para>
					</section>
					<section type="none" id="sidelem4x7164">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7167">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7171">
									<item>
										<label>•</label>
										<para>With meals to prevent GI symptoms; may crush, add to foods or fluids</para>
									</item>
									<item>
										<label>•</label>
										<para>Begin 1-2 days before antineoplastic therapy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7182">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7186">
									<item>
										<label>•</label>
										<para>Reconstitute 30-ml vial with 25 ml of sterile water for inj; dilute to desired concentrations (≤6 mg/ml) with 0.9% NaCl for inj or D<emphasis style="inf">5</emphasis> for inj; begin infusion within 10 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7197">
						<sec_title>Y-site compatibilities:</sec_title>
						<para> Acyclovir, aminophylline, amphotericin B lipid complex, anidulafungin, argatroban, atenolol, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, caspofungin, ceFAZolin, cefoTEtan, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, CISplatin, cyclophosphamide, DACTINomycin, DAUNOrubicin citrate liposome, dexamethasone, dexmedetomidine, DOCEtaxel, DOXOrubicin liposomal, enalaprilat, etoposide, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, fluorouracil, furosemide, gallium, ganciclovir, gatifloxacin, gemcitabine, gemtuzumab, granisetron hydrochloride, heparin, hydrocortisone phosphate, hydrocortisone succinate, HYDROmorphone, ifosfamide, linezolid injection, LORazepam, mannitol, mesna, methotrexate, metroNIDAZOLE, milrinone, mitoXANtrone, morphine, nesiritide, octreotide, oxytocin, PACLitaxel, pamidronate, pantoprazole, PEMEtrexed, piperacillin, piperacillin-tazobactam, plicamycin, potassium chloride, ranitidine, sodium acetate, sulfamethoxazole-trimethoprim, teniposide, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, vancomycin, vasopressin, vinBLAStine, vinCRIStine, voriconazole, zidovudine, zoledronic acid</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7202">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7205">
					<section type="none" id="sidelem4x7206">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, malaise,</emphasis> cramps, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x7214">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x7219">
						<sec_title>MS:</sec_title>
						<para> Acute gouty attack</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7224">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding &lt;1%, half-life 1-2 hr</para>
				<section type="none" id="sidelem4x7229">
					<section type="none" id="sidelem4x7230">
						<sec_title>PO:</sec_title>
						<para> Peak 1.5 hr; excreted in feces, urine</para>
					</section>
					<section type="none" id="sidelem4x7235">
						<sec_title>IV:</sec_title>
						<para> Peak up to 30 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7240">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> kidney stone formation—ammonium chloride, vit C, potassium/sodium phosphate</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> rash—ampicillin, amoxicillin, avoid concurrent use</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of oral anticoagulants, oral antidiabetics, theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypersensitivity, toxicity—ACE inhibitors, thiazides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow depression—antineoplastics (mercaptopurine, azaTHIOprine)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> xanthine nephropathy, calculi—rasburicase</para>
			</section>
			<section type="considerations" id="sidelem4x7267">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7270">
					<section type="none" id="sidelem4x7271">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7279">
							<label>•</label>
							<sec_title>For gout</sec_title>
							<para>
								<list id="lidelem4x7279">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For gout:</emphasis> joint pain, swelling; may use with NSAIDs for acute gouty attacks; uric acid levels q2wk; uric acid levels should be ≤6 mg/dl, effect may take several wk</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7283">
								<item>
									<label>•</label>
									<para>CBC, AST, BUN, creatinine before starting treatment, periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7288">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; increase fluids to 2 L/day to prevent stone formation and toxicity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7293">
								<item>
									<label>•</label>
									<para>For rash, hypersensitivity reactions, discontinue allopurinol</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7298">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7302">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain in joints, decreased stone formation in kidneys, decreased uric acid levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7308">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7312">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, take as soon as remembered; do not double dose; tabs may be crushed</para>
								</item>
								<item>
									<label>•</label>
									<para>To increase fluid intake to 2 L/day</para>
								</item>
								<item>
									<label>•</label>
									<para>To report skin rash, stomatitis, malaise, fever, aching; product should be discontinued</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsiness or dizziness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, caffeine; will increase uric acid levels</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid large doses of vit C; kidney stone formation may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To reduce dairy products, refined sugars, sodium, meat if taking for calcium oxalate stones</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>almotriptan (Rx)</mono_name>
			<info>
				<pronunciation>(al-moh-trip′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x73540">Axert</tradename>
				</tradenames>
				<class type="func"> Antimigraine agent, abortive</class>
				<class type="chem"> 5-HT-receptor agonist, triptan</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7367">
				<para>
					<confusion>
						<tradename id="tnidelem4x73670">Axert</tradename>
						<drug type="generic" refid="idelem4x73670">Antivert</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7371">
				<sec_title>Action:</sec_title>
				<para>Binds selectively to the vascular 5-HT<emphasis style="inf">1B/1D/1F</emphasis>-receptors, exerts antimigraine effect</para>
			</section>
			<section type="uses" id="sidelem4x7379">
				<sec_title>Uses:</sec_title>
				<para>Acute treatment of migraine with or without aura (adult/adolescent/child ≥12 yr)</para>
			</section>
			<section type="contra" id="sidelem4x7384">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, acute MI, angina, CV disease, CAD, stroke, vasospastic angina, ischemic heart disease or risk for, peripheral vascular syndrome, uncontrolled hypertension, basilar or hemiplegic migraine</para>
				<section type="none" id="sidelem4x7389">
					<section type="none" id="sidelem4x7390">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), postmenopausal women, men &gt;40 yr, breastfeeding, children &lt;18 yr, geriatric patients, risk factors for CAD, MI; hypercholesterolemia, obesity, diabetes, impaired renal/hepatic function, sulfonamide hypersensitivity, cardiac dysrhythmias, Raynaud’s disease, tobacco smoking, Wolff-Parkinson-White syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7395">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7403">
					<label>•</label>
					<sec_title>Adult, adolescent, and child ≥12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7403">
							<item>
								<label>•</label>
								<para> 6.25 or 12.5 mg; may repeat dose after 2 hr; max 2 doses/24 hr, 25 mg/day or 4 treatment cycles within any 30-day period</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7407">
					<section type="none" id="sidelem4x7408">
						<sec_title>Hepatic/renal dose CCr 10-30 ml/min</sec_title>
						<section type="none" id="sidelem4x7416">
							<label>•</label>
							<sec_title>Adult<route> PO 6.25 mg initially, max 12.5 mg</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7419">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 6.25, 12.5 mg</para>
					</section>
					<section type="none" id="sidelem4x7424">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7428">
								<item>
									<label>•</label>
									<para>Avoid using more than 2×/24 hr; rebound headache may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Swallow tabs whole; do not break, crush, chew, without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7439">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7442">
					<section type="none" id="sidelem4x7443">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> headache, <emphasis style="bold">seizures,</emphasis> paresthesias</para>
					</section>
					<section type="none" id="sidelem4x7454">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Flushing,</emphasis> palpitations, tachycardia, <emphasis style="bold">coronary artery vasospasm, MI, ventricular fibrillation, ventricular tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7464">
						<sec_title>EENT:</sec_title>
						<para> Throat, mouth, nasal discomfort; vision changes</para>
					</section>
					<section type="none" id="sidelem4x7469">
						<sec_title>GI:</sec_title>
						<para> Nausea, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x7474">
						<sec_title>INTEG:</sec_title>
						<para> Sweating, rash</para>
					</section>
					<section type="none" id="sidelem4x7479">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Weakness, neck stiffness,</emphasis> myalgia</para>
					</section>
					<section type="none" id="sidelem4x7487">
						<sec_title>RESP:</sec_title>
						<para> Chest tightness, pressure</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7492">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset of pain relief 2 hr; peak 1-3 hr; duration 3-4 hr; bioavailability 70%; protein binding 35%; metabolized in the liver (metabolite), metabolized by MAO-A, CYP2D6, CYP3A4; excreted in urine (40%), feces (13%); half-life 3-4 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7497">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs, serotonin-receptor agonists, sibutramine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> vasospastic effects—ergot, ergot derivatives, other 5-HT<emphasis style="inf">1</emphasis> agonists; avoid concurrent use</para>
				<para>
					<emphasis alert="nurse">Increase: almotriptan effect—MAOIs, do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentration of almotriptan—(CYP3A4 inhibitors) itraconazole, ritonavir, erythromycin, ketoconazole, avoid concurrent use in renal/hepatic disease</para>
				<section type="none" id="sidelem4x7519">
					<section type="none" id="sidelem4x7520">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x7524">
								<item>
									<label>•</label>
									<para>Avoid use with feverfew</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> serotonin syndrome—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7534">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7537">
					<section type="none" id="sidelem4x7538">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7546">
							<label>•</label>
							<sec_title>Migraine</sec_title>
							<para>
								<list id="lidelem4x7546">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Migraine:</emphasis> pain location, aura, duration, intensity, nausea, vomiting</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7553">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> occurs in those taking SSRIs, SNRIs; agitation, confusion, hallucinations, diaphoresis, hypertension, diarrhea, fever, tremors, usually occurs when dose is increased</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7556">
								<item>
									<label>•</label>
									<para>B/P; signs/symptoms of coronary vasospasms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7561">
								<item>
									<label>•</label>
									<para>For stress level, activity, recreation, coping mechanisms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7567">
								<item>
									<label>•</label>
									<para>Neurologic status: LOC, blurring vision, nausea, vomiting, tingling, hot sensation, burning, feeling of pressure, numbness, flushing preceding headache</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7575">
							<label>•</label>
							<sec_title>
								<route>Tyramine foods</route>
							</sec_title>
							<para>
								<list id="lidelem4x7575">
									<item>
										<label>•</label>
										<para> (pickled products, beer, wine, aged cheese), food additives, preservatives, colorings, artificial sweeteners, chocolate, caffeine, which may precipitate these types of headaches</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7579">
								<item>
									<label>•</label>
									<para>Quiet, calm environment with decreased stimulation from noise, bright light, excessive talking</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7584">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7588">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in severity of migraine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7594">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7598">
								<item>
									<label>•</label>
									<para>To report chest pain, drowsiness, dizziness, tingling, flushing</para>
								</item>
								<item>
									<label>•</label>
									<para>To use contraception while taking product, to notify prescriber if pregnancy is planned or suspected, to avoid breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>That if one dose does not relieve migraine, to take another after 2 hr, max 4 doses/30 days, do not take MAOIs for ≥ 24 hrs</para>
								</item>
								<item>
									<label>•</label>
									<para>That product does not prevent or reduce number of migraine attacks; use to relieve attack only</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>alogliptin</mono_name>
			<info>
				<pronunciation>(al′oh-glip′tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x76240">Nesina</tradename>
				</tradenames>
				<class type="func"> Antidiabetic</class>
				<class type="chem"> Dipeptidyl peptidase-4 (DPP-4) inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x7634">
				<sec_title>Action:</sec_title>
				<para>A dipeptidyl-peptidase-IV (DDP-IV) inhibitor for the treatment of type 2 diabetes mellitus (monotherapy or in combination with other antidiabetic agents), potentiates the effects of the incretin hormones by inhibiting their breakdown by DDP-IV</para>
			</section>
			<section type="uses" id="sidelem4x7639">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus (T2DM)</para>
			</section>
			<section type="contra" id="sidelem4x7644">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x7649">
					<section type="none" id="sidelem4x7650">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, hepatic disease, burns, ketoacidosis, diarrhea, fever, GI obstruction, hyper/hypoglycemia, hyper/hypothyroidism, type 1 diabetes, hypercortisolism, children, ileus, malnutrition, pancreatitis, surgery, trauma, vomiting, kidney disease, adrenal insufficiency, <emphasis style="bold">angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7657">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7665">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7665">
							<item>
								<label>•</label>
								<para> 25 mg/day; when used in combination, a lower dose of the other antidiabetic may be needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7669">
					<section type="none" id="sidelem4x7670">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7678">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30–59 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7681">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 6.25, 12.5, 25 mg</para>
					</section>
					<section type="none" id="sidelem4x7686">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7690">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7696">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7699">
					<section type="none" id="sidelem4x7700">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x7705">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7712">
						<sec_title>META:</sec_title>
						<para> Hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x7717">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory infection, nasopharyngitis</para>
					</section>
					<section type="none" id="sidelem4x7722">
						<sec_title>SYST:</sec_title>
						<para> Rash, hypersensitivity, <emphasis style="bold">angioedema, Stevens–Johnson syndrome, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7729">
				<sec_title>Pharmacokinetics</sec_title>
				<para>20% protein binding, excreted unchanged (urine), peak 1-2 hr, effect decreased in liver disease and increased in kidney disease, half-life 21 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7734">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia-insulin, sulfonylureas</para>
				<section type="none" id="sidelem4x7741">
					<section type="none" id="sidelem4x7742">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7754">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7757">
					<section type="none" id="sidelem4x7758">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7766">
							<label>•</label>
							<sec_title>Diabetes</sec_title>
							<para>
								<list id="lidelem4x7766">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Diabetes:</emphasis> monitor blood glucose, glycosylated hemoglobin A1c (A1c), LFTs, serum creatinine/BUN</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7771">
								<item>
									<para>
										<emphasis alert="nurse">Pancreatitis: can occur during use</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7777">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitivity reactions: angioedema, Stevens–Johnson syndrome; product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7782">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7786">
								<item>
									<label>•</label>
									<para>Positive therapeutic response: decrease in polyuria, polydipsia, polyphagia, clear sensorium, absence of dizziness, improvement in A1c, daily blood glucose monitoring</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7792">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7796">
								<item>
									<label>•</label>
									<para>That diabetes is a life-long condition, product does not cure disease</para>
								</item>
								<item>
									<label>•</label>
									<para>That all food in diet plan must be eaten to prevent hypoglycemia; to continue with weight control, dietary medical nutrition therapy, physical activity, hygiene</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID with prescriber, medications, and condition listed</para>
								</item>
								<item>
									<label>•</label>
									<para>To test blood glucose using a blood glucose meter</para>
								</item>
								<item>
									<label>•</label>
									<para>To report allergic reactions, nausea, vomiting, abdominal pain, dark urine</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>alosetron</mono_name>
			<info>
				<pronunciation>(ah-loss′a-tron)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x78270">Lotronex</tradename>
				</tradenames>
				<class type="func"> Antidiarrheal, anti-IBS agent</class>
				<class type="chem"> Serotonin receptor antagonist</class>
			</info>
			<section type="confusion" id="sidelem4x7837">
				<para>
					<confusion>
						<tradename id="tnidelem4x78370">Lotronex</tradename>
						<drug type="generic" refid="idelem4x78370">Lovenox</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7841">
				<sec_title>Action:</sec_title>
				<para>A potent and selective antagonist at serotonin 5-HT<emphasis style="inf">3</emphasis> receptors, which are extensively distributed on enteric neurons in GI tract. Antagonism at these receptors in the GI tract modulates the regulation of visceral pain, colonic transit, and GI secretions</para>
			</section>
			<section type="uses" id="sidelem4x7849">
				<sec_title>Uses:</sec_title>
				<para>Severe, chronic, diarrhea-predominant irritable bowel syndrome (IBS) in women who have failed conventional therapy</para>
			</section>
			<section type="contra" id="sidelem4x7854">
				<sec_title>Contraindications:</sec_title>
				<para>Crohn’s disease, severe hepatic disease, diverticulitis, toxic megacolon, GI adhesions/strictures/obstruction/perforation, thrombophlebitis, ulcerative colitis</para>
				<para>
					<bbw>Ischemic colitis, severe constipation</bbw>
				</para>
				<section type="none" id="sidelem4x7869">
					<section type="none" id="sidelem4x7870">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, pregnancy (B), child &lt;18 yr, mild-moderate hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7875">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7883">
					<label>•</label>
					<sec_title>Adult woman<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7883">
							<item>
								<label>•</label>
								<para> 0.5 mg bid, may increase to 1 mg bid after 4 wk if well tolerated; if symptoms are not controlled after 4 wk of treatment with 1 mg bid, discontinue</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7887">
					<section type="none" id="sidelem4x7888">
						<sec_title>Available forms:</sec_title>
						<para>Tab 0.5 mg, 1 mg</para>
					</section>
					<section type="none" id="sidelem4x7893">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7897">
								<item>
									<label>•</label>
									<para>Without regard to meals with full glass of water
<bbw>Only after “Physician–Patient Agreement Form” is signed and patient receives official Medication Guide</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature, protect from light and moisture</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7917">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7920">
					<section type="none" id="sidelem4x7921">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, headache</para>
					</section>
					<section type="none" id="sidelem4x7926">
						<sec_title>GI:</sec_title>
						<para> Constipation, abdominal pain, distention, reflux, nausea, <emphasis style="bold">obstruction,</emphasis> impaction, <emphasis style="bold">ischemic colitis, ileus perforation, small-bowel mesenteric ischemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7936">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Urinary tract infection</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7943">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Muscle spasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7950">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Cough, nasopharyngitis, upper respiratory tract infection</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7957">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1 hr, half-life 1½ hr, metabolized extensively in the liver, mainly excreted in urine</para>
			</section>
			<section type="interactions" id="sidelem4x7963">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x7971">
					<label>•</label>
					<sec_title>
						<route>Do not use with fluvoxaMINE</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> Alosetron metabolism—CYP3A4, 1A2, 2C9 inducers</para>
				<para>
					<emphasis alert="lifethreat">Increase: serious adverse reactions, drugs that decrease GI motility—drugs with anticholinergic effect such as TCAs, H1-blockers, orphenadrine, OLANZapine, maprotiline, disopyramide, cyclobenzaprine, cloZAPine, buPROPion, amoxapine, amantadine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> Alosetron metabolism—CYP3A4, 1A2, 2C9 inhibitors, hydrALAZINE, procainamide</para>
				<section type="none" id="sidelem4x7985">
					<section type="none" id="sidelem4x7986">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7993">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7996">
					<section type="none" id="sidelem4x7997">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Irritable bowel syndrome—constipation, diarrhea, abdominal pain, fecal incontinence; discontinue immediately if bloody diarrhea, severe constipation, rectal bleeding, or severe abdominal pain occur</bbw>
						</para>
						<para>
							<bbw>Only clinicians enrolled in the Prometheus Prescribing Program for Lotronex should use this product</bbw>
						</para>
						<para>
							<list id="lidelem4x8020">
								<item>
									<label>•</label>
									<para>Geriatric female patients can experience more severe side effects</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8026">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8030">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing symptoms of IBS</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8036">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Immediately report severe constipation, bloody diarrhea, rectal bleeding, or worsening abdominal pain</bbw>
						</para>
						<para>
							<list id="lidelem4x8049">
								<item>
									<label>•</label>
									<para>Not to double doses; if a dose is missed skip it; do not take with other meds or herbs without prescriber approval</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may be taken without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>That product does not cure disorder, only controls symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Provide medication guide and clarify, if needed, that improvement in symptoms can take 1-4 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is only used for women with IBS</para>
								</item>
								<item>
									<label>•</label>
									<para>To report if pregnancy is planned or suspected; product should not be used during pregnancy, effects are unknown</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active">
			<mono_name>ALPRAZolam (Rx)</mono_name>
			<info>
				<pronunciation>(al-pray′zoe-lam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x80855">
						<country code="CAN">Apo-Alpraz </country>
					</tradename>
					<tradename id="tnidelem4x80854">Niravam</tradename>
					<tradename id="tnidelem4x80853">
						<country code="CAN">Novo-Alprazol </country>
					</tradename>
					<tradename id="tnidelem4x80852">
						<country code="CAN">Nu-Alpraz </country>
					</tradename>
					<tradename id="tnidelem4x80851">Xanax</tradename>
					<tradename id="tnidelem4x80850">Xanax XR</tradename>
				</tradenames>
				<class type="func"> Antianxiety</class>
				<class type="chem"> Benzodiazepine (short/intermediate acting)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x8107">
				<para>
					<confusion>
						<tradename id="tnidelem4x81070">ALPRAZolam</tradename>
						<drug type="generic" refid="idelem4x81070">LORazepam</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8114">
				<sec_title>Action:</sec_title>
				<para>Depresses subcortical levels of CNS, including limbic system, reticular formation</para>
			</section>
			<section type="uses" id="sidelem4x8119">
				<sec_title>Uses:</sec_title>
				<para>Anxiety, panic disorders with or without agoraphobia, anxiety with depressive symptoms</para>
				<section type="none" id="sidelem4x8124">
					<section type="none" id="sidelem4x8125">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Premenstrual dysphoric disorders, insomnia, PMS, alcohol withdrawal syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8130">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity to benzodiazepines, closed-angle glaucoma, psychosis, addiction</para>
				<section type="none" id="sidelem4x8135">
					<section type="none" id="sidelem4x8136">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, debilitated patients, hepatic disease, obesity, severe pulmonary disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8141">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8144">
					<section type="none" id="sidelem4x8145">
						<sec_title>Anxiety disorder</sec_title>
						<section type="none" id="sidelem4x8153">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8153">
									<item>
										<label>•</label>
										<para> 0.25-0.5 mg tid, may increase q3-4days if needed, max 4 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8160">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8160">
									<item>
										<label>•</label>
										<para> 0.25 mg bid; increase by 0.125 mg as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8165">
						<sec_title>Panic disorder</sec_title>
						<section type="none" id="sidelem4x8173">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8173">
									<item>
										<label>•</label>
										<para> 0.5 mg tid, may increase up to 1 mg/day q3-4days, max 10 mg/day;  (Xanax XR) give daily in <emphasis style="smallcaps">am</emphasis>, 0.5-1 mg initially, maintenance 3-6 mg/day, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8183">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x8191">
							<label>•</label>
							<sec_title>
								<route>Reduce dose by 50%-60%</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8194">
						<sec_title>Premenstrual dysphoric disorders/PMS (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8202">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8202">
									<item>
										<label>•</label>
										<para> 0.25 mg bid-tid starting on day 16-18 of menses, taper over 2-3 days when menses occurs, max 4 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8206">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.25, 0.5, 1, 2 mg; ext rel tabs (Xanax XR) 0.5, 1, 2, 3 mg; orally disintegrating tabs 0.25, 0.5, 1, 2 mg; oral sol 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x8211">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8216">
								<item>
									<label>•</label>
									<para>Tabs may be crushed, mixed with food, fluids if patient is unable to swallow medication whole; do not break, crush, chew ext rel (XR), give ext rel tab in <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8223">
								<item>
									<label>•</label>
									<para>With food or milk for GI symptoms; high-fat meal will decrease absorption</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8228">
								<item>
									<label>•</label>
									<para>To discontinue, decrease by 0.5 mg q3days</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8233">
								<item>
									<label>•</label>
									<para>May divide total daily doses into more times/day if anxiety occurs between doses</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8241">
							<label>•</label>
							<sec_title>
								<route>Orally disintegrating tabs</route>
							</sec_title>
							<para>
								<list id="lidelem4x8241">
									<item>
										<label>•</label>
										<para> on tongue to dissolve and swallow, protect from moisture</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8245">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8248">
					<section type="none" id="sidelem4x8249">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, fatigue, depression, insomnia, hallucinations, memory impairment, poor coordination, <emphasis style="bold">suicide</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8259">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis><emphasis style="bold">ECG changes, tachycardia,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x8269">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis</para>
					</section>
					<section type="none" id="sidelem4x8277">
						<sec_title>GI:</sec_title>
						<para> Constipation, dry mouth, nausea, vomiting, anorexia, diarrhea, weight gain/loss, increased appetite, <emphasis style="bold">ileus perforation, ischemic colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8284">
						<sec_title>GU:</sec_title>
						<para> Decreased libido</para>
					</section>
					<section type="none" id="sidelem4x8289">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, itching, <emphasis style="bold">angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8296">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8299">
					<section type="none" id="sidelem4x8300">
						<sec_title>PO:</sec_title>
						<para> Well absorbed; widely distributed; onset 30 min; peak 1-2 hr; duration 4-6 hr; <emphasis style="italic">oral disintegrating tab</emphasis> peak 1.5-2 hr; therapeutic response 2-3 days; metabolized by liver (CYP3A4), excreted by kidneys; crosses placenta, breast milk; half-life 12-15 hr, protein binding 80%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8308">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> ALPRAZolam action—CYP3A4 inhibitors (cimetidine, disulfiram, erythromycin, FLUoxetine, isoniazid, itraconazole, ketoconazole, metoprolol, propranolol, valproic acid)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—anticonvulsants, alcohol, antihistamines, sedative/hypnotics, opioids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> sedation—xanthines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ALPRAZolam action—CYP3A4 inducers (barbiturates, rifampin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of levodopa</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> product level—cigarette smoking</para>
				<section type="none" id="sidelem4x8335">
					<section type="none" id="sidelem4x8336">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, melatonin, St. John’s wort, valerian</para>
					</section>
					<section type="none" id="sidelem4x8343">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> product level—grapefruit juice, avoid concurrent use</para>
					</section>
					<section type="none" id="sidelem4x8350">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, alk phos</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8357">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8360">
					<section type="none" id="sidelem4x8361">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8369">
							<label>•</label>
							<sec_title>
								<route>suicidal thoughts, behaviors</route>
							</sec_title>
							<para>
								<list id="lidelem4x8369">
									<item>
										<label>•</label>
										<para>Mental status: anxiety, mood, sensorium, orientation, affect, sleeping pattern, drowsiness, dizziness, especially in geriatric patients both before and during treatment, </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8373">
								<item>
									<label>•</label>
									<para>B/P lying, standing; pulse; if systolic B/P drops 20 mm Hg, hold product, notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8378">
								<item>
									<label>•</label>
									<para>Hepatic, blood studies: AST, ALT, bilirubin, creatinine, LDH, alk phos, CBC; may cause neutropenia, decreased Hct, increased LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8385">
								<item>
									<para>
										<emphasis alert="nurse">Physical dependency, withdrawal symptoms: anxiety, panic attacks, agitation, seizures, headache, nausea, vomiting, muscle pain, weakness; withdrawal seizures may occur after rapid decrease in dose or abrupt discontinuation; because duration of action is short, considered to be the product of choice for geriatric patients</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8393">
							<label>•</label>
							<sec_title>Pregnancy<route> if planned or suspected, pregnancy (D), to avoid breastfeeding</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8396">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8400">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anxiety, restlessness, sleeplessness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8406">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8411">
								<item>
									<label>•</label>
									<para>Not to double doses; take exactly as prescribed; if dose is missed, take within 1 hr as scheduled; that product may be taken with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8416">
								<item>
									<label>•</label>
									<para>Not to use for everyday stress or for more than 4 mo unless directed by prescriber; not to take more than prescribed amount; that product may be habit forming; that memory impairment is a result of long-term use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8421">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8429">
							<label>•</label>
							<sec_title>
								<route>Not to use during pregnancy (D), to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8432">
								<item>
									<label>•</label>
									<para>Not to discontinue medication abruptly after long-term use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8437">
								<item>
									<label>•</label>
									<para>To avoid driving, activities that require alertness because drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8442">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other psychotropic medications unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8447">
								<item>
									<label>•</label>
									<para>To rise slowly or fainting may occur, especially among geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8452">
								<item>
									<label>•</label>
									<para>That drowsiness may worsen at beginning of treatment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x8457">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, VS, supportive care, flumazenil</para>
			</section>
		</monograph>
<monograph id="30" status="active" ru="yes">
			<mono_name>alprostadil (Rx)</mono_name>
			<info>
				<pronunciation>(al-pros′ta-dil)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x84694">Caverject</tradename>
					<tradename id="tnidelem4x84693">Caverject Impulse</tradename>
					<tradename id="tnidelem4x84692">Edex</tradename>
					<tradename id="tnidelem4x84691">Muse</tradename>
					<tradename id="tnidelem4x84690">Prostin VR Pediatric</tradename>
				</tradenames>
				<class type="func"> Hormone</class>
			</info>
			<section type="uses" id="sidelem4x8475">
				<sec_title>Uses:</sec_title>
				<para>To maintain patent ductus arteriosus (temporary treatment), erectile dysfunction</para>
			</section>
			<section type="contra" id="sidelem4x8480">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, respiratory distress syndrome, those at risk for priapism</para>
			</section>
			<section type="doses" id="sidelem4x8485">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8488">
					<section type="none" id="sidelem4x8489">
						<sec_title>Patent ductus arteriosus</sec_title>
						<section type="none" id="sidelem4x8497">
							<label>•</label>
							<sec_title>Infant<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x8497">
									<item>
										<label>•</label>
										<para> 0.05-0.1 mcg/kg/min until desired response, then reduce to lowest effective amount, max 0.4 mcg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8501">
						<sec_title>Erectile dysfunction of vasculogenic or mixed etiology, psychogenic</sec_title>
						<section type="none" id="sidelem4x8509">
							<label>•</label>
							<sec_title>Men<route> INTRACAVERNOSAL</route></sec_title>
							<para>
								<list id="lidelem4x8509">
									<item>
										<label>•</label>
										<para> 2.5 mcg, may increase by 2.5 mcg, may then increase by 5-10 mcg until adequate response occurs (max 60 mcg/dose);  125-250 mcg, max 2 doses/24 hr, max dose 1000 mcg; administer as needed to achieve erection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active" ha="yes">
			<mono_name>alteplase (Rx)</mono_name>
			<info>
				<pronunciation>(al-ti-plaze′)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x85231">Activase</tradename>
					<tradename id="tnidelem4x85230">Cathflo</tradename>
				</tradenames>
				<class type="func"> Thrombolytic enzyme</class>
				<class type="chem"> Tissue plasminogen activator (TPA)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8533">
				<para>
					<confusion>
						<tradename id="tnidelem4x85330">alteplase</tradename>
						<drug type="generic" refid="idelem4x85330">Altace Activase/Cathflo Activase</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8537">
				<sec_title>Action:</sec_title>
				<para>Produces fibrin conversion of plasminogen to plasmin; able to bind to fibrin, convert plasminogen in thrombus to plasmin, which leads to local fibrinolysis, limited systemic proteolysis</para>
			</section>
			<section type="uses" id="sidelem4x8542">
				<sec_title>Uses:</sec_title>
				<para>Lysis of obstructing thrombi associated with acute MI, ischemic conditions that require thrombolysis (i.e., PE, unclotting arteriovenous shunts, acute ischemic CVA), central venous catheter occlusion (Cathflo)</para>
				<section type="none" id="sidelem4x8547">
					<section type="none" id="sidelem4x8548">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Arterial thromboembolism, deep vein thrombosis (DVT), occlusion prophylaxis, percutaneous coronary intervention (PCI)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8553">
				<sec_title>Contraindications:</sec_title>
				<para>Active internal bleeding, history of CVA, severe uncontrolled hypertension, intracranial/intraspinal surgery/trauma (within 3 mo), aneurysm, brain tumor, platelets &lt;100,000 mm<emphasis style="sup">3</emphasis>, bleeding diathesis including INR &gt;1.7 or PR &gt;15 sec, arteriovenous malformation, subarachnoid hemorrhage, intracranial hemorrhage, uncontrolled hypertension, seizure at onset of stroke</para>
				<section type="none" id="sidelem4x8563">
					<section type="none" id="sidelem4x8564">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, neurologic deficits, mitral stenosis, recent GI/GU bleeding, diabetic retinopathy, subacute bacterial endocarditis, arrhythmias, diabetic hemorrhage retinopathy, CVA, recent major surgery, hypertension, acute pericarditis, hemostatic defects, significant hepatic disease, septic thrombophlebitis, occluded AV cannula at seriously infected site</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8569">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8572">
					<section type="none" id="sidelem4x8573">
						<sec_title>MI (standard infusion) (Activase)</sec_title>
						<section type="none" id="sidelem4x8581">
							<label>•</label>
							<sec_title>Adult &gt;65 kg</sec_title>
							<para>
								<list id="lidelem4x8581">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult &gt;65 kg:</emphasis> 100 mg total given over 3 hr as follows: 6- to 10-mg IV BOL over 1-2 min; remaining 50-54 mg given over the remainder of the hr; during 2nd, 3rd hr 20 mg given by  (20 mg/hr)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8591">
							<label>•</label>
							<sec_title>Adult &lt;65 kg</sec_title>
							<para>
								<list id="lidelem4x8591">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult &lt;65 kg:</emphasis> 1.25 mg/kg over 3 hr: 60% during 1st hr (6%-10% as bolus); remaining 50% given over remainder of hr; during 2nd hr, 20% of dose given by CONT IV INFUSION; 20% given during 3rd hr by CONT IV INFUSION</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8595">
						<sec_title>MI (accelerated infusion) (Activase)</sec_title>
						<section type="none" id="sidelem4x8603">
							<label>•</label>
							<sec_title>Adult &gt;67 kg</sec_title>
							<para>
								<list id="lidelem4x8603">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult &gt;67 kg:</emphasis> 100 mg total dose: give 15-mg IV bolus, then 50 mg over 30 min, then 35 mg over 60 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8610">
							<label>•</label>
							<sec_title>Adult &lt;67 kg</sec_title>
							<para>
								<list id="lidelem4x8610">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult &lt;67 kg:</emphasis> 15-mg IV bolus, then 0.75 mg/kg (max 50 mg) over 30 min, then 0.5 mg/kg (max 35 mg) over next 60 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8614">
						<sec_title>Pulmonary embolism (Activase)</sec_title>
						<section type="none" id="sidelem4x8622">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8622">
									<item>
										<label>•</label>
										<para> 100 mg over 2 hr, then heparin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8626">
						<sec_title>Acute ischemic stroke (Activase)</sec_title>
						<section type="none" id="sidelem4x8634">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8634">
									<item>
										<label>•</label>
										<para> 0.9 mg/kg, max 90 mg; give as  over 1 hr, give 10% of dose  over 1st min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8644">
						<sec_title>Occluded venous access devices (Cathflo Activase)</sec_title>
						<section type="none" id="sidelem4x8652">
							<label>•</label>
							<sec_title>Adult/child ≥30 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8652">
									<item>
										<label>•</label>
										<para> 2 mg/2 ml instilled in occluded catheter, may repeat if needed after 2 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8659">
							<label>•</label>
							<sec_title>Child 10-29 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8659">
									<item>
										<label>•</label>
										<para> 110% of lumen volume, max 2 mg/2 ml instilled in occluded catheter, may repeat if needed after 2 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8663">
						<sec_title>Deep venous thrombosis (DVT) (Activase) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8671">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8671">
									<item>
										<label>•</label>
										<para> 4 mcg/kg/min as 2-hr infusion, then 1 mcg/kg/min × 33 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8675">
						<sec_title>Percutaneous coronary intervention (PCI) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8683">
							<label>•</label>
							<sec_title>Adult<route> INTRACARDIAC</route></sec_title>
							<para>
								<list id="lidelem4x8683">
									<item>
										<label>•</label>
										<para> 20 mg over 5 min, then 50 mg over the next 60 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8687">
						<sec_title>Occlusion prophylaxis (unlabeled) (Cathflo Activase)</sec_title>
						<section type="none" id="sidelem4x8695">
							<label>•</label>
							<sec_title>Adult &gt;30 kg</sec_title>
							<para>
								<list id="lidelem4x8695">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult &gt;30 kg:</emphasis> Do not exceed 2 mg in 2 ml; may use up to 2 doses 120 min apart</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8699">
						<sec_title>Complicated pleural effusions (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8707">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x8707">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> Intrapleural 10 mg in 30 ml NS bid in well time of 1 hr × 3 days, then after ≥2 hr intrapleural dornase alfa</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8711">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 50 mg (29 million international units/vial), 100 mg (58 million international units/vial); Cathflo Activase: lyophilized powder for inj 2 mg</para>
					</section>
					<section type="none" id="sidelem4x8716">
						<sec_title>Administer: (Activase)</sec_title>
						<section type="none" id="sidelem4x8719">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x8723">
									<item>
										<label>•</label>
										<para>After reconstituting with provided diluent, add appropriate amount of sterile water for inj (no preservatives) 20-mg vial/20 ml or 50-mg vial/50 ml to make 1 mg/ml, mix by slow inversion or dilute with NaCl, D<emphasis style="inf">5</emphasis>W to a concentration of 0.5 mg/ml; 1.5 to &lt;0.5 mg/ml may result in precipitation of product; use 18G needle; flush line with NaCl after administration, give over 3 hr for MI, 2 hr for PE</para>
									</item>
									<item>
										<label>•</label>
										<para>Heparin therapy after thrombolytic therapy is discontinued, TT, ACT, or APTT less than 2× control (about 3-4 hr); treatment can be initiated before coagulation study results obtained, infusion should be discontinued if pretreatment INR &gt;1.7, PT &gt;15 sec, or elevated APTT is identified</para>
									</item>
									<item>
										<label>•</label>
										<para>Use reconstituted IV solution within 8 hr or discard</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid invasive procedures, inj, rectal temperature</para>
									</item>
									<item>
										<label>•</label>
										<para>Pressure for 30 sec to minor bleeding sites; 30 min to sites of atrial puncture followed by pressure dressing; inform prescriber if this does not attain hemostasis; apply pressure dressing</para>
									</item>
									<item>
										<label>•</label>
										<para>Store powder at room temperature or refrigerate; protect from excessive light</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x8766">
								<label>•</label>
								<sec_title>Cathflo Activase</sec_title>
								<para>
									<list id="lidelem4x8766">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cathflo Activase:</emphasis> Use this product after other options used for declotting a line; reconstitute by using 2.2 ml of sterile water provided and injecting in vial, direct flow into powder (1 mg/ml), foam will disappear after standing; swirl, do not shake, sol will be pale yellow or clear, use within 8 hr, instill 2 ml of reconstituted sol into occluded catheter, try to aspirate after <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; if unable to remove, allow 2 hr, a 2nd dose may be used; aspirate 5 ml of blood to remove clot and product, irrigate with normal saline</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8776">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8779">
					<section type="none" id="sidelem4x8780">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Sinus bradycardia, cholesterol microembolization, ventricular tachycardia, accelerated idioventricular rhythm, bradycardia, recurrent ischemic stroke,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x8788">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="bold">Orolingual angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8795">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria, rash</para>
					</section>
					<section type="none" id="sidelem4x8800">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">GI, GU, intracranial, retroperitoneal bleeding,</emphasis><emphasis style="italic">surface bleeding,</emphasis><emphasis style="bold">anaphylaxis,</emphasis> fever</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8812">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Cleared by liver, 80% cleared within 10 min of product termination, onset immediate, half-life 35 min</para>
			</section>
			<section type="interactions" id="sidelem4x8817">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—anticoagulants, salicylates, dipyridamole, other NSAIDs, abciximab, eptifibatide, tirofiban, clopidogrel, ticlopidine, some cephalosporins, plicamycin, valproic acid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> orolingual angioedema—ACE inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect—nitroglycerin</para>
				<section type="none" id="sidelem4x8832">
					<section type="none" id="sidelem4x8833">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> risk for bleeding—feverfew, garlic, ginger, ginkgo, ginseng, green tea</para>
					</section>
					<section type="none" id="sidelem4x8840">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> PT, APTT, TT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8847">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8850">
					<section type="none" id="sidelem4x8851">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8856">
								<item>
									<label>•</label>
									<para>Treatment is not recommended for patients with acute ischemic stroke &gt;3 hr after symptom onset or with minor neurologic deficits or rapidly improving symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8861">
								<item>
									<label>•</label>
									<para>VS, B/P, pulse, respirations, neurologic signs, temperature at least q4hr; temperature &gt;104° F (40° C) indicates internal bleeding; monitor rhythm closely; ventricular dysrhythmias may occur with hyperfusion; monitor heart, breath sounds, neurologic status, peripheral pulses; assess neurologic status, neurologic change may indicate intracranial bleeding; those with severe neurologic deficit (NIH SS &gt;22) at presentation have increased risk of hemorrhage</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8867">
								<item>
									<para>
										<emphasis alert="nurse">For bleeding during 1st hour of treatment and 24 hr after procedure: hematuria, hematemesis, bleeding from mucous membranes, epistaxis, ecchymosis; guaiac all body fluids, stools; do not use 150 mg or more total dose because intracranial bleeding may occur; do not use in severe uncontrolled hypertension, aneurysm, head trauma, for MI, pulmonary embolism</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8873">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitivity: fever, rash, itching, chills, facial swelling, dyspnea, notify prescriber immediately; stop product, keep resuscitative equipment nearby; mild reaction may be treated with antihistamines</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8878">
								<item>
									<label>•</label>
									<para>Previous allergic reactions or streptococcal infection; alteplase may be less effective</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8887">
							<label>•</label>
							<sec_title>
								<route>Blood studies (Hct, platelets, PTT, PT, TT, APTT) before starting therapy; PT or APTT must be less than 2× control before starting therapy TT or PT q3-4hr during treatment</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8893">
							<label>•</label>
							<sec_title>MI<route> ECG continuously, cardiac enzymes, radionuclide myocardial scanning/coronary angiography; chest pain intensity, character; monitor those with major early infarct signs on CT scan with substantial edema, mass effect, midline shift</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8899">
							<label>•</label>
							<sec_title>PE<route> pulse, B/P, ABGs, rate/rhythm of respirations</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8905">
							<label>•</label>
							<sec_title>Occlusion<route> have patient exhale then hold breath when connecting/disconnecting syringe to prevent air embolism</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8911">
							<label>•</label>
							<sec_title>Cholesterol embolism<route> purple toe syndrome, acute renal failure, gangrenous digits, hypertension, livedo reticularis, pancreatitis, MI, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, rhabdomyolysis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8914">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8918">
								<item>
									<label>•</label>
									<para>Therapeutic response: lysis of thrombi</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8924">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8928">
								<item>
									<label>•</label>
									<para>The purpose and expected results of the treatment; to report adverse reactions, bleeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active">
			<mono_name>aluminum hydroxide (OTC)</mono_name>
			<info>
				<class type="func"> Antacid, hypophosphatemic</class>
				<class type="chem"> Aluminum product, phosphate binder</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8945">
				<sec_title>Action:</sec_title>
				<para>Neutralizes gastric acidity; binds phosphates in GI tract; these phosphates are then excreted</para>
			</section>
			<section type="uses" id="sidelem4x8950">
				<sec_title>Uses:</sec_title>
				<para>Antacid, hyperphosphatemia in chronic renal failure; adjunct in gastric, peptic, duodenal ulcers; hyperacidity, reflux esophagitis, heartburn, stress ulcer prevention in critically ill, GERD</para>
				<section type="none" id="sidelem4x8955">
					<section type="none" id="sidelem4x8956">
						<sec_title>Unlabeled uses:</sec_title>
						<para> GI bleeding</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8961">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to product or aluminum products</para>
				<section type="none" id="sidelem4x8966">
					<section type="none" id="sidelem4x8967">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, fluid restriction, decreased GI motility, GI obstruction, dehydration, renal disease, sodium-restricted diets, GI bleeding, hypokalemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8972">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8975">
					<section type="none" id="sidelem4x8976">
						<sec_title>Antacid</sec_title>
						<section type="none" id="sidelem4x8984">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8984">
									<item>
										<label>•</label>
										<para> 500-1500 mg 3-6× daily, max 6 doses/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8988">
						<sec_title>Hyperphosphatemia</sec_title>
						<section type="none" id="sidelem4x8996">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8996">
									<item>
										<label>•</label>
										<para> 300-600 mg tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9003">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9003">
									<item>
										<label>•</label>
										<para> 50-150 mg/kg/day in 4-6 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9007">
						<sec_title>Available forms:</sec_title>
						<para> Susp 320 mg/5 ml, 600 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x9012">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9016">
								<item>
									<label>•</label>
									<para>2 tsp (10 ml) will neutralize 20 mEq of acid</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9022">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x9030">
								<label>•</label>
								<sec_title>Hyperphosphatemia</sec_title>
								<para>
									<list id="lidelem4x9030">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Hyperphosphatemia:</emphasis> give with 8 oz water, meals unless contraindicated</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x9034">
									<item>
										<label>•</label>
										<para>Laxatives or stool softeners if constipation occurs, especially for geriatric patients</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9039">
									<item>
										<label>•</label>
										<para>After shaking susp</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">NG route:</emphasis> By nasogastric tube if patient unable to swallow</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9048">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9051">
					<section type="none" id="sidelem4x9052">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation,</emphasis> anorexia, <emphasis style="bold">obstruction,</emphasis> fecal impaction</para>
					</section>
					<section type="none" id="sidelem4x9063">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hypophosphatemia,</emphasis> hypercalciuria, hypomagnesemia, aluminum toxicity</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9071">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9074">
					<section type="none" id="sidelem4x9075">
						<sec_title>PO:</sec_title>
						<para> Onset 20-40 min, duration 1-3 hr, excreted in feces</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9080">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effectiveness of—allopurinol, amprenavir, cephalosporins, corticosteroids, delavirdine, digoxin, gabapentin, gatifloxacin, H<emphasis style="inf">2</emphasis>-antagonists, iron salts, isoniazid, ketoconazole, penicillamine, phenothiazines, phenytoin, quiNIDine, quinolones, tetracyclines, thyroid hormones, ticlopidine, anticholinergics; separate by at least 4-6 hr</para>
				<section type="none" id="sidelem4x9090">
					<section type="none" id="sidelem4x9091">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> product effect—high-protein meal</para>
					</section>
					<section type="none" id="sidelem4x9098">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease: phosphate interference:</emphasis> Tc-99m</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9105">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9108">
					<section type="none" id="sidelem4x9109">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9117">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x9117">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, intensity, duration, character, aggravating, alleviating factors</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9121">
								<item>
									<label>•</label>
									<para>Phosphate, calcium levels because product is bound in GI system</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9129">
							<label>•</label>
							<sec_title>Hypophosphatemia</sec_title>
							<para>
								<list id="lidelem4x9129">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypophosphatemia:</emphasis> anorexia, weakness, fatigue, bone pain, hyporeflexia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9134">
								<item>
									<label>•</label>
									<para>Constipation; increase bulk in diet if needed, may use stool softeners or laxatives; record amount and consistency of stools</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9142">
							<label>•</label>
							<sec_title>Aluminum toxicity<route> severe renal disease, may also be used for hyperphosphatemia</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9145">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9149">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain, decreased acidity, healed ulcers, decreased phosphate levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9155">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9160">
								<item>
									<label>•</label>
									<para>Not to use for prolonged periods for patients with low serum phosphate or patients on low-sodium diets; to shake liquid well</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9165">
								<item>
									<label>•</label>
									<para>That stools may appear white or speckled</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9170">
								<item>
									<label>•</label>
									<para>To check with prescriber after 2 wk of self-prescribed antacid use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9175">
								<item>
									<label>•</label>
									<para>To separate from other medications by 2 hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9183">
							<label>•</label>
							<sec_title>Hyperphosphatemia</sec_title>
							<para>
								<list id="lidelem4x9183">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperphosphatemia:</emphasis> to avoid phosphate foods (most dairy products, eggs, fruits, carbonated beverages) during product therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9187">
								<item>
									<label>•</label>
									<para>To notify prescriber of black tarry stools, which may indicate bleeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active">
			<mono_name>alvimopan</mono_name>
			<info>
				<pronunciation>(al-vim′oh-pan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x91970">Entereg</tradename>
				</tradenames>
				<class type="func"> Functional GI disorder agent</class>
				<class type="chem"> Peripheral mu-opioid receptor antagonist</class>
			</info>
			<section type="actions" id="sidelem4x9207">
				<sec_title>Action:</sec_title>
				<para>A peripherally selective mu-opioid receptor antagonist with activity restricted to the GI tract</para>
			</section>
			<section type="uses" id="sidelem4x9212">
				<sec_title>Uses:</sec_title>
				<para>Prevention of postoperative ileus</para>
				<section type="none" id="sidelem4x9217">
					<section type="none" id="sidelem4x9218">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Opiate-agonist–induced constipation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9223">
				<sec_title>Contraindications:</sec_title>
				<para>Those who have taken therapeutic doses of opioids for more than 7 consecutive days immediately before starting alvimopan, end-stage renal disease, Child-Pugh C</para>
				<section type="none" id="sidelem4x9228">
					<section type="none" id="sidelem4x9229">
						<sec_title>Precautions:</sec_title>
						<para> Risk for MI, surgery for complete GI obstruction, hepatic disease, renal disease, pregnancy B, breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9234">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9242">
					<label>•</label>
					<sec_title>Adult/geriatric patient<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9242">
							<item>
								<label>•</label>
								<para> 12 mg 30 min-5 hr before surgery, then 12 mg bid beginning the day after surgery; max 7 days or hospital discharge; max 15 doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9246">
					<section type="none" id="sidelem4x9247">
						<sec_title>Opiate agonist–induced constipation (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9255">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9255">
									<item>
										<label>•</label>
										<para> 0.5 mg or 1 mg every day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9259">
						<sec_title>Renal/hepatic dosage</sec_title>
						<section type="none" id="sidelem4x9267">
							<label>•</label>
							<sec_title>Adult<route> PO Do not use in end-stage renal disease or Child-Pugh Class C</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9270">
						<sec_title>Available forms:</sec_title>
						<para> Cap 12 mg</para>
					</section>
					<section type="none" id="sidelem4x9275">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9279">
								<item>
									<label>•</label>
									<para>Without regard to food
<bbw>Only in a hospital setting approved for the ENTEREG Access Support and Education (E.A.S.E.) program, MI</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9299">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9302">
					<section type="none" id="sidelem4x9303">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation, dyspepsia</emphasis>, flatulence, diarrhea, abdominal pain, cramping</para>
					</section>
					<section type="none" id="sidelem4x9311">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="italic">Anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9318">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x9323">
						<sec_title>MISC:</sec_title>
						<para> Back pain, urinary retention, <emphasis style="bold">MI</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9330">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 10-17 hr, extended in hepatic/renal disease, protein binding 80%-94%</para>
			</section>
			<section type="interactions" id="sidelem4x9335">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> Alvimopan concentrations, toxicity—amiodarone, bepridil, cycloSPORINE, diltiazem, itraconazole, quiNIDine, quiNINE, spironolactone, verapamil</para>
				<para>
					<bbw>Do not use if opiate agonists have been used for 7 consecutive days before alvimopan</bbw>
				</para>
				<para>
					<bbw>Do not use concurrently with other opiate antagonists</bbw>
				</para>
			</section>
			<section type="considerations" id="sidelem4x9362">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9365">
					<section type="none" id="sidelem4x9366">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9370">
								<item>
									<label>•</label>
									<para>Blood studies: Hgb/Hct, potassium; hyperkalemia occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>Recent opioid use, do not use within 7 consecutive days
<bbw>Opioid use for chronic pain; MI is more common in this population</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9390">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9394">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of postoperative ileus</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9400">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9404">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected, avoid breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is only used for a limited time in a hospital setting</para>
								</item>
								<item>
									<label>•</label>
									<para>To report constipation, abdominal pain, cramping</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active">
			<mono_name>amantadine (Rx)</mono_name>
			<info>
				<pronunciation>(a-man′ta-deen)</pronunciation>
				<class type="func"> Antiviral, antiparkinsonian agent</class>
				<class type="chem"> Tricyclic amine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9433">
				<para>
					<confusion>
						<tradename id="tnidelem4x94330">amantadine</tradename>
						<drug type="generic" refid="idelem4x94330">ranitidine/rimantidine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9437">
				<sec_title>Action:</sec_title>
				<para>Prevents uncoating of nucleic acid in viral cell, thereby preventing penetration of virus to host; causes release of DOPamine from neurons</para>
			</section>
			<section type="uses" id="sidelem4x9442">
				<sec_title>Uses:</sec_title>
				<para>Prophylaxis or treatment of influenza type A, EPS, parkinsonism, Parkinson’s disease</para>
				<section type="none" id="sidelem4x9447">
					<section type="none" id="sidelem4x9448">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Neuroleptic malignant syndrome, MS-associated fatigue</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9453">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding, children &lt;1, eczematic rash</para>
				<section type="none" id="sidelem4x9458">
					<section type="none" id="sidelem4x9459">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, epilepsy, CHF, orthostatic hypotension, psychiatric disorders, renal/hepatic disease, peripheral edema, CV disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9464">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9467">
					<section type="none" id="sidelem4x9468">
						<sec_title>Influenza type A</sec_title>
						<section type="none" id="sidelem4x9476">
							<label>•</label>
							<sec_title>Adult and child &gt;9 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9476">
									<item>
										<label>•</label>
										<para> 200 mg/day in single dose or divided bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9483">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9483">
									<item>
										<label>•</label>
										<para> No more than 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9490">
							<label>•</label>
							<sec_title>Child 1-8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9490">
									<item>
										<label>•</label>
										<para> 4.4-8.8 mg/kg/day divided bid-tid, max 150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9494">
						<sec_title>Drug induced EPS</sec_title>
						<section type="none" id="sidelem4x9502">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9502">
									<item>
										<label>•</label>
										<para> 100 mg bid, up to 300 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9509">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9509">
									<item>
										<label>•</label>
										<para> 100 mg bid up to 400 mg/day in divided doses in EPS</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9513">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9521">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-50 ml/min 200 mg 1st day then 100 mg/day; CCr 15-29 ml/min 100 mg 1st day, then 100 mg on alternate days; CCr 15 ml/min reduce dose and interval to 200 mg q7days</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9524">
						<sec_title>MS-associated fatigue (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9532">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9532">
									<item>
										<label>•</label>
										<para> 200 mg/day or 100 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9536">
						<sec_title>Neuroleptic malignant syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9544">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9544">
									<item>
										<label>•</label>
										<para> 100 mg bid × 3 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9548">
						<sec_title>Available forms:</sec_title>
						<para> Caps 100 mg; oral sol 50 mg/5 ml; tab 100 mg</para>
					</section>
					<section type="none" id="sidelem4x9553">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9561">
							<label>•</label>
							<sec_title>Prophylaxis</sec_title>
							<para>
								<list id="lidelem4x9561">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Prophylaxis:</emphasis> before exposure to influenza; continue for 10 days after contact; <emphasis style="bold">treatment:</emphasis> initiate within 24-48 hr of onset of symptoms, continue for 24-48 hr after symptoms disappear</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9568">
								<item>
									<label>•</label>
									<para>After meals for better absorption to decrease GI symptoms; at least 4 hr before bedtime to prevent insomnia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9573">
								<item>
									<label>•</label>
									<para>In divided doses to prevent CNS disturbances: headache, dizziness, fatigue, drowsiness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9578">
								<item>
									<label>•</label>
									<para>Store in tight, dry container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9583">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9586">
					<section type="none" id="sidelem4x9587">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness</emphasis>, drowsiness, fatigue, <emphasis style="italic">anxiety,</emphasis> psychosis, <emphasis style="italic">depression, hallucinations</emphasis>, tremors, <emphasis style="bold">seizures,</emphasis> confusion, <emphasis style="italic">insomnia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9606">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension</emphasis>, <emphasis style="bold">CHF</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9616">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x9621">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> constipation, dry mouth, anorexia</para>
					</section>
					<section type="none" id="sidelem4x9629">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Frequency, retention</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9636">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9643">
						<sec_title>INTEG:</sec_title>
						<para> Photosensitivity, dermatitis, livedo reticularis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9649">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9652">
					<section type="none" id="sidelem4x9653">
						<sec_title>PO:</sec_title>
						<para> Onset 48 hr, peak 1-4 hr, half-life 24 hr, not metabolized, excreted in urine (90%) unchanged, crosses placenta, excreted in breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9658">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic response—atropine, other anticholinergics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS stimulation—CNS stimulants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> amantadine effect—metoclopramide, phenothiazines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> renal excretion of amantadine—triamterene, hydrochlorothiazide</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect—S/B H1N1 influenza A virus vaccine; avoid use 2 wk before or 48 hr after amantadine</para>
				<section type="none" id="sidelem4x9681">
					<section type="none" id="sidelem4x9682">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, creatinine, alk phos, CK, LDH, bilirubin, AST, ALT, GGT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9689">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9692">
					<section type="none" id="sidelem4x9693">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9698">
								<item>
									<label>•</label>
									<para>Mental status: may cause increased psychiatric disorders especially in the elderly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9706">
							<label>•</label>
							<sec_title>
								<route>CHF</route>
							</sec_title>
							<para>
								<list id="lidelem4x9706">
									<item>
										<label>•</label>
										<para> (weight gain, jugular venous distention, dyspnea, crackles)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9710">
								<item>
									<label>•</label>
									<para>Skin eruptions, photosensitivity after administration of product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9715">
								<item>
									<label>•</label>
									<para>Serum creatinine, BUN in renal impairment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9720">
								<item>
									<label>•</label>
									<para>Reaction to each medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9725">
								<item>
									<label>•</label>
									<para>Signs of infection</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9733">
							<label>•</label>
							<sec_title>Livedo reticularis</sec_title>
							<para>
								<list id="lidelem4x9733">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Livedo reticularis:</emphasis> mottling of the skin, usually red; edema; itching in lower extremities, usually in Parkinson’s disease</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9740">
							<label>•</label>
							<sec_title>Parkinson’s disease</sec_title>
							<para>
								<list id="lidelem4x9740">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Parkinson’s disease:</emphasis> gait, tremors, akinesia, rigidity, may be effective if anticholinergics have not been effective</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9745">
								<item>
									<para>
										<emphasis alert="nurse">Toxicity: confusion, behavioral changes, hypotension, seizures</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9750">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9754">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, malaise, cough, dyspnea with infection; tremors, shuffling gait with Parkinson’s disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9760">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9765">
								<item>
									<label>•</label>
									<para>To change body position slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9770">
								<item>
									<label>•</label>
									<para>About aspects of product therapy: to report dyspnea, weight gain, dizziness, poor concentration, dysuria, complex sleep behaviors</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9775">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness, blurred vision occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9783">
							<label>•</label>
							<sec_title>
								<route>To take product exactly as prescribed; parkinsonian crisis may occur if product is discontinued abruptly; not to double dose; if a dose is missed, not to take within 4 hr of next dose; caps may be opened and mixed with food</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9786">
								<item>
									<label>•</label>
									<para>To avoid alcohol</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x9791">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Withdraw product, maintain airway, administer EPINEPHrine, aminophylline, O<emphasis style="inf">2</emphasis>, IV corticosteroids, physostigmine</para>
			</section>
		</monograph>
<monograph id="35" status="active">
			<mono_name>ambrisentan (Rx)</mono_name>
			<info>
				<pronunciation>(am-bri-sen′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x98041">Letairis</tradename>
					<tradename id="tnidelem4x98040">
						<country code="CAN">Volibris </country>
					</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x9816">
				<sec_title>Action:</sec_title>
				<para>Endothelin-A receptor antagonist; endothelin-A is a vasoconstrictor</para>
			</section>
			<section type="uses" id="sidelem4x9821">
				<sec_title>Uses:</sec_title>
				<para>Pulmonary arterial hypertension, alone or in combination with other antihypertensives in WHO class II (significant exertion), III (mild exertion)</para>
			</section>
			<section type="contra" id="sidelem4x9826">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity, idiopathic pulmonary fibrosis (IPF)</para>
				<para>
					<bbw>Pregnancy (X)</bbw>
				</para>
				<section type="none" id="sidelem4x9841">
					<section type="none" id="sidelem4x9842">
						<sec_title>Precautions:</sec_title>
						<para> Children, females, geriatric patients, hepatitis, anemia, heart failure, jaundice, peripheral edema, hepatic disease, pulmonary disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9847">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9855">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9855">
							<item>
								<label>•</label>
								<para> 5 mg/day; may increase to 10 mg/day if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9860">
					<section type="none" id="sidelem4x9861">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x9869">
							<label>•</label>
							<sec_title>Adult<route> PO Discontinue if AST/ALT &gt;5× ULN, or if elevations are accompanied by bilirubin &gt;2× ULN, or other signs of liver dysfunction</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9872">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x9877">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9881">
								<item>
									<label>•</label>
									<para>Do not break, crush, chew tabs</para>
								</item>
								<item>
									<label>•</label>
									<para>Daily with a full glass of water without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not discontinue abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>Only those facilities enrolled in the LEAP program (866-664-5327) may administer this product</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9907">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9910">
					<section type="none" id="sidelem4x9911">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> fever, flushing, fatigue</para>
					</section>
					<section type="none" id="sidelem4x9919">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, hypotension, <emphasis style="italic">peripheral edema,</emphasis> palpitations</para>
					</section>
					<section type="none" id="sidelem4x9927">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x9932">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, constipation, anorexia, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9939">
						<sec_title>GU:</sec_title>
						<para> Decreased sperm counts</para>
					</section>
					<section type="none" id="sidelem4x9944">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="italic">Anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9951">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9958">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, dyspnea, <emphasis style="bold">pulmonary edema, veno-occlusive disease (VOD)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9965">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, peak 2 hr, protein binding 99%, metabolized by CYP3A4, CYP2C19, UGTa, terminal half-life 15 hr, effective half-life 9 hr</para>
			</section>
			<section type="interactions" id="sidelem4x9970">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x9974">
						<item>
							<label>•</label>
							<para>Possibly increase ambrisentan: cimetidine, clopidogrel, efavirenz, felbamate, FLUoxetine, modafinil, OXcarbazepine, ticlopidine</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—other antihypertensives, diuretics, MAOIs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ambrisentan—CYP3A4 inhibitors (amprenavir, aprepitant, atazanavir, clarithromycin, conivaptan, cycloSPORINE, dalfopristin, danazol, darunavir, erythromycin, estradiol, imatinib, itraconazole, ketoconazole, nefazodone, nelfinavir, quinupristin, ritonavir, RU-486, saquinavir, tamoxifen, telithromycin, troleandomycin, zafirlukast); CYP2C19/CYP3A4 (chloramphenicol, delavirdine, fluconazole, fluvoxaMINE, isoniazid, voriconazole)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ambrisentan—CYP3A4 inducers (carBAMazepine, PHENobarbital, phenytoin, rifampin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ambrisentan absorption—mefloquine, niCARdipine, propafenone, quiNIDine, ranolazine, tacrolimus, testosterone</para>
				<section type="none" id="sidelem4x9996">
					<section type="none" id="sidelem4x9997">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x10001">
								<item>
									<label>•</label>
									<para>Need for ambrisentan dosage change: St. John’s wort, ephedra (ma huang)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10007">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x10011">
								<item>
									<label>•</label>
									<para>Avoid use with grapefruit products</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10017">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hct, Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10028">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10031">
					<section type="none" id="sidelem4x10032">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x10040">
							<label>•</label>
							<sec_title>Pulmonary status</sec_title>
							<para>
								<list id="lidelem4x10040">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pulmonary status:</emphasis> improvement in breathing, ability to exercise; pulmonary edema that may indicate veno-occlusive disease</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10044">
								<item>
									<label>•</label>
									<para>Blood studies: CBC with differential; Hct, Hgb may be decreased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10049">
								<item>
									<label>•</label>
									<para>Liver function tests: AST, ALT, bilirubin
<bbw>Assess pregnancy status before giving this product and monthly; pregnancy (X)</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10066">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> nausea, vomiting, abdominal pain/cramping, jaundice, anorexia, itching</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10069">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10073">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P; decreased shortness of breath; importance of follow up with labs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10079">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10084">
								<item>
									<label>•</label>
									<para>The importance of complying with dosage schedule even if feeling better
<bbw>To notify if pregnancy is planned or suspected (if pregnant, product will need to be discontinued, pregnancy test done monthly); to use 2 contraception methods while taking this product</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10098">
								<item>
									<label>•</label>
									<para>Not to use OTC products including herbs, supplements unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10107">
							<label>•</label>
							<sec_title>To report to prescriber immediately<route> dizziness, faintness, chest pain, palpitations, uneven or rapid heart rate, headache, edema, weight gain</route></sec_title>
						</section>
						<section type="none" id="sidelem4x10113">
							<label>•</label>
							<sec_title>To report hepatic dysfunction<route> nausea/vomiting, anorexia, fatigue, jaundice, right upper quadrant abdominal pain, itching, fever, malaise</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>amikacin (Rx)</mono_name>
			<info>
				<pronunciation>(am-i-kay′sin)</pronunciation>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Aminoglycoside</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10129">
				<para>
					<confusion>
						<tradename id="tnidelem4x101290">Amikacin</tradename>
						<drug type="generic" refid="idelem4x101290">anakinra</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10133">
				<sec_title>Action:</sec_title>
				<para>Interferes with protein synthesis in bacterial cells by binding to ribosomal subunits, which causes misreading of genetic code; inaccurate peptide sequence forms in protein chain, thereby causing bacterial death</para>
			</section>
			<section type="uses" id="sidelem4x10138">
				<sec_title>Uses:</sec_title>
				<para>Severe systemic infections of CNS, respiratory tract, GI tract, urinary tract, bone, skin, soft tissues caused by <emphasis style="italic">Staphylococcus aureus</emphasis> (MSSA), <emphasis style="italic">Pseudomonas aeruginosa, Escherichia coli, Enterobacter, Acinetobacter, Providencia, Citrobacter, Serratia, Proteus, Klebsiella pneumoniae</emphasis></para>
				<section type="none" id="sidelem4x10148">
					<section type="none" id="sidelem4x10149">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Mycobacterium avium</emphasis> complex (MAC) (intrathecal or intraventricular) in combination; actinomycotic mycetoma, febrile neutropenia, cystic fibrosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10157">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to aminoglycosides, sulfites</para>
				<section type="none" id="sidelem4x10162">
					<section type="none" id="sidelem4x10163">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, neonates, geriatric patients, myasthenia gravis, Parkinson’s disease, mild to moderate infections, dehydration</para>
						<para>
							<bbw>Hearing impairment, renal/neuromuscular disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10178">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10181">
					<section type="none" id="sidelem4x10182">
						<sec_title>Severe systemic infections</sec_title>
						<section type="none" id="sidelem4x10190">
							<label>•</label>
							<sec_title>Adult and child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x10190">
									<item>
										<label>•</label>
										<para> 15 mg/kg/day in 2-3 divided doses q8-12hr in 100-200 ml D<emphasis style="inf">5</emphasis>W over 30-60 min, max 1.5 g/day;  (once-daily dosing) may be used with some infections;  10-15 mg/kg/day in divided doses q8-12hr; or extended-interval dosing as an alternative dosing regimen</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10206">
							<label>•</label>
							<sec_title>Neonate<route> IV/IM</route></sec_title>
							<para>
								<list id="lidelem4x10206">
									<item>
										<label>•</label>
										<para> 10 mg/kg initially, then 7.5 mg/kg q8-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10210">
						<sec_title>Severe urinary tract infections</sec_title>
						<section type="none" id="sidelem4x10218">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x10218">
									<item>
										<label>•</label>
										<para> 10-15 mg/kg/day divided q8-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10222">
						<sec_title>Hemodialysis</sec_title>
						<section type="none" id="sidelem4x10230">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x10230">
									<item>
										<label>•</label>
										<para> 7.5 mg/kg followed by 5 mg/kg 3×/wk after each dialysis session (for TIW dialysis)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10234">
						<sec_title>Renal dose (extended interval dosing)</sec_title>
						<section type="none" id="sidelem4x10242">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 40-59 ml/min 15 mg/kg q36hr; CCr 20-39 ml/min 15 mg/kg q48hr; &lt;20 ml/min adjust based on serum concentrations and MIC (use traditional dosing)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10245">
						<sec_title>Traditional dosing</sec_title>
						<section type="none" id="sidelem4x10253">
							<label>•</label>
							<sec_title>
								<route>Decrease dose and maintain interval or maintain dose and decrease interval</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10256">
						<sec_title>
							<emphasis style="italic">Mycobacterium avium</emphasis> complex (MAC) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10266">
							<label>•</label>
							<sec_title>Adult and adolescent<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x10266">
									<item>
										<label>•</label>
										<para> 15-20 mg/kg/day or 5× per wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10273">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x10273">
									<item>
										<label>•</label>
										<para> 15-30 mg/kg/day divided q12-24hr as part of multiple-drug regimen, max 1.5 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10277">
						<sec_title>Actinomycotic mycetoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10285">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x10285">
									<item>
										<label>•</label>
										<para> 15 mg/kg/day in 2 divided doses × 3 wk with co-trimoxazole for 5 wk; repeat cycle once, may be repeated 2×</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10289">
						<sec_title>Available forms:</sec_title>
						<para> Inj 50, 250 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x10294">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10298">
								<item>
									<label>•</label>
									<para>Obtain C&amp;S before administration; begin treatment before results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10304">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x10308">
									<item>
										<label>•</label>
										<para>Inj in large muscle mass; rotate inj sites</para>
									</item>
									<item>
										<label>•</label>
										<para>Obtain peak 1 hr after IM, trough before next dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10319">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x10323">
									<item>
										<label>•</label>
										<para>Dilute 500 mg of product/100-200 ml of D<emphasis style="inf">5</emphasis>W, 0.9% NaCl and give over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr; dilute in sufficient volume to allow for infusion over 1-2 hr (infants); flush after administration with D<emphasis style="inf">5</emphasis>W or 0.9% NaCl; sol clear or pale yellow; discard if precipitate or dark color develops</para>
									</item>
									<item>
										<label>•</label>
										<para>In children, amount of fluid will depend on ordered dose; in infants, infuse over 1-2 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>In evenly spaced doses to maintain blood level, separate from penicillins by at least 1 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alatrafloxacin, aldesleukin, alemtuzumab, alfentanil, amifostine, aminophylline, amiodarone, amsacrine, anidulafungin, argatroban, ascorbic acid, atracurium, atropine, aztreonam, benztropine, bivalirudin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefepime, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, doxycycline, eftifibatide, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, ertapenem, erythromycin, esmolol, etoposide, famotidine, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, furosemide, gemcitabine, gentamicin, glycopyrrolate, granisetron, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, IL-2, imipenem/cilastin, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoXANtrone, morphine, multivitamins, nafcillin, nalbuphine, naloxone, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pantoprazole, papaverine, PEMEtrexed, penicillin G, pentazocine, perphenazine, PHENobarbital, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, rantidine, remifentanil, riTUXimab, rocuromium, sargramostim, sodium acetate, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimethaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, warfarin, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10357">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10360">
					<section type="none" id="sidelem4x10361">
						<sec_title>CNS:</sec_title>
						<para> Confusion, depression, numbness, tremors, <emphasis style="bold">seizures,</emphasis> muscle twitching, <emphasis style="bold">neurotoxicity,</emphasis> dizziness, vertigo, tinnitus, <emphasis style="bold">neuromuscular blockade with respiratory paralysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10374">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x10379">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Ototoxicity,</emphasis> deafness</para>
					</section>
					<section type="none" id="sidelem4x10387">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia;</emphasis> bilirubin</para>
					</section>
					<section type="none" id="sidelem4x10395">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Oliguria, hematuria, renal damage, azotemia, renal failure, nephrotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10402">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Eosinophilia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10409">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> burning, urticaria, dermatitis, alopecia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10417">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x10420">
					<section type="none" id="sidelem4x10421">
						<sec_title>IM:</sec_title>
						<para> Onset rapid, peak 1 hr, leads to unpredictable concentrations, IV preferred</para>
					</section>
					<section type="none" id="sidelem4x10426">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, peak 15-30 min, half-life 2 hr, prolonged up to 7 hr in infants; not metabolized; excreted unchanged in urine; crosses placenta; removed by hemodialysis</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10431">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> masking ototoxicity: dimenhyDRINATE, ethacrynic acid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum trough and peak—NSAIDs</para>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> nephrotoxicity—cephalosporins, acyclovir, vancomycin, amphotericin B, cycloSPORINE, loop diuretics, cidofovir</bbw>
				</para>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> Ototoxicito-IV loop diuretics</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> neuromuscular blockade, respiratory depression—anesthetics, nondepolarizing neuromuscular blockers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> amikacin effect—parenteral penicillins, do not combine</para>
				<section type="none" id="sidelem4x10475">
					<section type="none" id="sidelem4x10476">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, creatinine, urea levels (urine)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10483">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10486">
					<section type="none" id="sidelem4x10487">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10491">
								<item>
									<label>•</label>
									<para>Weight before treatment; calculation of dosage is usually based on ideal body weight but may be calculated on actual body weight, in those underweight and not obese, use total body weight (TBW) instead of ideal body weight</para>
								</item>
								<item>
									<label>•</label>
									<para>I&amp;O ratio; urinalysis daily for proteinuria, cells, casts; report sudden change in urine output</para>
								</item>
								<item>
									<label>•</label>
									<para>VS during infusion; watch for hypotension, change in pulse</para>
								</item>
								<item>
									<label>•</label>
									<para>IV site for thrombophlebitis including pain, redness, swelling q30min; change site if needed; apply warm compresses to discontinued site
<bbw>Renal impairment; obtain urine for CCr, BUN, serum creatinine; lower dosage should be given with renal impairment; nephrotoxicity may be reversible if product stopped at 1st sign</bbw>

<bbw>Deafness: audiometric testing, ringing, roaring in ears, vertigo; assess hearing before, during, after treatment</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Dehydration: high specific gravity, decrease in skin turgor, dry mucous membranes, dark urine</para>
								</item>
								<item>
									<label>•</label>
									<para>Overgrowth of infection: increased temperature, malaise, redness, pain, swelling, perineal itching, diarrhea, stomatitis, change in cough, sputum</para>
								</item>
								<item>
									<label>•</label>
									<para>Vestibular dysfunction: nausea, vomiting, dizziness, headache; product should be discontinued if severe
<bbw>Neuromuscular blockade; respiratory paralysis may occur</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Provide adequate fluids of 2-3 L/day, unless contraindicated, to prevent irritation of tubules</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10559">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10563">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, draining wounds, negative C&amp;S after treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10569">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10574">
								<item>
									<label>•</label>
									<para>To report headache, dizziness, symptoms of overgrowth of infection, renal impairment, symptoms of neurotoxicity, hepatotoxicity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10580">
								<item>
									<para>
										<emphasis alert="nurse">To report loss of hearing; ringing, roaring in ears; feeling of fullness in head</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10588">
							<label>•</label>
							<sec_title>To report hypersensitivity<route> rash, itching, trouble breathing, facial edema; notify health care provider</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x10591">
				<sec_title>Treatment of hypersensitivity:</sec_title>
				<para>
					<emphasis alert="lifethreat">Hemodialysis, exchange transfusion in the newborn, monitor serum levels of product, may give ticarcillin or carbenicillin</emphasis>
				</para>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>aMILoride (Rx)</mono_name>
			<info>
				<pronunciation>(a-mill′oh-ride)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x106024">
						<country code="CAN">Apo-Amilzide </country>
					</tradename>
					<tradename id="tnidelem4x106023">Midamor</tradename>
					<tradename id="tnidelem4x106022">
						<country code="CAN">Moduret </country>
					</tradename>
					<tradename id="tnidelem4x106021">
						<country code="CAN">Novamilor </country>
					</tradename>
					<tradename id="tnidelem4x106020">
						<country code="CAN">Nu-Amilzide </country>
					</tradename>
				</tradenames>
				<class type="func"> Potassium-sparing diuretic</class>
				<class type="chem"> Pyrazine</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10623">
				<para>
					<confusion>
						<tradename id="tnidelem4x106230">aMILoride</tradename>
						<drug type="generic" refid="idelem4x106230">amLODIPine/amiodarone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10627">
				<sec_title>Action:</sec_title>
				<para>Inhibits sodium, potassium ion exchange in the distal tubule, cortical collecting duct resulting in inhibition of sodium reabsorption and decreasing potassium secretion</para>
			</section>
			<section type="uses" id="sidelem4x10633">
				<sec_title>Uses:</sec_title>
				<para>Edema in CHF in combination with other diuretics, for hypertension, adjunct with other diuretics to maintain potassium</para>
				<section type="none" id="sidelem4x10638">
					<section type="none" id="sidelem4x10639">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Ascites</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10644">
				<sec_title>Contraindications:</sec_title>
				<para>Anuria, hypersensitivity, diabetic nephropathy, renal failure</para>
				<para>
					<bbw>Hyperkalemia</bbw>
				</para>
				<section type="none" id="sidelem4x10659">
					<section type="none" id="sidelem4x10660">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, dehydration, diabetes, respiratory acidosis, hyponatremia, impaired renal function</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10665">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10673">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10673">
							<item>
								<label>•</label>
								<para> 5-10 mg/day in 1-2 divided doses; may be increased to 10-20 mg/day if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10680">
					<label>•</label>
					<sec_title>Infant/child (6-20 kg)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10680">
							<item>
								<label>•</label>
								<para> 0.625 mg/kg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10684">
					<section type="none" id="sidelem4x10685">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x10693">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-50 ml/min reduce dose by 50%; however, avoid if possible; CCr &lt;10 ml/min contraindicated</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10696">
						<sec_title>Ascites (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10704">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10704">
									<item>
										<label>•</label>
										<para> 10 mg/day, max 40 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10708">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5 mg</para>
					</section>
					<section type="none" id="sidelem4x10713">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10717">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> to avoid interference with sleep if using as diuretic; if 2nd daily dose is needed, give in late afternoon</para>
								</item>
								<item>
									<label>•</label>
									<para>With food; if nausea occurs, absorption may be decreased slightly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10731">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10734">
					<section type="none" id="sidelem4x10735">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> dizziness, fatigue, weakness, paresthesias, tremors, depression, anxiety, <emphasis style="bold">encephalopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10745">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> dysrhythmias, chest pain</para>
					</section>
					<section type="none" id="sidelem4x10753">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, increased intraocular pressure</para>
					</section>
					<section type="none" id="sidelem4x10758">
						<sec_title>ELECT:</sec_title>
						<para> <emphasis style="bold">Hyperkalemia,</emphasis> dehydration, hyponatremia, hypochloremia</para>
					</section>
					<section type="none" id="sidelem4x10766">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea,</emphasis> dry mouth, <emphasis style="italic">vomiting, anorexia,</emphasis> cramps, constipation, abdominal pain, jaundice</para>
					</section>
					<section type="none" id="sidelem4x10777">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Polyuria,</emphasis> dysuria, urinary frequency, impotence</para>
					</section>
					<section type="none" id="sidelem4x10785">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Aplastic anemia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10792">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis> alopecia, urticaria</para>
					</section>
					<section type="none" id="sidelem4x10800">
						<sec_title>MS:</sec_title>
						<para> Cramps</para>
					</section>
					<section type="none" id="sidelem4x10805">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, dyspnea,</emphasis> shortness of breath</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10813">
				<sec_title>Pharmacokinetics</sec_title>
				<para>50% absorbed from GI tract; widely distributed; onset 2 hr; peak 6-10 hr; duration 24 hr; excreted in urine, feces; half-life 6-9 hr</para>
			</section>
			<section type="interactions" id="sidelem4x10818">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>Hyperkalemia: other potassium-sparing diuretics, potassium products, ACE inhibitors, salt substitutes, cycloSPORINE, tacrolimus; avoid concurrent use, if using together monitor potassium level</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> lithium toxicity: lithium, monitor lithium levels</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of antihypertensives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of aMILoride—NSAIDs, avoid concurrent use</para>
				<section type="none" id="sidelem4x10843">
					<section type="none" id="sidelem4x10844">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—hawthorn, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x10851">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x10855">
								<item>
									<label>•</label>
									<para>Possible hyperkalemia: foods high in potassium, potassium-based salt substitutes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10861">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, BUN, potassium, sodium</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> GTT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10872">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10875">
					<section type="none" id="sidelem4x10876">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10881">
								<item>
									<label>•</label>
									<para>Heart rate, B/P lying, standing; postural hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10886">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chloride; glucose (serum), BUN, CBC, serum creatinine, blood pH, ABGs, periodic ECG
<bbw>Discontinue potassium-sparing diuretics 3 days before GTT, hyperkalemia may occur</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10904">
							<label>•</label>
							<sec_title>Hypokalemia</sec_title>
							<para>
								<list id="lidelem4x10904">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypokalemia:</emphasis> weakness, polyuria, polydipsia, fatigue, ECG U wave
<bbw>Hyperkalemia: fatigue, weakness, paresthesia, confusion, dyspnea, dysrhythmias, ECG changes</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10917">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10921">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in edema of feet, legs, sacral area daily if medication is being used for CHF; decreased B/P; prevention of hypokalemia (diuretics)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10927">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10931">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take when remembered within 1 hr of next dose; to take with food or milk for GI symptoms; to take early in day to prevent nocturia; to avoid alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>About adverse reactions: muscle cramps, weakness, nausea, dizziness, blurred vision</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid potassium-rich foods: oranges, bananas, salt substitutes, dried fruits, potassium supplements</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly from sitting to standing to avoid orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness occurs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x10957">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if taken orally, monitor electrolytes, administer sodium bicarbonate for potassium &gt;6.5 mEq/L, IV glucose, kayoxalate as needed; monitor hydration, CV, renal status</para>
			</section>
		</monograph>
<monograph id="38" status="active">
			<mono_name>amino acids</mono_name>
			<info>
				<pronunciation>(a-mee′noe)</pronunciation>
			</info>
		</monograph>
<monograph id="39" status="active">
			<mono_name>amino acid infusions (crystalline)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x109707">Aminosyn</tradename>
					<tradename id="tnidelem4x109706">Aminosyn II</tradename>
					<tradename id="tnidelem4x109705">Aminosyn-PF</tradename>
					<tradename id="tnidelem4x109704">Clinisol</tradename>
					<tradename id="tnidelem4x109703">FreAmine III</tradename>
					<tradename id="tnidelem4x109702">Premasol</tradename>
					<tradename id="tnidelem4x109701">Travasol</tradename>
					<tradename id="tnidelem4x109700">TrophAmine</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="40" status="active">
			<mono_name>amino acid infusions/dextrose</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x109752">Aminosyn II with dextrose</tradename>
					<tradename id="tnidelem4x109751">Clinimix</tradename>
					<tradename id="tnidelem4x109750">Amino Acid Infusions/electrolytes</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="41" status="active">
			<mono_name>aminosyn with electrolytes</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x109803">Aminosyn II with electrolytes</tradename>
					<tradename id="tnidelem4x109802">FreAmine III with electrolytes</tradename>
					<tradename id="tnidelem4x109801">ProcalAmine with electrolytes</tradename>
					<tradename id="tnidelem4x109800">Travasol with electrolytes</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="42" status="active">
			<mono_name>amino acid infusions/electrolytes/dextrose</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x109850">Aminosyn II with electrolytes in dextrose</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="43" status="active">
			<mono_name>amino acid infusions (hepatic failure)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x109901">HepatAmine</tradename>
					<tradename id="tnidelem4x109900">Hepatasol</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="44" status="active">
			<mono_name>amino acid infusions (high metabolic stress)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x109951">Aminosyn-HBC</tradename>
					<tradename id="tnidelem4x109950">FreAmine HBC</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="45" status="active">
			<mono_name>amino acid infusions (renal failure)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x110001">Aminosyn-RF</tradename>
					<tradename id="tnidelem4x110000">NephrAmine</tradename>
				</tradenames>
				<class type="func"> Nutritional supplement/protein</class>
				<class type="chem"> n/a</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11010">
				<sec_title>Action:</sec_title>
				<para>Needed for anabolism to maintain structure, decrease catabolism, promote healing</para>
				<para>
					<bbw>Central infusions: Administration by central venous catheter should be used only by those familiar with this technique and its complications</bbw>
				</para>
			</section>
			<section type="uses" id="sidelem4x11026">
				<sec_title>Uses:</sec_title>
				<para>Hepatic encephalopathy, cirrhosis, hepatitis, nutritional support in cancer; burn or solid organ transplant patients; to prevent nitrogen loss when adequate nutrition by mouth, gastric, or duodenal tube cannot be obtained</para>
			</section>
			<section type="contra" id="sidelem4x11031">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe electrolyte imbalances, anuria, severe liver damage, maple syrup urine disease, PKU, azotemia, genetic disease of amino acid metabolism</para>
				<section type="none" id="sidelem4x11036">
					<section type="none" id="sidelem4x11037">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, renal disease, diabetes mellitus, CHF, sulfite sensitivity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11042">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11045">
					<section type="none" id="sidelem4x11046">
						<sec_title>Nutritional support (cirrhosis, hepatic encephalopathy, hepatitis)</sec_title>
						<section type="none" id="sidelem4x11054">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11054">
									<item>
										<label>•</label>
										<para> 80-120 g/day amino acids/12-18 g nitrogen of hepatic failure formula</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11058">
						<sec_title>TPN</sec_title>
						<section type="none" id="sidelem4x11066">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11066">
									<item>
										<label>•</label>
										<para> 1-1.5 g/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11070">
						<sec_title>Metabolic stress (severe)</sec_title>
						<section type="none" id="sidelem4x11078">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11078">
									<item>
										<label>•</label>
										<para> 1.5 g/kg, use formula for high metabolic stress</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11082">
						<sec_title>Renal failure (nutritional support)</sec_title>
						<section type="none" id="sidelem4x11090">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11090">
									<item>
										<label>•</label>
										<para> Minosyn-RF 300-600 ml/70% dextrose/day; NephrAmine 250-500 ml/70% dextrose/day; the total daily dosage is calculated based on the daily protein requirements, as well as the patient’s metabolic and clinical response. Check product instructions for specific directions</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11097">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11097">
									<item>
										<label>•</label>
										<para> 2-3 g/kg/day</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11101">
								<item>
									<label>•</label>
									<para>The dosage and constant infusion rate of IV dextrose must be selected with caution in children, particularly neonates and low birth weight infants, because of the increased risk of hyper/hypoglycemia. Owing to their concentration, these solutions are not recommended for use in children younger than 1 year</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11106">
								<item>
									<label>•</label>
									<para>The total daily dosage is calculated based on the daily protein requirements, as well as the patient’s metabolic and clinical response. Check each product’s instructions for specific directions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11111">
						<sec_title>Available forms:</sec_title>
						<para>
							<emphasis style="bold">Injection:</emphasis> 250, 500, 1000, 2000 ml, containing amino acids in various concentrations; amino acid infusions, crystalline: Aminosyn: 3.5%, 5%, 7%, 8.5%, 10%; Aminosyn II: 3.5%, 5%, 7%, 8.5%, 10%, 15%; Aminosyn-PF: 7%, 10%; Clinisol: 15%; FreAmine III: 8.5%, 10%; Premasol: 6%, 10%; Travasol: 10%; TrophAmine: 6%, 10%</para>
						<section type="none" id="sidelem4x11118">
							<sec_title>Amino acid infusion/dextrose:</sec_title>
							<para>Aminosyn II: 3.5% in 5% dextrose, 4.25% in 20% dextrose, 4.25% in 10% dextrose, 4.25% in 25% dextrose; Clinimix: 2.75% in 5% dextrose, 4.25% in 5% dextrose, 4.25% in 10% dextrose, 4.25% in 20% dextrose, 4.25% in 25% dextrose, 5% in 10% dextrose, 5% in 15% dextrose, 5% in 20% dextrose, 5% in 25% dextrose, 5 amino acid infusions/electrolytes: Aminosyn: 3.5%, 7%, 8.5%; Aminosyn II: 3.5%, 7%, 8.5%; FreAmine III: 3%, 8.5%; ProcalAmine: 3%; Travasol: 3.5%, 5.5%, 8.5%</para>
						</section>
						<section type="none" id="sidelem4x11123">
							<sec_title>Amino acid infusions/electrolytes/dextrose:</sec_title>
							<para>Aminosyn II: 3.5% with electrolytes in 5% dextrose, 3.5% with electrolytes in 25% dextrose, 4.25% with electrolytes in 10% dextrose, 4.25% with electrolytes in 20% dextrose, 4.25% with electrolytes in 25% dextrose; Amino acid infusions (hepatic failure): HepatAmine: 8%; Hepatasol: 8%</para>
						</section>
						<section type="none" id="sidelem4x11128">
							<sec_title>Amino acid infusions (high metabolic stress):</sec_title>
							<para>Aminosyn-HBC 7%; Freamine HBC: 6.9%; Amino acid (renal failure): Aminosyn-RF:5.2%; NephrAmine: 5.4%</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11133">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11136">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x11140">
									<item>
										<label>•</label>
										<para>Up to 40% protein and dextrose (up to 12.5%) via peripheral vein; stronger sol requires central IV administration</para>
									</item>
									<item>
										<label>•</label>
										<para>TPN only mixed with dextrose to promote protein synthesis</para>
									</item>
									<item>
										<label>•</label>
										<para>Immediately after mixing under strict aseptic technique, use infusion pump, in-line filter (0.22 µm) unless mixed with fat emulsion and dextrose (3 in 1); using careful monitoring technique; do not speed up infusion; pulmonary edema, glucose overload will result</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11158">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11161">
					<section type="none" id="sidelem4x11162">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, confusion, loss of concentration, fever</para>
					</section>
					<section type="none" id="sidelem4x11167">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">CHF/pulmonary edema,</emphasis> flushing, <emphasis style="bold">thrombosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11177">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia, rebound hypoglycemia, electrolyte imbalances, hyperosmolar hyperglycemic nonketotic syndrome, alkalosis, hypophosphatemia, hyperammonemia, dehydration, hypocalcemia</para>
					</section>
					<section type="none" id="sidelem4x11182">
						<sec_title>GI:</sec_title>
						<para> Nausea, abdominal pain, cholestasis</para>
					</section>
					<section type="none" id="sidelem4x11187">
						<sec_title>GU:</sec_title>
						<para> Glycosuria osmotic diuresis</para>
					</section>
					<section type="none" id="sidelem4x11192">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Extravasation necrosis, phlebitis at inj site</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11199">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x11202">
					<section type="none" id="sidelem4x11203">
						<sec_title>Individual Drugs</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Protein-sparing effects—tetracycline</para>
					</section>
					<section type="none" id="sidelem4x11210">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, ammonia glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Potassium, phosphate, glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11221">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11224">
					<section type="none" id="sidelem4x11225">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11230">
								<item>
									<label>•</label>
									<para>Electrolytes (potassium, sodium, phosphate, chloride, magnesium, bicarbonate, blood glucose, ammonia, ketones)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11235">
								<item>
									<label>•</label>
									<para>Renal/hepatic studies: BUN, creatinine, ALT, AST, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11240">
								<item>
									<label>•</label>
									<para>Weight changes, triglycerides before and after infusion; vit A level with renal disease</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11248">
							<label>•</label>
							<sec_title>Inj site for extravasation<route> redness along vein, edema at site, necrosis, pain, hard tender area; site should be changed immediately</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x11251">
								<item>
									<label>•</label>
									<para>Discontinue infusion, culture tubing and sol</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11259">
							<label>•</label>
							<sec_title>Sepsis<route> chills, fever, increased temperature, if sepsis is suspected</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11265">
							<label>•</label>
							<sec_title>For impending hepatic coma<route> asterixis, confusion, uremic fetor, lethargy</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11271">
							<label>•</label>
							<sec_title>Hyperammonemia<route> nausea, vomiting, malaise, tremors, anorexia, seizures</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x11274">
								<item>
									<label>•</label>
									<para>Change of dressing and IV tubing to prevent infection every 24-48 hr if chills, fever, other signs of infection occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11279">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11283">
								<item>
									<label>•</label>
									<para>Therapeutic response: weight gain, decrease in jaundice with liver disorders, increased LOC</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11289">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11294">
								<item>
									<label>•</label>
									<para>Reason for use of TPN</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11302">
							<label>•</label>
							<sec_title>
								<route>If chills, sweating are experienced to report at once, risk for infection is higher</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11305">
								<item>
									<label>•</label>
									<para>About infusion pump, how to care for tubing/site; and blood glucose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="46" status="active" ha="yes">
			<mono_name>amiodarone (Rx)</mono_name>
			<info>
				<pronunciation>(a-mee-oh′da-rone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x113172">Cordarone</tradename>
					<tradename id="tnidelem4x113171">Nexterone</tradename>
					<tradename id="tnidelem4x113170">Pacerone</tradename>
				</tradenames>
				<class type="func"> Antidysrhythmic (class III)</class>
				<class type="chem"> Iodinated benzofuran derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11327">
				<para>
					<confusion>
						<tradename id="tnidelem4x113270">amiodarone</tradename>
						<drug type="generic" refid="idelem4x113270">Inamrinone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11334">
				<sec_title>Action:</sec_title>
				<para>Prolongs duration of action potential and effective refractory period, noncompetitive α- and β-adrenergic inhibition; increases PR and QT intervals, decreases sinus rate, decreases peripheral vascular resistance</para>
			</section>
			<section type="uses" id="sidelem4x11339">
				<sec_title>Uses:</sec_title>
				<para>Hemodynamically unstable ventricular tachycardia, supraventricular tachycardia, ventricular fibrillation not controlled by 1st-line agents</para>
				<section type="none" id="sidelem4x11344">
					<section type="none" id="sidelem4x11345">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Atrial fibrillation treatment/prophylaxis, atrial flutter, cardiac arrest, cardiac surgery, CPR, heart failure, PSVT, Wolff-Parkinson-White (WPW) syndrome, supraventricular tachycardia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11350">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, neonates, infants, severe sinus node dysfunction, hypersensitivity to this product/iodine/benzyl alcohol, cardiogenic shock</para>
				<para>
					<bbw>2nd- to 3rd-degree AV block, bradycardia</bbw>
				</para>
				<section type="none" id="sidelem4x11366">
					<section type="none" id="sidelem4x11367">
						<sec_title>Precautions:</sec_title>
						<para> Children, goiter, Hashimoto’s thyroiditis, electrolyte imbalances, CHF, respiratory disease, torsades de pointes</para>
						<para>
							<bbw>Severe hepatic disease, cardiac arrhythmias, pneumonitis, pulmonary fibrosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11382">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11385">
					<section type="none" id="sidelem4x11386">
						<sec_title>Ventricular dysrhythmias</sec_title>
						<section type="none" id="sidelem4x11394">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11394">
									<item>
										<label>•</label>
										<para> Loading dose 800-1600 mg/day for 1-3 wk, then 600-800 mg/day for 1 mo, maintenance 400 mg/day;  loading dose (1st rapid) 150 mg over the first 10 min, then slow 360 mg over the next 6 hr, maintenance 540 mg given over the remaining 18 hr, decrease rate of the slow infusion to 0.5 mg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11401">
						<sec_title>Supraventricular dysrhythmias (atrial fibrillation, atrial flutter, PSVT, WPW syndrome) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11409">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11409">
									<item>
										<label>•</label>
										<para> 1.2-1.8 g/day divided until a total of 10 g has been given, then 200-400 mg/day (class IIa recommendation);  5-7 mg/kg over 30-60 min, then 1.2-1.8 g as  or in divided PO doses until 10 g, then 200-400 mg/day (class IIa recommendation)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11422">
							<label>•</label>
							<sec_title>Child and infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11422">
									<item>
										<label>•</label>
										<para> 10-20 mg/kg/day in divided doses for 7-10 days, then 5-10 mg/kg/day once daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11426">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200, 400 mg; inj 50 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x11431">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11434">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x11438">
									<item>
										<label>•</label>
										<para>May be used with/without food but be consistent</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11444">
							<sec_title>IV, direct route</sec_title>
							<section type="none" id="sidelem4x11452">
								<label>•</label>
								<sec_title>Peripheral</sec_title>
								<para>
									<list id="lidelem4x11452">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Peripheral:</emphasis> max 2 mg/ml for more than 1 hr; preferred through central venous line with in-line filter; concentrations of more than 2 mg/ml should be given by central line</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11459">
								<label>•</label>
								<sec_title>Cardiac arrest</sec_title>
								<para>
									<list id="lidelem4x11459">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cardiac arrest:</emphasis> give 300 mg IV bol; diluted to a total volume of 20 ml D<emphasis style="inf">5</emphasis>W; may repeat 150 mg after 3-5 min</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x11466">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x11474">
								<label>•</label>
								<sec_title>Rapid loading</sec_title>
								<para>
									<list id="lidelem4x11474">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Rapid loading:</emphasis> add 3 ml (150 mg), 100 ml D<emphasis style="inf">5</emphasis>W (1.5 mg/ml), give over 10 min</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11484">
								<label>•</label>
								<sec_title>Slow loading</sec_title>
								<para>
									<list id="lidelem4x11484">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Slow loading:</emphasis> add 18 ml (900 mg), 500 ml D<emphasis style="inf">5</emphasis>W (1.8 mg/ml), give over next 6 hr</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x11491">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x11495">
									<item>
										<label>•</label>
										<para>After 24 hr, dilute 50 ml to 1-6 mg/ml, give 1-6 mg/ml at 1 mg/min for the 1st 6 hr, then 0.5 mg/min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amikacin, clindamycin, DOBUTamine, DOPamine, doxycycline, erythromycin, esmolol, gentamicin, insulin, isoproterenol, labetalol, lidocaine, metaraminol, metroNIDAZOLE, midazolam, morphine, nitroglycerin, norepinephrine, penicillin G potassium, phenylephrine, potassium chloride, procainamide, tobramycin, vancomycin</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11505">
						<sec_title>Solution compatibility:</sec_title>
						<para> D<emphasis style="inf">5</emphasis>W, 0.9% NaCl</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11513">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11516">
					<section type="none" id="sidelem4x11517">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> involuntary movement, <emphasis style="italic">tremors, peripheral neuropathy,</emphasis> malaise, <emphasis style="italic">fatigue,</emphasis> ataxia, <emphasis style="italic">paresthesias,</emphasis> insomnia</para>
					</section>
					<section type="none" id="sidelem4x11534">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension, bradycardia,</emphasis><emphasis style="bold">sinus arrest, CHF, dysrhythmias, SA node dysfunction, AV block,</emphasis> increased defibrillation energy requirement</para>
					</section>
					<section type="none" id="sidelem4x11544">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, halos, photophobia, <emphasis style="italic">corneal microdeposits,</emphasis> dry eyes</para>
					</section>
					<section type="none" id="sidelem4x11552">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="italic">Hypo</emphasis>/hyperthyroidism</para>
					</section>
					<section type="none" id="sidelem4x11560">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> diarrhea, abdominal pain, <emphasis style="italic">anorexia, constipation,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11572">
						<sec_title>GU:</sec_title>
						<para> Epididymitis, ED</para>
					</section>
					<section type="none" id="sidelem4x11577">
						<sec_title>INTEG:</sec_title>
						<para> Rash, photosensitivity, blue-gray skin discoloration, alopecia, spontaneous ecchymosis, <emphasis style="bold">toxic epidermal necrolysis,</emphasis> urticaria, <emphasis style="bold">pancreatitis,</emphasis> phlebitis (IV)</para>
					</section>
					<section type="none" id="sidelem4x11588">
						<sec_title>MISC:</sec_title>
						<para> Flushing, abnormal taste or smell, edema, abnormal salivation, coagulation abnormalities</para>
					</section>
					<section type="none" id="sidelem4x11593">
						<sec_title>MS:</sec_title>
						<para> Weakness, pain in extremities</para>
					</section>
					<section type="none" id="sidelem4x11598">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pulmonary fibrosis/toxicity,</emphasis> pulmonary inflammation, <emphasis style="bold">ARDS; gasping syndrome if used with neonates</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11608">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x11611">
					<section type="none" id="sidelem4x11612">
						<sec_title>PO:</sec_title>
						<para> Onset 1-3 wk, peak 3-7 hr, half-life 26-107 days, increased in geriatric patients, metabolized by liver (an inhibitor of CYP1A2, CYP3A4, CYP2C8, CYP2C9, CYP2C19, CYP2A6, CYP2B6, CYP2D6, P-glycoprotein), organic cation transporter, excreted by kidneys, 99% protein binding</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11618">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—azoles, fluoroquinolones, macrolides</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: amiodarone concentrations, possible serious dysrhythmias-protease inhibitors, reduce dose</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myopathy—HMG-CoA reductase inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia—β-blockers, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of cycloSPORINE, dextromethorphan, digoxin, disopyramide, flecainide, methotrexate, phenytoin, procainamide, quiNIDine, theophylline, class I antidysrhythmics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant effects—dabigatran, warfarin</para>
				<section type="none" id="sidelem4x11643">
					<section type="none" id="sidelem4x11644">
						<sec_title>Drug/Food</sec_title>
						<section type="none" id="sidelem4x11652">
							<label>•</label>
							<sec_title>Toxicity<route> grapefruit juice</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11655">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> T<emphasis style="inf">4</emphasis>, ALT, AST, GGT alk phos, cholesterol, lipids, PT, INR</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> T<emphasis style="inf">3</emphasis></para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11671">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11674">
					<section type="none" id="sidelem4x11675">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Pulmonary toxicity: dyspnea, fatigue, cough, fever, chest pain; product should be discontinued; for ARDS, pulmonary fibrosis, crackles, tachypnea, increased at higher doses, toxicity is common</bbw>
						</para>
						<para>
							<bbw>ECG continuously to determine product effectiveness; measure PR, QRS, QT intervals; check for PVCs, other dysrhythmias, B/P continuously for hypo/hypertension; report dysrhythmias, slowing heart rate; monitor amiodarone level: therapeutic 1-2.5 mcg/ml; toxic &gt;2.5 mcg/ml</bbw>
						</para>
						<para>
							<list id="lidelem4x11699">
								<item>
									<label>•</label>
									<para>Electrolytes (sodium, potassium, chloride); hepatic studies: AST, ALT, bilirubin, alk phos; for dehydration, hypovolemia, monitor PT, INR if using warfarin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11704">
								<item>
									<label>•</label>
									<para>Chest x-ray, thyroid function tests</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11709">
								<item>
									<label>•</label>
									<para>CNS symptoms: confusion, psychosis, numbness, depression, involuntary movements; product should be discontinued</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11717">
							<label>•</label>
							<sec_title>Hypothyroidism</sec_title>
							<para>
								<list id="lidelem4x11717">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypothyroidism:</emphasis> lethargy; dizziness; constipation; enlarged thyroid gland; edema of extremities; cool, pale skin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11724">
							<label>•</label>
							<sec_title>Hyperthyroidism</sec_title>
							<para>
								<list id="lidelem4x11724">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperthyroidism:</emphasis> restlessness; tachycardia; eyelid puffiness; weight loss; frequent urination; menstrual irregularities; dyspnea; warm, moist skin</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11728">
								<item>
									<label>•</label>
									<para>Ophthalmic exams at baseline and periodically (PO); to prevent corneal deposits, use methylcellulose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11733">
								<item>
									<label>•</label>
									<para>Cardiac rate, respirations: rate, rhythm, character, chest pain; start with patient hospitalized and monitored up to 1 wk; for rebound hypertension after 1-2 hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11738">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11742">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in ventricular tachycardia, supraventricular tachycardia, fibrillation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11748">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11752">
								<item>
									<label>•</label>
									<para>To take this product as directed; to avoid missed doses; not to use with grapefruit juice; not to discontinue abruptly, not to use other drugs, herbs without prescriber approval, many interactions</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sunscreen or stay out of sun to prevent burns; that dark glasses may be needed for photophobia</para>
								</item>
								<item>
									<label>•</label>
									<para>To report side effects immediately; more common at high dose</para>
								</item>
								<item>
									<label>•</label>
									<para>That skin discoloration is usually reversible</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x11773">
				<sec_title>Treatment of overdose:</sec_title>
				<para>O<emphasis style="inf">2</emphasis>, artificial ventilation, ECG, administer DOPamine for circulatory depression, administer diazepam, thiopental for seizures, isoproterenol</para>
			</section>
		</monograph>
<monograph id="47" status="active">
			<mono_name>amitriptyline (Rx)</mono_name>
			<info>
				<pronunciation>(a-mee-trip′ti-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x117862">
						<country code="CAN">Elavil </country>
					</tradename>
					<tradename id="tnidelem4x117861">
						<country code="CAN">Levate </country>
					</tradename>
					<tradename id="tnidelem4x117860">
						<country code="CAN">Novo-Triptyn </country>
					</tradename>
				</tradenames>
				<class type="func"> Antidepressant—tricyclic</class>
				<class type="chem"> Tertiary amine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11805">
				<para>
					<confusion>
						<tradename id="tnidelem4x118050">amitriptyline</tradename>
						<drug type="generic" refid="idelem4x118050">nortriptyline/aminophylline</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11809">
				<sec_title>Action:</sec_title>
				<para>Blocks reuptake of norepinephrine, serotonin into nerve endings, thereby increasing action of norepinephrine, serotonin in nerve cells</para>
			</section>
			<section type="uses" id="sidelem4x11814">
				<sec_title>Uses:</sec_title>
				<para>Major depression</para>
				<section type="none" id="sidelem4x11819">
					<section type="none" id="sidelem4x11820">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Neuropathic pain, prevention of cluster/migraine headaches, fibromyalgia, ADHD, bulimia nervosa, diabetic neuropathy, enuresis, insomnia, panic disorder, postherpetic neuralgia, hiccups, social phobia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11825">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to tricyclics; recovery phase of myocardial infarction</para>
				<section type="none" id="sidelem4x11830">
					<section type="none" id="sidelem4x11831">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, seizure disorders, prostatic hypertrophy, schizophrenia, psychosis, severe depression, increased intraocular pressure, closed-angle glaucoma, urinary retention, renal/hepatic/cardiac disease, hyperthyroidism, electroshock therapy, elective surgery</para>
						<para>
							<bbw>Children &lt;12 yr, suicidal patients</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11846">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11849">
					<section type="none" id="sidelem4x11850">
						<sec_title>Depression</sec_title>
						<section type="none" id="sidelem4x11858">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11858">
									<item>
										<label>•</label>
										<para> 25-75 mg/day as single dose at bedtime or in divided doses, may increase to 200 mg/day; max 300 mg/day (if hospitalized)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11865">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11865">
									<item>
										<label>•</label>
										<para> 10-25 mg at bedtime, may be increased to 150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11869">
						<sec_title>Cluster/migraine headache (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11877">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11877">
									<item>
										<label>•</label>
										<para> 25-200 mg/day, initiate at lowest dose, titrate</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11881">
						<sec_title>Pain (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11889">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11889">
									<item>
										<label>•</label>
										<para> 75-300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11893">
						<sec_title>Fibromyalgia/insomnia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11901">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11901">
									<item>
										<label>•</label>
										<para> 10-50 mg nightly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11905">
						<sec_title>Enuresis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11913">
							<label>•</label>
							<sec_title>Child 11-14 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11913">
									<item>
										<label>•</label>
										<para> 50 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11920">
							<label>•</label>
							<sec_title>Child 6-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11920">
									<item>
										<label>•</label>
										<para> 25 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11924">
						<sec_title>ADHD/bulimia nervosa (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11932">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11932">
									<item>
										<label>•</label>
										<para> 25 mg tid, titrate to 150 mg/day by 25-50 mg at weekly intervals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11939">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11939">
									<item>
										<label>•</label>
										<para> 10-30 mg/day or 1-5 mg/kg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11943">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 25, 50, 75, 100, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x11948">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11952">
								<item>
									<label>•</label>
									<para>Increase fluids, bulk in diet if constipation, urinary retention occur, especially in geriatric patients</para>
								</item>
								<item>
									<label>•</label>
									<para>With food, milk for GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Crushed if patient unable to swallow medication whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Dosage at bedtime if oversedation occurs during day; may take entire dose at bedtime; geriatric patients may not tolerate once daily dosing</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11978">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11981">
					<section type="none" id="sidelem4x11982">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, weakness, <emphasis style="italic">insomnia,</emphasis> nightmares, EPS (geriatric patients), increased psychiatric symptoms, <emphasis style="bold">seizures, suicidal thoughts,</emphasis> anxiety</para>
					</section>
					<section type="none" id="sidelem4x11996">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis><emphasis style="bold">ECG changes, tachycardia, hypertension,</emphasis> palpitations, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12008">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis, ophthalmoplegia, amblyopia</para>
					</section>
					<section type="none" id="sidelem4x12016">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation, dry mouth,</emphasis> weight gain, nausea, vomiting, <emphasis style="bold">paralytic ileus,</emphasis> increased appetite, cramps, epigastric distress, jaundice, <emphasis style="bold">hepatitis,</emphasis> stomatitis</para>
					</section>
					<section type="none" id="sidelem4x12030">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary retention,</emphasis> sexual dysfunction</para>
					</section>
					<section type="none" id="sidelem4x12038">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, eosinophilia, leukopenia, aplastic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12045">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, sweating, pruritus, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x12050">
						<sec_title>RESP:</sec_title>
						<para> Asthma, exacerbation, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x12055">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Neuroleptic malignant syndrome, serotonin syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12062">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 45 min; peak 2-12 hr; therapeutic response 4-10 days; metabolized by liver to nortriptyline; excreted in urine, feces; crosses placenta; excreted in breast milk; half-life 10-46 hr</para>
			</section>
			<section type="interactions" id="sidelem4x12068">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Hyperpyretic crisis, seizures, hypertensive episode: MAOIs, do not use within 14 days of MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk for agranulocytosis—antithyroid agents</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—procainamide, quiNIDine, amiodarone, tricyclics, class IA, III antidysrhythmics</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: amitriptyline levels, toxicity—cimetidine, FLUoxetine, phenothiazines, oral contraceptives, antidepressants, carBAMazepine, class IC antidysrhythmics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of direct-acting sympathomimetics (EPINEPHrine), alcohol, barbiturates, benzodiazepines, CNS depressants, opioids, sedative/hypnotics</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, linezolid, methyline blue, use cautiously</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of guanethidine, cloNIDine, indirect-acting sympathomimetics (ePHEDrine)</para>
				<section type="none" id="sidelem4x12097">
					<section type="none" id="sidelem4x12098">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Increase: serotonin syndrome—SAM-e, St. John’s wort, yohimbe</emphasis>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, hops, chamomile, lavender, valerian</para>
					</section>
					<section type="none" id="sidelem4x12108">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum bilirubin, blood glucose, alk phos, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBCs, platelets, granulocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12119">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12122">
					<section type="none" id="sidelem4x12123">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12128">
								<item>
									<label>•</label>
									<para>B/P lying, standing; pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take vital signs q4hr with CV disease; ECG for flattening of T wave, prolongation of QTc interval, bundle branch block, AV block, dysrhythmias in cardiac patients, avoid use immediately after MI</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12136">
							<label>•</label>
							<sec_title>Blood studies</sec_title>
							<para>
								<list id="lidelem4x12136">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blood studies:</emphasis> CBC, leukocytes, differential, cardiac enzymes if patient is receiving long-term therapy, thyroid function tests</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12143">
							<label>•</label>
							<sec_title>Hepatic studies</sec_title>
							<para>
								<list id="lidelem4x12143">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic studies:</emphasis> AST, ALT, bilirubin</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12147">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may increase with product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12152">
								<item>
									<label>•</label>
									<para>EPS primarily in geriatric patients: rigidity, dystonia, akathisia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12157">
								<item>
									<label>•</label>
									<para>Paralytic ileus, glaucoma exacerbation
<bbw>Mental status: mood, sensorium, affect, suicidal tendencies; increase in psychiatric symptoms: depression, panic; suicidal tendencies are higher in those ≤24 yr, restrict amount of product available</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12174">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> may occur with other serotonergic products (hyperthermia, hypertension, rigidity, delirium)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x12177">
								<item>
									<label>•</label>
									<para>Urinary retention, constipation; constipation is most likely to occur in children and geriatric patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12185">
							<label>•</label>
							<sec_title>Withdrawal symptoms<route> headache, nausea, vomiting, muscle pain, weakness; do not usually occur unless product was discontinued abruptly</route></sec_title>
						</section>
						<section type="none" id="sidelem4x12191">
							<label>•</label>
							<sec_title>Alcohol consumption</sec_title>
							<para>
								<list id="lidelem4x12191">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Alcohol consumption:</emphasis> if alcohol is consumed, hold dose until morning</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12198">
							<label>•</label>
							<sec_title>Pain syndromes (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x12198">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain syndromes (unlabeled):</emphasis> intensity, location, severity; use pain scale; product may be taken for 1-2 mo before effective</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12205">
							<label>•</label>
							<sec_title>Sexual dysfunction</sec_title>
							<para>
								<list id="lidelem4x12205">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Sexual dysfunction:</emphasis> erectile dysfunction, decreased libido</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12209">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12213">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in depression, absence of suicidal thoughts</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12219">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12224">
								<item>
									<label>•</label>
									<para>To take medication as directed; not to double dose; that therapeutic effects may take 2-3 wk; not to discontinue medication quickly after long-term use: may cause nausea, headache, malaise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12229">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities that require alertness because of drowsiness, dizziness, blurred vision; to avoid rising quickly from sitting to standing (especially geriatric patients); how to manage anticholinergic effects</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12234">
								<item>
									<label>•</label>
									<para>The symptoms of serotonin syndrome</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12239">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12245">
								<item>
									<label>•</label>
									<para>To wear sunscreen or large hat when outdoors, photosensitivity occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12253">
							<label>•</label>
							<sec_title>
								<route>That contraception is recommended during treatment; to avoid breastfeeding</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x12259">
							<label>•</label>
							<sec_title>
								<route>To watch for suicide</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x12262">
				<sec_title>Treatment of overdose:</sec_title>
				<para>ECG monitoring, lavage; administer anticonvulsant, sodium bicarbonate</para>
			</section>
		</monograph>
<monograph id="48" status="active">
			<mono_name>amLODIPine (Rx)</mono_name>
			<info>
				<pronunciation>(am-loe′di-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x122720">Norvasc</tradename>
				</tradenames>
				<class type="func"> Antianginal, antihypertensive, calcium channel blocker</class>
				<class type="chem"> Dihydropyridine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x12282">
				<para>
					<confusion>
						<tradename id="tnidelem4x122820">amLODIPine</tradename>
						<drug type="generic" refid="idelem4x122820">aMILoride</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12286">
				<sec_title>Action:</sec_title>
				<para>Inhibits calcium ion influx across cell membrane during cardiac depolarization; produces relaxation of coronary vascular smooth muscle, peripheral vascular smooth muscle; dilates coronary vascular arteries; increases myocardial O<emphasis style="inf">2</emphasis> delivery in patients with vasospastic angina</para>
			</section>
			<section type="uses" id="sidelem4x12294">
				<sec_title>Uses:</sec_title>
				<para>Chronic stable angina pectoris, hypertension, variant angina (Prinzmetal’s angina); may coadminister with other antihypertensives, antianginals</para>
				<section type="none" id="sidelem4x12299">
					<section type="none" id="sidelem4x12300">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hypertension (pediatric patients)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12305">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or dihydropyridine, severe aortic stenosis, severe obstructive CAD</para>
				<para>
					<bbw>Hypersensitivity to dihydropyridine</bbw>
				</para>
				<section type="none" id="sidelem4x12320">
					<section type="none" id="sidelem4x12321">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, hypotension, hepatic injury, GERD</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12326">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12329">
					<section type="none" id="sidelem4x12330">
						<sec_title>Coronary artery disease</sec_title>
						<section type="none" id="sidelem4x12338">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12338">
									<item>
										<label>•</label>
										<para> 5-10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12345">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12345">
									<item>
										<label>•</label>
										<para> 5 mg/day, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12349">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x12357">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12357">
									<item>
										<label>•</label>
										<para> 2.5-5 mg/day initially, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12364">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12364">
									<item>
										<label>•</label>
										<para> 2.5 mg/day, may increase to 5 mg/day, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12371">
							<label>•</label>
							<sec_title>Child 6-16 yr (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12371">
									<item>
										<label>•</label>
										<para> 2.5-5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12378">
							<label>•</label>
							<sec_title>Child &lt;6 yr (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12378">
									<item>
										<label>•</label>
										<para> 0.05-0.2 mg/kg/day in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12382">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x12390">
							<label>•</label>
							<sec_title>Adult<route> PO 2.5 mg/day; may increase to 10 mg/day (antihypertensive); 5 mg/day, may increase to 10 mg/day (antianginal)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12393">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x12398">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12402">
								<item>
									<label>•</label>
									<para>Once a day without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12408">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12411">
					<section type="none" id="sidelem4x12412">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> fatigue, dizziness, asthenia, anxiety, depression, insomnia, paresthesia, somnolence</para>
					</section>
					<section type="none" id="sidelem4x12420">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Peripheral edema,</emphasis> bradycardia, hypotension, palpitations, syncope, chest pain</para>
					</section>
					<section type="none" id="sidelem4x12428">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, gastric upset, constipation, flatulence, anorexia, gingival hyperplasia, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x12433">
						<sec_title>GU:</sec_title>
						<para> Nocturia, polyuria, sexual difficulties</para>
					</section>
					<section type="none" id="sidelem4x12438">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria, alopecia</para>
					</section>
					<section type="none" id="sidelem4x12443">
						<sec_title>OTHER:</sec_title>
						<para> Flushing, muscle cramps, cough, weight gain, tinnitus, epistaxis, pulmonary edema, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12448">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 6-12 hr; half-life 30-50 hr; increased in geriatric patients, hepatic disease; metabolized by liver (CYP3A4); excreted in urine (90% as metabolites); protein binding &gt;93%</para>
			</section>
			<section type="interactions" id="sidelem4x12453">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> amLODIPine level—diltiazem, conivaptan; CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> level of cycloSPORINE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myopathy simvastatin</para>
			</section>
			<section type="considerations" id="sidelem4x12469">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12472">
					<section type="none" id="sidelem4x12473">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12478">
								<item>
									<label>•</label>
									<para>Cardiac status: B/P, pulse, respirations, ECG; some patients have developed severe angina, acute MI after calcium channel blockers if obstructive CAD is severe</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12483">
								<item>
									<label>•</label>
									<para>Peripheral edema, dyspnea, jugular vein distention, crackles</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12491">
							<label>•</label>
							<sec_title>Angina</sec_title>
							<para>
								<list id="lidelem4x12491">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Angina:</emphasis> intensity, location, duration of pain</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12495">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12499">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anginal pain, decreased B/P, increased exercise tolerance</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12505">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12510">
								<item>
									<label>•</label>
									<para>To take product as prescribed, not to double or skip dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12515">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product, dizziness is no longer a problem</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12520">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12525">
								<item>
									<label>•</label>
									<para>To comply in all areas of medical regimen: diet, exercise, stress reduction, product therapy, smoking cessation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12533">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of irregular heartbeat; shortness of breath; swelling of feet, face, hands; severe dizziness; constipation; nausea; hypotension; if chest pain does not improve, use nitroglycerin when angina is severe</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12536">
								<item>
									<label>•</label>
									<para>To use correct technique when monitoring pulse; to contact prescriber if pulse &lt;50 bpm</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12541">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12546">
								<item>
									<label>•</label>
									<para>To continue with good oral hygiene to prevent gingival disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12551">
								<item>
									<label>•</label>
									<para>To use sunscreen, protective clothing to prevent photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12556">
								<item>
									<label>•</label>
									<para>To notify all health care providers of use of this product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x12561">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Defibrillation, β-agonists, IV calcium inotropic agents, diuretics, atropine for AV block, vasopressor for hypotension</para>
			</section>
		</monograph>
<monograph id="49" status="active">
			<mono_name>amoxicillin (Rx)</mono_name>
			<info>
				<pronunciation>(a-mox-i-sill′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x125716">
						<country code="CAN">Amoxil </country>
					</tradename>
					<tradename id="tnidelem4x125715">
						<country code="CAN">Apo-Amoxi </country>
					</tradename>
					<tradename id="tnidelem4x125714">Larotid</tradename>
					<tradename id="tnidelem4x125713">
						<country code="CAN">Lin-Amox </country>
					</tradename>
					<tradename id="tnidelem4x125712">Moxatag</tradename>
					<tradename id="tnidelem4x125711">
						<country code="CAN">Novamoxin </country>
					</tradename>
					<tradename id="tnidelem4x125710">
						<country code="CAN">Nu-Amoxil </country>
					</tradename>
				</tradenames>
				<class type="func"> Antiinfective, antiulcer</class>
				<class type="chem"> Aminopenicillin</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x12595">
				<para>
					<confusion>
						<tradename id="tnidelem4x125950">amoxicillin</tradename>
						<drug type="generic" refid="idelem4x125950">amoxapine/Amoxil</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12605">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell wall replication of susceptible organisms; bactericidal: lysis mediated by bacterial cell wall autolysins</para>
			</section>
			<section type="uses" id="sidelem4x12610">
				<sec_title>Uses:</sec_title>
				<para>Treatment of skin, respiratory, GI, GU infections, otitis media, gonorrhea; for gram-positive cocci <emphasis style="italic">(Staphylococcus aureus, Streptococcus pyogenes, Streptococcus faecalis, Streptococcus pneumoniae),</emphasis> gram-negative cocci <emphasis style="italic">(Neisseria gonorrhoeae, Neisseria meningitidis),</emphasis> gram-positive bacilli <emphasis style="italic">(Corynebacterium diphtheriae, Listeria monocytogenes),</emphasis> gram-negative bacilli <emphasis style="italic">(Haemophilus influenzae, Escherichia coli, Proteus mirabilis, Salmonella);</emphasis> gastric ulcer, β-lactase–negative organisms</para>
				<section type="none" id="sidelem4x12627">
					<section type="none" id="sidelem4x12628">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Lyme disease, anthrax treatment and prophylaxis, cervicitis, <emphasis style="italic">Chlamydia trachomatis,</emphasis> dental abscess/infection, dyspepsia, non-gonococcal urethritis, periodontitis, typhoid fever; prophylaxis of bacterial endocarditis; in combination with other products for treatment of <emphasis style="italic">Helicobacter pylori</emphasis></para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12638">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to penicillins</para>
				<section type="none" id="sidelem4x12643">
					<section type="none" id="sidelem4x12644">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, neonates, hypersensitivity to cephalosporins, carbapenems; severe renal disease, mononucleosis, phenylketonuria, diabetes, geriatric patients, asthma, child, colitis, dialysis, eczema, pseudomembranous colitis, syphilis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12651">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12654">
					<section type="none" id="sidelem4x12655">
						<sec_title>Upper respiratory infections</sec_title>
						<section type="none" id="sidelem4x12663">
							<label>•</label>
							<sec_title>Adult/adolescent/child (≥40 kg)<route> (mild-moderate infections) PO</route></sec_title>
							<para>
								<list id="lidelem4x12663">
									<item>
										<label>•</label>
										<para> 500 mg q12hr, or 250 mg q8hr;  875 mg q12hr or 500 mg q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12673">
							<label>•</label>
							<sec_title>Child (&lt;40 kg)<route> (mild-moderate infections)</route></sec_title>
							<para>
								<list id="lidelem4x12673">
									<item>
										<label>•</label>
										<para> 25 mg/kg/day individual doses q12hr;  40 mg/kg/day divided q8hr or 45 mg/kg/day divided q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12680">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">S. pyogenes</emphasis>
							</emphasis> infection (pharyngitis/tonsillitis)</sec_title>
						<section type="none" id="sidelem4x12691">
							<label>•</label>
							<sec_title>Adult/child &gt;12 yr<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x12691">
									<item>
										<label>•</label>
										<para> 775 mg every day with meal × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12695">
						<sec_title>Otitis Media</sec_title>
						<section type="none" id="sidelem4x12703">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12703">
									<item>
										<label>•</label>
										<para> 500 mg q12hr or 250 mg q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12710">
							<label>•</label>
							<sec_title>Infants &gt;3 mo/children/adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12710">
									<item>
										<label>•</label>
										<para> 80-90 mg/kg/day in divided doses q8-12hr, max 500 mg/dose if given q8hr or 875 mg/dose if given q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12714">
						<sec_title>Gonorrhea (not CDC approved)</sec_title>
						<section type="none" id="sidelem4x12722">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12722">
									<item>
										<label>•</label>
										<para> 3 g given with 1 g probenecid as a single dose followed by tetracycline or erythromycin therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12726">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">C. trachomatis</emphasis>
							</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x12736">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12736">
									<item>
										<label>•</label>
										<para> 500 mg/tid × 1 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12740">
						<sec_title>Duodenal/gastric ulcer/dyspepsia from <emphasis style="bold">
								<emphasis style="italic">H. pylori</emphasis>
							</emphasis> infection (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12752">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12752">
									<item>
										<label>•</label>
										<para> 1000 mg bid with lansoprazole or clarithromycin/omeprazole</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12756">
						<sec_title>Bacterial endocarditis prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12764">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12764">
									<item>
										<label>•</label>
										<para> 2 g 1 hr before procedure</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12771">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12771">
									<item>
										<label>•</label>
										<para> 50 mg/kg 1 hr before procedure; max 2 g</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12775">
						<sec_title>Lyme disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12783">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12783">
									<item>
										<label>•</label>
										<para> 500 mg tid × 14-21 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12790">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12790">
									<item>
										<label>•</label>
										<para> 50 mg/kg/day in divided doses q8hr × 14-21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12794">
						<sec_title>Anthrax treatment/prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12802">
							<label>•</label>
							<sec_title>Adult and child &gt;20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12802">
									<item>
										<label>•</label>
										<para> 500 mg q8hr × 10-14 days (prophylaxis), 60 days (treatment)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12809">
							<label>•</label>
							<sec_title>Child &lt;20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12809">
									<item>
										<label>•</label>
										<para> 80 mg/kg divided in 3 doses q8hr × 60 days (treatment)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12813">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x12821">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-30 ml/min 250-500 mg q12hr; CCr &lt;10 ml/min 250-500 mg q24hr; do not use 775, 875 mg strength if CCr &lt;30 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12824">
						<sec_title>Available forms:</sec_title>
						<para> Caps 250, 500 mg; chew tabs 125, 200, 250, 400 mg; tabs, 500, 875 mg; ext rel tab (Moxatag) 775 mg; susp 125, 200, 250, 400 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x12829">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x12832">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x12837">
									<item>
										<label>•</label>
										<para>Identify allergies before use</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x12845">
								<label>•</label>
								<sec_title>Susp</sec_title>
								<para>
									<list id="lidelem4x12845">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Susp:</emphasis> shake well before each dose; use calibrated spoon, oral syringe, or measuring cup; may be used alone, mixed in drinks; use immediately; discard unused portion after 14 days, store in refrigerator</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x12849">
									<item>
										<label>•</label>
										<para>Give around the clock; caps may be emptied, mixed with liquids if needed without regard to food</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x12857">
								<label>•</label>
								<sec_title>Ext rel</sec_title>
								<para>
									<list id="lidelem4x12857">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Ext rel:</emphasis> do not crush, chew, break; take with food</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12861">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12864">
					<section type="none" id="sidelem4x12865">
						<sec_title>CNS:</sec_title>
						<para> Headache, <emphasis style="bold">seizures,</emphasis> agitation, confusion, dizziness, insomnia</para>
					</section>
					<section type="none" id="sidelem4x12873">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> increased AST, ALT, abdominal pain, glossitis, colitis, <emphasis style="bold">pseudomembranous colitis,</emphasis> jaundice, cholestasis</para>
					</section>
					<section type="none" id="sidelem4x12884">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, increased bleeding time, <emphasis style="bold">bone marrow depression, granulocytopenia, hemolytic anemia, eosinophilia, thrombocytopenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12891">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Urticaria, rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12898">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, respiratory distress, serum sickness, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12905">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x12908">
					<section type="none" id="sidelem4x12909">
						<sec_title>PO:</sec_title>
						<para> Peak 1-2 hr, duration 6-8 hr, half-life 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">3</emphasis> hr extended in renal disease metabolized in liver, excreted in urine, crosses placenta, enters breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x12920">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> rash—allopurinol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> amoxicillin level—probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant action—warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> methotrexate levels—methotrexate</para>
				<section type="none" id="sidelem4x12940">
					<section type="none" id="sidelem4x12941">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, alk phos, LDH, eosinophils</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, WBC, platelets</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> urine glucose test (Clinitest, Benedict’s reagent, cupric SO<emphasis style="inf">4</emphasis>)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12959">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12962">
					<section type="none" id="sidelem4x12963">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12971">
							<label>•</label>
							<sec_title>
								<route>Report hematuria, oliguria, penicillin products, in high doses are nephrotoxic</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12974">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12979">
								<item>
									<label>•</label>
									<para>Blood studies: WBC, RBC, Hgb, Hct, bleeding time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12984">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, protein, blood, BUN, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12989">
								<item>
									<label>•</label>
									<para>C&amp;S before product therapy; product may be given as soon as culture is taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12995">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: bowel pattern before, during treatment; diarrhea, cramping, blood in stools; report to prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13003">
							<label>•</label>
							<sec_title>
								<route>Skin eruptions after administration of penicillin to 1 wk after discontinuing product; rash is more common if allopurinol is taken concurrently</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13007">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: rash, itching, dyspnea, facial/laryngeal edema</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13012">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13016">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of infection; prevention of endocarditis, resolution of ulcer symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13022">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13027">
								<item>
									<label>•</label>
									<para>That caps may be opened, contents taken with fluids; that chewable form is available; to take as prescribed, not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13032">
								<item>
									<label>•</label>
									<para>All aspects of product therapy: to complete entire course of medication to ensure organism death (10-14 days); that culture may be taken after completed course of medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13038">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue, diarrhea (superinfection or agranulocytopenia), blood in stool, abdominal pain (pseudomembranous colitis), decreased urinary output</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13043">
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals around the clock to maintain blood levels; to take without regard to food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13048">
								<item>
									<label>•</label>
									<para>To wear or carry emergency ID if allergic to penicillins</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x13053">
				<sec_title>Treatment of anaphylaxis:</sec_title>
				<para>Withdraw product, maintain airway; administer EPINEPHrine, aminophylline, O<emphasis style="inf">2</emphasis>, IV corticosteroids</para>
			</section>
		</monograph>
<monograph id="50" status="active">
			<mono_name>amoxicillin/clavulanate (Rx)</mono_name>
			<info>
				<pronunciation>(a-mox-i-sill′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x130663">
						<country code="CAN">Apo-Amoxi Clav </country>
					</tradename>
					<tradename id="tnidelem4x130662">Augmentin</tradename>
					<tradename id="tnidelem4x130661">Augmentin XR</tradename>
					<tradename id="tnidelem4x130660">
						<country code="CAN">Clavulin </country>
					</tradename>
				</tradenames>
				<class type="func"> Broad-spectrum antiinfective</class>
				<class type="chem"> Aminopenicillin β-lactamase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x13081">
				<para>
					<confusion>
						<tradename id="tnidelem4x130810">Augmentin</tradename>
						<drug type="generic" refid="idelem4x130810">amoxicillin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13085">
				<sec_title>Action:</sec_title>
				<para>Bacteriocidal, interferes with cell wall replication of susceptible organisms; lysis mediated by bacterial cell wall autolytic enzymes, combination increases spectrum of activity against β-lactamase–resistant organisms</para>
			</section>
			<section type="uses" id="sidelem4x13090">
				<sec_title>Uses:</sec_title>
				<para>Lower respiratory tract infections, sinus infections, pneumonia, otitis media, impetigo, skin infection, UTI; effective for <emphasis style="italic">Actinomyces</emphasis> sp., <emphasis style="italic">Bacillus anthracis, Bacteroides</emphasis> sp., <emphasis style="italic">Bordetta pertassis, Borrelia burdofer; Brucella</emphasis> sp., <emphasis style="italic">Burkholderia pseudomallei, Clostridium perfringens/tetani, Corynebacterium diphtheriae, Eikenella corodens, Enterobacter</emphasis> sp., <emphasis style="italic">Enterococcus faecalis, Erysipelothrix rhusioputhae, Escherichiacoli, Eubacterium</emphasis> sp., <emphasis style="italic">Fusobacterium</emphasis> sp., <emphasis style="italic">Haemophilus ducrey/parainfluenzal (positive/negative beta-lactamase), Heliobacter pylori, Klebsiella</emphasis> sp., <emphasis style="italic">Lactobacillus</emphasis> sp., <emphasis style="italic">Listeria monocytogenes, Moraxella catarrholis, Neisseria gonorrheal/meningitis, Nocardia brasilensis, Peptococcus</emphasis> sp., <emphasis style="italic">Peptostreptococcus</emphasis> sp., <emphasis style="italic">Prevotella melaninogemica, Propionibacterium</emphasis> sp., <emphasis style="italic">shigella</emphasis> sp., <emphasis style="italic">Staphylococcus aureus (MSSA)/epidermidis/ Saprophyticus, streptococcus agalactial (group B Streptococci)/dysglactial/ pneumonia/pygenes (group A Streptococci) reponema pallidium, Vibrocholeral, viridans streptococci</emphasis></para>
				<section type="none" id="sidelem4x13134">
					<section type="none" id="sidelem4x13135">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Actinomycotic mycetoma, chancroid, dental infections, dentoalveolar infection, melioidosis, pericoronitis, SARS</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13140">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to penicillins, severe renal disease, dialysis</para>
				<section type="none" id="sidelem4x13145">
					<section type="none" id="sidelem4x13146">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, neonates, children, hypersensitivity to cephalosporins; renal/GI disease, asthma, colitis, diabetes, eczema, leukemia, mononucleosis, viral infections, phenylketonuria</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13151">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13159">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13159">
							<item>
								<label>•</label>
								<para> 250-500 mg q8hr or 500-875 mg q12hr, depending on severity of infection</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13166">
					<label>•</label>
					<sec_title>Child ≤40 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13166">
							<item>
								<label>•</label>
								<para> 20-90 mg/kg/day in divided doses q8-12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13170">
					<section type="none" id="sidelem4x13171">
						<sec_title>Community-acquired pneumonia or acute bacterial sinusitis</sec_title>
						<section type="none" id="sidelem4x13179">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13179">
									<item>
										<label>•</label>
										<para> 2000 mg/125 mg (Augmentin XR) q12 hr × 7-10 days (pneumonia), 10 days (sinusitis)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13183">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x13191">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-30 ml/min dose q12hr; CCr &lt;10 ml/min dose q24hr; do not use 875-mg strength or ext rel if CCr &lt;30 ml/min; Augmentin XR is contraindicated with renal disease</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x13194">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500, 875 mg/125 mg clavulanate; chew tabs 200/28.5, 400/57 mg; powder for oral susp 250/28.5, 200/28.5, 400/57, 600/42.9 mg/5 ml; ext rel tabs (XR) 1000 mg amoxicillin, 62.5 mg clavulanate; powder for oral susp (ES) 600 mg amoxicillin, 42.9 mg clavulanate</para>
					</section>
					<section type="none" id="sidelem4x13199">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x13202">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x13207">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew ext rel product</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13213">
									<item>
										<para>
											<emphasis alert="nurse">Only as directed; two 250-mg tabs not equivalent to one 500-mg tab due to strength of clavulanate</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13218">
									<item>
										<label>•</label>
										<para>Shake susp well before each dose; may be used alone, mixed in drinks; use immediately, discard unused portion of susp after 14 days, store in refrigerator</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13223">
									<item>
										<label>•</label>
										<para>Give around the clock</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13228">
									<item>
										<label>•</label>
										<para>Give with light meal for increased absorption, fewer GI effects, confusion, behavioral changes</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13233">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13236">
					<section type="none" id="sidelem4x13237">
						<sec_title>CNS:</sec_title>
						<para> Headache, fever, <emphasis style="bold">seizures,</emphasis> agitation, insomnia</para>
					</section>
					<section type="none" id="sidelem4x13245">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting,</emphasis> increased AST/ALT, abdominal pain, glossitis, colitis, black tongue, <emphasis style="bold">pseudomembranous colitis,</emphasis> jaundice</para>
					</section>
					<section type="none" id="sidelem4x13256">
						<sec_title>GU:</sec_title>
						<para> Oliguria, proteinuria, hematuria, <emphasis style="italic">vaginitis, moniliasis,</emphasis><emphasis style="bold">glomerulonephritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13265">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">bone marrow depression, granulocytopenia, leukopenia, eosinophilia,</emphasis> thrombocytopenic purpura</para>
					</section>
					<section type="none" id="sidelem4x13273">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, dermatitis, <emphasis style="bold">toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13283">
						<sec_title>META:</sec_title>
						<para> Hypo/hyperkalemia, alkalosis, hypernatremia</para>
					</section>
					<section type="none" id="sidelem4x13288">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, respiratory distress, serum sickness, Stevens-Johnson syndrome, superinfection,</emphasis> candidiasis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13296">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13299">
					<section type="none" id="sidelem4x13300">
						<sec_title>PO:</sec_title>
						<para> Peak 1-2.5 hr, duration 6-8 hr, half-life 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">3</emphasis> hr, metabolized in liver, excreted in urine, crosses placenta, excreted in breast milk, removed by hemodialysis</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13311">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> amoxicillin levels—probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant effect—warfarin; monitor closely, dose adjustment may be needed</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> skin rash—allopurinol</para>
				<section type="none" id="sidelem4x13327">
					<section type="none" id="sidelem4x13328">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption by a high-fat meal</para>
					</section>
					<section type="none" id="sidelem4x13335">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, alk phos, LDH</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> urine glucose tests (Clinitest, Benedict’s reagent, Cupric SO<emphasis style="inf">4</emphasis>)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13349">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13352">
					<section type="none" id="sidelem4x13353">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13359">
								<item>
									<para>
										<emphasis alert="nurse">Nephrotoxicity at high doses: I&amp;O ratio; report hematuria, oliguria</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13364">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13369">
								<item>
									<label>•</label>
									<para>Blood studies: WBC, RBC, Hgb, Hct, bleeding time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13374">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, protein, blood, BUN, creatinine; if urine output decreases, long-acting products should not be used</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13379">
								<item>
									<label>•</label>
									<para>C&amp;S before product therapy; product may be given as soon as culture is taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13385">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: bowel pattern before, during treatment; diarrhea, cramping, blood in stools; report to prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13391">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: rash, itching, dyspnea, facial/laryngeal edema; skin eruptions after administration of penicillin to 1 wk after discontinuing product</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13396">
								<item>
									<label>•</label>
									<para>Adrenaline, suction, tracheostomy set, endotracheal intubation equipment on unit</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13401">
								<item>
									<label>•</label>
									<para>Adequate intake of fluids (2 L) during diarrhea episodes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13406">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13410">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13416">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13421">
								<item>
									<label>•</label>
									<para>To take as prescribed, not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13426">
								<item>
									<label>•</label>
									<para>All aspects of product therapy: to complete entire course of medication to ensure organism death (10-14 days); that culture may be taken after completed course of medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13432">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue (superinfection or agranulocytosis); diarrhea, cramping, blood in stools (pseudomembranous colitis)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13437">
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals around the clock to maintain blood levels</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13442">
								<item>
									<label>•</label>
									<para>To wear or carry emergency ID if allergic to penicillins</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x13447">
				<sec_title>Treatment of hypersensitivity:</sec_title>
				<para>Withdraw product, maintain airway, administer EPINEPHrine, aminophylline, O<emphasis style="inf">2</emphasis>, IV corticosteroids for anaphylaxis</para>
			</section>
		</monograph>
<monograph id="51" status="active" ha="yes">
			<mono_name>amphotericin B lipid complex (ABLC)</mono_name>
			<info>
				<pronunciation>(am-foe-ter′i-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x134620">Abelcet</tradename>
				</tradenames>
				<class type="func"> Antifungal</class>
				<class type="chem"> Amphoteric polyene</class>
			</info>
			<section type="actions" id="sidelem4x13472">
				<sec_title>Action:</sec_title>
				<para>Increases cell membrane permeability in susceptible fungi by binding sterols; alters cell membrane, thereby causing leakage of cell components, cell death</para>
			</section>
			<section type="uses" id="sidelem4x13477">
				<sec_title>Uses:</sec_title>
				<para>Indicated for the treatment of invasive fungal infections in patients who cannot tolerate or have failed conventional amphotericin B therapy; broad-spectrum activity against many fungal, yeast and mold pathogen infections, including <emphasis style="italic">Aspergillus, Zygomycetes, Fusarium, Cryptococcus,</emphasis> and many hard-to-treat <emphasis style="italic">Candida</emphasis> species; <emphasis style="italic">Aspergillus fumigatus, Aspergillus</emphasis> sp., <emphasis style="italic">Blastomyces dermatitidis, Candida albicans, Candida guilliermondii, Candida</emphasis> sp., <emphasis style="italic">Candida stellatoidea, Candida tropicalis, Coccidioides immitis, Cryptococcus</emphasis> sp., <emphasis style="italic">Histoplasma</emphasis> sp., <emphasis style="italic">sporotiaichosis</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x13502">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x13507">
					<section type="none" id="sidelem4x13508">
						<sec_title>Precautions:</sec_title>
						<para> Anemia, breastfeeding, cardiac disease, children, electrolyte imbalance, geriatric, hematologic/hepatic/renal disease, hypotension, pregnancy (B)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13513">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13521">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x13521">
							<item>
								<label>•</label>
								<para> 3-5 mg/kg/day as a single infusion given at 2.5 mg/kg/hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13526">
					<section type="none" id="sidelem4x13527">
						<sec_title>Renal dose</sec_title>
						<para>
							<emphasis alert="lifethreat">Adult: IV CCr &lt;10 ml/min give 5 mg/kg q24-36hr</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x13533">
						<sec_title>Available forms:</sec_title>
						<para> Susp for inj 100 mg/20-ml vial</para>
					</section>
					<section type="none" id="sidelem4x13538">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13544">
								<item>
									<para>
										<emphasis alert="nurse">Do not confuse four different types; these are not interchangeable: conventional amphotericin B, amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13549">
								<item>
									<label>•</label>
									<para>May premedicate with acetaminophin, diphenhydrAMINE</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13554">
								<item>
									<label>•</label>
									<para>Use only after C&amp;S confirms organism</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13559">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x13563">
									<item>
										<label>•</label>
										<para>Give product only after C&amp;S confirms organism, product needed to treat condition; make sure product is used for life-threatening infections</para>
									</item>
									<item>
										<label>•</label>
										<para>Handle with aseptic technique because amphotericin B lipid complex (ABLC) has no preservatives; visually inspect parenteral products for particulate matter and discoloration before use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13574">
							<sec_title>Filtration and dilution:</sec_title>
							<para>
								<list id="lidelem4x13579">
									<item>
										<label>•</label>
										<para>Before dilution, store at 36°-46° F (2°-8° C), protected from moisture and light; do not freeze; the diluted, ready-for-use admixture is stable for up to 48 hours at 36°-46° F (2°-8° C) and an additional 6 hr at room temperature; do not freeze</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13584">
									<item>
										<label>•</label>
										<para>Prepare the admixture for infusion by first shaking the vial until there is no evidence of yellow sediment on the bottom of the vial</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13589">
									<item>
										<label>•</label>
										<para>Transfer the appropriate amount of drug from the required number of vials into one or more sterile syringes using an 18-gauge needle</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13594">
									<item>
										<label>•</label>
										<para>Attach the provided 5-micron filter needle to the syringe; inject the syringe contents through the filter needle, into an IV bag containing the appropriate amount of D<emphasis style="inf">5</emphasis>W injection; each filter needle may be used on the contents of no more than four 100-mg vials</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x13605">
								<label>•</label>
								<sec_title>
									<route>DO NOT USE SALINE SOLUTIONS OR MIX WITH OTHER DRUGS OR ELECTROLYTES</route>
								</sec_title>
								<para>
									<list id="lidelem4x13605">
										<item>
											<label>•</label>
											<para>The suspension must be diluted with D<emphasis style="inf">5</emphasis>W injection to a final concentration of 1 mg/ml; for pediatric patients and patients with cardiovascular disease, the final concentration may be 2 mg/ml; </para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x13612">
									<item>
										<label>•</label>
										<para>The diluted ready-for-use admixture is stable for up to 48 hr at 2-8° C (36-46° F) and an additional 6 hr at room temperature; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13617">
							<sec_title>IV INFUSION</sec_title>
							<section type="none" id="sidelem4x13625">
								<label>•</label>
								<sec_title>
									<route>DO NOT USE AN IN-LINE FILTER</route>
								</sec_title>
								<para>
									<list id="lidelem4x13625">
										<item>
											<label>•</label>
											<para>Flush IV line with D<emphasis style="inf">5</emphasis>W injection before use or use a separate IV line; </para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x13632">
									<item>
										<label>•</label>
										<para>Before infusion, shake the bag until the contents are thoroughly mixed; max rate 2.5 mg/kg/hr; if the infusion time exceeds 2 hr, mix the contents by shaking the infusion bag every 2 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> acyclovir, allopurinol, aminocaproic acid, aminophylline, amiodarone, anidulafungin, argatroban, arsenic trioxide, atracurium, azithromycin, aztreonam, bumetanide, buprenorphine, busulfan, butorphanol, CARBOplatin, carmustine, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, dexamethasone, digoxin, diphenhydrAMINE, DOCEtaxel, doxacurium, DOXOrubicin liposomal, enalaprilat, EPINEPHrine eptifibatide, ertapenem, etoposide, famotidine, fentaNYL, fludarabine, fluorouracil, fosphenytoin, furosemide, ganciclovir, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, insulin, regular ketorolac, lepirudin, lidocaine, linezolid, LORazepam, mannitol, melphalan, meperidine, methotrexate, methylPREDNISolone, metoclopramide, mitoMYcin, mivacurium, nafcillin, nesiritide, nitroglycerin, nitroprusside, octreotide, oxaliplatin, PACLitaxel, pamidronate, pantoprazole, PEMEtrexed, pentazocine, PENTobarbital, PHENobarbital, phentolamine, piperacillin-tazobactam, procainamide, ranitidine, succinylcholine, SUFentanil, tacrolimus, telavancin, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticaracillin-clavulanate, trimethobenzamide, verapamil, vinBLAStine, vinCRIStine, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13643">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13646">
					<section type="none" id="sidelem4x13647">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, fever, chills,</emphasis> peripheral nerve pain, paresthesias, peripheral neuropathy, <emphasis style="bold">seizures,</emphasis> dizziness</para>
					</section>
					<section type="none" id="sidelem4x13658">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, hypotension, <emphasis style="bold">cardiac arrest,</emphasis> chest pain, hypertension</para>
					</section>
					<section type="none" id="sidelem4x13666">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, deafness, diplopia, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x13671">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> diarrhea, cramps, <emphasis style="bold">hemorrhagic gastroenteritis, acute liver failure,</emphasis> jaundice, bilirubinemia</para>
					</section>
					<section type="none" id="sidelem4x13682">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Hypokalemia,</emphasis><emphasis style="bold">azotemia, hyposthenuria, renal tubular acidosis, nephrocalcinosis, permanent renal impairment, anuria, oliguria</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13691">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Normochromic, normocytic anemia, thrombocytopenia, agranulocytosis, leukopenia, eosinophilia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13698">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Burning, irritation,</emphasis> pain, <emphasis style="bold">necrosis at inj site with extravasation,</emphasis> flushing, dermatitis</para>
					</section>
					<section type="none" id="sidelem4x13709">
						<sec_title>META:</sec_title>
						<para> Hyponatremia, hypomagnesemia, hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x13714">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia, generalized pain, weakness, weight loss</para>
					</section>
					<section type="none" id="sidelem4x13719">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm, dyspnea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13726">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Toxic epidermal neurolysis, exfoliative dermatitis, anaphylaxis, sepsis, infection, infusion reactions</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13733">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13736">
					<section type="none" id="sidelem4x13737">
						<sec_title>IV:</sec_title>
						<para> terminal half-life lipid complex mean 7 days</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13742">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x13750">
					<label>•</label>
					<sec_title>
						<route>Do not use with cidofovir</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: nephrotoxicity—other nephrotoxic antibiotics (aminoglycosides, CISplatin, vancomycin, cycloSPORINE, polymyxin B), antineoplastics, pentamidine, salicylates, tacrolimus, tenofovir</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—corticosteroids, digoxin, skeletal muscle relaxants, thiazides, loop diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> amphotericin B lipid complexazole antifungals may still be used concurrently in serious resistant infections</para>
				<section type="none" id="sidelem4x13764">
					<section type="none" id="sidelem4x13765">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, alk phos, BUN, creatinine, LDH, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> magnesium, potassium, Hgb, WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13776">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13779">
					<section type="none" id="sidelem4x13780">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13785">
								<item>
									<label>•</label>
									<para>VS every 15-30 min during first infusion; note changes in pulse, B/P</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13790">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; watch for decreasing urinary output, change in specific gravity; discontinue product to prevent permanent damage to renal tubules</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13795">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, potassium, sodium, calcium, magnesium every 2 wk; BUN, creatinine 2-3 ×/wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13800">
								<item>
									<label>•</label>
									<para>Weight weekly; if weight increases by more than 2 lb/wk, edema is present; renal damage should be considered</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13808">
							<label>•</label>
							<sec_title>For renal toxicity<route> increasing BUN, serum creatinine; if BUN is &gt;40 mg/dl or if serum creatinine is &gt;3 mg/dl, product may be discontinued, dosage reduced</route></sec_title>
						</section>
						<section type="none" id="sidelem4x13814">
							<label>•</label>
							<sec_title>For hepatotoxicity<route> increasing AST, ALT, alk phos, bilirubin</route></sec_title>
						</section>
						<section type="none" id="sidelem4x13820">
							<label>•</label>
							<sec_title>For allergic reaction<route> dermatitis, rash; product should be discontinued, antihistamines (mild reaction) or EPINEPHrine (severe reaction) should be administered</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x13823">
								<item>
									<label>•</label>
									<para>For hypokalemia: anorexia, drowsiness, weakness, decreased reflexes, dizziness, increased urinary output, increased thirst, paresthesias</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13828">
								<item>
									<label>•</label>
									<para>Infusion reactions: fever, chills, pain, swelling at site</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13833">
								<item>
									<label>•</label>
									<para>For ototoxicity: tinnitus (ringing, roaring in ears), vertigo, loss of hearing (rare)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13838">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13842">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased fever, malaise, rash, negative C&amp;S for infecting organism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13848">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13853">
								<item>
									<label>•</label>
									<para>That long-term therapy may be needed to clear infection (2 wk-3 mo, depending on type of infection)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13862">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of bleeding, bruising, or soft-tissue swelling, neurologic, renal symptoms</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="52" status="active" ha="yes">
			<mono_name>amphotericin B liposomal (LAmB)</mono_name>
			<info>
				<pronunciation>(am-foe-ter′i-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x138720">AmBisome</tradename>
				</tradenames>
				<class type="func"> Antifungal</class>
				<class type="chem"> Amphoteric polyene</class>
			</info>
			<section type="actions" id="sidelem4x13882">
				<sec_title>Action:</sec_title>
				<para>Increases cell membrane permeability in susceptible fungi by binding to membrane sterols; alters cell membrane, thereby causing leakage of cell components, cell death</para>
			</section>
			<section type="none" id="sidelem4x13887">
				<sec_title>Therapeutic outcome</sec_title>
				<para>Resolution of infection</para>
			</section>
			<section type="uses" id="sidelem4x13892">
				<sec_title>Uses:</sec_title>
				<para>Empirical therapy for presumed fungal infection in febrile neutropenic patients; treatment of <emphasis style="italic">Cryptococcal</emphasis> meningitis in HIV-infected patients; treatment of <emphasis style="italic">Aspergillus</emphasis> species, <emphasis style="italic">Candida</emphasis> species, and/or <emphasis style="italic">Cryptococcus</emphasis> species infections refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate <emphasis style="italic">(Aspergillus flavus, Aspergillus fumigatus, Blastomyces dermatitidis, Candida albicans, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans)</emphasis>; treatment of visceral leishmaniasis</para>
				<section type="none" id="sidelem4x13912">
					<section type="none" id="sidelem4x13913">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Coccidioidomycosis, histoplasmosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13918">
				<sec_title>Contraindications</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x13923">
					<section type="none" id="sidelem4x13924">
						<sec_title>Precautions:</sec_title>
						<para> Anemia, breastfeeding, cardiac disease, children, electrolyte imbalance, geriatric, hematologic/hepatic/renal disease, hypotension pregnancy (B), severe bone marrow depression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13929">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13932">
					<section type="none" id="sidelem4x13933">
						<sec_title>Visceral leishmaniasis</sec_title>
						<section type="none" id="sidelem4x13941">
							<label>•</label>
							<sec_title>Adult and child ≥1 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x13941">
									<item>
										<label>•</label>
										<para> 3 mg/kg every 24 hr days 1-5, and days 14, 21 (immunocompetent), 4 mg/kg every 24 hr days 1-5, and days 10, 17, 24, 31, 38 (immunocompromised)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13945">
						<sec_title>Cryptococcal meningitis in HIV</sec_title>
						<section type="none" id="sidelem4x13953">
							<label>•</label>
							<sec_title>Adult and child ≥1 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x13953">
									<item>
										<label>•</label>
										<para> 6 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13957">
						<sec_title>Fungal infection, empirical</sec_title>
						<section type="none" id="sidelem4x13965">
							<label>•</label>
							<sec_title>Adult and child ≥1 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x13965">
									<item>
										<label>•</label>
										<para> 3 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13969">
						<sec_title>Fungal infection, systemic</sec_title>
						<section type="none" id="sidelem4x13977">
							<label>•</label>
							<sec_title>Adult and child ≥1 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x13977">
									<item>
										<label>•</label>
										<para> 3-5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13981">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x13989">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x13989">
									<item>
										<label>•</label>
										<para> CCr &lt;10 ml/min use 3 mg/kg q24hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13993">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 50-mg vial</para>
					</section>
					<section type="none" id="sidelem4x13998">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14004">
								<item>
									<para>
										<emphasis alert="nurse">Do not confuse four different types; these are not interchangeable: conventional amphotericin B, amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14009">
								<item>
									<label>•</label>
									<para>May premedicate with acetaminophen, diphenhydrAMINE</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14014">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x14018">
									<item>
										<label>•</label>
										<para>Make sure product is used for life-threatening infections</para>
									</item>
									<item>
										<label>•</label>
										<para>Administer by IV infusion only; handle with aseptic technique as LAmB does not contain any preservatives</para>
									</item>
									<item>
										<label>•</label>
										<para>Visually inspect products for particulate matter and discoloration</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14034">
							<sec_title>Reconstitution</sec_title>
							<section type="none" id="sidelem4x14042">
								<label>•</label>
								<sec_title>
									<route>DO NOT RECONSTITUTE WITH SALINE OR ADD SALINE TO THE RECONSTITUTED SUSPENSION, DO NOT MIX WITH OTHER DRUGS;</route>
								</sec_title>
								<para>
									<list id="lidelem4x14042">
										<item>
											<label>•</label>
											<para>LAmB <emphasis style="italic">must</emphasis> be reconstituted using sterile water for injection (without a bacteriostatic agent);  doing so can cause a precipitate to form</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x14050">
									<item>
										<label>•</label>
										<para>Reconstitute vials containing 50 mg of LAmB /12 ml of sterile water (4 mg/ml)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x14055">
									<item>
										<label>•</label>
										<para>Immediately after the addition of water, SHAKE THE VIAL VIGOROUSLY for 30 sec; the suspension should be yellow and translucent; visually inspect vial for particulate matter and continue shaking until product is completely dispersed</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x14060">
									<item>
										<label>•</label>
										<para>Store suspension for up to 24 hours refrigerated if using sterile water for injection; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14066">
							<sec_title>Filtration and dilution</sec_title>
							<para>
								<list id="lidelem4x14070">
									<item>
										<label>•</label>
										<para>Calculate the amount of reconstituted (4 mg/ml) suspension to be further diluted and withdraw this amount into a sterile syringe</para>
									</item>
									<item>
										<label>•</label>
										<para>Attach the provided 5-micron filter to the syringe; inject the syringe contents through the filter, into the appropriate amount of D<emphasis style="inf">5</emphasis>W injection; use only one filter per vial</para>
									</item>
									<item>
										<label>•</label>
										<para>The suspension must be diluted with D<emphasis style="inf">5</emphasis>W injection to a final concentration of 1-2 mg/ml before administration; for infants and small children, lower concentrations (0.2-0.5 mg/ml) may be appropriate to provide sufficient volume for infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Use injection of LAmB within 6 hr of dilution with D<emphasis style="inf">5</emphasis>W</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14100">
							<sec_title>IV INFUSION</sec_title>
							<para>
								<list id="lidelem4x14104">
									<item>
										<label>•</label>
										<para>Flush intravenous line with D5W injection before infusion; if this cannot be done, then a separate IV line must be used</para>
									</item>
									<item>
										<label>•</label>
										<para>An inline membrane filter may be used provided the mean pore diameter of the filter is not less than 1 micron</para>
									</item>
									<item>
										<label>•</label>
										<para>Administer by IV infusion using a controlled infusion device over a period of approximately 120 min; infusion time may be reduced to approximately 60 min in patients who tolerate the infusion; if discomfort occurs during infusion, the duration of infusion may be increased</para>
									</item>
									<item>
										<label>•</label>
										<para>Store protected from moisture and light; diluted solution is stable for 24 hr at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14125">
							<sec_title>Acetaminophen and diphenhydrAMINE</sec_title>
							<para>
								<list id="lidelem4x14129">
									<item>
										<label>•</label>
										<para>30 min before infusion to reduce fever, chills, headache</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14135">
							<sec_title>Y-site compatibilities:</sec_title>
							<para>Acyclovir, amifostine, aminophylline, anidulafungin, atropine, azithromycin, bivalirudin, bumetanide, buprenorphine, busulfan, butorphanol, CARBOplatin, carmustine, ceFAZolin, ceFOXitin, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, clindamycin, cyclophosphamide, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, diphenhydrAMINE, doxacurium, enalaprilat, ePHEDrine, EPINEPHrine, eptifibatide, ertapenem, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fludarabine, fluorouracil, fosphenytoin, furosemide, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, ifosfamide, isoproterenol, ketorolac, levorphanol, lidocaine, linezolid, mesna, methotrexate, methylPREDNISolone, metoprolol, milrinone, mitoMYcin, nesiritide, nitroglycerin, nitroprusside, octreotide, oxaliplatin, oxytocin, palonosetron, pancuronium, pantoprazole, PEMEtrexed, PENTobarbital, PHENObarbital, phenylephrine, piperacillin/tazobactam, potassium chloride, procainamide, ranitidine, SUFentanil, tacrolimus, theophylline, thiopental, thiotepa, ticarcillin/clavulanate, tigecycline, trimethoprim-sulfamethoxazole, vasopressin, vinCRIStine, voriconazole, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14140">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14143">
					<section type="none" id="sidelem4x14144">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, fever, chills,</emphasis> peripheral nerve pain, paresthesias, peripheral neuropathy, <emphasis style="bold">seizures,</emphasis> dizziness, insomnia</para>
					</section>
					<section type="none" id="sidelem4x14155">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, hypotension, cardiac arrest</para>
					</section>
					<section type="none" id="sidelem4x14160">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, deafness, diplopia, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x14165">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x14170">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> diarrhea, cramps, <emphasis style="bold">hemorrhagic gastroenteritis, acute liver failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14180">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Hypokalemia,</emphasis><emphasis style="bold">azotemia, hyposthenuria,</emphasis> renal tubular acidosis, <emphasis style="bold">nephrocalcinosis, permanent renal impairment, anuria,</emphasis> oliguria</para>
					</section>
					<section type="none" id="sidelem4x14193">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Normochromic normocytic anemia, thrombocytopenia, agranulocytosis, leukopenia, eosinophilia,</emphasis> hyponatremia, hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x14201">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Burning, irritation,</emphasis> pain, <emphasis style="bold">necrosis at inj site with extravasation,</emphasis> flushing, dermatitis, skin rash (topical route)</para>
					</section>
					<section type="none" id="sidelem4x14212">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia, generalized pain, weakness, weight loss</para>
					</section>
					<section type="none" id="sidelem4x14217">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
					<section type="none" id="sidelem4x14223">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens–Johnson syndrome, toxic epidermal neurolysis, exfoliative dermatitis, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14230">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x14233">
					<section type="none" id="sidelem4x14234">
						<sec_title>IV:</sec_title>
						<para> Initial half-life (LAmB) mean 4-6 days; metabolized in liver; excreted in urine (metabolites), breast milk; protein binding 90%; poorly penetrates CSF, bronchial secretions, aqueous humor, muscle, bone; terminal half-life mean 4-6 days</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x14239">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: nephrotoxicity—other nephrotoxic antibiotics (aminoglycosides, CISplatin, vancomycin, cycloSPORINE, polymyxin B)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—corticosteroids, digoxin, skeletal muscle relaxants, thiazides</para>
			</section>
			<section type="considerations" id="sidelem4x14249">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14252">
					<section type="none" id="sidelem4x14253">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14258">
								<item>
									<label>•</label>
									<para>VS every 15-30 min during first infusion; note changes in pulse, B/P</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14263">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; watch for decreasing urinary output, change in specific gravity; discontinue product to prevent permanent damage to renal tubules</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14268">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, potassium, sodium, calcium, magnesium every 2 wk, BUN, creatinine 2-3 ×/wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14273">
								<item>
									<label>•</label>
									<para>Weight weekly; if weight increases by more than 2 lb/wk, edema is present; renal damage should be considered</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14281">
							<label>•</label>
							<sec_title>For renal toxicity<route> increasing BUN, serum creatinine; if BUN is &gt;40 mg/dl or if serum creatinine is &gt;3 mg/dl, product may be discontinued, dosage reduced</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14287">
							<label>•</label>
							<sec_title>For hepatotoxicity<route> increasing AST, ALT, alk phos, bilirubin, monitor LFTs</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14293">
							<label>•</label>
							<sec_title>For allergic reaction<route> dermatitis, rash; product should be discontinued, antihistamines (mild reaction) or EPINEPHrine (severe reaction) administered</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14299">
							<label>•</label>
							<sec_title>For hypokalemia</sec_title>
							<para>
								<list id="lidelem4x14299">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For hypokalemia:</emphasis> anorexia, drowsiness, weakness, decreased reflexes, dizziness, increased urinary output, increased thirst, paresthesias</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14306">
							<label>•</label>
							<sec_title>For ototoxicity<route> tinnitus (ringing, roaring in ears), vertigo, loss of hearing (rare)</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14312">
							<label>•</label>
							<sec_title>Infusion reaction</sec_title>
							<para>
								<list id="lidelem4x14312">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infusion reaction:</emphasis> chills, fever, pain, swelling at site</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14316">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14320">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased fever, malaise, rash, negative C&amp;S for infecting organism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14326">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14331">
								<item>
									<label>•</label>
									<para>That long-term therapy may be needed to clear infection (2 wk-3 mo, depending on type of infection)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14339">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of bleeding, bruising, or soft-tissue swelling, renal, neurologic side effects</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="53" status="active">
			<mono_name>ampicillin (Rx)</mono_name>
			<info>
				<pronunciation>(am-pi-sill′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x143473">
						<country code="CAN">Ampicin </country>
					</tradename>
					<tradename id="tnidelem4x143472">
						<country code="CAN">Apo-Ampi </country>
					</tradename>
					<tradename id="tnidelem4x143471">
						<country code="CAN">Nu-Ampi </country>
					</tradename>
					<tradename id="tnidelem4x143470">
						<country code="CAN">Penbritin </country>
					</tradename>
				</tradenames>
				<class type="func"> Antiinfective—broad-spectrum</class>
				<class type="chem"> Aminopenicillin</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x14368">
				<para>
					<confusion>
						<tradename id="tnidelem4x143680">Omnipen</tradename>
						<drug type="generic" refid="idelem4x143680">imipenem</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x14372">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell wall replication of susceptible organisms; the cell wall, rendered osmotically unstable, swells, bursts from osmotic pressure; lysis mediated by cell wall autolysins</para>
			</section>
			<section type="uses" id="sidelem4x14377">
				<sec_title>Uses:</sec_title>
				<para>Effective for gram-positive cocci <emphasis style="italic">(Staphylococcus aureus, Streptococcus pyogenes, Streptococcus faecalis, Streptococcus pneumoniae),</emphasis> gram-negative cocci <emphasis style="italic">(Neisseria meningitidis),</emphasis> gram-negative bacilli <emphasis style="italic">(Haemophilus influenzae, Proteus mirabilis, Salmonella, Shigella, Listeria monocytogenes),</emphasis> gram-positive bacilli; meningitis, GI/GU/respiratory infections, endocarditis, septicemia, otitis media, skin infection, bacterial endocarditis</para>
				<section type="none" id="sidelem4x14391">
					<section type="none" id="sidelem4x14392">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Biliary tract infection, shigellosis, typhoid fever, PID, OB/GYN infections, leptospirosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14398">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to penicillins, antimicrobial resistance</para>
				<section type="none" id="sidelem4x14403">
					<section type="none" id="sidelem4x14404">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, neonates, hypersensitivity to cephalosporins, renal disease, mononucleosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14409">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14412">
					<section type="none" id="sidelem4x14413">
						<sec_title>Systemic infections</sec_title>
						<section type="none" id="sidelem4x14421">
							<label>•</label>
							<sec_title>Adult and child ≥40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14421">
									<item>
										<label>•</label>
										<para> 250-500 mg q6hr;  2-8 g/day in divided doses q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14431">
							<label>•</label>
							<sec_title>Child &lt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14431">
									<item>
										<label>•</label>
										<para> 50-100 mg/kg/day in divided doses q6-8hr;  50-500 mg/kg/day in divided doses q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14438">
						<sec_title>Bacterial meningitis</sec_title>
						<section type="none" id="sidelem4x14446">
							<label>•</label>
							<sec_title>Adult and adolescent<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x14446">
									<item>
										<label>•</label>
										<para> 150-200 mg/kg/day in divided doses q3-4hr; IDSA dose IV 12 g in divided doses q4hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14453">
							<label>•</label>
							<sec_title>Infant and child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x14453">
									<item>
										<label>•</label>
										<para> 150-200 mg/kg/day in divided doses q3-4hr; IDSA dose IV 300 mg/kg/day in divided doses q6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14460">
							<label>•</label>
							<sec_title>Neonates &gt;7 days and &gt;2000 g<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x14460">
									<item>
										<label>•</label>
										<para> 200 mg/kg/day in divided doses q6hr; IDSA dose IV 200 mg/kg/day in divided doses q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14464">
						<sec_title>Prevention of bacterial endocarditis</sec_title>
						<section type="none" id="sidelem4x14472">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x14472">
									<item>
										<label>•</label>
										<para> 2 g 30 min before procedure</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14479">
							<label>•</label>
							<sec_title>Child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x14479">
									<item>
										<label>•</label>
										<para> 50 mg/kg 30 min before procedure, max 2 g</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14483">
						<sec_title>GI/GU infections other than <emphasis style="bold">
								<emphasis style="italic">N. gonorrhoeae</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x14494">
							<label>•</label>
							<sec_title>Adult and child &gt;20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14494">
									<item>
										<label>•</label>
										<para> 500 mg q6hr, may use larger dose for more serious infections</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14501">
							<label>•</label>
							<sec_title>Child &lt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14501">
									<item>
										<label>•</label>
										<para> 50 mg/kg/day in divided doses q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14505">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x14513">
							<label>•</label>
							<sec_title>Adult and child<route> CCr 10-50 ml/min extend to q6-12hr; CCr &lt;10 ml/min extend to q12-16hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14516">
						<sec_title>Typhoid fever (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14524">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14524">
									<item>
										<label>•</label>
										<para> 100 mg/kg/day in divided doses q6hr × 14 days or more</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14528">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 125, 250, 500 mg, 1, 2, 10 g; IV inj 500 mg, 1, 2 g; caps 250, 500 mg; powder for oral susp 125, 250 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x14533">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x14536">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x14540">
									<item>
										<label>•</label>
										<para>On empty stomach with plenty of water for best absorption (1-2 hr before meals or 2-3 hr after meals)</para>
									</item>
									<item>
										<label>•</label>
										<para>Shake susp well before each dose; store after reconstituting in refrigerator up to 2 wk, 1 wk room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14551">
							<sec_title>IM route (painful)</sec_title>
							<section type="none" id="sidelem4x14559">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x14559">
										<item>
											<label>•</label>
											<para> by adding 0.9-1.2 ml/125-mg vial; 0.9-1.9 ml/250-mg vial; 1.2-1.8 ml/500-mg vial; 2.4-7.4 ml/1-g vial; 6.8 ml/2-g vial</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x14563">
							<sec_title>IV route</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x14567">
							<sec_title>IV direct</sec_title>
							<para>
								<list id="lidelem4x14571">
									<item>
										<label>•</label>
										<para>After diluting with sterile water 0.9-1.2 ml/125 mg product, administer over 3-5 min (up to 500 mg), 10-15 min (&gt;500 mg)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14577">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x14581">
									<item>
										<label>•</label>
										<para>May be diluted in 50 ml or more of D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis> 0.45% NaCl to a concentrations of 30 mg/ml or less; IV sol is stable for 1 hr; give at prescribed rate, do not give in same tubing as aminoglycosides, separate by ≥1 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alemtuzumab, alprostadil, amifostine, aminocaproic acid, anidulafungin, argatroban, atenolol, azithromycin, bivalirudin, bleomycin, CARBOplatin, carmustine, CISplatin, clarithromycin, cyclophosphamide, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin liposome, dexmedetomidine, dexrazoxane, DOCEtaxel, doxacurium, doxapram, DOXOrubicin liposome, eptifibatide, etoposide, etoposide phosphate, filgrastim, fludarabine, fluorouracil, foscarnet, gallium, gatafloxacin, gemcitabine, gemtuzumab, granisetron, hetastarch, ifosfamide, irinotecan, lepirudin, leucovorin, levofloxacin, linezolid, mannitol, mechlorethamine, melphalan, methotrexate, metroNIDAZOLE, milrinone, octreotide, ofloxacin, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, penicillin G potassium, perphenazine, potassium acetate, propofol, remifentanil, riTUXimab, rocuronium, sodium acetate, teniposide, thiotepa, tigecycline, tirofiban, TNA, trastuzumab, vecuronium, vinBLAStine, vinCRIStine, vit B/C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14599">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14602">
					<section type="none" id="sidelem4x14603">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis><emphasis style="bold">pseudomembranous colitis,</emphasis> stomatitis, black hairy tongue</para>
					</section>
					<section type="none" id="sidelem4x14613">
						<sec_title>GU:</sec_title>
						<para> Oliguria, proteinuria, hematuria, <emphasis style="italic">vaginitis, moniliasis,</emphasis><emphasis style="bold">glomerulonephritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14622">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, increased bleeding time, <emphasis style="bold">bone marrow depression, granulocytopenia,</emphasis> leukopenia, eosinophilia, <emphasis style="bold">hemolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14632">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, urticaria,</emphasis> erythema multiforme</para>
					</section>
					<section type="none" id="sidelem4x14640">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, serum sickness, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14647">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 50-110 min; excreted in urine, bile, breast milk; crosses placenta; removed by dialysis</para>
				<section type="none" id="sidelem4x14652">
					<section type="none" id="sidelem4x14653">
						<sec_title>PO:</sec_title>
						<para> Peak 2 hr, duration 6-8 hr</para>
					</section>
					<section type="none" id="sidelem4x14658">
						<sec_title>IM:</sec_title>
						<para> Peak 1 hr</para>
					</section>
					<section type="none" id="sidelem4x14663">
						<sec_title>IV:</sec_title>
						<para> Peak rapid</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x14668">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding, oral anticoagulants, monitor INR/PIJ</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ampicillin concentrations—probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ampicillin-induced skin rash—allopurinol, monitor for rash</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ampicillin level—H2 antagonists, proton pump inhibitors</para>
				<section type="none" id="sidelem4x14687">
					<section type="none" id="sidelem4x14688">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> eosinophil</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> conjugated estrone during pregnancy, conjugated estriol, Hgb, WBC, platelets</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine glucose</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> urine glucose, (Clinitest, Benedict’s reagent, cupric SO4)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14707">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14710">
					<section type="none" id="sidelem4x14711">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x14719">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x14719">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> characteristics of wound, sputum, WBC; baseline, periodically; C&amp;S before product therapy, product may be taken as soon as culture is taken</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x14724">
								<item>
									<para>
										<emphasis alert="nurse">Nephrotoxicity: I&amp;O ratio; report hematuria, oliguria; renal studies: urinalysis, protein, blood, BUN, creatinine</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14729">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14734">
								<item>
									<label>•</label>
									<para>Blood studies: WBC, RBC, Hgb, Hct, bleeding time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14739">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14747">
							<label>•</label>
							<sec_title>
								<route>Skin eruptions after administration of penicillin to 1 wk after discontinuing product; identify allergies before using</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14750">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, tightness in chest</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14756">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: rash, itching, dyspnea, facial swelling; stop product, notify prescriber, have emergency equipment available</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14761">
								<item>
									<label>•</label>
									<para>Adequate intake of fluids (2 L) during diarrhea episodes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14766">
								<item>
									<label>•</label>
									<para>Scratch test to assess allergy after securing order from prescriber; usually done when penicillin is only product of choice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14771">
								<item>
									<label>•</label>
									<para>Store in tight container; after reconstituting, oral suspension refrigerated for 2 wk or stored at room temperature for 1 wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14776">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14780">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, draining wounds, other symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14786">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14791">
								<item>
									<label>•</label>
									<para>To take oral ampicillin on empty stomach with full glass of water; to use alternate contraception</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14796">
								<item>
									<label>•</label>
									<para>All aspects of product therapy: to complete entire course of medication to ensure organism death (10-14 days); that culture may be taken after completed course of medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14802">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue, diarrhea (may indicate superinfection); to report rash, other signs of allergy</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14807">
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals around the clock to maintain blood levels</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14812">
								<item>
									<label>•</label>
									<para>To wear or carry emergency ID if allergic to penicillins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14821">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> diarrhea with blood or pus; notify prescriber</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x14824">
				<sec_title>Treatment of anaphylaxis:</sec_title>
				<para>Withdraw product, maintain airway; administer EPINEPHrine, aminophylline, O<emphasis style="inf">2</emphasis>, IV corticosteroids</para>
			</section>
		</monograph>
<monograph id="54" status="active">
			<mono_name>ampicillin, sulbactam (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x148350">Unasyn</tradename>
				</tradenames>
				<class type="func"> Antiinfective—broad-spectrum</class>
				<class type="chem"> Aminopenicillin with β-lactamase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x14845">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell wall replication of susceptible organisms; the cell wall, rendered osmotically unstable, swells, bursts from osmotic pressure; lysis due to cell wall autolytic enzymes; combination extends spectrum of activity by β-lactamase inhibition</para>
			</section>
			<section type="uses" id="sidelem4x14850">
				<sec_title>Uses:</sec_title>
				<para>Skin infections, intraabdominal infections, cellulitis, diabetic foot ulcer, nosocomial pneumonicus, gynecologic infections; <emphasis style="italic">acinetobacter</emphasis> sp., <emphasis style="italic">actinomyces</emphasis> sp., <emphasis style="italic">Bacillus anthracias, Bacteroides</emphasis> sp., <emphasis style="italic">Bifidobacterium</emphasis> sp., <emphasis style="italic">Bordetella pertussis, Borrelia burgdorferi, Brucella</emphasis> sp., <emphasis style="italic">Clostridium</emphasis> sp., <emphasis style="italic">Corynebacterium diptherial/xerosis, Eikenella corrodens, Entercoccus faecalis, Erysipelothrix rhusiopathial, Escherichia coli, Eubacterium</emphasis> sp., <emphasis style="italic">Fusobacterium</emphasis> sp., <emphasis style="italic">Gardnerella vaginalis, Haemophilas influenzal (beta-lactamase negative/ positive) Helicobacter pylori, Klebsiella</emphasis> sp., <emphasis style="italic">Lactobacillus</emphasis> sp., <emphasis style="italic">Leptospira</emphasis> sp., <emphasis style="italic">Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Pasteurella multocida Peptococcus</emphasis> sp., <emphasis style="italic">Pepto streptococcus</emphasis> sp., <emphasis style="italic">Porphyromonas</emphasis> sp., <emphasis style="italic">Prevotella</emphasis> sp., <emphasis style="italic">Propionibacterium Sp. Proteus mirabilis, Proteus vulgaris, Provedencia rettgeri, Provedencia stuarti, Salmonella</emphasis> sp., <emphasis style="italic">Shigella</emphasis> sp., <emphasis style="italic">Staphylococcus aureus (MSSA)/epidermidis/saprophyticus, Streptococcus agalactinel, dysgalactial pneumonial/pyogenes, Treponema pallidum, Viridans Streptococci</emphasis></para>
				<section type="none" id="sidelem4x14908">
					<section type="none" id="sidelem4x14909">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Aspiration pneumonia, bone/joint infections, asthma, diabetes mellitus, dialysis, diarrhea, eczema, IBS, leukemia, pseudomembranous colitis, ulcerative colitis, hospital/community-acquired pneumonia, infective endocarditis, pelvic inflammatory disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14914">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to penicillins, sulbactam</para>
				<section type="none" id="sidelem4x14919">
					<section type="none" id="sidelem4x14920">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, neonates, hypersensitivity to cephalosporins/carbapenems, renal disease, mononucleosis, viral infections, syphilis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14925">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14933">
					<label>•</label>
					<sec_title>Adult/adolescent/child ≥40 kg<route> IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x14933">
							<item>
								<label>•</label>
								<para> 1.5-3 g q6hr, max 4 g/day sulbactam</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14940">
					<label>•</label>
					<sec_title>Child ≤40 kg<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x14940">
							<item>
								<label>•</label>
								<para> 150-300 mg/kg/day divided q6hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14944">
					<section type="none" id="sidelem4x14945">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x14953">
							<label>•</label>
							<sec_title>Adult ≥40 kg<route> IM/IV CCr 15-30 ml/min dose q12hr; CCr 5-15 ml/min dose q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14956">
						<sec_title>Community-acquired pneumonia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14964">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14964">
									<item>
										<label>•</label>
										<para> 3 g q12hr in combination × ≥5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14968">
						<sec_title>Endocarditis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14976">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14976">
									<item>
										<label>•</label>
										<para> 12 g divided q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14983">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14983">
									<item>
										<label>•</label>
										<para> 300 mg/kg/day divided q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14987">
						<sec_title>Pelvic inflammatory disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14995">
							<label>•</label>
							<sec_title>Adult/Adolescent<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14995">
									<item>
										<label>•</label>
										<para> 3 g q6hr in combination</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14999">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 1.5 g (1 g ampicillin, 0.5 g sulbactam), 3 g (2 g ampicillin, 1 g sulbactam), 15 g (10 g ampicillin, 5 g sulbactam)</para>
					</section>
					<section type="none" id="sidelem4x15004">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15008">
								<item>
									<label>•</label>
									<para>Scratch test to assess allergy after securing order from prescriber; usually done when penicillin is only product choice</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15020">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x15024">
									<item>
										<label>•</label>
										<para>Reconstitute by adding 3.2 ml sterile water/1.5-g vial; 6.4 ml/3-g vial, give deep in large muscle, aspirate</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use IM in child</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15035">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x15039">
									<item>
										<label>•</label>
										<para>After diluting 1.5 g/3.2 ml sterile water for inj or 3 g/6.4 ml (250 mg ampicillin/ 125 mg sulbactam), allow to stand until foaming stops; may give over 15 min, inject slowly</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15045">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x15049">
									<item>
										<label>•</label>
										<para>Dilute further in 50 ml or more of D<emphasis style="inf">5</emphasis>W, NaCl; administer within 1 hr after reconstitution; give over 15-30 min, separate doses from aminoglycosides by ≥1 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, amifostine, aminocaproic acid, anidulafungin, argatroban, atenolol, bivalirudin, bleomycin, CARBOplatin, carmustine, cefepime, CISplatin, codeine, cyclophosphamide, cytarabine, DAPTOmycin, DAUNOrubicin liposome, dexmedetomidine, DOCEtaxel, doxacurium, DOXOrubicin liposomal, eptifibatide, etoposide, fenoldopam, filgrastim, fludarabine, fluorouracil, foscarnet, gallium, gatifloxacin, gemcitabine, granisetron, hetastarch, irinotecan, levofloxacin, linezolid, methotrexate, metroNIDAZOLE, octreotide, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, remifentanil, riTUXimab, rocuronium, tacrolimus, teniposide, thiotepa, tigecycline, tirofiban, TNA, TPN, trastuzumab, vencuronium, vinCRIStine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15062">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15065">
					<section type="none" id="sidelem4x15066">
						<sec_title>CNS:</sec_title>
						<para> Lethargy, hallucinations, anxiety, depression, twitching, <emphasis style="bold">coma, seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15073">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> increased AST/ALT, abdominal pain, glossitis, colitis, <emphasis style="bold">pseudomembranous colitis, hepatic necrosis/failure,</emphasis> black hairy tongue</para>
					</section>
					<section type="none" id="sidelem4x15084">
						<sec_title>GU:</sec_title>
						<para> Oliguria, proteinuria, hematuria, <emphasis style="italic">vaginitis, moniliasis,</emphasis><emphasis style="bold">glomerulonephritis,</emphasis> dysuria</para>
					</section>
					<section type="none" id="sidelem4x15094">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, increased bleeding time, <emphasis style="bold">bone marrow depression, granulocytopenia, leukopenia, eosinophilia, hemolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15101">
						<sec_title>INTEG:</sec_title>
						<para> Injection site reactions, rash, edema, urticaria</para>
					</section>
					<section type="none" id="sidelem4x15106">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, serum sickness, toxic epidermal necrolysis, Stevens-Johnson syndrome,</emphasis> hypoalbuminemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15114">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x15117">
					<section type="none" id="sidelem4x15118">
						<sec_title>IV:</sec_title>
						<para> Peak 5 min, IM 1 hr; half-life 50-110 min, little metabolized in liver, 75%-85% of both products excreted in urine, diffuses to breast milk, crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x15123">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—oral anticoagulants; check, INR, PT</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ampicillin-induced skin rash—allopurinol, check for rash</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ampicillin level—probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> methotrexate level—methotrexate</para>
				<section type="none" id="sidelem4x15142">
					<section type="none" id="sidelem4x15143">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine glucose, urine protein</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15150">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15153">
					<section type="none" id="sidelem4x15154">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15162">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x15162">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> characteristics of wound, sputum; take temperature, WBC count; C&amp;S before product therapy, product may be given as soon as culture is taken</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15166">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15171">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report hematuria, oliguria because penicillin in high doses is nephrotoxic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15177">
								<item>
									<para>
										<emphasis alert="nurse">Any patient with compromised renal system, because product excreted slowly with poor renal system function; toxicity may occur rapidly</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15182">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT if on long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15187">
								<item>
									<label>•</label>
									<para>Blood studies: WBC, RBC, Hct, Hgb, bleeding time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15192">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, protein, blood, BUN, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15198">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: skin eruptions after administration of ampicillin to 1 wk after discontinuing product</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15203">
								<item>
									<label>•</label>
									<para>Allergies before treatment; reaction to each medication; report allergies</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15209">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15213">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, draining wounds; negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15219">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15224">
								<item>
									<label>•</label>
									<para>To report superinfection: vaginal itching; loose, foul-smelling stools; black furry tongue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15230">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: fever, diarrhea with pus, blood, mucus; may occur up to 4 wk after treatment; report immediately to health care provider</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15235">
								<item>
									<label>•</label>
									<para>To wear or carry emergency ID if allergic to penicillin products</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x15240">
				<sec_title>Treatment of anaphylaxis:</sec_title>
				<para>Withdraw product, maintain airway; administer EPINEPHrine, aminophylline, O<emphasis style="inf">2</emphasis>, IV corticosteroids</para>
			</section>
		</monograph>
<monograph id="55" status="active">
			<mono_name>anakinra (Rx)</mono_name>
			<info>
				<pronunciation>(an-ah-kin′rah)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x152530">Kineret</tradename>
				</tradenames>
				<class type="func"> Antirheumatic (DMARD), immunomodulator</class>
				<class type="chem"> Recombinant form of human interleukin-1 receptor antagonist (IL-1Ra)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x15263">
				<para>
					<confusion>
						<tradename id="tnidelem4x152630">Anakinra</tradename>
						<drug type="generic" refid="idelem4x152630">amikacin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x15267">
				<sec_title>Action:</sec_title>
				<para>A form of human interleukin-1 receptor antagonist (IL-1Ra) produced by DNA technology; blocks activity of IL-1, thereby resulting in decreased inflammation, cartilage degradation, bone resorption</para>
			</section>
			<section type="uses" id="sidelem4x15272">
				<sec_title>Uses:</sec_title>
				<para>Reduction in signs and symptoms of moderate to severe active rheumatoid arthritis in patients ≥18 yr who have not responded to other disease-modifying agents, neonatal-onset multisystem inflammatory disease. <emphasis style="bold">Unlabeled uses:</emphasis> Cryopyrin-associated periodic syndromes</para>
			</section>
			<section type="contra" id="sidelem4x15280">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to <emphasis style="italic">Escherichia coli</emphasis>–derived proteins, product, latex; sepsis</para>
				<section type="none" id="sidelem4x15288">
					<section type="none" id="sidelem4x15289">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal impairment, active infections, immunosuppression, neoplastic disease, asthma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15294">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15297">
					<section type="none" id="sidelem4x15298">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x15306">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x15306">
									<item>
										<label>•</label>
										<para> 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15310">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x15318">
							<label>•</label>
							<sec_title>Adult<route> CCr &lt;30 ml/min SUBCUT 100 mg every other day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x15321">
						<sec_title>Neonatal-onset multisystem inflammatory disease</sec_title>
						<section type="none" id="sidelem4x15329">
							<label>•</label>
							<sec_title>Adult/Child<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x15329">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg/day, may increase by 0.5-1 mg to max 8 mg/kg/day (adult) or 7.6 mg/kg/day (child)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15333">
						<sec_title>Available form:</sec_title>
						<para> Inj 100 mg/0.67 ml prefilled glass syringe</para>
					</section>
					<section type="none" id="sidelem4x15338">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x15341">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x15345">
									<item>
										<label>•</label>
										<para>Do not use if cloudy, discolored, if particulate is present; protect from light</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not admix with other sol or medications; do not use filter; give at same time each day</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply cold compress before, after inj, allow sol to warm to room temperature before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Use middle thigh, abdomen (outside 2 inches from navel), upper outer buttocks, upper outer area of arm; rotate sites, give inj at least 1 inch from old site; do not give in skin that is bruised, red, tender, hard; remove needle cover immediately before use, pull gently back on plunger, if no blood appears, inject entire contents of prefilled syringe; discard any unused portion</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15366">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15369">
					<section type="none" id="sidelem4x15370">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15377">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Sinusitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15384">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain, nausea, diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15391">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15398">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="italic">inj site reaction,</emphasis> allergic reaction</para>
					</section>
					<section type="none" id="sidelem4x15406">
						<sec_title>MISC:</sec_title>
						<para> Flulike symptoms, infection</para>
					</section>
					<section type="none" id="sidelem4x15412">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Worsening of RA, arthralgia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15419">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">URI</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15426">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 4-6 hr; eliminated renally</para>
			</section>
			<section type="interactions" id="sidelem4x15431">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x15439">
					<label>•</label>
					<sec_title>
						<route>Do not use rilonacept</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: risk for severe infection—TNF-blocking agents, do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody reactions—vaccines, avoid concurrent use</para>
			</section>
			<section type="considerations" id="sidelem4x15449">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15452">
					<section type="none" id="sidelem4x15453">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15461">
							<label>•</label>
							<sec_title>Rheumatoid arthritis</sec_title>
							<para>
								<list id="lidelem4x15461">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Rheumatoid arthritis:</emphasis> pain, stiffness, ROM, swelling of joints, baseline, periodically during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15465">
								<item>
									<label>•</label>
									<para>For inj site pain, swelling; usually occurs after 2 inj (4-5 days)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15473">
							<label>•</label>
							<sec_title>
								<route>For infections (increased WBC, fever, flulike symptoms); stop treatment if present; do not start if patient has active infection</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15476">
								<item>
									<label>•</label>
									<para>CBC with differential, neutrophil counts before treatment, monthly × 3 mo, quarterly for up to 1 yr thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15481">
								<item>
									<label>•</label>
									<para>For allergic reactions (rash, dyspnea), discontinue if severe</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15486">
								<item>
									<label>•</label>
									<para>For urinary status: decreasing urinary output</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15491">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15495">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation, pain in joints</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15501">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15505">
								<item>
									<label>•</label>
									<para>Not to receive vaccines while taking this product; to update vaccines before treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>About self-administration, if appropriate: inj should be made in thigh, abdomen, upper arm; rotate sites at least 1 inch from old site; give at same time of day, store in refrigerator, do not freeze</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned, suspected; to avoid breastfeeding; to notify prescriber of allergic reaction, decreasing urine output, signs/symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="56" status="active" ha="yes">
			<mono_name>anastrozole (Rx)</mono_name>
			<info>
				<pronunciation>(an-a-stroh′zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x155280">Arimidex</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Aromatase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x15538">
				<sec_title>Action:</sec_title>
				<para>Highly selective nonsteroidal aromatase inhibitor that lowers serum estradiol concentrations; many breast cancers have strong estrogen receptors</para>
			</section>
			<section type="uses" id="sidelem4x15543">
				<sec_title>Uses:</sec_title>
				<para>Advanced breast carcinoma in estrogen-receptor–positive patients (postmenopausal); patients with advanced disease taking tamoxifen, adjunct therapy</para>
				<section type="none" id="sidelem4x15548">
					<section type="none" id="sidelem4x15549">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Uterine leiomyomata, endometriosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15554">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x15559">
					<section type="none" id="sidelem4x15560">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, premenopausal women, osteoporosis, hepatic/cardiac disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15565">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15573">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15573">
							<item>
								<label>•</label>
								<para> 1 mg/day, max 5 yrs, may also combine with tamoxifen for up to 10 yrs</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15577">
					<section type="none" id="sidelem4x15578">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1 mg</para>
					</section>
					<section type="none" id="sidelem4x15583">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15587">
								<item>
									<label>•</label>
									<para>Give without regard to meals at same time of day</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15598">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15601">
					<section type="none" id="sidelem4x15602">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Hot flashes, headache, light-headedness,</emphasis> depression, dizziness, confusion, insomnia, anxiety, fatigue, mood changes</para>
					</section>
					<section type="none" id="sidelem4x15610">
						<sec_title>CV:</sec_title>
						<para> Chest pain, <emphasis style="italic">hypertension,</emphasis><emphasis style="bold">thrombophlebitis,</emphasis><emphasis style="italic">edema,</emphasis> angina, <emphasis style="bold">MI, cerebral infarct, CVA,</emphasis><emphasis style="italic">vasodilation</emphasis>, <emphasis style="bold">PE, DVT</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15629">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> altered taste leading to anorexia, diarrhea, constipation, abdominal pain, dry mouth, weight gain</para>
					</section>
					<section type="none" id="sidelem4x15638">
						<sec_title>GU:</sec_title>
						<para> Vaginal bleeding, vaginal dryness, pelvic pain, pruritus vulvae, UTI</para>
					</section>
					<section type="none" id="sidelem4x15643">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15650">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15659">
						<sec_title>MISC:</sec_title>
						<para> Hypercholesterolemia</para>
					</section>
					<section type="none" id="sidelem4x15664">
						<sec_title>MS:</sec_title>
						<para> Bone pain, myalgia, <emphasis style="italic">asthenia,</emphasis> bone loss/osteoporosis, arthralgia, fractures</para>
					</section>
					<section type="none" id="sidelem4x15672">
						<sec_title>RESP:</sec_title>
						<para> Cough, sinusitis, dyspnea, <emphasis style="bold">pulmonary embolism</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15679">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2 hr; half-life 50 hr; metabolized in liver, excreted in feces, urine, terminal half-life 50 hr</para>
			</section>
			<section type="interactions" id="sidelem4x15684">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x15692">
					<label>•</label>
					<sec_title>
						<route>Do not use with oral contraceptives, estrogen, tamoxifen, androstenedione, DHEA</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x15695">
					<section type="none" id="sidelem4x15696">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> GGT, AST, ALT, alk phos, cholesterol, LDL</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15703">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15706">
					<section type="none" id="sidelem4x15707">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x15712">
								<item>
									<label>•</label>
									<para>Bone mineral density, cholesterol, lipid panel, periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15718">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin reactions: Stevens-Johnson syndrome</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15723">
								<item>
									<label>•</label>
									<para>Not effective in hormone-receptor–negative disease, use only in postmenopausal women</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15728">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15732">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15738">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15743">
								<item>
									<label>•</label>
									<para>To report any complaints, side effects to prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15748">
								<item>
									<label>•</label>
									<para>That vaginal bleeding, pruritus, hot flashes reversible after discontinuing treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15753">
								<item>
									<label>•</label>
									<para>To report continued vaginal bleeding immediately</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15761">
							<label>•</label>
							<sec_title>
								<route>That tumor flare—increase in size of tumor, increased bone pain—may occur and will subside rapidly; may take analgesics for pain</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15764">
								<item>
									<label>•</label>
									<para>To take adequate calcium and vitamin D due to risk for bone loss/fractures</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="57" status="active">
			<mono_name>anidulafungin (Rx)</mono_name>
			<info>
				<pronunciation>(a-nid-yoo-luh-fun′jin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x157740">Eraxis</tradename>
				</tradenames>
				<class type="func"> Antifungal, systemic</class>
				<class type="chem"> Echinocandin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x15784">
				<sec_title>Action:</sec_title>
				<para>Inhibits fungal enzyme synthesis; causes direct damage to fungal cell wall</para>
			</section>
			<section type="uses" id="sidelem4x15789">
				<sec_title>Uses:</sec_title>
				<para>Esophageal candidiasis, <emphasis style="italic">Candida albicans, C. glabrata, C. parapsilosis, C. tropicalis</emphasis></para>
				<section type="none" id="sidelem4x15796">
					<section type="none" id="sidelem4x15797">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Fungal prophylaxis, disseminated candidiasis, oropharyngeal candidiasis, <emphasis style="italic">Aspergillosis</emphasis> sp.</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15805">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to product, other echinocandins</para>
				<section type="none" id="sidelem4x15810">
					<section type="none" id="sidelem4x15811">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, severe hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15816">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15819">
					<section type="none" id="sidelem4x15820">
						<sec_title>Candidemia and other <emphasis style="bold">Candida</emphasis> infections; serious systemic infections (unlabeled)</sec_title>
						<section type="none" id="sidelem4x15831">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15831">
									<item>
										<label>•</label>
										<para> 200 mg loading dose on day 1, then 100 mg/day × 14 days or more until last positive culture</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15835">
						<sec_title>Esophageal candidiasis</sec_title>
						<section type="none" id="sidelem4x15843">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15843">
									<item>
										<label>•</label>
										<para> 100 mg loading dose on day 1, then 50 mg/day × 14 days, for at least 7 days after symptoms resolved</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15847">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj, lyophilized 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x15852">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x15855">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x15860">
									<item>
										<label>•</label>
										<para>Visually inspect prepared infusions for particulate matter and discoloration, do not use if present; give by IV infusion only, after dilution</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x15868">
								<label>•</label>
								<sec_title>Reconstitution</sec_title>
								<para>
									<list id="lidelem4x15868">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Reconstitution:</emphasis> Reconstitute each 50 mg or 100 mg vial/15 ml or 30 ml of sterile water for injection, respectively (3.33 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x15875">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x15875">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> Reconstituted solutions are stable for up to 24 hours at room temperature</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x15883">
								<label>•</label>
								<sec_title>Dilution</sec_title>
								<para>
									<list id="lidelem4x15883">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Dilution:</emphasis> Do not use any other diluents besides D<emphasis style="inf">5</emphasis>W or sodium chloride 0.9% (NS)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x15893">
								<label>•</label>
								<sec_title>Preparation of the 200 mg loading dose infusion</sec_title>
								<para>
									<list id="lidelem4x15893">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Preparation of the 200 mg loading dose infusion:</emphasis> Withdraw the contents of either four 50 mg reconstituted vials OR two 100 mg reconstituted vials and add to an IV infusion bag or bottle containing 200 ml of D<emphasis style="inf">5</emphasis>W or NS to give a total infusion volume of 260 ml</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x15903">
								<label>•</label>
								<sec_title>Preparation of the 100 mg daily infusion</sec_title>
								<para>
									<list id="lidelem4x15903">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Preparation of the 100 mg daily infusion:</emphasis> Withdraw the contents of one 100 mg reconstituted vial OR two 50-mg reconstituted vials and add to an IV infusion bag or bottle containing 100 ml of D<emphasis style="inf">5</emphasis>W or NS to give a total infusion volume of 130 ml</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x15913">
								<label>•</label>
								<sec_title>Preparation of a 50 mg daily infusion</sec_title>
								<para>
									<list id="lidelem4x15913">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Preparation of a 50 mg daily infusion:</emphasis> Withdraw the contents of one 50 mg reconstituted vial and add to an IV infusion bag or bottle containing 50 ml of D<emphasis style="inf">5</emphasis>W or NS to give a total infusion volume of 65 ml</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x15923">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x15923">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> Diluted solutions are stable for up to 48 hr at temperatures up to 77° F (25° C) or for 72 hours if stored frozen</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x15927">
							<sec_title>Intermittent IV Infusion</sec_title>
							<para>
								<list id="lidelem4x15931">
									<item>
										<label>•</label>
										<para>Do not mix or co-infuse with other medications</para>
									</item>
									<item>
										<label>•</label>
										<para>Administer as a slow IV infusion at a rate of 1.4 ml/min or 84 ml/h; the minimum duration of infusion is 180 min for the 200 mg dose, 90 min for the 100 mg dose, and 45 min for the 50 mg dose</para>
									</item>
									<item>
										<label>•</label>
										<para>Store reconstituted vials at 59° F-86° F for up to 24 hr, do not freeze (dehydrated alcohol); store reconstituted vials at 36° F-46° F (sterile water) for up to 24 hr, do not freeze</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin sulbactam, argatroban, arsenic trioxide, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAUNOrubicin liposome, DAUNOrubicin hydrochloride, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUtamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gallium nitrate, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, lidocaine, linezolid injection, LORazepam, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, metaraminol, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoMYcin, mitoXANtrone, mivacurium, morphine, moxifloxacin, mycophenolate mofetil, nafcillin, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, piperacillin-tazobactam, polymyxin B, potassium acetate/chloride, procainamide, prochlorperazine, promethazine, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate, streptozocin, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tirofiban, tobramycin, topotecan, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15953">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15956">
					<sec_title>Candidemia/other Candida infections</sec_title>
					<section type="none" id="sidelem4x15959">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis> dizziness, <emphasis style="italic">headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15969">
						<sec_title>CV:</sec_title>
						<para> DVT, <emphasis style="bold">atrial fibrillation, right bundle branch block,</emphasis> hypotension, <emphasis style="bold">sinus arrhythmia, thrombophlebitis superficial, ventricular extrasystoles, QT prolongation (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15979">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia, vomiting, diarrhea, increased AST, ALT</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15986">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
				</section>
				<section type="none" id="sidelem4x15991">
					<sec_title>Esophageal candidiasis</sec_title>
					<section type="none" id="sidelem4x15994">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16001">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia, vomiting, diarrhea,</emphasis><emphasis style="bold">hepatic necrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16010">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, leukopenia, coagulopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16017">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, itching, flushing</para>
					</section>
					<section type="none" id="sidelem4x16025">
						<sec_title>META:</sec_title>
						<para> Hypocalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypomagnesium (rare)</para>
					</section>
					<section type="none" id="sidelem4x16030">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Back pain, rigors</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16037">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Steady state after loading dose, distribution half-life 0.5-1 hr, terminal half-life 40-50 hr, protein binding 99%</para>
			</section>
			<section type="interactions" id="sidelem4x16042">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x16045">
					<section type="none" id="sidelem4x16046">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amylase, bilirubin, CPK, creatinine, ECG, lipase, PT, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, magnesium, potassium, transferase, urea</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16057">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16060">
					<section type="none" id="sidelem4x16061">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x16069">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x16069">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> clearing of cultures during treatment; obtain culture at baseline and throughout treatment; product may be started as soon as culture is taken, those with HIV pharyngeal candidiasis may need antifungals</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x16074">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias (rare): CBC (RBC, Hct, Hgb), differential, platelet count periodically; notify prescriber of results</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16079">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during treatment: bilirubin, AST, ALT, alk phos, as needed; also uric acid</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16085">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding: hematuria, heme-positive stools, bruising/petechiae of mucosa or orifices; blood dyscrasias can occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16090">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping; if severe diarrhea occurs, electrolytes may need to be given</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16095">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16099">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of <emphasis style="italic">Candida</emphasis> infection, negative culture</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16108">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16112">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected, planned; use nonhormonal form of contraception while taking this product</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid breastfeeding while taking this product</para>
								</item>
								<item>
									<label>•</label>
									<para>To inform prescriber of renal/hepatic disease</para>
								</item>
								<item>
									<label>•</label>
									<para>To report bleeding</para>
								</item>
								<item>
									<label>•</label>
									<para>To report signs of infection: increased temperature, sore throat, flulike symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of nausea, vomiting, diarrhea, jaundice, anorexia, clay-colored stools, dark urine; hepatotoxicity may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="58" status="active" ru="yes">
			<mono_name>antihemophilic factor Fc fusion protein</mono_name>
			<info>
				<pronunciation>(an-tee-hee-moe-fil′ik fak′tor)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x161500">Eloctate</tradename>
				</tradenames>
				<class type="func"> Hemostatic</class>
			</info>
			<section type="uses" id="sidelem4x16156">
				<sec_title>Uses:</sec_title>
				<para>Hemophilia A (congenital factor VIII deficiency), control/prevention of bleeding, perioperative management of surgical bleeding</para>
			</section>
			<section type="doses" id="sidelem4x16162">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16165">
					<section type="none" id="sidelem4x16166">
						<sec_title>Hemophilia A (congenital factor VIII deficiency)</sec_title>
						<section type="none" id="sidelem4x16174">
							<label>•</label>
							<sec_title>Adults, adolescents, children, infants, and neonates<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x16174">
									<item>
										<label>•</label>
										<para> Infuse dose ≤10 ml/min; Dose (IU) = body weight (kg) × desired factor VIII increase (IU/dl or % of normal) × 0.5 (IU/kg per IU/dl) <emphasis style="italic">OR</emphasis> estimated increment of factor VIII (IU/dl or % of normal) = [total dose (IU)/body weight (kg)] × 2 (IU/dl per IU/kg)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16181">
						<sec_title>Control/prevention of bleeding</sec_title>
						<section type="none" id="sidelem4x16189">
							<label>•</label>
							<sec_title>Adults, adolescents, children, infants, and neonates</sec_title>
							<para>
								<list id="lidelem4x16189">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adults, adolescents, children, infants, and neonates:</emphasis> Dose and duration of treatment depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient’s clinical condition</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16193">
						<sec_title>Perioperative management of surgical bleeding</sec_title>
						<section type="none" id="sidelem4x16201">
							<label>•</label>
							<sec_title>Adults, adolescents, children, infants, and neonates</sec_title>
							<para>
								<list id="lidelem4x16201">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adults, adolescents, children, infants, and neonates:</emphasis> Dose and duration of treatment depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient’s clinical condition</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<emphasis style="bold">Routine bleeding prophylaxis to prevent/reduce the frequency of bleeding episodes: IV</emphasis> Initially, 50 IU/kg q4days; adjust dose based on response</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="59" status="active">
			<mono_name>antithymocyte</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x162120">See lymphocyte immune globulin</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="60" status="active" ha="yes">
			<mono_name>apixaban</mono_name>
			<info>
				<pronunciation>(a-pix’-a-ban)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x162210">Eliquis</tradename>
				</tradenames>
				<class type="func"> Anticoagulant</class>
			</info>
			<section type="actions" id="sidelem4x16231">
				<sec_title>Action:</sec_title>
				<para>Inhibits factor Xa and thereby decreases thrombin and clot formation</para>
			</section>
			<section type="uses" id="sidelem4x16236">
				<sec_title>Uses:</sec_title>
				<para>Deep venous thrombosis (DVT) after hip or knee replacement, to prevent stroke and embolism in atrial fibrillation (nonvalvular)</para>
			</section>
			<section type="contra" id="sidelem4x16241">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, active bleeding</para>
				<section type="none" id="sidelem4x16246">
					<section type="none" id="sidelem4x16247">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, dialysis, hepatic/renal disease, labor, pregnancy, surgery, prosthetic heart valves</para>
						<para>
							<bbw>Abrupt discontinuation, epidural, spinal anesthesia, lumbar puncture</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16262">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16265">
					<section type="none" id="sidelem4x16266">
						<sec_title>DVT or pulmonary embolism (PE)</sec_title>
						<section type="none" id="sidelem4x16274">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16274">
									<item>
										<label>•</label>
										<para> 10 mg bid × 7 days, then 5 mg bid ≥6 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16278">
						<sec_title>Stroke prophylaxis and systemic embolism prophylaxis in patients with nonvalvular atrial fibrillation</sec_title>
						<section type="none" id="sidelem4x16286">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16286">
									<item>
										<label>•</label>
										<para> 5 mg bid; in those with any 2 of the following: age ≥ 80 years; body weight ≤ 60 kg; or serum creatinine ≥ 1.5 mg/dL, reduce the dose to 2.5 mg bid. Also decrease the dose to 2.5 mg bid (strong inhibitor of both CYP3A4 and P-glycoprotein)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16290">
						<sec_title>Reduction in risk of recurrent DVT and/or PE after completion of treatment for acute DVT or PE</sec_title>
						<section type="none" id="sidelem4x16298">
							<label>•</label>
							<sec_title>Adults</sec_title>
							<para>
								<list id="lidelem4x16298">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adults:</emphasis> 2.5 mg bid daily after at least 6 months of treatment for DVT or PE</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16302">
						<sec_title>DVT prophylaxis and PE prophylaxis in patients undergoing knee or hip replacement surgery</sec_title>
						<section type="none" id="sidelem4x16310">
							<label>•</label>
							<sec_title>Adults</sec_title>
							<para>
								<list id="lidelem4x16310">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adults:</emphasis> 2.5 mg bid × 12 days after knee replacement surgery or for 35 days after hip replacement surgery. Give initial dose 12-24 hr after surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16314">
						<sec_title>Renal dose:</sec_title>
						<section type="none" id="sidelem4x16325">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16325">
									<item>
										<label>•</label>
										<para>No dosage adjustment needed when used for treatment/prevention of venous thromboembolism.  serum CCr ≥ 1.5 mg/dL: ≤60 kg and/or are ≥80 yr, then decrease dose to 2.5 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16331">
						<sec_title>Hemodialysis end-stage renal disease maintained on hemodialysis</sec_title>
						<para>
							<list id="lidelem4x16335">
								<item>
									<label>•</label>
									<para>5 mg bid reduce, to 2.5 mg bid if patient is ≥80 yr or ≤60 kg</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16341">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5 mg</para>
					</section>
					<section type="none" id="sidelem4x16346">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16350">
								<item>
									<label>•</label>
									<para>May be taken without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>If unable to swallow whole, may crush and suspend the tablet in 60 ml 5% dextrose solution; give immediately via NG</para>
								</item>
								<item>
									<label>•</label>
									<para>If a dose is missed, it should be taken as soon as possible on the same day. Twice daily dosing should be resumed. Do not double the dose to make up for a missed dose.</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16366">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16369">
					<section type="none" id="sidelem4x16370">
						<sec_title>CNS:</sec_title>
						<para> Syncope, <emphasis style="bold">intracranial bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16377">
						<sec_title>CV:</sec_title>
						<para> Hypotension</para>
					</section>
					<section type="none" id="sidelem4x16382">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Severe bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16389">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16396">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Hypersensitivity</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16403">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3-4 hr, half-life 12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x16408">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—antiplatelets, other anticoagulants, salicylates, NSAIDs, SNRIs, SSRIs, thrombolytics, avoid concurrent use</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> apixaban effect—strong inducers of CYP3A4 and also P-glycoprotein (carbamazepine, ketoconazole, itraconazole, phenytoin, rifampin), use lower dose</para>
				<section type="none" id="sidelem4x16419">
					<section type="none" id="sidelem4x16420">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> apixaban effect—St. John’s Wort, avoid concurrent use</para>
					</section>
					<section type="none" id="sidelem4x16427">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> PT, PTT, INR, coagulation studies</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16434">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16437">
					<section type="none" id="sidelem4x16438">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bleeding:</emphasis> bleeding may occur from any body system, may be fatal if severe</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x16453">
						<sec_title>Neurological status:</sec_title>
						<para> monitor for impairment, including numbness, paresthesia, weakness, confusion, back pain, bowel/bladder impairment, notify prescriber immediately</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Abrupt discontinuation:</emphasis> do not discontinue abruptly, if bleeding occurs, consider using another anticoagulant to prevent thromboembolic events</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Epidural, spinal anesthesia, lumbar puncture:</emphasis> avoid use in these conditions, risk of hematoma and permanent paralysis, may be increased with use of other anticoagulants, thrombolytics, antiplatelets</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x16482">
						<sec_title>Hypersensitivity:</sec_title>
						<para> rash, itching, chills, fever, report to prescriber</para>
					</section>
					<section type="none" id="sidelem4x16487">
						<sec_title>Evaluate:</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x16491">
						<sec_title>Therapeutic response:</sec_title>
						<para> prevention/treatment of DVT, adequate anticoagulation</para>
					</section>
					<section type="none" id="sidelem4x16496">
						<sec_title>Teach Patient/Family:</sec_title>
						<para>
							<list id="lidelem4x16500">
								<item>
									<label>•</label>
									<para>To avoid breastfeeding, it is not known if the product appears in breast milk, to notify prescriber if pregnancy is planned or suspected
<bbw>Not to discontinue without prescriber approval</bbw>

<bbw>Bleeding: to report bleeding, bruising, confusion, weakness, numbness of limbs</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC products, supplements, herbs, unless approved by prescriber, serious product interactions may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID with product taken</para>
								</item>
								<item>
									<label>•</label>
									<para>To report hypersensitivity reactions: rash, chills, fever, itching</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="61" status="active" ru="yes">
			<mono_name> apomorphine</mono_name>
			<info>
				<pronunciation>(ah-poe-more′feen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x165470">Apokyn</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> Dopamine agonist, non-ergot</class>
			</info>
			<section type="uses" id="sidelem4x16557">
				<sec_title>Uses:</sec_title>
				<para>For use as rescue of “off” episodes associated with advanced Parkinson’s disease</para>
			</section>
			<section type="contra" id="sidelem4x16562">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, sulfites, or benzyl alcohol, IV use, major psychotic disorder; concurrent treatment with drugs of the 5-HT<emphasis style="inf">3</emphasis> antagonist class (e.g., ondansetron, granisetron, alosetron)</para>
			</section>
			<section type="doses" id="sidelem4x16570">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16578">
					<label>•</label>
					<sec_title>Adult<route> Test dose</route></sec_title>
					<para>
						<list id="lidelem4x16578">
							<item>
								<label>•</label>
								<para> 0.2 ml (2 mg) (test dose) where B/P can be closely monitored (before dose and 20, 40, 60 min after); if tolerated and patient response, then begin with 0.2 ml (2 mg); may increase by 1 mg every few days, max 0.6 ml (6 mg); if the test dose of 0.2 ml (2 mg) is tolerated but the patient does not respond, give a test dose of 0.4 ml (4 mg) no sooner than 2 hr after the 0.2 ml (2 mg) test dose, where BP can be closely monitored (before dose and 20, 40, and 60 min after the dose); if the 0.4 ml (4 mg) test dose is tolerated, the starting dose should be 0.3 ml (3 mg); may be increased by 1 mg every few days as required, max 0.6 ml (6 mg). If the 0.4 ml (4 mg) test dose is not tolerated, administer a test dose of 0.3 ml (3 mg) no sooner than 2 hr after the 0.4 ml (4 mg) test dose where BP can be closely monitored (before dose and 20, 40, and 60 min after the dose); if the 0.3 ml (3 mg) test dose is tolerated, begin with 0.2 ml (2 mg); may be increased by 0.1 ml (1 mg) every few days as required, max 0.4 ml (4 mg; outpatient)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16585">
					<label>•</label>
					<sec_title>Usual dosage</sec_title>
					<para>
						<list id="lidelem4x16585">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Usual dosage:</emphasis> 0.3-0.6 ml (3-6 mg), average frequency three times a day</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="62" status="active">
			<mono_name>apraclonidine ophthalmic</mono_name>
			<section type="none" id="sidelem4x16592">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="63" status="active">
			<mono_name>apremilast</mono_name>
			<info>
				<pronunciation>(a-pre′mi-last)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x166010">Otezla</tradename>
				</tradenames>
				<class type="func"> Musculoskeletal agents: disease-modifying antirheumatic drugs (DMARDs)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x16607">
				<sec_title>Action:</sec_title>
				<para> A phosphodiesterase-4 (PDE4) inhibitor specific for cyclic adenosine monophosphate (cAMP). Inhibition of PDE4 results in an increase in intracellular concentration of cAMP, with a partial inhibition of proinflammatory mediators and an increase in the production of some antiinflammatory mediators</para>
			</section>
			<section type="uses" id="sidelem4x16612">
				<sec_title>Uses:</sec_title>
				<para> Treatment of active psoriatic arthritis; severe plaque psoriasis (in those not a candidate for phototherapy)</para>
			</section>
			<section type="contra" id="sidelem4x16617">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
				<section type="none" id="sidelem4x16622">
					<section type="none" id="sidelem4x16623">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, depression/suicidal, renal disease (CrCl &lt;30 ml/min)</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16628">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16631">
					<section type="none" id="sidelem4x16632">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> depression, <emphasis style="bold">suicidal ideation,</emphasis> fatigue, insomnia</para>
					</section>
					<section type="none" id="sidelem4x16643">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, vomiting, abdominal pain, frequent bowel movements, dyspepsia, weight loss</para>
					</section>
					<section type="none" id="sidelem4x16648">
						<sec_title>RESP:</sec_title>
						<para> URI, pharyngitis, bronchitis</para>
					</section>
					<section type="none" id="sidelem4x16653">
						<sec_title>SYST:</sec_title>
						<para> Hypersensitivity reactions</para>
					</section>
					<section type="none" id="sidelem4x16658">
						<sec_title>MS:</sec_title>
						<para> Back pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16663">
				<sec_title>Pharmacokinetics</sec_title>
				<para>68% bound to plasma proteins; metabolized by CYP3A4, half-life is 6-9 hr; elimination in urine (58%), feces (39%); peak 2.5 hr</para>
			</section>
			<section type="doses" id="sidelem4x16669">
				<sec_title>Dosages and routes</sec_title>
				<section type="none" id="sidelem4x16672">
					<section type="none" id="sidelem4x16673">
						<sec_title>Treatment of active psoriatic arthritis/severe plaque psoriasis</sec_title>
						<section type="none" id="sidelem4x16681">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16681">
									<item>
										<label>•</label>
										<para> To reduce the risk for gastrointestinal symptoms, titrate to a final dose of 30 mg bid; day 1: 10 mg PO <emphasis style="smallcaps">am</emphasis>; day 2: 10 mg <emphasis style="smallcaps">am</emphasis> and <emphasis style="smallcaps">pm</emphasis>; day 3: 10 mg <emphasis style="smallcaps">am</emphasis> and 20 mg <emphasis style="smallcaps">pm</emphasis>; day 4: 20 mg <emphasis style="smallcaps">am</emphasis> and <emphasis style="smallcaps">pm</emphasis>; day 5: 20 mg <emphasis style="smallcaps">am</emphasis> and 30 mg <emphasis style="smallcaps">pm</emphasis>; day 6 and thereafter: 30 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16712">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x16720">
							<label>•</label>
							<sec_title>Adult<route> PO CrCl ≥ 30 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16733">
						<sec_title>Available forms:</sec_title>
						<para> Tab 30 mg; starter pack</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x16738">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decreased:</emphasis> apremilast—CYP3A4 inducers (rifampin, isoniazid, pyrazinamide, barbiturates, phenytoin, carbamazepine, enzalutamide), avoid concurrent use</para>
				<section type="none" id="sidelem4x16745">
					<section type="none" id="sidelem4x16746">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decreased:</emphasis> apremilast—CYP3A4 inducers (St. John’s wort), avoid concurrent use</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16753">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16756">
					<section type="none" id="sidelem4x16757">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x16765">
							<label>•</label>
							<sec_title>Psoriatic arthritis/severe plaque psoriasis</sec_title>
							<para>
								<list id="lidelem4x16765">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Psoriatic arthritis/severe plaque psoriasis:</emphasis> assess for hypersensitivity reactions</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16772">
							<label>•</label>
							<sec_title>Pregnancy and breastfeeding<route> if used during pregnancy, call 1-877-311-8972; avoid use in breastfeeding</route></sec_title>
						</section>
						<section type="none" id="sidelem4x16778">
							<label>•</label>
							<sec_title>
								<route>For depression and suicidal ideation, mood changes; for renal failure or severe renal impairment (CrCl &lt;30 ml/min), dosage reduction is required</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16781">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16785">
								<item>
									<label>•</label>
									<para>Give whole, do not crush, break, or chew; give without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16791">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16795">
								<item>
									<label>•</label>
									<para>Therapeutic response: resolution of symptoms of psoriatic arthritis or plaque psoriasis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16801">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16806">
								<item>
									<label>•</label>
									<para>To report rash, hypersensitivity reactions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16811">
								<item>
									<label>•</label>
									<para>To avoid use in pregnancy and breastfeeding; if used during pregnancy, call 1-877-311-8972</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16819">
							<label>•</label>
							<sec_title>
								<route>To be alert for depression and suicidal ideation, mood changes; if these occur, notify prescriber immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="64" status="active">
			<mono_name>aprepitant (Rx)</mono_name>
			<info>
				<pronunciation>(ap-re′pi-tant)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x168270">Emend</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="65" status="active">
			<mono_name>fosaprepitant</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x168320">Emend</tradename>
				</tradenames>
				<class type="func"> Antiemetic</class>
				<class type="chem"> Miscellaneous</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x16842">
				<para>
					<confusion>
						<tradename id="tnidelem4x168420">aprepitant</tradename>
						<drug type="generic" refid="idelem4x168420">fosaprepitant</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x16846">
				<sec_title>Action:</sec_title>
				<para>Selective antagonist of human substance P/neurokinin 1 (NK<emphasis style="inf">1</emphasis>) receptors that decreases emetic reflex</para>
			</section>
			<section type="uses" id="sidelem4x16854">
				<sec_title>Uses:</sec_title>
				<para>Prevention of nausea/vomiting associated with cancer chemotherapy (highly emetogenic/moderately emetogenic), including high-dose CISplatin; used in combination with other antiemetics; postoperative nausea/vomiting</para>
			</section>
			<section type="contra" id="sidelem4x16859">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, polysorbate 80</para>
				<section type="none" id="sidelem4x16864">
					<section type="none" id="sidelem4x16865">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16870">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16873">
					<section type="none" id="sidelem4x16874">
						<sec_title>Prevention of nausea/vomiting after chemotherapy</sec_title>
						<section type="none" id="sidelem4x16882">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16882">
									<item>
										<label>•</label>
										<para> Day 1 (1 hr before chemotherapy) aprepitant 125 mg with 12 mg dexamethasone  with 32 mg ondansetron IV; day 2 aprepitant 80 mg with 8 mg dexamethasone  day 3 aprepitant 80 mg with 8 mg dexamethasone  day 4 only dexamethasone 8 mg  115 mg over 15 min, 30 min before chemotherapy as alternative to 1st dose of aprepitant on day 1 of regimen (fosaprepitant)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16900">
						<sec_title>Prevention of postoperative nausea/vomiting</sec_title>
						<section type="none" id="sidelem4x16908">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16908">
									<item>
										<label>•</label>
										<para> 40 mg within 3 hr of induction of anesthesia</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16912">
						<sec_title>Available forms:</sec_title>
						<para> Caps 40, 80, 125 mg; powder for inj 150 mg; combo pack cap 80-125 mg</para>
					</section>
					<section type="none" id="sidelem4x16917">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x16920">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x16924">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew</para>
									</item>
									<item>
										<label>•</label>
										<para>PO on 3-day schedule, give with full glass of water 1 hr before chemotherapy, with or without food, given with other antiemetics</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature; keep in original bottles, blisters</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16940">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x16945">
									<item>
										<label>•</label>
										<para>Only approved as a substitute for the 1st dose of aprepitant in 3-day regimen</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x16953">
								<label>•</label>
								<sec_title>Reconstitution</sec_title>
								<para>
									<list id="lidelem4x16953">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Reconstitution:</emphasis> use aseptic technique; inject 5 ml 0.9% NaCl into the vial, directing stream to wall of vial to prevent foam; swirl (do not shake)</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x16957">
									<item>
										<label>•</label>
										<para>Prepare infusion bag 145 ml/150 mg; do not dilute, reconstitute with any divalent cations such as calcium, magnesium, including LR, Hartmann’s sol</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x16962">
									<item>
										<label>•</label>
										<para>Withdraw entire volume from vial, transfer to infusion bag; total volume 115 ml (1 mg/1 ml)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x16967">
									<item>
										<label>•</label>
										<para>Gently invert bag 2-3 times; reconstituted sol stable for 24 hr at lower room temperature or &lt;25° C</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x16972">
									<item>
										<label>•</label>
										<para>Visually inspect for particulates, discoloration</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x16977">
									<item>
										<label>•</label>
										<para>Infuse over 20-30 min, stable for 24 hr at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16982">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16985">
					<section type="none" id="sidelem4x16986">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> insomnia, anxiety, depression, confusion, peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x16994">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, tachycardia, <emphasis style="bold">DVT,</emphasis> hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x17002">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, constipation,</emphasis> abdominal pain, anorexia, gastritis, increased AST, ALT<emphasis style="italic">, nausea,</emphasis> vomiting, heartburn</para>
					</section>
					<section type="none" id="sidelem4x17013">
						<sec_title>GU:</sec_title>
						<para> Increased BUN, serum creatinine, proteinuria, dysuria</para>
					</section>
					<section type="none" id="sidelem4x17018">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">thrombocytopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17025">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, rash, urticaria, infection reaction</para>
					</section>
					<section type="none" id="sidelem4x17030">
						<sec_title>MISC:</sec_title>
						<para> Asthenia, fatigue, dehydration, fever, hiccups, tinnitus, alopecia</para>
					</section>
					<section type="none" id="sidelem4x17035">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17042">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption 60%-65%, peak 4 hr, metabolized in liver by CYP3A4 enzymes to active metabolite, half-life 9-12 hr, 95% protein bound, not excreted in kidneys, crosses blood-brain barrier</para>
			</section>
			<section type="interactions" id="sidelem4x17047">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> aprepitant action—CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir, diltiazem)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of CYP3A4 substrates (pimozide, cisapride, dexamethasone, methylPREDNISolone, midazolam, ALPRAZolam, triazolam, DOCEtaxel, PACLitaxel, etoposide, irinotecan, imatinib, ifosfamide, vinorelbine, vinBLAStine, vinCRIStine)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> aprepitant action—CYP3A4 inducers (rifampin, carBAMazepine, phenytoin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of CYP2C9 substrates (warfarin, TOLBUTamide, phenytoin), oral contraceptives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of both products—PARoxetine</para>
				<section type="none" id="sidelem4x17070">
					<section type="none" id="sidelem4x17071">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17078">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17081">
					<section type="none" id="sidelem4x17082">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x17088">
								<item>
									<para>
										<emphasis alert="nurse">For hypersensitive reactions: pruritus, rash, urticaria, anaphylaxis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17093">
								<item>
									<label>•</label>
									<para>CV status: hypo/hypertension, bradycardia, tachycardia, DVT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17098">
								<item>
									<label>•</label>
									<para>For absence of nausea, vomiting during chemotherapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17103">
								<item>
									<label>•</label>
									<para>CBC, LFTs, creatinine baseline and periodically</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17109">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17113">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting during cancer chemotherapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17119">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17123">
								<item>
									<label>•</label>
									<para>To report diarrhea, constipation</para>
								</item>
								<item>
									<label>•</label>
									<para>To take only as prescribed; to take 1st dose 1 hr before chemotherapy</para>
								</item>
								<item>
									<label>•</label>
									<para>To report all medications and herbals to prescriber before taking this medication</para>
								</item>
								<item>
									<label>•</label>
									<para>To use nonhormonal form of contraception while taking this agent and for 1 mo thereafter; oral contraceptive effect may be decreased</para>
								</item>
								<item>
									<label>•</label>
									<para>That those patients also taking warfarin should have clotting monitored closely during 2-wk period after administration of aprepitant</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="66" status="active">
			<mono_name>arformoterol (Rx)</mono_name>
			<info>
				<pronunciation>(ar-for-moe′ter-ole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x171590">Brovana</tradename>
				</tradenames>
				<class type="func"> Long-acting adrenergic β-agonist, sympathomimetic, bronchodilator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x17168">
				<para>
					<confusion>
						<tradename id="tnidelem4x171680">Brovana</tradename>
						<drug type="generic" refid="idelem4x171680">Boniva</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x17172">
				<sec_title>Action:</sec_title>
				<para>Causes bronchodilation by action on β<emphasis style="inf">2</emphasis> (pulmonary) receptors by increasing levels of cAMP, which relaxes smooth muscle; produces bronchodilation and CNS, cardiac stimulation as well as increased diuresis and gastric acid secretion; longer acting than isoproterenol</para>
			</section>
			<section type="uses" id="sidelem4x17180">
				<sec_title>Uses:</sec_title>
				<para>Maintenance bronchospasm prevention in COPD, including chronic bronchitis, emphysema</para>
			</section>
			<section type="contra" id="sidelem4x17185">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics, product, racemic formoterol; tachydysrhyhmias, severe cardiac disease, heart block, children, monotherapy in asthma</para>
				<section type="none" id="sidelem4x17190">
					<section type="none" id="sidelem4x17191">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, cardiac disorders, hyperthyroidism, diabetes mellitus, hypertension, prostatic hypertrophy, angle-closure glaucoma, seizures, hypoglycemia</para>
						<para>
							<bbw>Asthma-related death</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17206">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17209">
					<section type="none" id="sidelem4x17210">
						<sec_title>COPD</sec_title>
						<section type="none" id="sidelem4x17218">
							<label>•</label>
							<sec_title>Adult<route> NEB</route></sec_title>
							<para>
								<list id="lidelem4x17218">
									<item>
										<label>•</label>
										<para> 15 mcg, bid, <emphasis style="smallcaps">am, pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17224">
						<sec_title>Available forms:</sec_title>
						<para> Inh sol 15 mcg/2 ml</para>
					</section>
					<section type="none" id="sidelem4x17229">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x17233">
								<item>
									<label>•</label>
									<para>By nebulization only; no dilution needed; give over 5-10 min; sol should be colorless</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in refrigerator; if stored at room temperature, discard after 6 wk or if past expiration date, whichever is sooner</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17244">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17247">
					<section type="none" id="sidelem4x17248">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, anxiety,</emphasis> insomnia, headache, dizziness, stimulation, <emphasis style="italic">restlessness,</emphasis> hallucinations, flushing, irritability</para>
					</section>
					<section type="none" id="sidelem4x17259">
						<sec_title>CV:</sec_title>
						<para> Palpitations, tachycardia, hypertension, angina, hypotension, dysrhythmias, <emphasis style="bold">AV block, heart failure, prolonged QT, supraventricular tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17266">
						<sec_title>EENT:</sec_title>
						<para> Dry nose, irritation of nose, throat</para>
					</section>
					<section type="none" id="sidelem4x17271">
						<sec_title>GI:</sec_title>
						<para> Heartburn, nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x17276">
						<sec_title>MISC:</sec_title>
						<para> Flushing, sweating, anorexia, bad taste/smell changes, hypokalemia, <emphasis style="bold">anaphylaxis,</emphasis><emphasis style="italic">hypoglycemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17285">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps, back pain</para>
					</section>
					<section type="none" id="sidelem4x17290">
						<sec_title>RESP:</sec_title>
						<para> Cough, wheezing, dyspnea, <emphasis style="bold">bronchospasm,</emphasis> dry throat</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17298">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset rapid; peak 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; duration 4-6 hr; terminal half-life (COPD) 26 hr; extensively metabolized by direct conjugation by CYP2D6, CYP2C19; crosses placenta; protein binding 52%-65%; excreted in urine 63%, feces 11%</para>
			</section>
			<section type="interactions" id="sidelem4x17309">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—Class IA/III antidysrthymics, MAOIs, tricyclics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe hypotension—oxytocics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ECG changes/hypokalemia—potassium-losing diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of nebulized bronchodilators</para>
				<para>
					<emphasis alert="lifethreat">Increase: action of arformoterol—tricyclics, MAOIs, other adrenergics; do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> arformoterol action, asthma-related death—other β-blockers</para>
				<section type="none" id="sidelem4x17339">
					<section type="none" id="sidelem4x17340">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> stimulation—caffeine (cola nut, green/black tea, guarana, yerba maté, coffee, chocolate)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17347">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17350">
					<section type="none" id="sidelem4x17351">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Respiratory function: vital capacity, forced expiratory volume, ABGs; lung sounds, heart rate, rhythm, B/P, sputum (baseline, peak); actively deteriorating COPD may occur; a rescue inhaler should be readily available</bbw>
						</para>
						<para>
							<list id="lidelem4x17365">
								<item>
									<label>•</label>
									<para>Whether patient has received theophylline therapy, other bronchodilators before giving dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17370">
								<item>
									<label>•</label>
									<para>Patient’s ability to self-medicate</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17375">
								<item>
									<label>•</label>
									<para>For evidence of allergic reactions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17383">
							<label>•</label>
							<sec_title>
								<route>For paradoxical bronchospasm; hold medication, notify prescriber if bronchospasm occurs</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17386">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17390">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of dyspnea, wheezing after 1 hr, improved airway exchange, improved ABGs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17396">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>To use exactly as prescribed; that death has resulted from asthma with products similar to this one; to have a rescue inhaler always</bbw>
						</para>
						<para>
							<list id="lidelem4x17409">
								<item>
									<label>•</label>
									<para>Not to use OTC medications because excess stimulation may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That an opened unit-dose vial should be used right away</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if there is more frequent use needed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="67" status="active" ha="yes">
			<mono_name>argatroban (Rx)</mono_name>
			<info>
				<pronunciation>(are-ga-troe′ban)</pronunciation>
				<class type="func"> Anticoagulant</class>
				<class type="chem"> Thrombin inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x17440">
				<para>
					<confusion>
						<tradename id="tnidelem4x174400">argatroban</tradename>
						<drug type="generic" refid="idelem4x174400">Aggrastat</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x17444">
				<sec_title>Action:</sec_title>
				<para>Direct inhibitor of thrombin, it reversibly binds to thrombin active site</para>
			</section>
			<section type="uses" id="sidelem4x17449">
				<sec_title>Uses:</sec_title>
				<para>Anticoagulation prevention/treatment of thrombosis in heparin-induced thrombocytopenia; adjunct to percutaneous coronary intervention (PCI) in those with history of HIT, deep vein thrombosis, pulmonary embolism</para>
				<section type="none" id="sidelem4x17454">
					<section type="none" id="sidelem4x17455">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute MI, DIC, use in infants/children/adolescents</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17460">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, overt major bleeding</para>
				<section type="none" id="sidelem4x17465">
					<section type="none" id="sidelem4x17466">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, intracranial bleeding, renal function impairment, hepatic disease, severe hypertension, after lumbar puncture, spinal anesthesia, major surgery/trauma, congenital/acquired bleeding, GI ulcers, abrupt discontinuation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17471">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17474">
					<section type="none" id="sidelem4x17475">
						<sec_title>DVT, Pulmonary Embolism</sec_title>
						<section type="none" id="sidelem4x17483">
							<label>•</label>
							<sec_title>Adult<route> CONT IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x17483">
									<item>
										<label>•</label>
										<para> 2 mcg/kg/min; adjust dose until steady-state aPTT is 1.5-3× initial baseline, max 100 sec, max dose 10 mcg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17490">
							<label>•</label>
							<sec_title>Infant/child/adolescent (unlabeled)<route> CONT IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x17490">
									<item>
										<label>•</label>
										<para> 0.75 mcg/kg/min, monitor aPTT q2hr until stable, then at least daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17494">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x17502">
							<label>•</label>
							<sec_title>Adult<route> CONT INFUSION 0.5 mcg/kg/min, adjust rate based on aPTT</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17505">
						<sec_title>Percutaneous coronary intervention (PCI) in HIT</sec_title>
						<section type="none" id="sidelem4x17513">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x17513">
									<item>
										<label>•</label>
										<para> 25 mcg/kg/min and bolus of 350 mcg/kg given over 3-5 min, check ACT 5-10 min after bolus completed, </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17520">
						<sec_title>Acute MI (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17528">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x17528">
									<item>
										<label>•</label>
										<para> loading dose of 100 mcg/kg over 1 min, then 1-3 mcg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17532">
						<sec_title>DIC (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17540">
							<label>•</label>
							<sec_title>Adult<route> CONT IV</route></sec_title>
							<para>
								<list id="lidelem4x17540">
									<item>
										<label>•</label>
										<para> 0.7 mcg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17544">
						<sec_title>Available forms:</sec_title>
						<para> Inj 100 mg/ml (2.5 ml; must dilute 100-fold), 50 mg/50 ml, 125 mg/125 ml</para>
					</section>
					<section type="none" id="sidelem4x17549">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x17553">
								<item>
									<label>•</label>
									<para>Avoid all IM inj that may cause bleeding</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17559">
							<sec_title>IV, direct route</sec_title>
							<section type="none" id="sidelem4x17567">
								<label>•</label>
								<sec_title>For PCI</sec_title>
								<para>
									<list id="lidelem4x17567">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">For PCI:</emphasis> 350 mg/kg bol and continuous infusion of 25 mcg/kg/min; check ACT 5-10 min after bolus</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x17571">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x17579">
								<label>•</label>
								<sec_title>
									<route>Dilute</route>
								</sec_title>
								<para>
									<list id="lidelem4x17579">
										<item>
											<label>•</label>
											<para> in 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, LR to a final concentrations of 1 mg/ml;  each 2.5-ml vial 100-fold by mixing with 250 ml of diluent, mix by repeated inversion of the diluent bag for 1 min; may briefly be slightly hazy</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x17589">
									<item>
										<label>•</label>
										<para>Dosage adjustment may be made after review of aPTT, max 10 mcg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17594">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17597">
					<section type="none" id="sidelem4x17598">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever,</emphasis><emphasis style="bold">intracranial bleeding,</emphasis> headache</para>
					</section>
					<section type="none" id="sidelem4x17608">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Atrial fibrillation, coronary thrombosis, MI, myocardial ischemia, coronary occlusion, ventricular tachycardia, bradycardia,</emphasis><emphasis style="italic">chest pain, hypotension</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17617">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain, diarrhea,</emphasis><emphasis style="bold">GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17626">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hematuria,</emphasis> abnormal kidney function, UTI</para>
					</section>
					<section type="none" id="sidelem4x17634">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17641">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Back pain,</emphasis> infection</para>
					</section>
					<section type="none" id="sidelem4x17649">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, coughing, hemoptysis, pulmonary edema</para>
					</section>
					<section type="none" id="sidelem4x17654">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Sepsis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17661">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, distributed to extracellular fluid, 54% plasma protein binding, half-life 39-51 min, excreted in feces, steady state 1-3 hr</para>
			</section>
			<section type="interactions" id="sidelem4x17666">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—antiplatelets, NSAIDs, salicylates, dipyridamole, clopidogrel, ticlopidine, heparin, warfarin, glycoprotein IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide), thrombolytics (alteplase, reteplase, urokinase, tenecteplase), other anticoagulants</para>
				<section type="none" id="sidelem4x17673">
					<section type="none" id="sidelem4x17674">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—ginger, garlic, ginkgo, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x17681">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17688">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17691">
					<section type="none" id="sidelem4x17692">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x17697">
								<item>
									<label>•</label>
									<para>Baseline aPTT before treatment; do not start treatment if aPTT ratio is ≥2.5; then check aPTT 2 hr after initiation of treatment and at least daily thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17702">
								<item>
									<label>•</label>
									<para>aPTT, which should be 1.5-3× control, draw blood for ACT every 20-30 min during long PCI</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17708">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding: gums; petechiae; ecchymosis; black, tarry stools; hematuria/epistaxis; decreased B/P, Hct; vaginal bleeding, possible hemorrhage</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17714">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: dyspnea, rash during treatment</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17719">
								<item>
									<label>•</label>
									<para>Fever, skin rash, urticaria</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17724">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17728">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence or decrease of thrombosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17734">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17738">
								<item>
									<label>•</label>
									<para>To use a soft-bristle toothbrush to avoid bleeding gums; avoid contact sports; use electric razor; avoid IM inj</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any signs of bleeding: gums, under skin, urine, stools; trouble breathing wheezing, skin rash</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if planning to become pregnant, breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use OTC meds, herbal products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="68" status="active">
			<mono_name>ARIPiprazole (Rx)</mono_name>
			<info>
				<pronunciation>(a-rip-ip-pra′zol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x177652">Abilify</tradename>
					<tradename id="tnidelem4x177651">Abilify Discmelt</tradename>
					<tradename id="tnidelem4x177650">Abilify Maintena</tradename>
				</tradenames>
				<class type="func"> Antipsychotic</class>
				<class type="chem"> Quinolinone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x17775">
				<sec_title>Action:</sec_title>
				<para>Exact mechanism unknown; may be mediated through both DOPamine type 2 (D<emphasis style="inf">2</emphasis>, D<emphasis style="inf">3</emphasis>) and serotonin type 2 (5-HT<emphasis style="inf">1A</emphasis>, 5-HT<emphasis style="inf">2A</emphasis>) antagonism, DOPamine System Stabilizer</para>
			</section>
			<section type="uses" id="sidelem4x17792">
				<sec_title>Uses:</sec_title>
				<para>Schizophrenia and bipolar disorder (adults and adolescents), mania, major depressive disorder, short-term mania or mixed episodes of bipolar disorder; irritability in patients with autism</para>
			</section>
			<section type="contra" id="sidelem4x17797">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity, seizure disorders</para>
				<section type="none" id="sidelem4x17802">
					<section type="none" id="sidelem4x17803">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, renal/hepatic/cardiac disease, neutropenia</para>
						<para>
							<bbw>Children with depression, dementia, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17818">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17821">
					<section type="none" id="sidelem4x17822">
						<sec_title>Major depressive disorder</sec_title>
						<section type="none" id="sidelem4x17830">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17830">
									<item>
										<label>•</label>
										<para> 2-5 mg/day as an adjunct to other antidepressant treatment; adjust by 5 mg at ≥1 wk (range, 2-15 mg/day)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17834">
						<sec_title>Schizophrenia</sec_title>
						<section type="none" id="sidelem4x17842">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17842">
									<item>
										<label>•</label>
										<para> 10-15 mg/day; if needed, dosage may be increased to 30 mg/day after 2 wk; maintenance 15 mg/day; periodically reassess; IM/ext rel monthly inj susp) 400 mg monthly</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17849">
							<label>•</label>
							<sec_title>Adolescent 13-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17849">
									<item>
										<label>•</label>
										<para> 2 mg/day, may increase to 5 mg after 2 days, then 10 mg after 2 more days, max 30 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17853">
						<sec_title>Bipolar disorder</sec_title>
						<section type="none" id="sidelem4x17861">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17861">
									<item>
										<label>•</label>
										<para> 15 mg/day, may increase to 30 mg if needed (monotherapy); adjunctive to lithium or valproate PO 10-15 mg daily, may increase to 30 mg if needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17868">
							<label>•</label>
							<sec_title>Child &gt;10 yr, adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17868">
									<item>
										<label>•</label>
										<para> 2 mg, titrate to 5 mg/day after 2 days to target of 10 mg/day after another 2 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17872">
						<sec_title>Agitation with bipolar disorder/schizophrenia</sec_title>
						<section type="none" id="sidelem4x17880">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x17880">
									<item>
										<label>•</label>
										<para> 9.75 mg as a single dose, may start with a lower dose, max 30 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17884">
						<sec_title>Irritability associated with autism</sec_title>
						<section type="none" id="sidelem4x17892">
							<label>•</label>
							<sec_title>Child ≥6 yr, adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17892">
									<item>
										<label>•</label>
										<para> 2 mg/day, increase to 5 mg/day after 1 wk, may increase to 10-15 mg/day if needed; dose changes should not occur more frequently than q1wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17896">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Potential CYP2D6 inhibitor, strong CYP3A4 inhibitors</emphasis>
							</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x17906">
							<label>•</label>
							<sec_title>Adult<route> PO Reduce to 50% of usual dose; increase dose when CYP2D6, CYP3A4 inhibitor withdrawn</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17909">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Combination of strong CYP3A4/CYP2D6 inhibitors</emphasis>
							</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x17919">
							<label>•</label>
							<sec_title>Adult<route> PO reduce to 25% of usual dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17922">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2, 5, 10, 15, 20, 30 mg; inj 9.75 mg/1.3 ml; orally disintegrating tab 10, 15 mg; oral sol 1 mg/ml; susp for injection 441mg/1.6ml, 662mg/2.4ml, 882mg/3.2ml;</para>
					</section>
					<section type="none" id="sidelem4x17927">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x17930">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x17935">
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x17940">
									<item>
										<label>•</label>
										<para>May be given without regard to meals</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x17948">
								<label>•</label>
								<sec_title>
									<route>Orally disintegrating tabs;</route>
								</sec_title>
								<para>
									<list id="lidelem4x17948">
										<item>
											<label>•</label>
											<para> do not open blister until ready to use, do not push tab through foil; place on tongue, allow to dissolve, swallow, do not divide</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17955">
								<label>•</label>
								<sec_title>Oral liquid</sec_title>
								<para>
									<list id="lidelem4x17955">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral liquid:</emphasis> use calibrated measuring device</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17962">
								<label>•</label>
								<sec_title>Oral solution</sec_title>
								<para>
									<list id="lidelem4x17962">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral solution:</emphasis> can be substituted for tablet on a mg-per-mg, up to 25-mg dose. Patients receiving 30-mg tablets should receive 25 mg, immediate release of solution</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x17966">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x17970">
									<item>
										<label>•</label>
										<para>Give IM only; inject slowly, deeply into muscle mass; discard unused portion; do not give IV or subcut</para>
									</item>
									<item>
										<label>•</label>
										<para>Available as ready to use</para>
									</item>
									<item>
										<label>•</label>
										<para>Ext rel monthly (Abilify Maintena)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17986">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17989">
					<section type="none" id="sidelem4x17990">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, insomnia, agitation, anxiety, headache,</emphasis><emphasis style="bold">seizures, neuroleptic malignant syndrome,</emphasis><emphasis style="italic">light-headedness, akathisia, asthenia, tremor,</emphasis><emphasis style="bold">stroke, suicidal ideation,</emphasis> dystonia, cogwheel rigidity</para>
					</section>
					<section type="none" id="sidelem4x18005">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, <emphasis style="bold">tachycardia</emphasis>, chest pain, hypertension, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x18013">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision, rhinitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18020">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation, nausea, vomiting,</emphasis> jaundice, <emphasis style="italic">weight gain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18030">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18037">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia, dyslipidemia</para>
					</section>
					<section type="none" id="sidelem4x18042">
						<sec_title>MS:</sec_title>
						<para> Musculoskeletal pain/stiffness, myalgia</para>
					</section>
					<section type="none" id="sidelem4x18047">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18054">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Death among geriatric patients with dementia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18061">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x18064">
					<section type="none" id="sidelem4x18065">
						<sec_title>PO:</sec_title>
						<para> Absorption 87%; extensively metabolized by liver to a major active metabolite; plasma protein binding &gt;99%; terminal half-life 75-146 hr; excretion via urine 25%, feces 55%; clearance decreased in geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x18070">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of ARIPiprazole—CYP3A4 inhibitors (ketoconazole, erythromycin), CYP2D6 inhibitors (quiNIDine, FLUoxetine, PARoxetine); reduce dose of ARIPiprazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—other CNS depressants, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> EPS—other antipsychotics, lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ARIPiprazole level—famotidine, valproate</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of ARIPiprazole—CYP3A4 inducers (carBAMazepine)</para>
				<section type="none" id="sidelem4x18093">
					<section type="none" id="sidelem4x18094">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> ARIPiprazole effect—St. John’s wort</para>
					</section>
				</section>
				<section type="none" id="sidelem4x18101">
					<section type="none" id="sidelem4x18102">
						<sec_title>Drug/Lab</sec_title>
						<para>False positive: amphetephine drug screen</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18107">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18110">
					<section type="none" id="sidelem4x18111">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Mental status</emphasis> before initial administration, children/young adults may exhibit suicidal thoughts/behaviors, therefore smallest amount of product should be given; elderly patients with dementia-related psychosis are at increased risk of death</bbw>
						</para>
						<para>
							<list id="lidelem4x18127">
								<item>
									<label>•</label>
									<para>Swallowing of PO medication; check for hoarding, giving of medication to other patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18132">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; palpate bladder if urinary output is low</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18137">
								<item>
									<label>•</label>
									<para>AIMS assessment, neurologic function, LFTs, weight, lipid profile, blood glucose monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18142">
								<item>
									<label>•</label>
									<para>Affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18147">
								<item>
									<label>•</label>
									<para>B/P standing and lying; also pulse, respirations; take q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; watch for ECG changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18152">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18160">
							<label>•</label>
							<sec_title>
								<route>EPS, including akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of the jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x18164">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignant syndrome: hyperthermia, increased CPK, altered mental status, muscle rigidity; notify prescriber immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18169">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; if these occur, increase bulk, water in diet; stool softeners, laxatives may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18174">
								<item>
									<label>•</label>
									<para>Supervised ambulation until patient is stabilized on medication; do not involve patient in strenuous exercise program because fainting is possible; patient should not stand still for a long time</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18179">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18183">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18189">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18194">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension may occur; to rise from sitting or lying position gradually</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18199">
								<item>
									<label>•</label>
									<para>To avoid hot tubs, hot showers, tub baths; hypotension may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18208">
							<label>•</label>
							<sec_title>
								<route>To avoid abrupt withdrawal of this product; EPS may result; product should be withdrawn slowly</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x18211">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber because serious product interactions may occur; to avoid use with alcohol, CNS depressants because increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18216">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsy, dizzy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18221">
								<item>
									<label>•</label>
									<para>About compliance with product regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18226">
								<item>
									<label>•</label>
									<para>To report impaired vision, tremors, muscle twitching, urinary retention</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18234">
							<label>•</label>
							<sec_title>
								<route>That heat stroke may occur in hot weather; to take extra precautions to stay cool</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x18237">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnant or intending to become pregnant; not to breastfeed
<bbw>To report suicidal thoughts/behaviors, dementia immediately</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x18251">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if orally ingested; provide airway; <emphasis style="italic">do not induce vomiting</emphasis></para>
			</section>
		</monograph>
<monograph id="69" status="active" ru="yes">
			<mono_name>armodafinil (Rx)</mono_name>
			<info>
				<pronunciation>(ar-moe-daf′in-il)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x182650">Nuvigil</tradename>
				</tradenames>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="uses" id="sidelem4x18270">
				<sec_title>Uses:</sec_title>
				<para>Narcolepsy, obstructive sleep apnea/hypoapnea syndrome, circadian rhythm disruption (shift-work sleep problems)</para>
			</section>
			<section type="contra" id="sidelem4x18275">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or modafinil</para>
			</section>
			<section type="doses" id="sidelem4x18280">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18283">
					<section type="none" id="sidelem4x18284">
						<sec_title>Narcolepsy, obstructive sleep apnea/hypoapnea syndrome</sec_title>
						<section type="none" id="sidelem4x18292">
							<label>•</label>
							<sec_title>Adult and adolescent ≥17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18292">
									<item>
										<label>•</label>
										<para> 150-250 mg in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18298">
						<sec_title>Circadian rhythm disruption (shift work sleep problems)</sec_title>
						<section type="none" id="sidelem4x18306">
							<label>•</label>
							<sec_title>Adult and adolescent ≥17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18306">
									<item>
										<label>•</label>
										<para> 150 mg at start of shift</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="70" status="active">
			<mono_name>asenapine (Rx)</mono_name>
			<info>
				<pronunciation>(a-sen′a-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x183150">Saphris</tradename>
				</tradenames>
				<class type="func"> Antipsychotic, atypical</class>
				<class type="chem"> Dibenzapine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x18325">
				<sec_title>Action:</sec_title>
				<para>Unknown; may be mediated through both DOPamine type 2 (D2) and serotonin type 2 (5-HT2A) antagonism</para>
			</section>
			<section type="uses" id="sidelem4x18330">
				<sec_title>Uses:</sec_title>
				<para>Bipolar 1 disorder, schizophrenia</para>
				<section type="none" id="sidelem4x18335">
					<section type="none" id="sidelem4x18336">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Agitation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x18341">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x18346">
					<section type="none" id="sidelem4x18347">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, geriatric patients, cardiac/renal/hepatic disease, breast cancer, Parkinson’s disease, dementia, seizure disorder, CNS depression, agranulocytosis, QT prolongation, torsades de pointes, suicidal ideation, substance abuse, diabetes mellitus</para>
						<para>
							<bbw>Increased mortality in elderly patients with dementia-related psychosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18362">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18365">
					<section type="none" id="sidelem4x18366">
						<sec_title>Schizophrenia</sec_title>
						<section type="none" id="sidelem4x18374">
							<label>•</label>
							<sec_title>Adult<route> SL</route></sec_title>
							<para>
								<list id="lidelem4x18374">
									<item>
										<label>•</label>
										<para> 5 mg bid, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18378">
						<sec_title>Bipolar 1 disorder</sec_title>
						<section type="none" id="sidelem4x18386">
							<label>•</label>
							<sec_title>Adult<route> SL</route></sec_title>
							<para>
								<list id="lidelem4x18386">
									<item>
										<label>•</label>
										<para> 10 mg bid, may decrease to 5 mg bid as needed, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18390">
						<sec_title>Available forms:</sec_title>
						<para> SL tab 2.5, 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x18395">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18400">
								<item>
									<label>•</label>
									<para>Anticholinergic agent to be used for EPS</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18405">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18413">
							<label>•</label>
							<sec_title>SL tab</sec_title>
							<para>
								<list id="lidelem4x18413">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">SL tab:</emphasis> remove tab; place tab under tongue; after it dissolves, swallow; advise patient not to chew, crush, swallow tabs, not to eat, drink for 10 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18419">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18422">
					<section type="none" id="sidelem4x18423">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">EPS, pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia; drowsiness, insomnia, agitation, anxiety, headache,</emphasis><emphasis style="bold">seizures, neuroleptic malignant syndrome, dizziness, suicidal ideation, drowsiness, depression</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18432">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, <emphasis style="bold">sinus tachycardia; heart failure, QT prolongation, stroke, bundle branch block</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18439">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia, hyperlipidemia</para>
					</section>
					<section type="none" id="sidelem4x18444">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, <emphasis style="italic">constipation,</emphasis> weight gain, increased appetite; oral hypoesthesia/parasthesia, mucosal ulcers, increased salivation (SL)</para>
					</section>
					<section type="none" id="sidelem4x18455">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, agranulocytosis,</emphasis> anemia, leukopenia</para>
					</section>
					<section type="none" id="sidelem4x18463">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Serious allergic reactions (anaphylaxis, angioedema)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18470">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Extensively metabolized by liver, protein binding 95%, peak 0.5-1.5 hr, terminal half-life 24 hr</para>
			</section>
			<section type="interactions" id="sidelem4x18475">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—other CNS depressants, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> EPS—CYP2D6 inhibitors/substrates (SSRIs)</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Seizure risk—buPROPion</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> EPS—other antipsychotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> asenapine excretion—carBAMazepine</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, methadone, chloroquine, clarithromycin, droperidol, erythromycin, pentamidine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> asenapine action—CYP2D6 inducers (carBAMazepine, barbiturates, phenytoins, rifampin)</para>
				<section type="none" id="sidelem4x18508">
					<section type="none" id="sidelem4x18509">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> EPS—betel palm, kava</para>
					</section>
					<section type="none" id="sidelem4x18520">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> prolactin levels, glucose LFTs, cholesterol, LFTs, lipids, triglycerides</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18531">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18534">
					<section type="none" id="sidelem4x18535">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status before initial administration; watch for suicidal thoughts and behaviors; dementia and death may occur among elderly patients</bbw>
						</para>
						<para>
							<list id="lidelem4x18550">
								<item>
									<label>•</label>
									<para>Affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18555">
								<item>
									<label>•</label>
									<para>B/P standing and lying; also pulse, respirations; take these q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; watch for ECG changes; QT prolongation may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18560">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18568">
							<label>•</label>
							<sec_title>
								<route>EPS,</route>
							</sec_title>
							<para>
								<list id="lidelem4x18568">
									<item>
										<label>•</label>
										<para> including akathisia, tardive dyskinesia (bizarre movements of the jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18575">
							<label>•</label>
							<sec_title>Neuroleptic malignant syndrome<route> hyperthermia, increased CPK, altered mental status, muscle rigidity</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x18578">
								<item>
									<label>•</label>
									<para>Constipation daily; increase bulk, water in diet if needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18583">
								<item>
									<label>•</label>
									<para>Weight, thyroid function studies, serum prolactin, lipid profile, serum electrolytes, creatinine, pregnancy test, neurologic function, LFTs, glycosylated hemoglobin A1c, CBC, blood glucose, AIMS assessment baseline and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18588">
								<item>
									<label>•</label>
									<para>Supervised ambulation until patient stabilized on medication; do not involve patient in strenuous exercise program because fainting is possible; patient should not stand still for a long time</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18593">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18597">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18604">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18608">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension may occur; to rise from sitting or lying position gradually</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hot tubs, hot showers, tub baths; hypotension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid abrupt withdrawal of this product; EPS may result; product should be withdrawn slowly</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber; serious product interactions may occur; to avoid use of alcohol; increased drowsiness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsy, dizzy</para>
								</item>
								<item>
									<label>•</label>
									<para>About compliance with product regimen</para>
								</item>
								<item>
									<label>•</label>
									<para>That heat stroke may occur in hot weather; to take extra precautions to stay cool</para>
								</item>
								<item>
									<label>•</label>
									<para>To use contraception; to inform prescriber if pregnancy is planned, suspected
<bbw>To report suicidal thoughts/behaviors, dementia immediately</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x18658">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if orally ingested; provide airway; <emphasis style="italic">do not induce vomiting</emphasis></para>
			</section>
		</monograph>
<monograph id="71" status="active" ru="yes">
			<mono_name>asparaginase Erwinia chrysanthemi</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x186730">Erwinaze</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, natural and semisynthetic</class>
			</info>
			<section type="uses" id="sidelem4x18679">
				<sec_title>Uses:</sec_title>
				<para>Treatment of acute lymphocytic leukemia (ALL) in combination with other chemotherapeutic agents in patients who have developed hypersensitivity to <emphasis style="italic">Escherichia coli</emphasis>–derived asparaginase</para>
			</section>
			<section type="contra" id="sidelem4x18687">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding, history of serious pancreatitis, bleeding, or serious thrombosis with prior <emphasis style="smallcaps">l</emphasis>-asparaginase therapy</para>
			</section>
			<section type="doses" id="sidelem4x18695">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18703">
					<label>•</label>
					<sec_title>Adult, adolescent, child ≥2 yr (substitute for pegaspargase)<route> IM</route></sec_title>
					<para>
						<list id="lidelem4x18703">
							<item>
								<label>•</label>
								<para> 25,000 IU/m<emphasis style="sup">2</emphasis> 3×/wk (Monday/Wednesday/Friday) × 6 doses for each planned dose of pegaspargase within a treatment</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18713">
					<label>•</label>
					<sec_title>
						<route>Adult (substitute for l-asparaginase E. coli</route>
					</sec_title>
					<para>
						<list id="lidelem4x18713">
							<item>
								<label>•</label>
								<para> 25,000 IU/m<emphasis style="sup">2</emphasis> for each scheduled dose of native <emphasis style="italic">E. coli</emphasis> asparaginase within a treatment</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18730">
					<section type="none" id="sidelem4x18731">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 10,000 units</para>
					</section>
					<section type="none" id="sidelem4x18736">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18740">
								<item>
									<label>•</label>
									<para>Slowly inject 1 or 2 ml of preservative-free sterile sodium chloride (0.9%) inj against inner vial wall; do not forcefully inject sol directly onto or into powder; if 1 ml of NS is used, concentrations is 10,000 IU/ml; if 2 ml of NS is used, concentrations is 5000 IU/ ml; dissolve contents by gentle mixing or swirling; do not shake or invert vial</para>
								</item>
								<item>
									<label>•</label>
									<para>Reconstituted sol should be clear and colorless; discard if any visible particles or protein aggregates are present</para>
								</item>
								<item>
									<label>•</label>
									<para>Calculate the volume needed to obtain dose; withdraw volume containing calculated dose from vial into polypropylene syringe within 15 min of reconstitution</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18756">
							<sec_title>IM route</sec_title>
							<para>Administer dose by IM inj within 4 hr of reconstitution; limit volume to 2 ml per inj site; multiple inj sites may be needed<list id="lidelem4x18761">
									<item>
										<label>•</label>
										<para>Do not freeze or refrigerate the reconstituted solution; discard any unused portions</para>
									</item>
								</list></para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="72" status="active">
			<mono_name>aspirin (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(as′pir-in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x1877624">
						<country code="CAN">APC-ASA Coated Aspirin </country>
					</tradename>
					<tradename id="tnidelem4x1877623">
						<country code="CAN">Apo-Asa </country>
					</tradename>
					<tradename id="tnidelem4x1877622">
						<country code="CAN">Asaphen </country>
					</tradename>
					<tradename id="tnidelem4x1877621">
						<country code="CAN">Asatab </country>
					</tradename>
					<tradename id="tnidelem4x1877620">A.S.A.</tradename>
					<tradename id="tnidelem4x1877619">Ascriptin Enteric</tradename>
					<tradename id="tnidelem4x1877618">Aspergum</tradename>
					<tradename id="tnidelem4x1877617">
						<country code="CAN">Aspirin </country>
					</tradename>
					<tradename id="tnidelem4x1877616">Aspir-Low</tradename>
					<tradename id="tnidelem4x1877615">
						<country code="CAN">Aspir-trin </country>
					</tradename>
					<tradename id="tnidelem4x1877614">Bayer Aspirin</tradename>
					<tradename id="tnidelem4x1877613">Bayer Children’s Aspirin</tradename>
					<tradename id="tnidelem4x1877612">Bufferin</tradename>
					<tradename id="tnidelem4x1877611">Ecotrin</tradename>
					<tradename id="tnidelem4x1877610">
						<country code="CAN">Entrophen </country>
					</tradename>
					<tradename id="tnidelem4x187769">Equaline</tradename>
					<tradename id="tnidelem4x187768">Good Sense Aspirin</tradename>
					<tradename id="tnidelem4x187767">Halfprin</tradename>
					<tradename id="tnidelem4x187766">
						<country code="CAN">Lowprin </country>
					</tradename>
					<tradename id="tnidelem4x187765">
						<country code="CAN">Novasen </country>
					</tradename>
					<tradename id="tnidelem4x187764">
						<country code="CAN">PMS-ASA </country>
					</tradename>
					<tradename id="tnidelem4x187763">
						<country code="CAN">Rivasa </country>
					</tradename>
					<tradename id="tnidelem4x187762">St. Joseph Children’s</tradename>
					<tradename id="tnidelem4x187761">St. Joseph’s Adult</tradename>
					<tradename id="tnidelem4x187760">Walgreens Aspirin Adult</tradename>
				</tradenames>
				<class type="func"> Nonopioid analgesic, nonsteroidal antiinflammatory, antipyretic, antiplatelet</class>
				<class type="chem"> Salicylate</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x18819">
				<para>
					<confusion>
						<tradename id="tnidelem4x188190">Aspirin/Ascendin</tradename>
						<drug type="generic" refid="idelem4x188190">Afrin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x18823">
				<sec_title>Action:</sec_title>
				<para>Blocks pain impulses by blocking COX-1 in CNS, reduces inflammation by inhibition of prostaglandin synthesis; antipyretic action results from vasodilation of peripheral vessels; decreases platelet aggregation</para>
			</section>
			<section type="uses" id="sidelem4x18828">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate pain or fever including RA, osteoarthritis, thromboembolic disorders; TIAs, rheumatic fever, post-MI, prophylaxis of MI, ischemic stroke, angina, acute MI</para>
				<section type="none" id="sidelem4x18833">
					<section type="none" id="sidelem4x18834">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Prevention of cataracts (long-term use), prevention of pregnancy loss in women with clotting disorders, bone pain, claudication, colorectal cancer prophylaxis, Kawasaki disease, PCI, preeclampsia/thrombosis prophylaxis, vernal keratoconjunctivitis, pericarditis, polycythemia vera</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x18839">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) 3rd trimester, breastfeeding, children &lt;12 yr, children with flulike symptoms, hypersensitivity to salicylates, tartrazine (FDC yellow dye #5), GI bleeding, bleeding disorders, vit K deficiency, peptic ulcer, acute bronchospasm, agranulocytosis, increased intracranial pressure, intracranial bleeding, nasal polyps, urticaria</para>
				<section type="none" id="sidelem4x18844">
					<section type="none" id="sidelem4x18845">
						<sec_title>Precautions:</sec_title>
						<para> Abrupt discontinuation, acetaminophen/NSAIDs hypersensitivity, acid/base imbalance, alcoholism, ascites, asthma, bone marrow suppression in elderly patients, dehydration, G6PD deficiency, gout, heart failure, anemia, renal/hepatic disease, pre/postoperatively, gastritis, pregnancy (C) 1st trimester</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18850">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18853">
					<section type="none" id="sidelem4x18854">
						<sec_title>Arthritis</sec_title>
						<section type="none" id="sidelem4x18862">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18862">
									<item>
										<label>•</label>
										<para> 3 g/day in divided doses q4-6hr, target salicylate level 150-300 mcg/ml</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18869">
							<label>•</label>
							<sec_title>Child<route> PO/RECT</route></sec_title>
							<para>
								<list id="lidelem4x18869">
									<item>
										<label>•</label>
										<para> 90-130 mg/kg/day in divided doses, target salicylate level 150-300 mcg/ml</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18873">
						<sec_title>Pain/fever</sec_title>
						<section type="none" id="sidelem4x18881">
							<label>•</label>
							<sec_title>Adult<route> PO/RECT</route></sec_title>
							<para>
								<list id="lidelem4x18881">
									<item>
										<label>•</label>
										<para> 325-1000 mg q4hr prn, max 4 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18888">
							<label>•</label>
							<sec_title>Child 2-11 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18888">
									<item>
										<label>•</label>
										<para> 10-15 mg/kg/dose q4hr, max 4 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18892">
						<sec_title>Thromboembolic disorders</sec_title>
						<section type="none" id="sidelem4x18900">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18900">
									<item>
										<label>•</label>
										<para> 325-650 mg/day or bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18904">
						<sec_title>Transient ischemic attacks (risk)</sec_title>
						<section type="none" id="sidelem4x18912">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18912">
									<item>
										<label>•</label>
										<para> 50-325 mg/day (grade 1A)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18916">
						<sec_title>Evolving MI with ST segment elevation (STEMI)</sec_title>
						<section type="none" id="sidelem4x18924">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18924">
									<item>
										<label>•</label>
										<para> 160-325 mg nonenteric, chewed and swallowed immediately, maintenance 75-162 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18928">
						<sec_title>MI, stroke prophylaxis</sec_title>
						<section type="none" id="sidelem4x18936">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18936">
									<item>
										<label>•</label>
										<para> 50-325 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18940">
						<sec_title>Prevention of recurrent MI</sec_title>
						<section type="none" id="sidelem4x18948">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18948">
									<item>
										<label>•</label>
										<para> 75-162 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18952">
						<sec_title>CABG</sec_title>
						<section type="none" id="sidelem4x18960">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18960">
									<item>
										<label>•</label>
										<para> 325 mg/day starting 6 hr postprocedure, continue for 1 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18964">
						<sec_title>PTCA</sec_title>
						<section type="none" id="sidelem4x18972">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18972">
									<item>
										<label>•</label>
										<para> 325 mg 2 hr before surgery, then 160-325 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18976">
						<sec_title>Polycythemia vera (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18984">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18984">
									<item>
										<label>•</label>
										<para> 75-100 mg/day during pregnancy and 6 wk after birth</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18989">
						<sec_title>Kawasaki disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18997">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18997">
									<item>
										<label>•</label>
										<para> 80-100 mg/kg/day in 4 divided doses, maintenance 3-5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19001">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 81, 325, 500, 650, 800 mg; chewable tabs 81 mg; supp 300, 600 mg; gum 227 mg; enteric-coated tabs 81, 325, 500, 975 mg; ext rel tabs 800 mg; del rel tabs 325, 500 mg; suppository 300, 600 mg</para>
					</section>
					<section type="none" id="sidelem4x19006">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x19009">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x19013">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew enteric product</para>
									</item>
									<item>
										<label>•</label>
										<para>Crushed or whole, chewable tablets may be chewed</para>
									</item>
									<item>
										<label>•</label>
										<para>
											<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr before planned exercise</para>
									</item>
									<item>
										<label>•</label>
										<para>With food or milk to decrease gastric symptoms; separate by 2 hr from enteric products</para>
									</item>
									<item>
										<label>•</label>
										<para>With 8 oz of water; sit upright for <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr after dose to facilitate product passing into stomach</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19050">
							<sec_title>Rectal route</sec_title>
							<para>
								<list id="lidelem4x19054">
									<item>
										<label>•</label>
										<para>Place suppository in refrigerator for at least 30 minutes before removing wrapper</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19060">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19063">
					<section type="none" id="sidelem4x19064">
						<sec_title>CNS:</sec_title>
						<para> Stimulation, drowsiness, dizziness, confusion, <emphasis style="bold">seizures,</emphasis> headache, flushing, hallucinations, <emphasis style="bold">coma, intracranial hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19074">
						<sec_title>CV:</sec_title>
						<para> Rapid pulse, pulmonary edema, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19081">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss</para>
					</section>
					<section type="none" id="sidelem4x19086">
						<sec_title>ENDO:</sec_title>
						<para> Hypoglycemia, hyponatremia, hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x19091">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis><emphasis style="bold">GI bleeding,</emphasis> diarrhea, heartburn, anorexia, <emphasis style="bold">hepatitis,</emphasis> GI ulcer</para>
					</section>
					<section type="none" id="sidelem4x19104">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, agranulocytosis, leukopenia, neutropenia, hemolytic anemia,</emphasis> increased PT, aPTT, bleeding time</para>
					</section>
					<section type="none" id="sidelem4x19112">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, bruising</para>
					</section>
					<section type="none" id="sidelem4x19120">
						<sec_title>RESP:</sec_title>
						<para> Wheezing, hyperpnea, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19127">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Reye’s syndrome (children), anaphylaxis, laryngeal edema, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19134">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Enteric metabolized by liver; inactive metabolites excreted by kidneys; crosses placenta; excreted in breast milk; half-life 15-20 min, up to 9 hr in large dose; rectal products may be erratic, protein binding 90%</para>
				<section type="none" id="sidelem4x19139">
					<section type="none" id="sidelem4x19140">
						<sec_title>PO:</sec_title>
						<para> Onset 15-30 min, peak 1-2 hr, duration 4-6 hr, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x19145">
						<sec_title>PO:</sec_title>
						<para> Enteric coated: onset 10-30 min, duration 2-4 hr; Solution: onset 10-30 min, peak 15-30 min, duration 2-4 hr</para>
					</section>
					<section type="none" id="sidelem4x19150">
						<sec_title>RECT:</sec_title>
						<para> Onset slow, duration 4-6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x19155">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> gastric ulcer risk—corticosteroids, antiinflammatories, NSAIDs, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—alcohol, plicamycin, cefamandole, thrombolytics, ticlopidine, clopidogrel, tirofiban, eptifibatide, anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of insulin, methotrexate, thrombolytic agents, penicillins, phenytoin, valproic acid, oral hypoglycemics, sulfonamides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> salicylate levels—urinary acidifiers, ammonium chloride, nizatidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—nitroglycerin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of aspirin—antacids (high doses), urinary alkalizers, corticosteroids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ACE inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of probenecid, spironolactone, sulfinpyrazone, sulfonylamides, NSAIDs, β-blockers, loop diuretics</para>
				<section type="none" id="sidelem4x19190">
					<section type="none" id="sidelem4x19191">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> risk of bleeding—feverfew, garlic, ginger, ginkgo, ginseng <emphasis style="italic">(Panax),</emphasis> horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x19201">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> risk of bleeding—fish oil (omega-3 fatty acids)<list id="lidelem4x19208">
								<item>
									<label>•</label>
									<para>Foods that acidify urine may increase aspirin level</para>
								</item>
							</list></para>
					</section>
					<section type="none" id="sidelem4x19214">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> coagulation studies, LFTs, serum uric acid, amylase, CO<emphasis style="inf">2</emphasis>, urinary protein</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> serum potassium, cholesterol</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> VMA, 5-HIAA, xylose tolerance test, TSH, pregnancy test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19233">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19236">
					<section type="none" id="sidelem4x19237">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x19245">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x19245">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> character, location, intensity; ROM before and 1 hr after administration</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19252">
							<label>•</label>
							<sec_title>Fever</sec_title>
							<para>
								<list id="lidelem4x19252">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Fever:</emphasis> temperature before and 1 hr after administration</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x19256">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, creatinine if patient is receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19261">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, urine creatinine; I&amp;O ratio; decreasing output may indicate renal failure (long-term therapy)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19266">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, Hct, Hgb, PT if patient is receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19272">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: dark urine, clay-colored stools, yellowing of skin, sclera, itching, abdominal pain, fever, diarrhea if patient is receiving long-term therapy</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19280">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x19280">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash, urticaria; if these occur, product may have to be discontinued; patients with asthma, nasal polyps, allergies: severe allergic reaction may occur</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19287">
							<label>•</label>
							<sec_title>Ototoxicity</sec_title>
							<para>
								<list id="lidelem4x19287">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ototoxicity:</emphasis> tinnitus, ringing, roaring in ears; audiometric testing needed before, after long-term therapy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19294">
							<label>•</label>
							<sec_title>Salicylate level</sec_title>
							<para>
								<list id="lidelem4x19294">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Salicylate level:</emphasis> therapeutic level 150-300 mcg/ml for chronic inflammation</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x19298">
								<item>
									<label>•</label>
									<para>Edema in feet, ankles, legs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19303">
								<item>
									<label>•</label>
									<para>Product history; many product interactions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19308">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19312">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, inflammation, fever</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19318">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x19326">
							<label>•</label>
							<sec_title>
								<route>To report any symptoms of hepatotoxicity, renal toxicity, visual changes, ototoxicity, allergic reactions, bleeding (long-term therapy)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x19332">
							<label>•</label>
							<sec_title>
								<route>To avoid if allergic to tartrazine</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x19338">
							<label>•</label>
							<sec_title>
								<route>Not to exceed recommended dosage; acute poisoning may result</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x19341">
								<item>
									<label>•</label>
									<para>To read labels on other OTC products because many contain aspirin, salicylates</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19346">
								<item>
									<label>•</label>
									<para>That the therapeutic response takes 2 wk (arthritis)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19351">
								<item>
									<label>•</label>
									<para>To report tinnitus, confusion, diarrhea, sweating, hyperventilation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19356">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion; GI bleeding may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19361">
								<item>
									<label>•</label>
									<para>That patients who have allergies, nasal polyps, asthma may develop allergic reactions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19366">
								<item>
									<label>•</label>
									<para>To discard tabs if vinegar-like smell is detected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19371">
								<item>
									<label>•</label>
									<para>That medication is not to be given to children or teens with flulike symptoms or chickenpox because Reye’s syndrome may develop</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19376">
								<item>
									<label>•</label>
									<para>To take with a full glass of water</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19384">
							<label>•</label>
							<sec_title>
								<route>Not to use during 3rd trimester of pregnancy (D)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x19387">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, activated charcoal, monitor electrolytes, VS</para>
			</section>
		</monograph>
<monograph id="73" status="active">
			<mono_name>atazanavir (Rx)</mono_name>
			<info>
				<pronunciation>(at-a-za-na′veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x193970">Reyataz</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x19407">
				<sec_title>Action:</sec_title>
				<para>Inhibits human immunodeficiency virus (HIV-1) protease, which prevents maturation of the infectious virus</para>
			</section>
			<section type="uses" id="sidelem4x19412">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 infection in combination with other antiretroviral agents</para>
			</section>
			<section type="contra" id="sidelem4x19417">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, Child-Pugh Class C</para>
				<section type="none" id="sidelem4x19422">
					<section type="none" id="sidelem4x19423">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, hepatic disease, alcoholism, drug resistance, AV block, diabetes, dialysis, elderly, females, hemophilia, hypercholesterolemia, immune reconstitution syndrome, lactic acidosis, pancreatitis, cholelithiasis, serious rash</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19428">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19431">
					<section type="none" id="sidelem4x19432">
						<sec_title>Antiretroviral-naive patients</sec_title>
						<section type="none" id="sidelem4x19440">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19440">
									<item>
										<label>•</label>
										<para> 400 mg/day (unable to take ritonavir); 300 mg with ritonavir 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19447">
							<label>•</label>
							<sec_title>Child ≥6 yr/adolescent ≥40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19447">
									<item>
										<label>•</label>
										<para> 300 mg with ritonavir 100 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19454">
							<label>•</label>
							<sec_title>Child ≥6 yr/adolescent 20 to &lt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19454">
									<item>
										<label>•</label>
										<para> 200 mg with ritonavir 100 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19462">
							<label>•</label>
							<sec_title>Child ≥6 yr/adolescent 15 to &lt;20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19462">
									<item>
										<label>•</label>
										<para> 150 mg with ritonavir 100 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19466">
						<sec_title>Antiretroviral-experienced patients</sec_title>
						<section type="none" id="sidelem4x19474">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19474">
									<item>
										<label>•</label>
										<para> 300 mg with ritonavir 100 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19481">
							<label>•</label>
							<sec_title>Pregnant adults/adolescents (2nd/3rd trimester) with H2 blocker or tenofovir<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19481">
									<item>
										<label>•</label>
										<para> 400 mg with ritonavir 100 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19488">
							<label>•</label>
							<sec_title>Child ≥6 yr/adolescent ≥40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19488">
									<item>
										<label>•</label>
										<para> 300 mg with ritonavir 100 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19495">
							<label>•</label>
							<sec_title>Child ≥6 yr/adolescent 20 to &lt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19495">
									<item>
										<label>•</label>
										<para> 200 mg with ritonavir 100 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19502">
							<label>•</label>
							<sec_title>Children and Adolescents ≥25 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19502">
									<item>
										<label>•</label>
										<para> (oral powder) 300 mg q24hr with ritonavir 100 mg q24hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19509">
							<label>•</label>
							<sec_title>Children 15 to 24 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19509">
									<item>
										<label>•</label>
										<para> (oral powder) 250 mg q24hr with ritonavir 80 mg q24hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19516">
							<label>•</label>
							<sec_title>Infants and Children ≥3 months and 5 to 14 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19516">
									<item>
										<label>•</label>
										<para> (Oral Powder) 200 mg q24hr with ritonavir 80 mg q24hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19520">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x19528">
							<label>•</label>
							<sec_title>Adult<route> PO Child-Pugh B</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x19531">
						<sec_title>Available forms:</sec_title>
						<para> Caps 100, 150, 200, 300 mg; oral powder 50 mg</para>
					</section>
					<section type="none" id="sidelem4x19536">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x19540">
								<item>
									<label>•</label>
									<para>With food; 2 hr before or 1 hr after antacid or didanosine; swallow cap whole, do not open</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19546">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19549">
					<section type="none" id="sidelem4x19550">
						<sec_title>CNS:</sec_title>
						<para> Headache, depression, dizziness, insomnia, peripheral neurologic symptoms</para>
					</section>
					<section type="none" id="sidelem4x19555">
						<sec_title>CV:</sec_title>
						<para> Increased PR interval</para>
					</section>
					<section type="none" id="sidelem4x19560">
						<sec_title>EENT:</sec_title>
						<para> Yellowing of sclera</para>
					</section>
					<section type="none" id="sidelem4x19565">
						<sec_title>GI:</sec_title>
						<para> Vomiting, <emphasis style="italic">diarrhea, abdominal pain, nausea,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> cholelithiasis</para>
					</section>
					<section type="none" id="sidelem4x19575">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">Stevens-Johnson syndrome,</emphasis><emphasis style="italic">photosensitivity,</emphasis><emphasis style="bold">DRESS</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19588">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, fever, arthralgia, back pain, cough, lipodystrophy, pain, gynecomastia, nephrolithiasis; <emphasis style="bold">lactic acidosis, hyperbilirubinemia (pregnancy, females, obesity)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19595">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, absorption increased with food, peak 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, 86% protein bound, extensively metabolized in liver by CYP3A4, 27% excreted unchanged in urine/feces (minimal), half-life 7 hr</para>
			</section>
			<section type="interactions" id="sidelem4x19606">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: levels, toxicity of immunosuppressants (cycloSPORINE, sirolimus, tacrolimus, sildenafil), tricylic antidepressants, warfarin, calcium channel blockers, clarithromycin, chlorazepate, diazepam, irinotecan, HMG-CoA reductase inhibitors, antidysrhythmics, midazolam, triazolam, ergots, pimozide, other protease inhibitors</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of estrogens, oral contraceptives (unboosted), decreased (boosted with ritonavir)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> atazanavir levels—CYP3A4 substrates, CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperbilirubinemia—indinavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> teleprevir level when used with atazanavir and ritonavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> atazanavir levels—CYP3A4 inducers, rifampin, antacids, didanosine, efavirenz, proton-pump inhibitors, H<emphasis style="inf">2</emphasis>-receptor antagonists</para>
				<section type="none" id="sidelem4x19637">
					<section type="none" id="sidelem4x19638">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> atazanavir levels—St. John’s wort, avoid concurrent use</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> myopathy, rhabdomyolysis—red yeast rice</para>
					</section>
					<section type="none" id="sidelem4x19649">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, total bilirubin, amylase, lipase, CK</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, neurophils, platelets</para>
					</section>
					<section type="none" id="sidelem4x19660">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x19664">
								<item>
									<label>•</label>
									<para>Increased drug bioavailability (to be taken with food)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19670">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19673">
					<section type="none" id="sidelem4x19674">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x19680">
								<item>
									<para>
										<emphasis alert="nurse">For hepatic failure; hepatic studies: ALT, AST, bilirubin</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19685">
								<item>
									<label>•</label>
									<para>Immune reconstitution syndrome: when given with combination antiretroviral therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19693">
							<label>•</label>
							<sec_title>
								<route>For lactic acidosis, hyperbilirubinemia (females, pregnancy, obesity), if pregnant call Antiretroviral Pregnancy Registry 800-258-4263</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x19696">
								<item>
									<label>•</label>
									<para>PR interval in those taking calcium channel blockers, digoxin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19701">
								<item>
									<label>•</label>
									<para>For signs of infection, anemia, nephrolithiasis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19706">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19713">
								<item>
									<label>•</label>
									<para>Viral load, CD4 count throughout treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19721">
							<label>•</label>
							<sec_title>Serious rash (Stevens-Johnson syndrome, DRESS)<route> most rashes last 1-4 wk; if serious, discontinue product</route></sec_title>
						</section>
						<section type="none" id="sidelem4x19727">
							<label>•</label>
							<sec_title>Immune reconstitution syndrome<route> time of onset is variable</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x19730">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19734">
								<item>
									<label>•</label>
									<para>Therapeutic response: increasing CD4 counts; decreased viral load, resolution of symptoms of HIV-1 infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19740">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19745">
								<item>
									<label>•</label>
									<para>To take as prescribed with other antiretrovirals as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose, share with others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19750">
								<item>
									<label>•</label>
									<para>That product must be taken daily to maintain blood levels for duration of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19755">
								<item>
									<label>•</label>
									<para>To report yellowing of skin, sclera</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19760">
								<item>
									<label>•</label>
									<para>To notify prescriber if diarrhea, nausea, vomiting, rash occurs; dizziness, lightheadedness may occur; ECG may be altered</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19765">
								<item>
									<label>•</label>
									<para>That product interacts with many products; St. John’s wort; to advise prescriber of all products, herbal products used</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19770">
								<item>
									<label>•</label>
									<para>That redistribution of body fat may occur, the effect is not known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19775">
								<item>
									<label>•</label>
									<para>That product does not cure HIV-1 infection, prevent transmission to others; only controls symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19783">
							<label>•</label>
							<sec_title>
								<route>That, if taking phosphodiesterase type 5 inhibitor with atazanavir, there may be increased risk of phosphodiesterase type 5 inhibitor–associated adverse events (hypotension, prolonged penile erection); to notify physician promptly of these symptoms</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="74" status="active">
			<mono_name>atenolol (Rx)</mono_name>
			<info>
				<pronunciation>(a-ten′oh-lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x197910">Tenormin</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, antianginal</class>
				<class type="chem"> β-Blocker, β-, β-blocker (high doses)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x19807">
				<para>
					<confusion>
						<tradename id="tnidelem4x198070">atenolol</tradename>
						<drug type="generic" refid="idelem4x198070">albuterol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x19814">
				<sec_title>Action:</sec_title>
				<para>Competitively blocks stimulation of β-adrenergic receptor within vascular smooth muscle; produces negative chronotropic activity (decreases rate of SA node discharge, increases recovery time), slows conduction of AV node, decreases heart rate, negative inotropic activity decreases O<emphasis style="inf">2</emphasis> consumption in myocardium; decreases action of renin-aldosterone-angiotensin system at high doses, inhibits β<emphasis style="inf">2</emphasis> receptors in bronchial system at higher doses</para>
			</section>
			<section type="uses" id="sidelem4x19825">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate hypertension, prophylaxis of angina pectoris; suspected or known MI (IV use); MI prophylaxis, atrial fibrillation/flutter</para>
				<section type="none" id="sidelem4x19830">
					<section type="none" id="sidelem4x19831">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Migraine prophylaxis, supraventricular tachycardia prophylaxis (PSVT), unstable angina, alcohol withdrawal, lithium-induced tremor</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x19836">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to β-blockers, cardiogenic shock, 2nd- or 3rd-degree heart block, sinus bradycardia, cardiac failure</para>
				<section type="none" id="sidelem4x19841">
					<section type="none" id="sidelem4x19842">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, major surgery, diabetes mellitus, thyroid/renal disease, CHF, COPD, asthma, well-compensated heart failure, dialysis, myasthenia gravis, Raynaud’s disease, pulmonary edema</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19857">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19865">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19865">
							<item>
								<label>•</label>
								<para> 25-50 mg/day, increasing q1-2wk to 100 mg/day; may increase to 200 mg/day for angina, up to 100 mg/day for hypertension</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19872">
					<label>•</label>
					<sec_title>Child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19872">
							<item>
								<label>•</label>
								<para> 0.8-1 mg/kg/dose initially; range, 0.8-1.5 mg/kg/day; max 2 mg/kg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19879">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19879">
							<item>
								<label>•</label>
								<para> 25 mg/day initially</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19884">
					<section type="none" id="sidelem4x19885">
						<sec_title>Chronic stable angina</sec_title>
						<section type="none" id="sidelem4x19893">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19893">
									<item>
										<label>•</label>
										<para> 50 mg/day, then 100 mg/day as needed after 7 days, max 200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19897">
						<sec_title>Post MI, MI prophylaxis</sec_title>
						<section type="none" id="sidelem4x19905">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19905">
									<item>
										<label>•</label>
										<para> 100 mg/day in 1-2 divided doses; may need for 1-3 yr after MI</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19909">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x19917">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19917">
									<item>
										<label>•</label>
										<para> CCr 15-35 ml/min, max 50 mg/day; CCr &lt;15 ml/min, max 25 mg/day; hemodialysis 25-50 mg after dialysis</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19921">
						<sec_title>PSVT prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19929">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19929">
									<item>
										<label>•</label>
										<para> 0.3-1.3 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19933">
						<sec_title>Ethanol withdrawal prevention (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19941">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19941">
									<item>
										<label>•</label>
										<para> 50-100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19945">
						<sec_title>Migraine prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19953">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19953">
									<item>
										<label>•</label>
										<para> 50-150 mg/day, titrate to response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19957">
						<sec_title>Lithium-induced tremor (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19965">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19965">
									<item>
										<label>•</label>
										<para> 50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19969">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x19974">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x19977">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x19981">
									<item>
										<label>•</label>
										<para>Before meals, at bedtime; tab may be crushed, swallowed whole, same time of day</para>
									</item>
									<item>
										<label>•</label>
										<para>Reduced dosage with renal dysfunction</para>
									</item>
									<item>
										<label>•</label>
										<para>Store protected from light, moisture; place in cool environment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19997">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20000">
					<section type="none" id="sidelem4x20001">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia, fatigue, dizziness, mental changes,</emphasis> memory loss, hallucinations, depression, lethargy, drowsiness, strange dreams, catatonia</para>
					</section>
					<section type="none" id="sidelem4x20009">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Profound hypotension, bradycardia, CHF,</emphasis><emphasis style="italic">cold extremities, postural hypotension, 2nd- or 3rd-degree heart block</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20018">
						<sec_title>ENDO:</sec_title>
						<para> Increased hypoglycemic response to insulin</para>
					</section>
					<section type="none" id="sidelem4x20023">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea,</emphasis> vomiting, <emphasis style="bold">mesenteric arterial thrombosis, ischemic colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20033">
						<sec_title>GU:</sec_title>
						<para> Impotence, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x20038">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia purpura</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20045">
						<sec_title>INTEG:</sec_title>
						<para> Rash, fever, alopecia</para>
					</section>
					<section type="none" id="sidelem4x20050">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea, wheezing, pulmonary edema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20058">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x20061">
					<section type="none" id="sidelem4x20062">
						<sec_title>PO:</sec_title>
						<para> Peak 2-4 hr; onset 1 hr; duration 24 hr; half-life 6-7 hr; excreted unchanged in urine, feces (50%); protein binding 5%-15%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x20067">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x20071">
						<item>
							<label>•</label>
							<para>Mutual inhibition: sympathomimetics (cough, cold preparations)</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension, bradycardia—reserpine, hydrALAZINE, methyldopa, prazosin, anticholinergics, digoxin, diltiazem, verapamil, cardiac glycosides, antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—insulins, oral antidiabetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypertension—amphetamines, ePHEDrine, pseudoephedrine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect—insulin, oral antidiabetic agents, theophylline, DOPamine, MAOIs</para>
				<section type="none" id="sidelem4x20093">
					<section type="none" id="sidelem4x20094">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> atenolol effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> atenolol effect—ephedra (ma huang)</para>
					</section>
					<section type="none" id="sidelem4x20105">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, potassium, triglycerides, uric acid, ANA titer, platelets alkaline phosphatase, creatinine, LDH, AST/ALT</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x20116">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20119">
					<section type="none" id="sidelem4x20120">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x20125">
								<item>
									<label>•</label>
									<para>I&amp;O, weight daily; watch for CHF (rales/crackles, jugular vein distention, weight gain, edema)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20133">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x20133">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, pulse q4hr; note rate, rhythm, quality; apical/radial pulse before administration; notify prescriber of any significant changes (&lt;50 bpm); ECG</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20140">
							<label>•</label>
							<sec_title>Hypotension</sec_title>
							<para>
								<list id="lidelem4x20140">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypotension:</emphasis> may be caused in hemodialysis</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20147">
							<label>•</label>
							<sec_title>Hypoglycemia</sec_title>
							<para>
								<list id="lidelem4x20147">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoglycemia:</emphasis> may be masked in diabetes mellitus</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x20151">
								<item>
									<label>•</label>
									<para>Baselines in renal/hepatic studies before therapy begins
<bbw>Taper gradually, do not discontinue abruptly, may precipitate angina, MI</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20165">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20169">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P after 1-2 wk, increased activity tolerance, decreased anginal pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20176">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Not to discontinue product abruptly, taper over 2 wk (angina); to take at same time each day as directed</bbw>
						</para>
						<para>
							<list id="lidelem4x20190">
								<item>
									<label>•</label>
									<para>Not to use OTC products unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20195">
								<item>
									<label>•</label>
									<para>To report bradycardia, dizziness, confusion, depression, fever</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20200">
								<item>
									<label>•</label>
									<para>To take pulse at home; advise when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20205">
								<item>
									<label>•</label>
									<para>To limit alcohol, smoking, sodium intake</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20210">
								<item>
									<label>•</label>
									<para>To comply with weight control, dietary adjustments, modified exercise program</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20215">
								<item>
									<label>•</label>
									<para>To carry emergency ID to identify product, allergies, conditions being treated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20220">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness is present</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20225">
								<item>
									<label>•</label>
									<para>To change position slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20230">
								<item>
									<label>•</label>
									<para>That product may mask symptoms of hypoglycemia in diabetic patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20238">
							<label>•</label>
							<sec_title>
								<route>To use contraception while taking this product, pregnancy (D); to avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x20241">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, IV atropine for bradycardia, IV theophylline for bronchospasm, dextrose for hypoglycemia, digoxin, O<emphasis style="inf">2</emphasis>, diuretic for cardiac failure, hemodialysis</para>
			</section>
		</monograph>
<monograph id="75" status="active">
			<mono_name>atomoxetine (Rx)</mono_name>
			<info>
				<pronunciation>(at-o-mox′eh-teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x202540">Strattera</tradename>
				</tradenames>
				<class type="func"> Psychotherapeutic—miscellaneous</class>
				<class type="chem"> Selective norepinephrine reuptake inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x20264">
				<sec_title>Action:</sec_title>
				<para>Selective norepinephrine reuptake inhibitor; may inhibit the presynaptic norepinephrine transporter</para>
			</section>
			<section type="uses" id="sidelem4x20269">
				<sec_title>Uses:</sec_title>
				<para>Attention deficit hyperactivity disorder</para>
			</section>
			<section type="contra" id="sidelem4x20274">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, closed-angle glaucoma, MAOI therapy, history of pleochromocytoma</para>
				<section type="none" id="sidelem4x20279">
					<section type="none" id="sidelem4x20280">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, hepatic disease, angioedema, bipolar disorder, dysrhythmias, CAD, hypo/hypertension, arteriosclerosis, cardiac disease, cardiomyopathy, heart failure, jaundice</para>
						<para>
							<bbw>Children &lt;6 yr, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20295">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20303">
					<label>•</label>
					<sec_title>Child ≤70 kg &gt;6 yrs<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x20303">
							<item>
								<label>•</label>
								<para> 0.5 mg/kg/day, increase after 3 days to target daily dose of 1.2 mg/kg in <emphasis style="smallcaps">am</emphasis> or evenly divided doses <emphasis style="smallcaps">am</emphasis>, late afternoon; max 1.4 mg/kg/day or 100 mg/day, whichever is less</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x20316">
					<label>•</label>
					<sec_title>Adult and child &gt;70 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x20316">
							<item>
								<label>•</label>
								<para> 40 mg/day, increase after 3 days to target daily dose of 80 mg in <emphasis style="smallcaps">am</emphasis> or evenly divided doses <emphasis style="smallcaps">am</emphasis>, late afternoon; max 100 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x20326">
					<section type="none" id="sidelem4x20327">
						<sec_title>Maintenance</sec_title>
						<section type="none" id="sidelem4x20335">
							<label>•</label>
							<sec_title>Adolescent ≤15 yr and child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20335">
									<item>
										<label>•</label>
										<para> 1.2-1.8 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20339">
						<sec_title>Initial dose titration with strong CYP2D6 inhibitors</sec_title>
						<section type="none" id="sidelem4x20347">
							<label>•</label>
							<sec_title>Adult and child &gt;6 yr weighing &gt;70 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20347">
									<item>
										<label>•</label>
										<para> 40 mg/day each <emphasis style="smallcaps">am</emphasis> or 2 evenly divided doses, titrate to target of 80 mg/day if symptoms do not improve after 4 wk and dose is well tolerated</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20354">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x20362">
							<label>•</label>
							<sec_title>Child-Pugh B<route> reduce dose by 50%; Child-Pugh C</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x20365">
						<sec_title>Available forms:</sec_title>
						<para> Caps 10, 18, 25, 40, 60, 80, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x20370">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x20374">
								<item>
									<label>•</label>
									<para>Whole; do not break, crush, chew</para>
								</item>
								<item>
									<label>•</label>
									<para>Gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20390">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20393">
					<section type="none" id="sidelem4x20394">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia,</emphasis> dizziness, headache, irritability, crying, mood swings, fatigue, hypoesthesia, lethargy, paresthesia</para>
					</section>
					<section type="none" id="sidelem4x20402">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations,</emphasis> hot flushes, tachycardia, increased B/P, palpitations</para>
					</section>
					<section type="none" id="sidelem4x20411">
						<sec_title>ENDO:</sec_title>
						<para> Growth retardation</para>
					</section>
					<section type="none" id="sidelem4x20416">
						<sec_title>GI:</sec_title>
						<para> Dyspepsia, nausea, anorexia, dry mouth, weight loss, vomiting, diarrhea, constipation, <emphasis style="bold">hepatic injury</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20423">
						<sec_title>GU:</sec_title>
						<para> Urinary hesitancy, retention, dysmenorrhea, erectile disturbance, ejaculation failure, impotence, prostatitis, abnormal orgasm, male pelvic pain</para>
					</section>
					<section type="none" id="sidelem4x20428">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Exfoliative dermatitis,</emphasis> sweating, rash</para>
					</section>
					<section type="none" id="sidelem4x20436">
						<sec_title>MISC:</sec_title>
						<para> Cough, rhinorrhea, dermatitis, ear infection, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20443">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr, metabolized by liver, excreted by kidneys, 98% protein binding, half-life 5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x20448">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: hypertensive crisis—MAOIs or within 14 days of MAOIs, vasopressors</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: cardiovascular effects of albuterol, pressor agents</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation, torsade de pointes dofetilide, grepafloxacin, mesoridazine, pimozide, probucol, sparfloxacin, ziprasidone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of atomoxetine—CYP2D6 inhibitors (amiodarone, cimetidine [weak], clomipramine, delavirdine, gefitinib, imatinib, propafenone, quiNIDine [potent], ritonavir, citalopram, escitalopram, FLUoxetine, sertraline, PARoxetine, thioridazine, venlafaxine)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P pressor agents</para>
			</section>
			<section type="considerations" id="sidelem4x20468">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20471">
					<section type="none" id="sidelem4x20472">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x20477">
								<item>
									<label>•</label>
									<para>VS, B/P; check patients with cardiac disease more often for increased B/P</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20485">
							<label>•</label>
							<sec_title>Hepatic injury<route> may cause liver failure</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x20489">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, stimulation, insomnia, aggressiveness, suicidal ideation in children/young adults</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20494">
								<item>
									<label>•</label>
									<para>Appetite, sleep, speech patterns</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20499">
								<item>
									<label>•</label>
									<para>For increased attention span, decreased hyperactivity with ADHD, growth rate, weight, therapy may need to be discontinued</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20504">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20508">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased hyperactivity (ADHD)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20514">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x20518">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations, other medication, herbs, supplements unless approved by prescriber, no tapering needed when discontinuing product</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication</para>
								</item>
								<item>
									<label>•</label>
									<para>To get needed rest; patients will feel more tired at end of day; not to take dose late in day, insomnia may occur
<bbw>To report suicidal ideation</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber immediately if erection &gt;4 hr</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="76" status="active">
			<mono_name>atorvastatin (Rx)</mono_name>
			<info>
				<pronunciation>(a-tore′va-stat-in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x205580">Lipitor</tradename>
				</tradenames>
				<class type="func"> Antilipidemic</class>
				<class type="chem"> HMG-CoA reductase inhibitor (statin)</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x20568">
				<para>
					<confusion>
						<tradename id="tnidelem4x205680">Lipitor</tradename>
						<drug type="generic" refid="idelem4x205680">Levatol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x20572">
				<sec_title>Action:</sec_title>
				<para>Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis; high doses lead to plaque regression</para>
			</section>
			<section type="uses" id="sidelem4x20577">
				<sec_title>Uses:</sec_title>
				<para>As adjunct for primary hypercholesterolemia (types Ia, Ib), dysbetalipoproteinemia, elevated triglyceride levels, prevention of CV disease by reduction of heart risk in those with mildly elevated cholesterol</para>
			</section>
			<section type="contra" id="sidelem4x20582">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, active hepatic disease</para>
				<section type="none" id="sidelem4x20587">
					<section type="none" id="sidelem4x20588">
						<sec_title>Precautions:</sec_title>
						<para> Previous hepatic disease, alcoholism, severe acute infections, trauma, severe metabolic disorders, electrolyte imbalance</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20594">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20602">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x20602">
							<item>
								<label>•</label>
								<para> 10-20 mg/day, usual range 10-80 mg/day, dosage adjustments may be made in 2- to 4-wk intervals, max 80 mg/day; patients who require &gt;45% reduction in LDL may be started at 40 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x20606">
					<section type="none" id="sidelem4x20607">
						<sec_title>Heterozygous familial hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x20615">
							<label>•</label>
							<sec_title>Child 10-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20615">
									<item>
										<label>•</label>
										<para> 10 mg daily, adjust q4wk, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20619">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20, 40, 80 mg</para>
					</section>
					<section type="none" id="sidelem4x20624">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x20628">
								<item>
									<label>•</label>
									<para>Total daily dose at any time of day without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment in tight container protected from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20639">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20642">
					<section type="none" id="sidelem4x20643">
						<sec_title>CNS:</sec_title>
						<para> Headache, asthenia, insomnia</para>
					</section>
					<section type="none" id="sidelem4x20648">
						<sec_title>EENT:</sec_title>
						<para> Lens opacities</para>
					</section>
					<section type="none" id="sidelem4x20653">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal cramps, constipation, diarrhea, flatus, heartburn,</emphasis> dyspepsia, <emphasis style="bold">liver dysfunction, pancreatitis,</emphasis> nausea, increased serum transaminase</para>
					</section>
					<section type="none" id="sidelem4x20664">
						<sec_title>GU:</sec_title>
						<para> Impotence</para>
					</section>
					<section type="none" id="sidelem4x20669">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, alopecia; photosensitivity (rare)</para>
					</section>
					<section type="none" id="sidelem4x20674">
						<sec_title>MISC:</sec_title>
						<para> Hypersensitivity; gynecomastia (child)</para>
					</section>
					<section type="none" id="sidelem4x20679">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia, <emphasis style="bold">rhabdomyolysis,</emphasis> myositis</para>
					</section>
					<section type="none" id="sidelem4x20687">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, sinusitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20692">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr, metabolized in liver, highly protein-bound, excreted primarily in urine, half-life 14 hr, protein binding 98%</para>
			</section>
			<section type="interactions" id="sidelem4x20697">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: rhabdomyolysis—azole antifungals, cycloSPORINE, erythromycin, niacin, gemfibrozil, clofibrate</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum level of digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of oral contraceptives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of atorvastatin, myopathy—CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> atorvastatin levels—colestipol</para>
				<section type="none" id="sidelem4x20723">
					<section type="none" id="sidelem4x20724">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x20731">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x20735">
								<item>
									<label>•</label>
									<para>Possible toxicity when used with grapefruit juice; oat bran may reduce effectiveness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20741">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, CK</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> thyroid function tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x20752">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20755">
					<section type="none" id="sidelem4x20756">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x20764">
							<label>•</label>
							<sec_title>Hypercholesterolemia</sec_title>
							<para>
								<list id="lidelem4x20764">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercholesterolemia:</emphasis> diet, obtain diet history including fat, cholesterol in diet; cholesterol triglyceride levels periodically during treatment; check lipid panel 6-12 wk after changing dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x20768">
								<item>
									<label>•</label>
									<para>Hepatic studies q1-2mo, at initiation, 6, 12 wk after initiation or change in dose, periodically thereafter; AST, ALT, LFTs may be increased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20773">
								<item>
									<label>•</label>
									<para>Renal studies in patients with compromised renal system: BUN, I&amp;O ratio, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20778">
								<item>
									<label>•</label>
									<para>Bowel status: constipation, stool softeners may be needed; if severe, add fiber, water to diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20784">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: for muscle pain, tenderness, obtain CPK baseline; if markedly increased, product may need to be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20789">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20793">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in LDL, total cholesterol, triglycerides, CAD; increase in HDL</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20799">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x20804">
								<item>
									<label>•</label>
									<para>That blood work and eye exam will be necessary during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20809">
								<item>
									<label>•</label>
									<para>To report blurred vision, severe GI symptoms, headache, muscle pain, weakness, avoid alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20814">
								<item>
									<label>•</label>
									<para>That previously prescribed regimen will continue: low-cholesterol diet, exercise program, smoking cessation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20822">
							<label>•</label>
							<sec_title>
								<route>Not to take product if pregnant (X), breastfeeding; to avoid alcohol</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x20825">
								<item>
									<label>•</label>
									<para>To stay out of the sun; to use sunscreen, protective clothing to prevent photosensitivity (rare)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="77" status="active">
			<mono_name>atovaquone (Rx)</mono_name>
			<info>
				<pronunciation>(a-toe′va-kwon)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x208360">Mepron</tradename>
				</tradenames>
				<class type="func"> Antiprotozoal</class>
				<class type="chem"> Analog of ubiquinone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x20846">
				<sec_title>Action:</sec_title>
				<para>Interferes with DNA/RNA synthesis in protozoa</para>
			</section>
			<section type="uses" id="sidelem4x20851">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="italic">Pneumocystis jiroveci</emphasis> infections in patients intolerant of trimethoprim-sulfamethoxazole, prophylaxis, <emphasis style="italic">Toxoplasma gondii,</emphasis> toxoplasmosis</para>
				<section type="none" id="sidelem4x20861">
					<section type="none" id="sidelem4x20862">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Babesiosis, malaria treatment/prophylaxis, toxoplasmosis prophylaxis, <emphasis style="italic">Plasmodium</emphasis> sp.</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x20870">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity or history of developing life-threatening allergic reactions to any component of the formulation, benzyl alcohol sensitivity</para>
				<section type="none" id="sidelem4x20875">
					<section type="none" id="sidelem4x20876">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, neonates, hepatic disease, GI disease, respiratory insufficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20881">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20884">
					<section type="none" id="sidelem4x20885">
						<sec_title>Acute, mild, moderate <emphasis style="bold">
								<emphasis style="italic">Pneumocystis jiroveci</emphasis>
							</emphasis> pneumonia</sec_title>
						<section type="none" id="sidelem4x20897">
							<label>•</label>
							<sec_title>Adult and adolescent 13-16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20897">
									<item>
										<label>•</label>
										<para> 750 mg with food bid for 21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20901">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Pneumocystis jiroveci</emphasis>
							</emphasis> pneumonia, prophylaxis</sec_title>
						<section type="none" id="sidelem4x20912">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20912">
									<item>
										<label>•</label>
										<para> 1500 mg/day with meal</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20916">
						<sec_title>Babesiosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20924">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20924">
									<item>
										<label>•</label>
										<para> 750 mg q12hr with azithromycin (1000 mg on day 1, then 250 mg/day × 7-14 days)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20928">
						<sec_title>Toxoplasmosis prophylaxis in AIDS (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20936">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20936">
									<item>
										<label>•</label>
										<para> 1500 mg alone or in combination</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20940">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Plasmodium falciparum</emphasis>
							</emphasis> (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20951">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20951">
									<item>
										<label>•</label>
										<para> 250 mg with proguanil daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20958">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20958">
									<item>
										<label>•</label>
										<para> 17 mg/kg with proguanil daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20962">
						<sec_title>Available forms:</sec_title>
						<para> Susp 750 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x20967">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x20971">
								<item>
									<label>•</label>
									<para>With high-fat food to increase absorption of product and higher plasma concentrations</para>
								</item>
								<item>
									<label>•</label>
									<para>Oral susp; shake before using</para>
								</item>
								<item>
									<label>•</label>
									<para>All contents of foil pouch</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20987">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20990">
					<section type="none" id="sidelem4x20991">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache, anxiety, insomnia,</emphasis> asthenia, fever</para>
					</section>
					<section type="none" id="sidelem4x20999">
						<sec_title>CV:</sec_title>
						<para> Hypotension</para>
					</section>
					<section type="none" id="sidelem4x21004">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea</emphasis>, anorexia, increased AST/ALT, <emphasis style="bold">acute pancreatitis,</emphasis> constipation, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x21015">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x21022">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, urticaria, <emphasis style="italic">rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x21029">
						<sec_title>META:</sec_title>
						<para> Hypoglycemia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x21034">
						<sec_title>OTHER:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x21039">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted unchanged in feces (94%), highly protein bound (99%), half-life 2-3 days</para>
			</section>
			<section type="interactions" id="sidelem4x21044">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> level of—zidovudine, monitor for toxicity</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of atovaquone—rifampin, rifabutin, tetracycline, avoid concurrent use</para>
				<section type="none" id="sidelem4x21055">
					<section type="none" id="sidelem4x21056">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> glucose, neutrophils, Hgb, sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x21067">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x21070">
					<section type="none" id="sidelem4x21071">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis style="bold">Infection:</emphasis> WBC, vital signs; sputum baseline, periodically; obtain specimens needed before giving 1st dose<list id="lidelem4x21078">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, dyspnea; risk for respiratory infection</para>
								</item>
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction to each medication</para>
								</item>
							</list></para>
					</section>
					<section type="none" id="sidelem4x21094">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x21098">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased temperature, ability to breathe</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21105">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x21109">
								<item>
									<label>•</label>
									<para>To take with food to increase plasma concentrations</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="78" status="active">
			<mono_name>atovaquone/proguanil</mono_name>
			<info>
				<pronunciation>(a-toe′va-kwon)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x211201">Malarone</tradename>
					<tradename id="tnidelem4x211200">Malarone Pediatric</tradename>
				</tradenames>
				<class type="func"> Antiprotozoal</class>
				<class type="chem"> Aromatic diamide derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x21130">
				<sec_title>Action:</sec_title>
				<para>The constituents of Malarone, atovaquone, and proguanil hydrochloride interfere with 2 different pathways involved in DNA/RNA synthesis in protozoa</para>
			</section>
			<section type="uses" id="sidelem4x21135">
				<sec_title>Uses:</sec_title>
				<para>Malaria, malaria prophylaxis</para>
			</section>
			<section type="contra" id="sidelem4x21140">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, malaria prophylaxis in patients with severe renal impairment</para>
				<section type="none" id="sidelem4x21145">
					<section type="none" id="sidelem4x21146">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, hepatic/GI/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x21151">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x21154">
					<section type="none" id="sidelem4x21155">
						<sec_title>Treatment of acute, uncomplicated <emphasis style="bold">
								<emphasis style="italic">P. falciparum</emphasis>
							</emphasis> malaria</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x21163">
						<sec_title>Malarone adult strength tabs</sec_title>
						<section type="none" id="sidelem4x21171">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21171">
									<item>
										<label>•</label>
										<para> 4 adult strength tabs every day as a single dose × 3 consecutive days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21178">
							<label>•</label>
							<sec_title>Child 31-40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21178">
									<item>
										<label>•</label>
										<para> 3 adult strength tabs every day as a single dose × 3 consecutive days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21185">
							<label>•</label>
							<sec_title>Child 21-30 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21185">
									<item>
										<label>•</label>
										<para> 2 adult strength tabs every day as a single dose × 3 consecutive days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21192">
							<label>•</label>
							<sec_title>Infant/child 11-20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21192">
									<item>
										<label>•</label>
										<para> 1 adult strength tab every day × 3 consecutive days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21196">
						<sec_title>Malarone Pediatric Tabs</sec_title>
						<section type="none" id="sidelem4x21204">
							<label>•</label>
							<sec_title>Infant/child 11-20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21204">
									<item>
										<label>•</label>
										<para> 4 pediatric tabs every day × 3 consecutive days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21211">
							<label>•</label>
							<sec_title>Infant/child 9-10 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21211">
									<item>
										<label>•</label>
										<para> 3 pediatric tabs every day × 3 consecutive days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21218">
							<label>•</label>
							<sec_title>Infant/child 5-8 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21218">
									<item>
										<label>•</label>
										<para> 2 pediatric tabs every day every 3 consecutive days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21222">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">P. falciparum</emphasis>
							</emphasis> malaria prophylaxis, including chloroquine resistance areas</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x21229">
						<sec_title>Malarone adult strength tabs</sec_title>
						<section type="none" id="sidelem4x21237">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21237">
									<item>
										<label>•</label>
										<para> 1 adult strength tab every day; begin prophylaxis 1-2 days before entering the endemic area; continue daily during the stay and for 7 days after leaving the area</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21241">
						<sec_title>Malarone Pediatric Tab</sec_title>
						<section type="none" id="sidelem4x21249">
							<label>•</label>
							<sec_title>Child 31-40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21249">
									<item>
										<label>•</label>
										<para> 3 pediatric tabs every day; begin prophylaxis 1-2 days before entering the endemic area; continue daily during the stay and for 7 days after leaving the area</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21256">
							<label>•</label>
							<sec_title>Child 21-30 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21256">
									<item>
										<label>•</label>
										<para> 2 pediatric tabs every day; begin prophylaxis 1-2 days before entering the endemic area; continue daily during the stay and for 7 days after leaving the area</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21263">
							<label>•</label>
							<sec_title>Infant/child 11-20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21263">
									<item>
										<label>•</label>
										<para> 1 pediatric tab every day; begin prophylaxis 1-2 days before entering the endemic area; continue daily during the stay and for 7 days after leaving the area</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21267">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x21275">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, do not use for prophylaxis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x21278">
						<sec_title>Available forms:</sec_title>
						<para> Tabs (adult) 250 mg atovaquone/proguanil 100 mg; tabs (pediatric) 62.5 atovaquone/proguanil 25 mg</para>
					</section>
					<section type="none" id="sidelem4x21283">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x21287">
								<item>
									<label>•</label>
									<para>Give with food or with milk or milk-based drink (nutritional supplement shake) to enhance oral absorption of atovaquone; food with high fat content is desired</para>
								</item>
								<item>
									<label>•</label>
									<para>Give dose at the same time each day; administer a repeat dose if vomiting occurs within 1 hr after dosing</para>
								</item>
								<item>
									<label>•</label>
									<para>Tabs may be crushed and mixed with condensed milk for children unable to swallow whole tablets</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x21303">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x21306">
					<section type="none" id="sidelem4x21307">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache, anxiety, insomnia,</emphasis> asthenia, fever</para>
					</section>
					<section type="none" id="sidelem4x21315">
						<sec_title>CV:</sec_title>
						<para> Hypotension</para>
					</section>
					<section type="none" id="sidelem4x21320">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> anorexia, increased AST/ALT, <emphasis style="bold">acute pancreatitis,</emphasis> constipation, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x21331">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, neutropenia</para>
					</section>
					<section type="none" id="sidelem4x21337">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, urticaria, <emphasis style="italic">rash</emphasis>, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x21345">
						<sec_title>META:</sec_title>
						<para> Hypoglycemia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x21350">
						<sec_title>OTHER:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x21355">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Atovaquone excreted unchanged in feces (94%), highly protein-bound (99%), proguanil 75% protein-bound, 40%-60% excreted in urine, hepatic metabolism; half-life 2-3 days</para>
			</section>
			<section type="interactions" id="sidelem4x21360">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> level of indinavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of atovaquone-rifampin, rifabutin, tetracycline, metoclopramide</para>
				<section type="none" id="sidelem4x21371">
					<section type="none" id="sidelem4x21372">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> glucose, neutrophils, Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x21383">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x21386">
					<section type="none" id="sidelem4x21387">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x21395">
							<label>•</label>
							<sec_title>Malaria</sec_title>
							<para>
								<list id="lidelem4x21395">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Malaria:</emphasis> identify when the patient will be entering an area with malaria</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x21399">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21404">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, dyspnea; risk for respiratory infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21409">
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction to each medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21414">
								<item>
									<label>•</label>
									<para>CBC, LFTs, serum amylase, creatinine/BUN, sodium; increases in LFTs can persist for 4 wk after discontinuation of treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21419">
						<sec_title>Evaluate:</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x21423">
						<sec_title>Therapeutic response:</sec_title>
						<para>
							<list id="lidelem4x21427">
								<item>
									<label>•</label>
									<para>Resolution/prevention of malaria</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21433">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x21437">
								<item>
									<label>•</label>
									<para>To take with food to increase plasma concentrations, at same time of day</para>
								</item>
								<item>
									<label>•</label>
									<para>To take whole course of treatment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="79" status="active" ru="yes">
			<mono_name>atracurium (Rx)</mono_name>
			<info>
				<pronunciation>(a-tra-kyoor′ee-um)</pronunciation>
				<class type="func"> Neuromuscular blocker (nondepolarizing)</class>
			</info>
			<section type="uses" id="sidelem4x21459">
				<sec_title>Uses:</sec_title>
				<para>Facilitation of endotracheal intubation, skeletal muscle relaxation during mechanical ventilation, surgery, or general anesthesia</para>
			</section>
			<section type="contra" id="sidelem4x21464">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Respiratory insufficiency</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x21479">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x21487">
					<label>•</label>
					<sec_title>Adult and child &gt;2 yr<route> IV BOL</route></sec_title>
					<para>
						<list id="lidelem4x21487">
							<item>
								<label>•</label>
								<para> 0.4-0.5 mg/kg, then 0.08-0.1 mg/kg 20-45 min after 1st dose if needed for prolonged procedures; give smaller doses with halothane</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x21494">
					<label>•</label>
					<sec_title>Child 1 mo-2 yr<route> IV BOL</route></sec_title>
					<para>
						<list id="lidelem4x21494">
							<item>
								<label>•</label>
								<para> 0.3-0.4 mg/kg</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="80" status="active" ha="yes">
			<mono_name>atropine (Rx)</mono_name>
			<info>
				<pronunciation>(a′troe-peen)</pronunciation>
				<class type="func"> Antidysrhythmic, anticholinergic parasympatholytic, antimuscarinic</class>
				<class type="chem"> Belladonna alkaloid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x21513">
				<para>
					<confusion>
						<tradename id="tnidelem4x215130">atropine</tradename>
						<drug type="generic" refid="idelem4x215130">Akarpine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x21517">
				<sec_title>Action:</sec_title>
				<para>Blocks acetylcholine at parasympathetic neuroeffector sites; increases cardiac output, heart rate by blocking vagal stimulation in heart; dries secretions by blocking vagus</para>
			</section>
			<section type="uses" id="sidelem4x21522">
				<sec_title>Uses:</sec_title>
				<para>Bradycardia &lt;40-50 bpm, bradydysrhythmia, reversal of anticholinesterase agents, insecticide poisoning, blocking cardiac vagal reflexes, decreasing secretions before surgery, antispasmodic with GU, biliary surgery, bronchodilator, AV heart block</para>
				<section type="none" id="sidelem4x21527">
					<section type="none" id="sidelem4x21528">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cardiac arrest, CPR, pulseless electrical activity, ventricular asystole, asthma, irinotecan-induced diarrhea, rapid-sequence intubation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x21534">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to belladonna alkaloids, closed-angle glaucoma, GI obstructions, myasthenia gravis, thyrotoxicosis, ulcerative colitis, prostatic hypertrophy, tachycardia/tachydysrhythmias, asthma, acute hemorrhage, severe hepatic disease, myocardial ischemia, paralytic ileus</para>
				<section type="none" id="sidelem4x21539">
					<section type="none" id="sidelem4x21540">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;6 yr, geriatric patients, renal disease, CHF, hyperthyroidism, COPD, hypertension, intraabdominal infection, Down syndrome, spastic paralysis, gastric ulcer</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x21545">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x21548">
					<section type="none" id="sidelem4x21549">
						<sec_title>Bradycardia/bradydysrhythmia</sec_title>
						<section type="none" id="sidelem4x21557">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x21557">
									<item>
										<label>•</label>
										<para> 0.5-1 mg given q3-5min, max 2 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21564">
							<label>•</label>
							<sec_title>Child<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x21564">
									<item>
										<label>•</label>
										<para> 0.02 mg/kg, may repeat ×1; min dose 0.1 mg to avoid paradoxical reaction, max single dose 0.5 mg, max total dose 1 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21568">
						<sec_title>Organophosphate poisoning</sec_title>
						<section type="none" id="sidelem4x21576">
							<label>•</label>
							<sec_title>Adult and child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x21576">
									<item>
										<label>•</label>
										<para> 1-2 mg q20-30min muscarinic symptoms disappear; may need 6 mg every hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21583">
							<label>•</label>
							<sec_title>Adult and child &gt;90 lb, usually &gt;10 yr<route> AtroPen</route></sec_title>
							<para>
								<list id="lidelem4x21583">
									<item>
										<label>•</label>
										<para> 2 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21590">
							<label>•</label>
							<sec_title>Child 40-90 lb, usually 4-10 yr<route> AtroPen</route></sec_title>
							<para>
								<list id="lidelem4x21590">
									<item>
										<label>•</label>
										<para> 1 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21597">
							<label>•</label>
							<sec_title>Child 15-40 lb<route> AtroPen</route></sec_title>
							<para>
								<list id="lidelem4x21597">
									<item>
										<label>•</label>
										<para> 0.5 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21604">
							<label>•</label>
							<sec_title>Infant &lt;15 lb<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x21604">
									<item>
										<label>•</label>
										<para> 0.05 mg/kg q5-20min as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21608">
						<sec_title>Presurgery</sec_title>
						<section type="none" id="sidelem4x21616">
							<label>•</label>
							<sec_title>Adult and child &gt;20 kg<route> SUBCUT/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x21616">
									<item>
										<label>•</label>
										<para> 0.4-0.6 mg 30-60 min before anesthesia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21623">
							<label>•</label>
							<sec_title>Child &lt;20 kg<route> IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x21623">
									<item>
										<label>•</label>
										<para> 0.01 mg/kg up to 0.4 mg <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr preop, max 0.6 mg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21633">
						<sec_title>Available forms:</sec_title>
						<para> Inj 0.05, 0.1, 0.4, 0.5, 0.8, 1 mg/ml; AtroPen 0.5, 1, 2 mg inj prefilled autoinjectors</para>
					</section>
					<section type="none" id="sidelem4x21638">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x21642">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21648">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x21652">
									<item>
										<label>•</label>
										<para>Atropine flush may occur in children and is not harmful</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21658">
							<sec_title>AtroPen</sec_title>
							<para>
								<list id="lidelem4x21662">
									<item>
										<label>•</label>
										<para>Use no more than 3 AtroPen inj unless under the supervision of trained medical provider</para>
									</item>
									<item>
										<label>•</label>
										<para>Use as soon as symptoms appear (tearing, wheezing, muscle fasciculations, excessive oral secretions), may use through clothing</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21673">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x21677">
									<item>
										<label>•</label>
										<para>Undiluted or diluted with 10 ml sterile water; give at 0.6 mg/min through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; do not add to IV sol; may cause paradoxical bradycardia for 2 min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amrinone, etomidate, famotidine, heparin, hydrocortisone, meropenem, nafcillin, potassium chloride, sufentanil, vit B/C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x21690">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x21693">
					<section type="none" id="sidelem4x21694">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, involuntary movement, confusion, psychosis, anxiety, <emphasis style="bold">coma,</emphasis> flushing, drowsiness, insomnia, weakness; delirium (geriatric patients)</para>
					</section>
					<section type="none" id="sidelem4x21702">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, paradoxical bradycardia, angina, PVCs, <emphasis style="bold">tachycardia,</emphasis> ectopic ventricular beats, <emphasis style="bold">bradycardia,</emphasis> palpitations</para>
					</section>
					<section type="none" id="sidelem4x21713">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, photophobia, glaucoma, eye pain, pupil dilation, nasal congestion, increased intraocular pressure</para>
					</section>
					<section type="none" id="sidelem4x21718">
						<sec_title>GI:</sec_title>
						<para> Dry mouth, nausea, vomiting, abdominal pain, anorexia, constipation, <emphasis style="bold">paralytic ileus,</emphasis> abdominal distention, altered taste</para>
					</section>
					<section type="none" id="sidelem4x21726">
						<sec_title>GU:</sec_title>
						<para> Retention, hesitancy, impotence, dysuria</para>
					</section>
					<section type="none" id="sidelem4x21731">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, contact dermatitis, dry skin, flushing</para>
					</section>
					<section type="none" id="sidelem4x21736">
						<sec_title>MISC:</sec_title>
						<para> Suppression of lactation, decreased sweating, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x21743">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 2-3 hr, terminal 12.5 hr, excreted by kidneys unchanged (70%-90% in 24 hr), metabolized in liver, 40%-50% crosses placenta, excreted in breast milk</para>
				<section type="none" id="sidelem4x21748">
					<section type="none" id="sidelem4x21749">
						<sec_title>IM/SUBCUT:</sec_title>
						<para> Onset 15-50 min, peak 30 min, duration 4-6 hr, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x21754">
						<sec_title>IV:</sec_title>
						<para> Peak 2-4 min, duration 4-6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x21759">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> mucosal lesions—potassium chloride tab</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effects—tricyclics, amantadine, antiparkinson agents</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—ketoconazole, levodopa</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of atropine—antacids</para>
			</section>
			<section type="considerations" id="sidelem4x21779">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x21782">
					<section type="none" id="sidelem4x21783">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x21788">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for urinary retention, daily output</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21796">
							<label>•</label>
							<sec_title>
								<route>ECG</route>
							</sec_title>
							<para>
								<list id="lidelem4x21796">
									<item>
										<label>•</label>
										<para> for ectopic ventricular beats, PVC, tachycardia in cardiac patients</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x21800">
								<item>
									<label>•</label>
									<para>For bowel sounds, constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21805">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, rhythm, cyanosis, wheezing, dyspnea, engorged neck veins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21813">
							<label>•</label>
							<sec_title>Increased intraocular pressure</sec_title>
							<para>
								<list id="lidelem4x21813">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Increased intraocular pressure:</emphasis> eye pain, nausea, vomiting, blurred vision, increased tearing</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x21817">
								<item>
									<label>•</label>
									<para>Cardiac rate: rhythm, character, B/P continuously</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21822">
								<item>
									<label>•</label>
									<para>Allergic reaction: rash, urticaria</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21827">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x21831">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased dysrhythmias, increased heart rate, secretions; GI, GU spasms; bronchodilation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21837">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x21841">
								<item>
									<label>•</label>
									<para>To report blurred vision, chest pain, allergic reactions, constipation, urinary retention, to use sunglasses to protect the eyes</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to perform strenuous activity in high temperatures; heat stroke may result</para>
								</item>
								<item>
									<label>•</label>
									<para>To take as prescribed; not to skip or double doses</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to operate machinery if drowsiness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to take OTC products without approval of prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to freeze or expose to light (AtroPen)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x21872">
				<sec_title>Treatment of overdose:</sec_title>
				<para>O<emphasis style="inf">2</emphasis>, artificial ventilation, ECG; administer DOPamine for circulatory depression; administer diazepam or thiopental for seizures; assess need for antidysrhythmics</para>
			</section>
		</monograph>
<monograph id="81" status="active">
			<mono_name>atropine ophthalmic</mono_name>
			<section type="none" id="sidelem4x21883">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="82" status="active">
			<mono_name>avanafil</mono_name>
			<info>
				<pronunciation>(a-van′a-fil)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x218920">Stendra</tradename>
				</tradenames>
				<class type="func"> Impotence agent</class>
				<class type="chem"> Phosphodiesterase type 5 inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x21902">
				<sec_title>Action:</sec_title>
				<para>Inhibits phosphodiesterase type 5 (PDE5); enhances erectile function by increasing the amount of cGMP causing smooth muscle relaxation and increasing blood flow to the corpus cavernosum</para>
			</section>
			<section type="uses" id="sidelem4x21907">
				<sec_title>Uses:</sec_title>
				<para>Treatment of erectile dysfunction</para>
			</section>
			<section type="contra" id="sidelem4x21912">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe renal/hepatic disease, current nitrates/nitrites, patients &lt;18 yr</para>
				<section type="none" id="sidelem4x21917">
					<section type="none" id="sidelem4x21918">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) although not indicated for women, anatomic penile deformities, sickle cell anemia, leukemia, multiple myeloma, renal/hepatic/CV disease, bleeding disorders, active peptic ulcer, prolonged erection, aortic stenosis, HIV, stroke, geriatric patients, tinnitus, MI, visual disturbances, retinitis pigmentosa</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x21923">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x21926">
					<section type="none" id="sidelem4x21927">
						<sec_title>Erectile dysfunction</sec_title>
						<section type="none" id="sidelem4x21935">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21935">
									<item>
										<label>•</label>
										<para> 100 mg 30 min before sexual activity, dose may be reduced to 50 mg or increased to 200 mg; usual max dose frequency is 1 time/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21939">
						<sec_title>Potent CYP3A4 inhibitors/nitrates</sec_title>
						<section type="none" id="sidelem4x21947">
							<label>•</label>
							<sec_title>
								<route>Do not use</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x21950">
						<sec_title>Moderate CYP3A4 inhibitors/α-blockers</sec_title>
						<section type="none" id="sidelem4x21958">
							<label>•</label>
							<sec_title>Adult<route> PO Max 50 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x21961">
						<sec_title>Hepatic dosage/severe renal disease</sec_title>
						<section type="none" id="sidelem4x21969">
							<label>•</label>
							<sec_title>Adult<route> Child-Pugh C</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x21972">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50, 100, 200 mg</para>
					</section>
					<section type="none" id="sidelem4x21978">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x21981">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x21985">
									<item>
										<label>•</label>
										<para>May be taken 30 min before sexual activity on an as-needed basis, but no more than once per day</para>
									</item>
									<item>
										<label>•</label>
										<para>May be used without regard to meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Products should not be used with nitrates or strong CYP3A4 inhibitors</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x22001">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x22004">
					<section type="none" id="sidelem4x22005">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, flushing</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22012">
						<sec_title>EENT:</sec_title>
						<para> Nasal congestion, nasopharyngitis, sudden hearing/vision loss</para>
					</section>
					<section type="none" id="sidelem4x22017">
						<sec_title>MISC:</sec_title>
						<para> Back pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x22022">
				<sec_title>Pharmacokinetics</sec_title>
				<para>99% protein binding, metabolized by CYP3A4, excreted as metabolites; urine 62%; 21% feces, half-life 5 hr, peak 30-45 min</para>
			</section>
			<section type="interactions" id="sidelem4x22027">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Do not use with nitrates/nitrites because of unsafe drop in B/P, which could result in MI, stroke</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Do not use with strong CYP3A4 inhibitors (ketoconazole, ritonavir, atazanavir, clarithromycin, indivinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, isoniazid, boceprevir, delavirdine, telaprevir, tipranavir)</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Avoid use with other phosphodiesterase type inhibitors (vardenafil, sildenafil, tadalafil)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Avanafil level—moderate CYP3A4 inhibitors (erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, verapamil, amiodarone, crizotinib, darunavir, dasantinib, dronedarone, imatinib, lapatinib, ticagrelor, voriconazole)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> B/P—alcohol, α-blockers, amLODIPine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Avanafil effect—grapefruit juice</para>
			</section>
			<section type="considerations" id="sidelem4x22051">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x22054">
					<section type="none" id="sidelem4x22055">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis style="bold">Erectile dysfunction:</emphasis> Assess for underlying cause before treatment; use of organic nitrates that should not be used with this product; any loss of vision/hearing while taking this product, hypersensitivity reactions</para>
					</section>
					<section type="none" id="sidelem4x22062">
						<sec_title>Evaluate:</sec_title>
						<para>
							<emphasis style="bold">Therapeutic response:</emphasis> Ability to engage in sexual intercourse</para>
					</section>
					<section type="none" id="sidelem4x22069">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x22074">
								<item>
									<label>•</label>
									<para>Sexual dysfunction: may be taken 30 min before sexual activity on an as-needed basis, but no more than once per day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22079">
								<item>
									<label>•</label>
									<para>May be used without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22085">
								<item>
									<para>
										<emphasis alert="nurse">That products should not be used with nitrates/nitrates, or strong CYP3A4 inhibitors</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22090">
								<item>
									<label>•</label>
									<para>That product does not protect against sexually transmitted disease including HIV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22095">
								<item>
									<label>•</label>
									<para>That product has no effect in the absence of sexual stimulation; to seek help if erection lasts &gt;4 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22100">
								<item>
									<label>•</label>
									<para>To tell prescriber about all medication, vitamins, herbs being taken, especially ritonavir, indinavir, ketoconazole, itraconazole, erythromycin, nitrates, α-blockers</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22105">
								<item>
									<label>•</label>
									<para>Not to drink large amounts of alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22111">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber immediately and to stop taking product if vision or hearing loss occurs, if erection lasts &gt;4 hr, or if chest pain occurs</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="83" status="active" ha="yes">
			<mono_name>axitinib</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x221210">Inlyta</tradename>
				</tradenames>
				<class type="func"> Antineoplastics, biologic response modifiers, signal transduction inhibitors (STIs)</class>
				<class type="chem"> Tyrosine kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x22131">
				<sec_title>Action:</sec_title>
				<para>Inhibits receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3; inhibits tumor growth and phosphorylation of VEGFR-2 and VEGF-mediated endothelial cell proliferation</para>
			</section>
			<section type="uses" id="sidelem4x22136">
				<sec_title>Uses:</sec_title>
				<para>Treatment of advanced renal cell cancer after failure of 1 prior systemic therapy</para>
			</section>
			<section type="contra" id="sidelem4x22141">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding</para>
				<section type="none" id="sidelem4x22147">
					<section type="none" id="sidelem4x22148">
						<sec_title>Precautions</sec_title>
						<para>Risk for or history of thromboembolic disease, recent bleeding, untreated brain metastasis, recent GI bleeding, GI perforation, fistula, surgery, moderate hepatic disease, uncontrolled hypertension, hyper/hypothyroidism, proteinuria, infertility, end-stage renal disease (CrCl &lt;15 ml/min); not intended for use in adolescents, children, infants, neonates</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x22153">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x22161">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x22161">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis> PO 5 mg bid (at 12-hr intervals), may increase to 7 mg bid and then to 10 mg bid in those not receiving antihypertensives who tolerate the lower dosage for at least 2 consecutive wk with no more than grade 2 adverse reactions; reduce to 3 mg bid if a dose reduction is needed; if further reduction is necessary, reduce to 2 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x22168">
					<label>•</label>
					<sec_title>Adult receiving a strong CYP3A4/5 inhibitor</sec_title>
					<para>
						<list id="lidelem4x22168">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult receiving a strong CYP3A4/5 inhibitor:</emphasis> Reduce dose by 1/2, adjust as needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x22172">
					<section type="none" id="sidelem4x22173">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 1, 5 mg</para>
					</section>
					<section type="none" id="sidelem4x22178">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x22182">
								<item>
									<label>•</label>
									<para>Give with or without food; swallow tablet whole with a glass of water</para>
								</item>
								<item>
									<label>•</label>
									<para>If patient vomits or misses a dose, an additional dose should not be taken; the next dose should be taken at the usual time</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x22198">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x22201">
					<section type="none" id="sidelem4x22202">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, <emphasis style="bold">reversible posterior leukoencephalopathy syndrome (RPLS),</emphasis> fatigue</para>
					</section>
					<section type="none" id="sidelem4x22210">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">arterial thromboembolic events (ATE), venous thromboembolic events (VTE)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22217">
						<sec_title>ENDO:</sec_title>
						<para> Hypothyroidism, hyperthyroidism</para>
					</section>
					<section type="none" id="sidelem4x22222">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Lower GI bleeding/perforation/fistula,</emphasis> abdominal pain, constipation, diarrhea, dysgeusia, dyspepsia, dysphonia, hemorrhoids, nausea, mucosal inflammation, stomatitis, vomiting, increased ALT/AST</para>
					</section>
					<section type="none" id="sidelem4x22230">
						<sec_title>GU:</sec_title>
						<para> Proteinuria</para>
					</section>
					<section type="none" id="sidelem4x22235">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bleeding, intracranial bleeding,</emphasis> anemia, polycythemia, decreased/increased hemoglobin, <emphasis style="bold">lymphopenia thrombocytopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22245">
						<sec_title>INTEG:</sec_title>
						<para> Palmar-plantar erythrodysesthesia (hand and foot syndrome) rash, dry skin, pruritus, alopecia, erythema</para>
					</section>
					<section type="none" id="sidelem4x22250">
						<sec_title>MISC:</sec_title>
						<para> Weight loss, dehydration, metabolic and electrolyte laboratory abnormalities</para>
					</section>
					<section type="none" id="sidelem4x22255">
						<sec_title>MS:</sec_title>
						<para> Asthenia, arthralgia, musculoskeletal pain, myalgia</para>
					</section>
					<section type="none" id="sidelem4x22260">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x22265">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption: bioavailability 58%; distribution: protein binding &gt;99%; metabolized in liver by CYP3A4/5, CYP1A2, CYP2C19, and UGT1A1; metabolites are carboxylic acid, sulfoxide, and <emphasis style="italic">N</emphasis>-glucuronide; excretion 41% in feces and 23% in urine, 12% unchanged; half-life: 2.5-6.1 hr; steady state 2-3 days; onset unknown, peak 2.5-4.1 hr, increased in moderate hepatic disease; duration unknown</para>
			</section>
			<section type="interactions" id="sidelem4x22273">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of axitinib—CYP3A4/5 inhibitor, strong, moderate (ketoconazole, boceprevir, chloramphenicol, conivaptan, delavirdine, fosamprenavir, imatinib, indinavir, isoniazid itraconazole, dalfopristin, quinupristin, posaconazole, ritonavir, telithromycin, tipranavir (boosted with ritonavir), darunavir (boosted with ritonavir), aldesleukin, IL-2, amiodarone, aprepitant, fosaprepitant atazanavir, bromocriptine, clarithromycin, crizotinib, danazol, diltiazem, dronedarone, erythromycin, fluvoxaMINE, lanreotide, lapatinib, miconazole, mifepristone, nefazodone, nelfinavir, niCARdipine, octreotide, pantoprazole, saquinavir, tamoxifen, verapamil, voriconazole, grapefruit juice)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of axitinib—CYP3A4/5 inducers, strong/moderate (rifampin, carBAMazepine, dexamethasone, phenytoin, PHENobarbital, rifabutin, rifapentine, St. John’s wort, ethanol, bexarotene, bosentan, efavirenz, etravirine, griseofulvin, metyrapone, modafinil, nafcillin, nevirapine, OXcarbazepine, vemurafenib, pioglitazone, topiramate)</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> effect of axitinib—CYP3A4/5 inhibitor and inducers (quiNINE)</para>
				<section type="none" id="sidelem4x22289">
					<section type="none" id="sidelem4x22290">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> creatinine, lipase, amylase, potassium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> bicarbonate, calcium, albumin, glucose, phosphate, sodium</para>
						<para>
							<emphasis style="bold">Increase or decrease:</emphasis> sodium, glucose</para>
					</section>
					<section type="none" id="sidelem4x22305">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> drug effect—grapefruit or grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x22312">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect of axitinib—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x22319">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x22322">
					<section type="none" id="sidelem4x22323">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x22331">
							<label>•</label>
							<sec_title>Bleeding<route> monitor for GI bleeding or perforation; temporarily discontinue therapy if a patient develops any bleeding that requires treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x22337">
							<label>•</label>
							<sec_title>Surgery<route> discontinue ≥24 hr before surgery; may be resumed after adequate wound healing</route></sec_title>
						</section>
						<section type="none" id="sidelem4x22343">
							<label>•</label>
							<sec_title>Hepatic/renal disease<route> dosage should be reduced in patients with moderate (Child-Pugh Class B) hepatic disease; monitor liver function tests (ALT, AST, bilirubin) before and periodically during therapy; monitor CCr before and during treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x22349">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x22349">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P should be well controlled before starting treatment; monitor patients for hypertension and administer antihypertensive therapy as needed before and during therapy; dose should be reduced for persistent hypertension; therapy should be discontinued if B/P remains elevated after a dosage reduction or if there is evidence of hypertensive crisis; after discontinuation monitor B/P for hypotension in those receiving antihypertensives</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x22356">
							<label>•</label>
							<sec_title>Hyper/hypothyroidism</sec_title>
							<para>
								<list id="lidelem4x22356">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyper/hypothyroidism:</emphasis> monitor thyroid function tests before and periodically during therapy; thyroid disease should be treated with thyroid medications</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x22360">
								<item>
									<label>•</label>
									<para>Monitor for proteinuria before and periodically during therapy; product may need to be decreased or discontinued if moderate to severe proteinuria occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22366">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy/breastfeeding: pregnancy (D); determine if the patient is pregnant or breastfeeding before using this product; may also cause infertility</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22371">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x22375">
								<item>
									<label>•</label>
									<para>Decreased spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22381">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x22387">
								<item>
									<para>
										<emphasis alert="nurse">To use contraception during treatment (pregnancy [D]) or to avoid use of this product; to notify prescriber if pregnancy is planned or suspected, not to breastfeed</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22393">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber of bleeding that is severe or that requires treatment</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x22401">
							<label>•</label>
							<sec_title>
								<route>That product will be discontinued ≥24 hr before surgery; may be resumed after adequate wound healing</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x22404">
								<item>
									<label>•</label>
									<para>That laboratory testing will be required before and periodically during product use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22409">
								<item>
									<label>•</label>
									<para>How to monitor B/P and that B/P products should be continued as directed by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="84" status="active" ha="yes">
			<mono_name>azaCITIDine (Rx)</mono_name>
			<info>
				<pronunciation>(a-za-sie-ti′deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x224210">Vidaza</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Pyrimidine nucleoside analogue</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x22431">
				<para>
					<confusion>
						<tradename id="tnidelem4x224310">azaCITIDine</tradename>
						<drug type="generic" refid="idelem4x224310">azaTHIOprine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x22435">
				<sec_title>Action:</sec_title>
				<para>Cytotoxic by producing damage to double-strand DNA during DNA synthesis</para>
			</section>
			<section type="uses" id="sidelem4x22440">
				<sec_title>Uses:</sec_title>
				<para>Myelodysplastic syndrome (MDS)</para>
				<section type="none" id="sidelem4x22445">
					<section type="none" id="sidelem4x22446">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x22451">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to product or mannitol, advanced malignant hepatic tumors</para>
				<section type="none" id="sidelem4x22457">
					<section type="none" id="sidelem4x22458">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, renal/hepatic disease, baseline albumin &lt;30 g/L; a man should not father a child while taking product</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x22463">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x22471">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
					<para>
						<list id="lidelem4x22471">
							<item>
								<label>•</label>
								<para> 75 mg/m<emphasis style="sup">2</emphasis>/day × 7 days q4wk, dose may be increased to 100 mg/m<emphasis style="sup">2</emphasis> if no response seen after 2 treatment cycles; minimum treatment, 4 cycles</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x22481">
					<section type="none" id="sidelem4x22482">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 100 mg</para>
					</section>
					<section type="none" id="sidelem4x22487">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x22491">
								<item>
									<label>•</label>
									<para>Use cytotoxic handling procedures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22497">
						<sec_title>SUBCUT route</sec_title>
						<section type="none" id="sidelem4x22505">
							<label>•</label>
							<sec_title>
								<route>Reconstitute</route>
							</sec_title>
							<para>
								<list id="lidelem4x22505">
									<item>
										<label>•</label>
										<para> with 4 ml sterile water for inj (25 mg/ml), inject diluents slowly into vial, invert vial 2-3 times, gently rotate; sol will be cloudy, use immediately; divide doses &gt;4 ml into 2 syringes; invert contents 2-3 times, gently roll syringe between the palms for 30 sec immediately before administration, rotate inj site</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22509">
						<sec_title>Intermittent IV INFUSION route</sec_title>
						<section type="none" id="sidelem4x22517">
							<label>•</label>
							<sec_title>
								<route>Reconstitute</route>
							</sec_title>
							<para>
								<list id="lidelem4x22517">
									<item>
										<label>•</label>
										<para> each vial with 10 ml sterile water for inj, shake well until all solids are dissolved, withdraw sol (10 mg/ml), inject in 50-100 NS or LR infusion run over 10-40 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x22521">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x22524">
					<section type="none" id="sidelem4x22525">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Anxiety, depression, dizziness, fatigue, headache, fever, insomnia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22532">
						<sec_title>CV:</sec_title>
						<para> Cardiac murmur, hypotension, tachycardia, peripheral edema, <emphasis style="italic">chest pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22539">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, vomiting,</emphasis> anorexia, <emphasis style="italic">constipation,</emphasis> abdominal pain, distention, tenderness, hemorrhoids, mouth hemorrhage, tongue ulceration, stomatitis, dyspepsia, <emphasis style="bold">hepatotoxicity, hepatic coma</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22552">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure, renal tubular acidosis,</emphasis> dysuria, UTI</para>
					</section>
					<section type="none" id="sidelem4x22560">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, anemia, thrombocytopenia, neutropenia, febrile neutropenia,</emphasis> ecchymosis, petechiae</para>
					</section>
					<section type="none" id="sidelem4x22568">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Irritation at site, rash,</emphasis> sweating, pyrexia, pruritus</para>
					</section>
					<section type="none" id="sidelem4x22576">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x22581">
						<sec_title>MS:</sec_title>
						<para> Weakness, arthralgia, muscle cramps, myalgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x22586">
						<sec_title>RESP:</sec_title>
						<para> Cough, <emphasis style="italic">dyspnea, pharyngitis,</emphasis><emphasis style="bold">pleural effusion</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x22595">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, metabolized in the liver, half-life 4 hr, excreted in urine</para>
			</section>
			<section type="interactions" id="sidelem4x22606">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow depression—other antineoplastics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—anticoagulants</para>
				<section type="none" id="sidelem4x22617">
					<section type="none" id="sidelem4x22618">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN/Creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, platelets, neutrophils, potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x22629">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x22632">
					<section type="none" id="sidelem4x22633">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x22638">
								<item>
									<label>•</label>
									<para>For CNS symptoms: fever, headache, chills, dizziness</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x22646">
							<label>•</label>
							<sec_title>Bone marrow suppression/hematologic response<route> CBC with differential, baseline WBC ≥3000/mm</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x22684">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores, or ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x22692">
							<label>•</label>
							<sec_title>Myelodysplastic syndrome<route> severe anemia, cytopenias, splenomegaly</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x22695">
								<item>
									<label>•</label>
									<para>Blood studies: BUN, bicarbonate, creatine, LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22700">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent dehydration unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22705">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicator for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22710">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x22714">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in blood counts with refractory anemia or refractory anemia with excess blasts</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22721">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x22726">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known infections; not to receive immunizations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22731">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid or hot or rough texture if stomatitis is present; to drink adequate fluids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22736">
								<item>
									<label>•</label>
									<para>To report stomatitis; any bleeding, white spots, ulcerations in mouth; to examine mouth daily, report symptoms, infection site reactions, pruritus, fever</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x22744">
							<label>•</label>
							<sec_title>
								<route>To use contraception during and for several months after therapy (pregnancy [D]); not to breastfeed; not to father a child while receiving product</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="85" status="active">
			<mono_name>azaTHIOprine (Rx)</mono_name>
			<info>
				<pronunciation>(ay-za-thye′oh-preen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x227521">Azasan</tradename>
					<tradename id="tnidelem4x227520">Imuran</tradename>
				</tradenames>
				<class type="func"> Immunosuppressant</class>
				<class type="chem"> Purine antagonist</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x22762">
				<para>
					<confusion>
						<tradename id="tnidelem4x227620">Imuran</tradename>
						<drug type="generic" refid="idelem4x227620">Imferon/Elmiron/IMDUR/Enduron/Tenormin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x22769">
				<sec_title>Action:</sec_title>
				<para>Produces immunosuppression by inhibiting purine synthesis in cells</para>
			</section>
			<section type="uses" id="sidelem4x22774">
				<sec_title>Uses:</sec_title>
				<para>Renal transplants to prevent graft rejection, refractory rheumatoid arthritis</para>
				<section type="none" id="sidelem4x22779">
					<section type="none" id="sidelem4x22780">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Myasthenia gravis, chronic ulcerative colitis, Crohn’s disease, Behçet’s disease, autoimmune hepatitis, dermatomyositis, thrombocytopenic purpura, lupus nephritis, polymyositis, pulmonary fibrosis, systemic lupus erythematosus (SLE), Wegener’s granulomatosis, vasculitis, atopic dermatitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x22785">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity, breastfeeding</para>
				<section type="none" id="sidelem4x22790">
					<section type="none" id="sidelem4x22791">
						<sec_title>Precautions:</sec_title>
						<para> Severe renal/hepatic disease, geriatric patients, thiopurine methyltransferase deficiency, infection</para>
						<para>
							<bbw>Bone marrow suppression, neoplastic disease, must be used by experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x22806">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x22809">
					<section type="none" id="sidelem4x22810">
						<sec_title>Prevention of rejection</sec_title>
						<section type="none" id="sidelem4x22818">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x22818">
									<item>
										<label>•</label>
										<para> 3-5 mg/kg/day, then maintenance  of ≥1-3 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22825">
						<sec_title>Renal Dose</sec_title>
						<section type="none" id="sidelem4x22833">
							<label>•</label>
							<sec_title>Adult<route> PO Give lower dose in tubular necrosis in immediate post-cadaveric transplant period</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x22836">
						<sec_title>Refractory rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x22844">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22844">
									<item>
										<label>•</label>
										<para> 1 mg/kg/day, may increase dose after 2 mo by 0.5 mg/kg/day and then q4wk, max 2.5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22848">
						<sec_title>Lupus nephritis/SLE/Wegener’s granulomatosis/idiopathic pulmonary fibrosis/multiple sclerosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x22856">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22856">
									<item>
										<label>•</label>
										<para> 2-3 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22860">
						<sec_title>Atopic dermatitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x22868">
							<label>•</label>
							<sec_title>Adult/adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22868">
									<item>
										<label>•</label>
										<para> 2.5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22872">
						<sec_title>Idiopathic thrombocytopenic purpura (unlabeled)</sec_title>
						<section type="none" id="sidelem4x22880">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22880">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg/day × 3-6 mo, max 150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22884">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50, 75, 100 mg; inj 100 mg</para>
					</section>
					<section type="none" id="sidelem4x22889">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x22893">
								<item>
									<label>•</label>
									<para>For several days before transplant surgery</para>
								</item>
								<item>
									<label>•</label>
									<para>All medications PO if possible; avoid IM inj because bleeding may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x22904">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x22908">
									<item>
										<label>•</label>
										<para>With meals to reduce GI upset</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x22914">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x22918">
									<item>
										<label>•</label>
										<para>Prepare in biologic cabinet with gown, gloves, mask</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x22924">
							<sec_title>Direct IV</sec_title>
							<section type="none" id="sidelem4x22932">
								<label>•</label>
								<sec_title>
									<route>Dilute</route>
								</sec_title>
								<para>
									<list id="lidelem4x22932">
										<item>
											<label>•</label>
											<para> to 10 mg/ml with 0.9% NaCl, 0.45% NaCl, D<emphasis style="inf">5</emphasis>W,  over 5 min</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x22942">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x22950">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x22950">
										<item>
											<label>•</label>
											<para> 100 mg/10 ml of sterile water for inj; rotate to dissolve;  with 50 ml or more saline or glucose in saline,  over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, atracurium, atropine, benztropine, calcium gluconate, cycloSPORINE, enalaprilat, epoetin alfa, erythromycin, fentaNYL, fluconazole, folic acid, furosemide, glycopyrrolate, heparin, insulin, mannitol, mechlorethamine, metoprolol, naloxone, nitroglycerin, oxytocin, penicillin G, potassium chloride, propranolol, protamine, SUFentanil, trimetaphan, vasopressin</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>W, NaCl 0.9%, NaCl 0.45%</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x22979">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x22982">
					<section type="none" id="sidelem4x22983">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> stomatitis, esophagitis, <emphasis style="bold">pancreatitis, hepatotoxicity, jaundice, hepatic veno-occlusive disease</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22993">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, anemia, pancytopenia, bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x23000">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia</para>
					</section>
					<section type="none" id="sidelem4x23005">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Serum sickness,</emphasis> Raynaud’s symptoms, <emphasis style="bold">secondary malignancy, infection</emphasis></para>
					</section>
					<section type="none" id="sidelem4x23015">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, muscle wasting</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x23020">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in urine (active metabolite), crosses placenta, half-life 3 hr</para>
			</section>
			<section type="interactions" id="sidelem4x23025">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> leukopenia—ACE inhibitors, sulfamethoxazole-trimethoprim</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—cycloSPORINE, mercaptopurine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of azaTHIOprine—allopurinol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> immune response—vaccines, toxoids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of warfarin—warfarin<list id="lidelem4x23048">
						<item>
							<label>•</label>
							<para>Do not admix with other products</para>
						</item>
					</list></para>
				<section type="none" id="sidelem4x23054">
					<section type="none" id="sidelem4x23055">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> uric acid</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> CBC, differential count</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x23070">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x23073">
					<section type="none" id="sidelem4x23074">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x23082">
							<label>•</label>
							<sec_title>For infection<route> increased temperature, WBC; sputum, urine</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x23085">
								<item>
									<label>•</label>
									<para>I&amp;O, weight daily, report decreasing urine output; toxicity may occur
<bbw>Bone marrow suppression: severe leukopenia, pancytopenia, thrombocytopenia; Hgb, WBC, platelets during treatment monthly; if leukocytes are &lt;3000/mm3 or platelets &lt;100,000/mm3, product should be discontinued, CBC</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23106">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: if dark urine, jaundice, itching, light-colored stools, increased LFTs, product should be discontinued; hepatic studies: alk phos, AST, ALT, bilirubin</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x23114">
							<label>•</label>
							<sec_title>Arthritis</sec_title>
							<para>
								<list id="lidelem4x23114">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Arthritis:</emphasis> pain, ROM, swelling, mobility before, during treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23118">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x23122">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of graft rejection, immunosuppression in autoimmune disorders</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23128">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x23133">
								<item>
									<label>•</label>
									<para>To take as prescribed; not to miss doses; if dose is missed on daily regimen, to skip dose; if taking multiple doses/day, to take as soon as remembered</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23138">
								<item>
									<label>•</label>
									<para>That therapeutic response may take 3-4 mo with RA; to continue with prescribed exercise, rest, other medications</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x23146">
							<label>•</label>
							<sec_title>
								<route>To report fever, rash, severe diarrhea, chills, sore throat, fatigue because serious infections may occur; report unusual bleeding, bruising; signs/symptoms of renal/hepatic toxicity</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x23152">
							<label>•</label>
							<sec_title>
								<route>To use contraceptive measures during treatment, for 16 wk after ending therapy (pregnancy [D]); to avoid vaccinations</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x23155">
								<item>
									<label>•</label>
									<para>To avoid crowds to reduce risk for infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23160">
								<item>
									<label>•</label>
									<para>To take with food to decrease GI intolerance</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23165">
								<item>
									<label>•</label>
									<para>About multiple significant drug–drug interactions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23170">
								<item>
									<label>•</label>
									<para>To use soft-bristled toothbrush to prevent bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23175">
								<item>
									<label>•</label>
									<para>That treatment is ongoing to prevent transplant rejection</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="86" status="active" ru="yes">
			<mono_name>azelaic acid</mono_name>
			<info>
				<pronunciation>(aze-eh-lay′ik)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x231881">Azelex</tradename>
					<tradename id="tnidelem4x231880">Finacea</tradename>
				</tradenames>
				<class type="func"> Antiacne agent</class>
				<class type="chem"> Dicarboxylic acid</class>
			</info>
			<section type="uses" id="sidelem4x23198">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate inflammatory acne vulgaris, rosacea</para>
			</section>
			<section type="contra" id="sidelem4x23203">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x23208">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x23211">
					<section type="none" id="sidelem4x23212">
						<section type="none" id="sidelem4x23213">
							<sec_title>Adult/child ≥12 yr:</sec_title>
							<para>
								<list id="lidelem4x23217">
									<item>
										<label>•</label>
										<para>Apply a thin film and massage into affected areas bid <emphasis style="smallcaps">am</emphasis> and <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23228">
						<sec_title>Available forms:</sec_title>
						<para>Cream 20%, Gel 15%</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="87" status="active">
			<mono_name>azelastine (ophthalmic)</mono_name>
			<info>
				<pronunciation>(ah-zell′ah-steen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x232380">Optivar</tradename>
				</tradenames>
				<class type="func"> Antihistamine (ophthalmic)</class>
				<class type="chem"> H1 receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x23248">
				<sec_title>Action:</sec_title>
				<para>Decreases the allergic response by inhibiting histamine release</para>
			</section>
			<section type="uses" id="sidelem4x23253">
				<sec_title>Uses:</sec_title>
				<para>Pruritus from allergic conjunctivitis</para>
			</section>
			<section type="contra" id="sidelem4x23258">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x23263">
					<section type="none" id="sidelem4x23264">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, child &lt;3 yr</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x23269">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x23277">
					<label>•</label>
					<sec_title>
						<route>Adult/child</route>
					</sec_title>
					<para>
						<list id="lidelem4x23277">
							<item>
								<label>•</label>
								<para> ≥ 1 drop into each affected eye bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x23284">
					<section type="none" id="sidelem4x23285">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic sol: 0.05%</para>
					</section>
					<section type="none" id="sidelem4x23290">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x23294">
								<item>
									<label>•</label>
									<para>Tip of dropper should not touch the eye</para>
								</item>
								<item>
									<label>•</label>
									<para>Store upright and tightly closed at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x23305">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x23308">
					<section type="none" id="sidelem4x23309">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x23314">
						<sec_title>EENT:</sec_title>
						<para> Eye burning/stinging/irritation, blurred vision, rhinitis, bitter taste</para>
					</section>
					<section type="none" id="sidelem4x23319">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus</para>
					</section>
					<section type="none" id="sidelem4x23324">
						<sec_title>RESP:</sec_title>
						<para> Asthma, dyspnea, wheezing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x23329">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 3 min, duration 8 hr, half-life 22 hr, protein binding 88%</para>
			</section>
			<section type="considerations" id="sidelem4x23334">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x23337">
					<section type="none" id="sidelem4x23338">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x23342">
								<item>
									<label>•</label>
									<para>Eyes: for itching, redness, use of soft or hard contact lenses</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23348">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x23352">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of redness, itching in the eyes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23358">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x23362">
								<item>
									<label>•</label>
									<para>To use in the eyes only; not to touch dropper to eye/eyelid</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to wear contact lenses if eyes are red and itching</para>
								</item>
								<item>
									<label>•</label>
									<para>To wait at least 10 min before inserting contact lenses; soft contact lenses can absorb preservative</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="88" status="active">
			<mono_name>azelastine nasal agent</mono_name>
			<section type="none" id="sidelem4x23381">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="89" status="active">
			<mono_name>azilsartan</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x233880">Edarbi</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin II receptor antagonist</class>
			</info>
			<section type="actions" id="sidelem4x23398">
				<sec_title>Action:</sec_title>
				<para>Antagonizes angiotensin II at the AT<emphasis style="inf">1</emphasis> receptor in tissues like vascular smooth muscle and the adrenal gland; two angiotensin II receptors, AT<emphasis style="inf">1</emphasis> and AT<emphasis style="inf">2</emphasis>, have been identified; azilsartan exhibits more than 10,000-fold greater affinity for the AT<emphasis style="inf">1</emphasis> receptor than the AT<emphasis style="inf">2</emphasis> receptor</para>
			</section>
			<section type="uses" id="sidelem4x23418">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with other antihypertensives</para>
			</section>
			<section type="contra" id="sidelem4x23424">
				<sec_title>Contraindications</sec_title>
				<para>
					<bbw>Pregnancy (D) 2nd/3rd trimesters</bbw>
				</para>
				<section type="none" id="sidelem4x23437">
					<section type="none" id="sidelem4x23438">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) 1st trimester, breastfeeding, children, geriatric patients, angioedema, African descent, renal disease, renal artery stenosis, heart failure, hypovolemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x23443">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x23451">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x23451">
							<item>
								<label>•</label>
								<para> 80 mg/day, may give an initial dose of 40 mg/day in patients receiving high-dose diuretic therapy</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x23455">
					<section type="none" id="sidelem4x23456">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 40, 80 mg</para>
					</section>
					<section type="none" id="sidelem4x23461">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x23465">
								<item>
									<label>•</label>
									<para>May administer without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Use original package to protect from light and moisture, heat</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x23476">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x23479">
					<section type="none" id="sidelem4x23480">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, fatigue, asthenia, syncope</para>
					</section>
					<section type="none" id="sidelem4x23485">
						<sec_title>CV:</sec_title>
						<para> Hypotension, orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x23490">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x23495">
						<sec_title>HEMA:</sec_title>
						<para> Anemia</para>
					</section>
					<section type="none" id="sidelem4x23500">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis>, rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x23508">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x23513">
						<sec_title>RESP:</sec_title>
						<para> Cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x23518">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding &gt;99% to serum albumin; metabolized by CYP2C9; elimination half-life 11 hr, steady-state within 5 days and no accumulation in plasma occurs with once-daily dosing; elimination 55% in feces, 42% in urine; hydrolyzed to the active metabolite, azilsartan, in GI tract during absorption, rapidly absorbed, peak 1.5-3 hr; absolute bioavailability (60%) not affected by food</para>
			</section>
			<section type="interactions" id="sidelem4x23523">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive effect—other antihypertensives, other angiotensin receptor antagonists, MAOIs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—antidiabetics</para>
				<para>
					<emphasis alert="nurse">Increase: renal failure risk—cyclosporine, diuretics, NSAIDs in those with poor renal function; monitor closely</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: lithium toxicity—lithium</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: phosphate nephropathy—sodium phosphate monobasic monohydrate; sodium phosphate dibasic anhydrous</emphasis>
				</para>
				<section type="none" id="sidelem4x23549">
					<section type="none" id="sidelem4x23550">
						<sec_title>Drug/Herb:</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—Hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x23561">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x23564">
					<section type="none" id="sidelem4x23565">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x23571">
								<item>
									<para>
										<emphasis alert="nurse">Angioedema: Assess for facial swelling, difficulty breathing</emphasis>
<bbw>For pregnancy (D) 2nd/3rd trimester, can cause fetal death</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23585">
								<item>
									<label>•</label>
									<para>Response and adverse reactions especially in renal disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23590">
								<item>
									<label>•</label>
									<para>B/P, pulse when beginning therapy and periodically thereafter; note rhythm, rate, quality; obtain electrolytes before beginning therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23595">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x23599">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23605">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x23610">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule even if feeling better</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23616">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber of facial swelling; if pregnancy is planned or suspected (category D 2nd/3rd trimester)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23621">
								<item>
									<label>•</label>
									<para>That diarrhea, dehydration, excessive perspiration, vomiting, may lead to fall in B/P; to consult prescriber if these occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23626">
								<item>
									<label>•</label>
									<para>To rise slowly from lying or sitting to minimize orthostatic hypotension; that product may cause dizziness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23631">
								<item>
									<label>•</label>
									<para>To avoid OTC medications unless approved by prescriber; to inform all health care providers of product use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23636">
								<item>
									<label>•</label>
									<para>To use proper technique for obtaining B/P</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="90" status="active">
			<mono_name>azithromycin (Rx)</mono_name>
			<info>
				<pronunciation>(ay-zi-thro-my′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x236474">AzaSite</tradename>
					<tradename id="tnidelem4x236473">Zithromax</tradename>
					<tradename id="tnidelem4x236472">Zmax</tradename>
					<tradename id="tnidelem4x236471">Zithromax Tri Pak</tradename>
					<tradename id="tnidelem4x236470">Zithromax Z Pak</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Macrolide (azalide)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x23657">
				<para>
					<confusion>
						<tradename id="tnidelem4x236570">azithromycin</tradename>
						<drug type="generic" refid="idelem4x236570">erythromycin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x23664">
				<sec_title>Action:</sec_title>
				<para>Binds to 50S ribosomal subunits of susceptible bacteria and suppresses protein synthesis; much greater spectrum of activity than erythromycin; more effective against gram-negative organisms</para>
			</section>
			<section type="uses" id="sidelem4x23669">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate infections of the upper respiratory tract, lower respiratory tract; uncomplicated skin and skin structure infections caused by <emphasis style="italic">Bacillus anthracias, Bacteroides bivius, Bordetella paertassis, Borrelia burgdorferi, Campylobacter jun juni, CDC coryneform group G, Chlamydia trachomatis, Chlamydophila pneumonial, Clostridium perffringes, Gardnerella vaginalis, Haemophilisducreyi, influenzal</emphasis> (beta-lactamase negative/positive) <emphasis style="italic">Helicobacter pylori, Klebsiella granulomatis, Legionella pnemohila moraxella catarrhalis, Mycobacterium arium/intracellulare, Mycoplasma genitalium/homonis/pneumonial, Neisseria gonorrhoel, Peptostreptococcus</emphasis> sp., <emphasis style="italic">Prevotella bivia, Rickettsia tsutsugamushi, Salmonella typhi, Staphylococcus aureus (MSSA)/epidermidis, Streptococcus</emphasis> sp., <emphasis style="italic">Toxoplasma gondi, Treponema pallidium, Ureaplasma urealytican, Vibriocholerae, Viridancs streptococci;</emphasis><emphasis style="bold">PO;</emphasis> acute pharyngitis/tonsillitis (group A streptococcal); acute skin/soft-tissue infections; community-acquired pneumonia; pharyngitis/tonsillitis; <emphasis style="bold">Ophthalmic:</emphasis> bacterial conjunctivitis</para>
				<section type="none" id="sidelem4x23691">
					<section type="none" id="sidelem4x23692">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Babesiosis, cholera, cystic fibrosis, dental abscess/infection, endocarditis prophylaxis, granuloma inguinale, Legionnaire’s disease, Lyme disease, lymphogranuloma venereum, MAC, periodontitis, pertussis, prostatitis, shigellosis, syphilis, toxoplasmosis, typhoid fever</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x23697">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to azithromycin, erythromycin, any macrolide, hepatitis, jaundice</para>
				<section type="none" id="sidelem4x23702">
					<section type="none" id="sidelem4x23703">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding; geriatric patients; renal/hepatic/cardiac disease; &lt;6 mo for otitis media; &lt;2 yr for pharyngitis, tonsillitis, QT prolongation, ulcerative colitis, torsades de pointes, sunlight exposure, sodium restriction, myasthenia gravis, <emphasis style="italic">Pseudomembranous colitis,</emphasis> contact lenses, hypokalemia, hypomagnesemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x23711">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x23714">
					<section type="none" id="sidelem4x23715">
						<sec_title>Most infections</sec_title>
						<section type="none" id="sidelem4x23723">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23723">
									<item>
										<label>•</label>
										<para> 500 mg on day 1, then 250 mg/day on days 2-5 for a total dose of 1.5 g or 500 mg a day × 3 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x23730">
							<label>•</label>
							<sec_title>Child 2-15 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23730">
									<item>
										<label>•</label>
										<para> 10 mg/kg on day 1, then 5 mg/kg × 4 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23734">
						<sec_title>Disseminated MAC infections</sec_title>
						<section type="none" id="sidelem4x23742">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23742">
									<item>
										<label>•</label>
										<para> 600 mg/day with ethambutol 15 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23746">
						<sec_title>Pelvic inflammatory disease</sec_title>
						<section type="none" id="sidelem4x23754">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x23754">
									<item>
										<label>•</label>
										<para> 500 mg  q24hr × 2 doses, then 250 mg  q24hr × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23764">
						<sec_title>Cervicitis, chlamydia, chancroid, nongonococcal urethritis, syphilis</sec_title>
						<section type="none" id="sidelem4x23772">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23772">
									<item>
										<label>•</label>
										<para> 1 g single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23776">
						<sec_title>Gonorrhea</sec_title>
						<section type="none" id="sidelem4x23784">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23784">
									<item>
										<label>•</label>
										<para> 2 g single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23788">
						<sec_title>Lower respiratory tract infections</sec_title>
						<section type="none" id="sidelem4x23796">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23796">
									<item>
										<label>•</label>
										<para> 500 mg day 1, then 250 mg × 4 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x23803">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23803">
									<item>
										<label>•</label>
										<para> 5-12 mg/kg/day × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23807">
						<sec_title>Acute otitis media</sec_title>
						<section type="none" id="sidelem4x23815">
							<label>•</label>
							<sec_title>Child &gt;6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23815">
									<item>
										<label>•</label>
										<para> 30 mg/kg as a single dose or 10 mg/kg/day × 3 days or 10 mg/kg as a single dose on day 1 (max 500 mg/day), then 5 mg/kg on days 2-5 (max 250 mg/day)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23819">
						<sec_title>Prevention of acute otitis media</sec_title>
						<section type="none" id="sidelem4x23827">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23827">
									<item>
										<label>•</label>
										<para> 10 mg/kg q wk × 6 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23832">
						<sec_title>MAC in HIV</sec_title>
						<section type="none" id="sidelem4x23840">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23840">
									<item>
										<label>•</label>
										<para> 1.2 g q1wk, alone or with rifabutin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23844">
						<sec_title>Bacterial Conjunctivitis</sec_title>
						<section type="none" id="sidelem4x23852">
							<label>•</label>
							<sec_title>Adult/Child ≥1 yr<route> Ophthalmic</route></sec_title>
							<para>
								<list id="lidelem4x23852">
									<item>
										<label>•</label>
										<para> Instill 1 drop in affected eye bid × 2 days, then 1 drop in eye daily × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23856">
						<sec_title>Legionnaire’s disease/early Lyme disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x23864">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23864">
									<item>
										<label>•</label>
										<para> 500 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23868">
						<sec_title>Pertussis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x23876">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23876">
									<item>
										<label>•</label>
										<para> 500 mg on day 1, then 250 mg/day for 2-5 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x23883">
							<label>•</label>
							<sec_title>Infant ≥6 mo and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23883">
									<item>
										<label>•</label>
										<para> 10 mg/kg/day (max 500 mg) on day 1, then 5 mg/kg/day (max 250 mg) on days 2-5</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x23890">
							<label>•</label>
							<sec_title>Infant &lt;6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23890">
									<item>
										<label>•</label>
										<para> 10 mg/kg/day × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23894">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500, 600 mg; powder for inj 500 mg; susp 100, 200 mg/5 ml 1 g single-dose powder for susp; ext rel powder for susp 2 g; ophthalmic drops 1% solution</para>
					</section>
					<section type="none" id="sidelem4x23899">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x23902">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x23906">
									<item>
										<label>•</label>
										<para>Store in refrigerator</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not touch dropper to eye</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x23917">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x23925">
								<label>•</label>
								<sec_title>
									<route>Susp</route>
								</sec_title>
								<para>
									<list id="lidelem4x23925">
										<item>
											<label>•</label>
											<para> 1 hr before meal or 2 hr after meal; reconstitute 1 g packet for susp with 60 ml water, mix, rinse glass with more water and have patient drink to consume all medication; packets not for pediatric use</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x23929">
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x23934">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x23942">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x23942">
										<item>
											<label>•</label>
											<para> 500 mg of product with 4.8 ml sterile water for inj (100 mg/ml); shake,  with 250 or 500 ml 0.9% NaCl, 0.45% NaCl, or LR to 1-2 mg/ml; diluted sol stable for 24 hr or 7 days if refrigerated</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x23952">
								<label>•</label>
								<sec_title>
									<route>Give</route>
								</sec_title>
								<para>
									<list id="lidelem4x23952">
										<item>
											<label>•</label>
											<para> 1 mg/ml sol over 3 hr or 2 mg/ml sol over 1 hr; never give IM or as bolus</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x23956">
									<item>
										<label>•</label>
										<para>Reconstituted product is stable for 24 hr at room temperature or 7 days refrigerated</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alatrofloxacin, alemtuzumab, alfentanol, aminocaproic acid, aminophyllum, amphotericin B liposome/complex, ampicillin, ampicillin-sulbactum, anidulafungin, atenolol, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, ceFAZolin, cefepime, cefoTEtan, cefoxitin, ceftaroline, cefTAZidime, ceftizoxime, cimetidine, cisatracurium, CISplatin, cyclophosphamide, cycloSPORINE, cytarabine, DAPTOmycin, DAUNOrubicin liposome, dexamethasome, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, doripenem, doxacurium, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, EPINEPHrine, epirubicin, eptifibatide, ertapenem, esmolol, etoposide, etoposide phosphate, fenoldopam, fluconozole, fluorouracil, foscarnet, fosphenytoin, gallium, ganciclovir, gatifloxacin, gemcitabine, granisetron, haloperidol, heparin, hydrocortisone phosphate/succinate, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, inamrinone, irinotecan, isoproterenol, labetalol, lepirudin, magnesium sulfate, mannitol, meperidine, meropenem, mesna, methochlorethamine, methohexital, methotrexate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, milrinone, minocycline, miralacurium, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, octreotide, ofloxacin, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pantoprazole, PEMEtrexed, PENTobarbital, phenylephrine, piperacillin, potassium acetate/phosphates, proclinimide, proclorperazine, promethazine, propranolol, ranitidine, remifentanil, rocuronium, sodium acetate, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, telavancin, teniposide, thiotepa, ticarcillin, tigecycline, tirofiban, TPN, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x23966">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x23969">
					<section type="none" id="sidelem4x23970">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, vertigo, somnolence, fatigue</para>
					</section>
					<section type="none" id="sidelem4x23975">
						<sec_title>CV:</sec_title>
						<para> Palpitations, chest pain, <emphasis style="bold">QT prolongation, torsades de pointes (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x23982">
						<sec_title>EENT:</sec_title>
						<para> Hearing loss, tinnitus, loss of smell (anosmia)</para>
					</section>
					<section type="none" id="sidelem4x23987">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> abdominal pain, stomatitis, heartburn, dyspepsia, flatulence, melena, <emphasis style="bold">cholestatic jaundice, pseudomembranous colitis,</emphasis> tongue discoloration</para>
					</section>
					<section type="none" id="sidelem4x24000">
						<sec_title>GU:</sec_title>
						<para> Vaginitis, moniliasis, nephritis</para>
					</section>
					<section type="none" id="sidelem4x24005">
						<sec_title>HEMA:</sec_title>
						<para> Anemia</para>
					</section>
					<section type="none" id="sidelem4x24010">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus, photosensitivity, pain at inj site</para>
					</section>
					<section type="none" id="sidelem4x24015">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x24022">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x24025">
					<section type="none" id="sidelem4x24026">
						<sec_title>PO:</sec_title>
						<para> Peak 2-4 hr, duration 24 hr</para>
					</section>
					<section type="none" id="sidelem4x24031">
						<sec_title>IV:</sec_title>
						<para> Peak end of infusion; duration 24 hr; half-life 11-57 hr; excreted in bile, feces, urine primarily as unchanged product; may be inhibitor of P-glycoprotein</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x24036">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> ergot toxicity—ergotamine</para>
				<para>
					<emphasis alert="nurse">Increase: dysrhythmias—pimozide: fatal reaction, do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> QT prolongation—amiodarone, quiNIDine, nilotinib, droperidol, methadone, propafenone, <emphasis style="bold">fluoroquinolones, lithium, paliperidone</emphasis></para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of oral anticoagulants, digoxin, theophylline, methylPREDNISolone, cycloSPORINE, bromocriptine, disopyramide, triazolam, carBAMazepine, phenytoin, tacrolimus, nelfinavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clearance of triazolam</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of azithromycin—aluminum, magnesium antacids, separate by ≥2 hr</para>
				<section type="none" id="sidelem4x24066">
					<section type="none" id="sidelem4x24067">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK, ALT, AST, bilirubin, BUN, creatinine, alk phos, potassium, blood glucose</para>
					</section>
					<section type="none" id="sidelem4x24074">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—food (susp)</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> blood glucose, potassium, sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x24085">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x24088">
					<section type="none" id="sidelem4x24089">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x24094">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report hematuria, oliguria with renal disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24099">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, CBC with differential</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24104">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, protein, blood</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24109">
								<item>
									<label>•</label>
									<para>C&amp;S before product therapy; product may be taken as soon as culture is taken; C&amp;S may be repeated after treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x24117">
							<label>•</label>
							<sec_title>QT prolongation, torsades de pointes<route> assess for patients with serious bradycardia, ongoing proarrhythmic conditions, or elderly; more common in these patients</route></sec_title>
						</section>
						<section type="none" id="sidelem4x24123">
							<label>•</label>
							<sec_title>Serious skin reactions<route> Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema; discontinue if rash develops, treat symptomatically</route></sec_title>
						</section>
						<section type="none" id="sidelem4x24129">
							<label>•</label>
							<sec_title>Superinfection<route> sore throat, mouth, tongue; fever, fatigue, diarrhea, anogenital pruritus</route></sec_title>
						</section>
						<section type="none" id="sidelem4x24135">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> diarrhea, abdominal pain, fever, fatigue, anorexia; obtain CBC, serum albumin</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x24138">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24143">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character; wheezing, tightness in chest: discontinue product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x24151">
							<label>•</label>
							<sec_title>
								<route>Cardiovascular death has occurred in those with serious bradycardia or ongoing hypokalemia, hypomagnesemia, avoid use</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x24154">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x24158">
								<item>
									<label>•</label>
									<para>Therapeutic response: C&amp;S negative for infection; decreased signs of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x24164">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x24170">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue, severe diarrhea, anal/genital itching (may indicate superinfection)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24175">
								<item>
									<label>•</label>
									<para>Not to take aluminum-magnesium–containing antacids simultaneously with this product (PO)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24181">
								<item>
									<para>
										<emphasis alert="nurse">To notify nurse of diarrhea, dark urine, pale stools; yellow discoloration of eyes, skin; severe abdominal pain</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24186">
								<item>
									<label>•</label>
									<para>To complete dosage regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24191">
								<item>
									<label>•</label>
									<para>To take ZMAX 1 hr before or 2 hr after a meal; shake well before use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24196">
								<item>
									<label>•</label>
									<para>To use protective clothing or stay out of the sun, photosensitivity may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x24202">
				<sec_title>Treatment of hypersensitivity:</sec_title>
				<para>Withdraw product, maintain airway; administer EPINEPHrine, aminophylline, O<emphasis style="inf">2</emphasis>, IV corticosteroids</para>
			</section>
		</monograph>
<monograph id="91" status="active">
			<mono_name>azithromycin ophthalmic</mono_name>
			<section type="none" id="sidelem4x24213">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="92" status="active" ru="yes">
			<mono_name>aztreonam (Rx)</mono_name>
			<info>
				<pronunciation>(az-tree′oh-nam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x242241">Azactam</tradename>
					<tradename id="tnidelem4x242240">Cayston</tradename>
				</tradenames>
				<class type="func"> Antibiotic—miscellaneous</class>
			</info>
			<section type="uses" id="sidelem4x24230">
				<sec_title>Uses:</sec_title>
				<para>Urinary tract infection; septicemia; skin, muscle, bone infection; lower respiratory tract, intraabdominal infections; other infections caused by gram-negative organisms</para>
			</section>
			<section type="contra" id="sidelem4x24235">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to product, severe renal disease</para>
			</section>
			<section type="doses" id="sidelem4x24240">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x24243">
					<section type="none" id="sidelem4x24244">
						<sec_title>Urinary tract infections</sec_title>
						<section type="none" id="sidelem4x24252">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x24252">
									<item>
										<label>•</label>
										<para> 500 mg-1 g q8-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24256">
						<sec_title>Systemic infections</sec_title>
						<section type="none" id="sidelem4x24264">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x24264">
									<item>
										<label>•</label>
										<para> 1-2 g q8-12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24271">
							<label>•</label>
							<sec_title>Child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x24271">
									<item>
										<label>•</label>
										<para> 90-120 mg/kg/day in divided doses q6-8hr; max 8 g/day </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24277">
						<sec_title>Severe systemic infections</sec_title>
						<section type="none" id="sidelem4x24285">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x24285">
									<item>
										<label>•</label>
										<para> 2 g q6-8hr; max 8 g/day; continue treatment for 48 hr after negative culture or until patient is asymptomatic</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24289">
						<sec_title>Cystic fibrosis with <emphasis style="bold">
								<emphasis style="italic">Pseudomonas aeruginosa</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x24300">
							<label>•</label>
							<sec_title>Adult, adolescent, child ≥7 yr<route> NEB</route></sec_title>
							<para>
								<list id="lidelem4x24300">
									<item>
										<label>•</label>
										<para> 75 mg tid × 28 days, then 28 days off; give q4hr or more; give bronchodilator before aztreonam</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>